verapamil has been researched along with Hypertension in 1018 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although verapamil is a well-established treatment for angina, cardiac arrhythmias and cardiomyopathies, this review reflects current interest in calcium antagonists as anti-hypertensive agents by focusing on the role of verapamil in hypertension." | 10.16 | Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. ( McTavish, D; Sorkin, EM, 1989) |
| "The Bergamo Nephrologic Diabetes Complications Trial-B was a multicentre, prospective, double-blind, parallel-group trial comparing renal and cardiovascular outcomes in 281 hypertensive type 2 diabetes patients with microalbuminuria randomized to at least 2-year VeraTran (verapamil/trandolapril 180 mg/2 mg daily) or trandolapril (2 mg daily, identical image) treatment." | 9.15 | Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. ( Bossi, A; Chiurchiu, C; Cravedi, P; Ene-Iordache, B; Fassi, A; Gaspari, F; Gherardi, G; Iliev, IP; Ilieva, A; Motterlini, N; Perna, A; Remuzzi, G; Rubis, N; Ruggenenti, P; Trevisan, R, 2011) |
| "In INternational VErapamil-trandolapril STudy, 22,576 CAD patients with hypertension (mean age 66 years) were randomized to verapamil-SR or atenolol-based strategies and followed for 2." | 9.14 | Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis. ( Bangalore, S; Champion, A; Franklin, SS; Mancia, G; Messerli, FH; Pepine, CJ, 2009) |
| "In hypertensive patients with prior MI, a verapamil-SR-based strategy was equivalent to a beta-blocker-based strategy for blood pressure control and prevention of cardiovascular events, with greater subjective feeling of well-being and a trend toward lower incidence of angina pectoris and stroke in the verapamil-SR-based group." | 9.13 | Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. ( Bacher, PH; Bangalore, S; Champion, A; Cohen, JD; Kowey, P; Mancia, G; Messerli, FH; Pepine, CJ; Sleight, P; Zhou, Q, 2008) |
| " We sought to determine if the CYP3A5 genetic polymorphisms were associated with level of blood pressure (BP), risk of hypertension (HTN), and the antihypertensive response to verapamil." | 9.12 | Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil. ( Cooper-DeHoff, RM; Gong, Y; Johnson, JA; Katz, DA; Langaee, TY; Pepine, CJ; Yarandi, HN, 2007) |
| "To use a nonparametric approach involving longitudinal splines to model the baseline blood pressure profile and investigate the impact of this modelling on the pharmacodynamic analysis for verapamil in patients with angina or hypertension." | 9.11 | Pharmacodynamics of controlled release verapamil in patients with hypertension: an analysis using spline functions. ( Aarons, L; Baxter, C; Gupta, S, 2004) |
| " Aim of the study was treatment of hypertension in patients with DM of both types by the ACE inhibitor trandolapril in dose of 2-4 mg, possibly in combination with the calcium channel blocker verapamil--240 mg." | 9.10 | [Treatment of hypertension in diabetics with trandolapril, an angiotensin converting enzyme inhibitor--a multicenter study]. ( Cech, F; Rosolová, H; Sefrna, F, 2002) |
| "To evaluate the clinical efficacy and safety of a new antihypertensive drug combination of trandolapril/verapamil compared to monotherapy with verapamil or trandolapril, in patients with mild to moderate primary hypertension." | 9.09 | Efficacy and safety of a new long-acting drug combination, trandolapril/verapamil as compared to monotherapy in primary hypertension. Swedish TARKA trialists. ( Andrup, M; Karlberg, BE; Odén, A, 2000) |
| "The objective of this randomised open, active controlled, cross-over study was to evaluate the effect of a fixed combination of verapamil SR/trandolapril compared to captopril/hydrochlorothiazide on serum lipids, lipoproteins, and other metabolic and electrolyte parameters in patients with essential hypertension." | 9.09 | Evaluation of the effects of fixed combinations of sustained-release verapamil/trandolapril versus captopril/hydrochlorothiazide on metabolic and electrolyte parameters in patients with essential hypertension. ( Cifková, R; Compagnone, D; Hejl, Z; Nakov, R; Novozámská, E; Petrzílková, Z; Poledne, R; Stávek, P, 2000) |
| "To evaluate the efficacy and safety of a novel delivery system of physiologic pattern release (PPR)-verapamil administered nocturnally to patients with stages I and II hypertension using ambulatory blood pressure (BP) monitoring, we performed a multicenter (17 centers), double-blind, randomized, placebo-controlled, parallel-group trial with placebo and 120, 180, 360, and 540 mg of verapamil in 287 randomized patients." | 9.08 | Nocturnal dosing of a novel delivery system of verapamil for systemic hypertension. Verapamil Study Group. ( Anders, RJ; Black, HR; MacIntyre, JM; Sica, DA; White, WB, 1995) |
| "The efficacy and safety of a low dose (120 mg) of a sustained-release capsule formulation of verapamil administered once daily in the treatment of 42 patients with mild hypertension were assessed in this clinical trial." | 9.08 | Treatment of mild hypertension with low once-daily doses of a sustained-release capsule formulation of verapamil. ( Davis, PJ; Fagan, TC; Ferdinand, KC; Levine, JH; Topmiller, MJ, 1995) |
| "To compare and contrast the antihypertensive efficacy of an angiotensin-converting enzyme (ACE) inhibitor to a calcium antagonist, 88 and 90 patients with essential hypertension were randomly assigned to receive moexipril and verapamil, respectively." | 9.08 | Moexipril in the treatment of mild to moderate essential hypertension: comparison with sustained-release verapamil. ( Abernethy, DR; Fox, AA; Stimpel, M, 1995) |
| "The VHAS (Verapamil-Hypertension Atherosclerosis Study) Investigators entered 1464 patients with essential hypertension and blood pressure (BP) values > or = 160 mmHg systolic and 95 mmHg diastolic (DBP) but excluded those with a DBP > or = 115 mmHg, and those with diabetes mellitus or previous myocardial infarction or cerebrovascular episodes." | 9.08 | Vascular complications in hypertension: the VHAS study. Verapamil-Hypertension Atherosclerosis Study. ( Zanchetti, A, 1995) |
| " To test this hypothesis, thirty patients with essential hypertension were placed on 240 mg once daily of a slow release verapamil preparation for a period of one month following a one month run-in period." | 9.08 | Parathyroid hypertensive factor predicts efficacy in the treatment of essential hypertension with verapamil. ( Hamilton, PG; Lewanczuk, RZ, 1996) |
| "The cardiovascular effects of a combination of trandolapril and verapamil were evaluated in 14 patients with mild to moderate essential hypertension." | 9.08 | Cardiovascular effects of a trandolapril/verapamil combination in patients with mild to moderate essential hypertension. ( Aepfelbacher, FC; Messerli, FH; Michalewicz, L; Nunez, E, 1997) |
| "In a placebo-controlled study of 13 subjects with systemic hypertension, sustained-release verapamil reduced the morning surge in systolic pressure by 10." | 9.08 | Effect of sustained-release Verapamil on the morning systemic arterial pressure surge during daily activity in patients with systemic hypertension. ( Gebara, OC; McKenna, CA; Muller, JE; Rosito, GA; Solomon, HS; Tofler, GH, 1997) |
| "We assessed the efficacy of monotherapy with trandolapril, an angiotensin converting enzyme (ACE) inhibitor, and of verapamil slow-release (SR), a calcium antagonist, each in a range of three doses as monotherapy, and in the nine possible combinations of therapy in patients with stage I to III diastolic hypertension." | 9.08 | Fixed-dose combination therapy with trandolapril and verapamil SR is effective in primary hypertension. Trandolapril Study Group. ( DeQuattro, V; Lee, D, 1997) |
| "In arterial hypertension, MBF during pacing tachycardia and after dipyridamole is impaired." | 9.08 | Comparative effects of enalapril and verapamil on myocardial blood flow in systemic hypertension. ( Gallopin, M; Giorgetti, A; L'Abbate, A; Marabotti, C; Neglia, D; Palombo, C; Parodi, O; Sambuceti, G; Simonetti, I, 1997) |
| "The regression of left ventricular hypertrophy in hypertensive patients was evaluated in a multicenter study with a combination therapy of verapamil 120 mg and captopril 25 mg given once or twice daily." | 9.08 | Treatment of left ventricular hypertrophy in hypertensive patients with a combination of verapamil and captopril--a multicenter study. ( Brandt, D; Hofmann, R; Magometschnigg, D; Sihorsch, K; Stoschitzky, K; Zangeneh, M; Zenker, G, 1997) |
| "A multiple drug regimen consisting of trandolapril, verapamil and hydrochlorothiazide (HCTZ) were sequentially added in an open-label evaluation of patients with severe hypertension." | 9.08 | The treatment of severe hypertension with trandolapril, verapamil, and hydrochlorothiazide. Trandolapril/Verapamil Multicenter Study Group. ( Novrit, BA; Punzi, HA, 1997) |
| "The Verapamil in Hypertension and Atherosclerosis Study (VHAS) is a prospective randomized study the objective of which was to compare the long-term effects of verapamil and chlorthalidone on the blood pressure, clinical safety, and the progression/regression of carotid wall lesions in members of a large population of hypertensive patients." | 9.08 | Clinical results of the Verapamil inHypertension and Atherosclerosis Study. VHAS Investigators. ( Dal Palù, C; Leonetti, G; Magnani, B; Pessina, A; Rosei, EA; Zanchetti, A, 1997) |
| "To investigate the dose-response relationship and contribution of verapamil SR and trandolapril given in combination once a day for the treatment of essential hypertension." | 9.08 | Verapamil SR and trandolapril combination therapy in hypertension--a clinical trial of factorial design. German Hypertension Study Group. ( Compagnone, D; Scholze, J; Zilles, P, 1998) |
| "A total of 27,000 CAD patients with hypertension will be randomized at 1,500 primary care sites to receive either a calcium antagonist-based (verapamil) or beta-blocker/diuretic-based (atenolol/hydrochlorothiazide) antihypertensive care strategy." | 9.08 | Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension. ( Conlon, M; Cooper-DeHoff, R; Handberg-Thurmond, E; Marks, RG; Pepine, CJ; Volkers, P; Zellig, P, 1998) |
| "The TEAM trial investigated the effectiveness and tolerance of a fixed combination of the ACE inhibitor and calcium channel blocker (2 mg trandolapril and 180 mg verapamil retard) (preparation Tarka) in an open multicentre prospective study of treatment of moderately severe hypertension (diastolic pressure at the end of the two-week wash-out period 100-115 mm Hg)." | 9.08 | [The TEAM study--a study of the effectiveness and tolerance of treatment of essential hypertension with a fixed combination of trandolapril and verapamil]. ( Dzúrik, R; Widimský, J, 1998) |
| " The present paper reports the principal results of the ultrasound substudy of the randomized, prospective, controlled, Verapamil in Hypertension and Atherosclerosis Study (VHAS)." | 9.08 | The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. ( Dal Palù, C; Leonetti, G; Magnani, B; Pessina, A; Rosei, EA; Zanchetti, A, 1998) |
| "Forty patients with mild to moderate hypertension were divided into two groups, 20 patients (group A) received 240 mg verapamil and 20 patients (group B) received 20 mg nitrendipine daily during the first six weeks." | 9.07 | Combination therapy with verapamil and nitrendipine in patients with hypertension. ( Kiliçcioğlu, B; Nalbantgil, I; Onder, R; Türkoğlu, C, 1993) |
| " The Verapamil in Hypertension Atherosclerosis Study is an ongoing multicentre randomised double-blind parallel group trial comparing the antihypertensive efficacy of verapamil SR 240 mg/day with that of chlorthalidone 25 mg/day in 1464 patients with essential hypertension aged 40 to 65 years." | 9.07 | Preliminary clinical experience with calcium antagonists in atherosclerosis. Verapamil in Hypertension Atherosclerosis Study Investigators. ( Dal Palù, C; Magnani, B; Zanchetti, A, 1992) |
| " The Verapamil in Hypertension Atherosclerosis Study (VHAS) is an ongoing randomized trial, comparing the antihypertensive efficacy of verapamil 240 mg SR with chlorthalidone 25 mg in 1,464 essential hypertensives aged 40-65 years." | 9.07 | Atherosclerosis and calcium antagonists: the VHAS. The Verapamil-Hypertension Atherosclerosis Study (VHAS) Investigators. ( Dal Palù, C; Magnani, B; Zanchetti, A, 1992) |
| "In this double-blind, parallel, multicenter study, sustained-release (SR) preparations of 2 calcium antagonists, nicardipine and verapamil, were compared for the treatment of mild to moderate systemic hypertension." | 9.07 | Comparison of sustained-release formulations of nicardipine and verapamil for mild to moderate systemic hypertension. ( Friday, KJ; Frishman, WH; Gradman, AH; Kaihlanen, PM; Wong, SC, 1992) |
| "Verapamil, the first calcium-channel blocker to be introduced for clinical use, is a major drug used for the treatment of systemic hypertension." | 9.07 | Sustained-release verapamil formulations for treating hypertension. ( Frishman, WH; Lazar, EJ, 1992) |
| "In 80 patients with moderate hypertension the effects of nisoldipine 10 mg b." | 9.07 | The effects of nisoldipine, diltiazem, nifedipine, and verapamil on hemodynamic parameters and red blood cells-platelet interactions in patients with arterial hypertension. ( Belousov, Y; Kushnaryov, V, 1991) |
| "The efficacy and tolerability of hydrochlorothiazide, sustained-release verapamil, and their combination was compared in patients with mild to moderate hypertension." | 9.07 | Hydrochlorothiazide and verapamil in the treatment of hypertension. The Verapamil Versus Diuretic (VERDI) Trial Research Group. ( Distler, A; Holzgreve, H; Michaelis, J; Philipp, T; Wellek, S, 1991) |
| "A randomised, double-blind, double-placebo trial compared the efficacy and safety/acceptability of sustained release verapamil and of captopril in two parallel groups of patients with mild to moderate hypertension." | 9.07 | [Comparison of the efficacy and tolerability of sustained-release verapamil and captopril in mild to moderate essential arterial hypertension]. ( Galey-Arcangioli, C; Imbs, JL; Maarek-Charbit, M; Stephan, D; Welsch, M, 1991) |
| "This double-blind, double-dummy, randomized clinical trial, conducted in elderly patients with mild hypertension, compared adherence to treatment, efficacy, side effects, and quality of life during treatment with transdermal clonidine versus oral sustained-release verapamil (verapamil-SR)." | 9.07 | Therapeutic adherence in the elderly: transdermal clonidine compared to oral verapamil for hypertension. ( Burris, JF; Cook, ME; Papademetriou, V; Wallin, JD; Weidler, DJ, 1991) |
| "The antihypertensive efficacy and tolerability of enalapril (E) and slow-release verapamil (V) were compared in a 2-month double-blind cross-over study in 22 patients with mild to moderate essential hypertension." | 9.07 | Antihypertensive efficacy and tolerability of enalapril and slow-release verapamil in essential hypertension: a double-blind, cross-over study. ( Fagher, B; Henningsen, NC; Hulthén, UL; Katzman, P; Thulin, T, 1991) |
| "Supine office blood pressures (SOBP) and 24-hour automated ambulatory blood pressure monitorings (AABPM) showed blood pressure reductions from a stable baseline to active treatment with 120-, 240-, and 480-mg doses of a new verapamil QD capsule (solid-spheroidal-oral once-daily drug-absorption system: (SODAS) in patients with mild-to-moderately severe (diastolic blood pressures 95-119 mm Hg) essential hypertension." | 9.07 | Once-daily verapamil in the treatment of mild-to-moderate hypertension: a double-blind placebo-controlled dose-ranging study. ( Bottini, PB; Carr, AA; Devane, JG; Fisher, LD; O'Brien, DE; Prisant, LM; Rhoades, RB, 1991) |
| "Seventeen adult patients with moderate and stable bronchial asthma and established essential hypertension (WHO I or II) were evaluated in a randomized, double-blind, crossover study of the effects of captopril (50-100 mg/day) and verapamil (160-240 mg/day) on blood pressure, orthostatic reactions, respiratory function, and asthmatic symptoms." | 9.06 | Effects of captopril on blood pressure and respiratory function compared to verapamil in patients with hypertension and asthma. ( Ahonen, A; Riska, H; Salorinne, Y; Sovijärvi, AR; Stenius-Aarniala, B; Sundberg, S, 1990) |
| "The arterial vasodilator properties of the dihydropyridine calcium antagonist amlodipine were compared with the effects of vascular muscle cyclic guanosine monophosphate production by sodium nitroprusside and with the effects of a combined infusion of amlodipine and the nondihydropyridine calcium antagonist verapamil in 8 untreated patients with primary hypertension." | 9.06 | Arterial vasodilator effects of the dihydropyridine calcium antagonist amlodipine alone and in combination with verapamil in systemic hypertension. ( Bühler, FR; Erne, P; Kiowski, W; Linder, L, 1990) |
| "The renal, metabolic and antihypertensive effects of enalapril (E) and slow-release verapamil (V) were compared in a 2-month double-blind crossover trial in 22 patients with newly discovered essential hypertension." | 9.06 | Antihypertensive and renal effects of enalapril and slow-release verapamil in essential hypertension. A double-blind, randomized study. ( Fagher, B; Henningsen, N; Hulthén, L; Katzman, P; Thulin, T, 1990) |
| "One hundred sixty patients with mild to moderate essential hypertension entered this double-blind parallel group comparison of amlodipine, verapamil, and placebo." | 9.06 | Comparison of amlodipine and verapamil in the treatment of mild to moderate hypertension. ( Lorimer, AR; Smedsrud, T; Tyler, HM; Walker, P, 1988) |
| "The blood-pressure (BP)-lowering efficacy of sustained-release verapamil, using both clinic and ambulatory measurements, was assessed in patients with essential hypertension." | 9.06 | The efficacy and duration of action of sustained-release verapamil in essential hypertension. ( Atkins, N; Latham, AN; McCormack, PM; Mee, F; O'Brien, ET; O'Malley, K, 1989) |
| "9% female; aged 17-89 years) with mild, moderate, or severe hypertension, the antihypertensive efficacy and in particular the tolerability of verapamil slow-release (SR) 240 mg (Isoptin RR) were studied." | 9.06 | Efficacy and safety of verapamil SR 240 mg in essential hypertension: results of a multicentric phase IV study. ( Pfennigsdorf, G; Schumacher, A; Sosna, J; Speders, S, 1989) |
| "We assessed the pharmacokinetics and pharmacodynamics of immediate-release (IR) and slow-release (SR) verapamil in Hispanic patients with mild to moderate essential hypertension." | 9.06 | Comparative efficacy, safety, and kinetics of immediate- and slow-release verapamil in hispanic patients with essential hypertension. ( Cubeddu, LX; Faggin, BM; Fuenmayor, NT, 1989) |
| "A close comparative study of the hypotensive effects of verapamil and chlorthalidone was carried out on 60 patients affected with mild essential hypertension showing systemic." | 9.06 | [Effects of a calcium antagonist, verapamil, on mild-moderate essential arterial hypertension]. ( Hergueta García de Guadiana, G; Paumard Fraguas, A, 1989) |
| "To compare the efficacy and tolerability of hydrochlorothiazide, sustained release verapamil, and their combination in patients with mild to moderate hypertension." | 9.06 | Verapamil versus hydrochlorothiazide in the treatment of hypertension: results of long term double blind comparative trial. Verapamil versus Diuretic (VERDI) Trial Research Group. ( Distler, A; Holzgreve, H; Michaelis, J; Philipp, T; Wellek, S, 1989) |
| "This is a double blind parallel group comparison in patients with mild-moderate hypertension, of amlodipine, verapamil and placebo." | 9.06 | A comparison of amlodipine, verapamil and placebo in the treatment of mild to moderate hypertension. Amlodipine Study Group. ( Lorimer, AR; Smedsrud, T; Tyler, HM; Walker, P, 1989) |
| "Quality of life was evaluated in a four-month randomised double-blind trial of verapamil compared with propranolol in the treatment of hypertension in 94 patients in the UK." | 9.06 | The effects of verapamil and propranolol on quality of life in hypertension. ( Bulpitt, CJ; Chester, PC; Fletcher, AE; Hawkins, CM; Latham, AN; Pike, LA, 1989) |
| "A total of 1337 patients with mild to moderate essential hypertension were included in an open, multicentre trial to assess the response rate to the diuretic etozolin (200 mg once a day) and to verify whether the addition of the calcium antagonist verapamil (120 mg twice a day) in non-responders may have a favourable effect." | 9.06 | Etozolin monotherapy and combination with verapamil in essential hypertension. ( Agabiti-Rosei, E; Muiesan, G, 1989) |
| "The antihypertensive effect of verapamil administered either two or three times daily was compared in a double blind, cross over study in 15 patients with mild to moderate essential hypertension." | 9.06 | Comparisons of verapamil administration twice and three times daily in hypertension. ( Gordin, A; Jounela, AJ; Ottoila, P; Salmela, PI; Salo, H, 1988) |
| "The efficacy, safety and toleration of sustained release verapamil (Securon SR, Knoll) and long acting propranolol (Inderal LA, ICI) in the treatment of mild to moderate hypertension were compared in a randomized, double-blind, parallel group study." | 9.06 | Verapamil SR and propranolol LA: a comparison of efficacy and side effects in the treatment of mild to moderate hypertension. ( Bochsler, JA; Chester, PC; Latham, AN; Simmons, RL; Ward, PJ, 1988) |
| "The long-term safety and efficacy of twice-daily sustained-release verapamil were assessed compared to thrice-daily immediate-release verapamil in 25 patients with mild to moderate systemic hypertension." | 9.06 | Long-term safety and efficacy comparison of immediate-release and sustained-release oral verapamil in systemic hypertension. ( Charlap, S; Eisen, G; Frishman, WH; Strom, JA, 1987) |
| "To compare responses of blood pressure to the calcium antagonist verapamil and the beta blocker metoprolol in black compared with white diabetics with hypertension and to monitor urinary albumin excretion in relation to fall in blood pressure." | 9.06 | Treating hypertension in black compared with white non-insulin dependent diabetics: a double blind trial of verapamil and metoprolol. ( Anderson, NM; Cruickshank, JK; Jepson, E; Wadsworth, J; Young, SM, 1988) |
| "A double blind, double dummy, randomized cross-over pharmacokinetic study comparing verapamil 120 mg, conventional tablets administered twice daily and verapamil 240 mg sustained release tablets once daily was performed in 12 patients with essential hypertension." | 9.06 | Pharmacokinetics of verapamil and norverapamil in patients with hypertension: a comparison of oral conventional and sustained release formulations. ( Jørgensen, NP; Walstad, RA, 1988) |
| "Plasma verapamil concentration was correlated with serial electrocardiographic P-R intervals in patients with essential hypertension receiving immediate-release (80 to 120 mg three times a day) or sustained-release (240 mg daily) verapamil." | 9.06 | Correlation between verapamil plasma concentration and P-R prolongation in essential hypertension. ( Carlson, CA; Schirger, A; Sheps, SG; Shub, C; Wolf, MK; Zachariah, PK, 1988) |
| "The effects of verapamil and bendrofluazide used singly and in combination were examined in patients with primary hypertension in a patient blind, partly observer blind placebo controlled study of parallel group design; there were ten subjects in each arm of the trial." | 9.06 | Verapamil and bendrofluazide in the treatment of hypertension: a controlled study of effectiveness alone and in combination. ( Benjamin, N; Phillips, RJ; Robinson, BF, 1988) |
| "To evaluate the hypotensive efficacy of Verapamil alone and combined with diuretic, in the treatment of essential hypertension in elderly patients, we studied 54 patients, mean age 67." | 9.06 | [Hypotensive efficacy of verapamil alone and in combination with a diuretic in the treatment of essential hypertension in geriatric patients]. ( Achilli, L; D'Amico, F; Latini, R; Lombi, V; Pierandrei, G, 1987) |
| " Exchangeable sodium, blood volume, plasma norepinephrine, renin, aldosterone, pressor responsiveness to norepinephrine, heart rate responses to isoproterenol, and lipid metabolism were studied in 15 patients with essential hypertension after 8 weeks of treatment with verapamil (348 +/- 68 (SD) mg/day)." | 9.06 | Cardiovascular effects of verapamil in essential hypertension. ( Beretta-Piccoli, C; Leonardi, L; Marone, C; Riesen, W; Städler, P; Ziegler, W, 1987) |
| "The antihypertensive effect and possible adverse effects of verapamil were assessed in 30 Thai patients with mild to moderate hypertension." | 9.06 | A multicenter study of verapamil in systemic hypertension in Thailand. ( Intharakoses, A; Jeam-Anukulkit, N; Ngarmukos, P; Nontakanun, S; Polsi, Y; Sansanayudth, P; Sitthisook, S; Sriratanaban, A; Tanprasert, P, 1986) |
| "In a series of controlled studies for periods of 4 to 6 weeks comprising 103 patients altogether, and in 1 long-term trial for 1 year, various dosages of instant and sustained-release verapamil were administered in the treatment of mild and moderate essential hypertension." | 9.06 | Instant and sustained-release verapamil in the treatment of essential hypertension. ( Hals, O; Lauve, O; Midtbø, K; Storstein, L; van der Meer, J, 1986) |
| " Verapamil is such a drug, but its clinical role in the management of hypertension is not clear." | 9.06 | Twice-daily verapamil for hypertension: a comparison with propranolol. ( Gould, BA; Hornung, RS; Jones, RI; Raftery, EB; Sonecha, T, 1986) |
| "The antihypertensive effect of a new sustained-release matrix formulation of verapamil 200 mg was investigated in a dose-response study in patients with mild to moderate essential hypertension." | 9.06 | Sustained release verapamil in hypertension. Results from a noninvasive ambulatory blood pressure monitoring and a clinical study. ( Gordin, A; Koistinen, A; Nissinen, A; Sundberg, S; Tuomilehto, J, 1986) |
| "The study was carried out in 24 patients with mild to moderate essential hypertension to assess the antihypertensive efficiency and tolerability of a new sustained-release formulation of verapamil (tablets containing 240 mg)." | 9.06 | A new sustained-release formulation of verapamil in the treatment of hypertension. ( Hals, O; Lauve, O; Midtbo, KA, 1986) |
| "The effects of graded doses of verapamil were compared with those of a combination of atenolol and hydralazine in a double-blind, randomised, crossover trial in 16 patients with essential hypertension." | 9.06 | Verapamil in essential hypertension: a comparison with atenolol plus hydralazine. ( Bailey, BP; Duggin, GG; Fletcher, PJ; Hall, B; Horvath, JS; Tiller, D, 1987) |
| " Therefore, the effects of 4-week treatment periods with verapamil and propranolol on metabolic parameters during an endurance bicycle ergometer test were studied in eight patients with mild to moderate essential hypertension." | 9.06 | Metabolic effects of verapamil and propranolol during submaximal endurance exercise in patients with essential hypertension. ( Böhm, RO; Petri, J; Rahn, KH; van Baak, MA, 1987) |
| "The antihypertensive effects of oral regular and slow-release verapamil, a calcium-channel blocking agent, were evaluated in 22 patients with mild to moderate hypertension (sitting diastolic blood pressure [DBP] 95 to 112 mm Hg)." | 9.06 | Verapamil and 24-hour ambulatory blood pressure monitoring in essential hypertension. ( O'Brien, PC; Schirger, A; Sheps, SG; Simpson, KK; Spiekerman, RE; Zachariah, PK, 1986) |
| "The relative efficacies of oral verapamil, a calcium-entry blocking drug, and propranolol, a beta-adrenergic blocking drug, were compared in 12 patients who had both stable angina pectoris and mild to moderate systemic hypertension, using a placebo-controlled, double-blind, randomized crossover protocol." | 9.05 | Comparison of oral propranolol and verapamil for combined systemic hypertension and angina pectoris. A placebo-controlled double-blind randomized crossover trial. ( Frishman, WH; Klein, NA; Klein, P; LeJemtel, TH; Pollack, S; Roth, S; Sonnenblick, EH; Strair, R; Strom, JA; Tawil, R; Wong, B, 1982) |
| "The aim of this study was to investigate and compare the effects of two calcium antagonist drugs, verapamil (VER) and nifedipine (NIF), on blood pressure (BP), heart rate (HR), plasma catecholamines (pCA), renin (PRA), plasma aldosterone (pALD), and plasma volume (PV) in a group of patients with mild to moderate essential hypertension." | 9.05 | Antihypertensive and humoral effects of verapamil and nifedipine in essential hypertension. ( Agabiti-Rosei, E; Alicandri, CL; Beschi, M; Castellano, M; Corea, L; Fariello, R; Muiesan, G; Romanelli, G, 1982) |
| "In a double-blind, cross-over study for 6 weeks that included 28 patients with essential hypertension, WHO stage I-II, the hypotensive action of verapamil (160 mg thrice daily) was compared with nifedipine (20 mg slow release twice daily)." | 9.05 | Verapamil compared with nifedipine in the treatment of essential hypertension. ( Hals, O; Midtbø, K; van der Meer, J, 1982) |
| " Their clinical place in the management of hypertension has yet to be clearly defined, and thus we have performed an open crossover trial to compare the 24-hour profiles of blood pressure reduction after chronic therapy with propranolol and verapamil." | 9.05 | Propranolol versus verapamil for the treatment of essential hypertension. ( Gould, BA; Hornung, RS; Jones, RI; Raftery, EB; Sonecha, T, 1984) |
| "Renal plasma flow, glomerular filtration rate plasma angiotensin II, aldosterone and arginine vasopressin, free water clearance, blood pressure and body weight in 11 patients with mild to moderate hypertension were determined at the end of consecutive 6 week periods of administration of placebo and verapamil up to 120 mg t." | 9.05 | Effect of verapamil on renal plasma flow, glomerular filtration rate and plasma angiotensin II, aldosterone and arginine vasopressin in essential hypertension. ( Danielsen, H; Pedersen, EB; Sørensen, SS; Thomsen, OO, 1985) |
| "In well designed studies in patients with mild to moderate hypertension, combinations of the sustained-release (SR) formulation of the nondihydropyridine calcium channel antagonist verapamil 120 to 240 mg/day and the ACE inhibitor trandolapril 0." | 8.81 | Fixed combination trandolapril/verapamil sustained-release: a review of its use in essential hypertension. ( Curran, MP; Muijsers, RB; Perry, CM, 2002) |
| "In all patients combined, the incidence of constipation (13% vs 2%), dizziness (6% vs 2%), and back pain (3% vs 1%) was higher in patients treated with COER verapamil than with placebo." | 8.81 | Safety of controlled-onset extended-release verapamil in middle-aged and older patients with hypertension and coronary artery disease. ( Anders, RJ; Black, HR; Elliott, WJ; Johnson, MF; White, WB, 2001) |
| "To evaluate the effects of COER-verapamil on circadian blood pressure (BP) and heart rate in African-American patients with hypertension." | 8.80 | Effects of the chronotherapeutic delivery of verapamil on circadian blood pressure in African-American patients with hypertension. ( Black, HR; Fakouhi, TD; Johnson, MF; White, WB, 1999) |
| "Various doses of verapamil, using the conventional and sustained release formulations, have been administered for the treatment of mild or moderate hypertension in different controlled studies for periods of 4-6 weeks, involving a total of 103 patients, and in one long-term trial for 1 year in 12 patients." | 8.77 | Studies on verapamil in the treatment of essential hypertension: a review. ( Hals, O; Lauve, O; Midtbø, K; Storstein, L; van der Meer, J, 1986) |
| " Medical history was notable for hypertension, hyperlipidaemia, type 2 diabetes, and a recently diagnosed SARS-CoV-2 (COVID-19) infection for which she was prescribed ritonavir-boosted nirmatrelvir (Paxlovid) two days before the presentation." | 8.31 | Pharmacokinetic interaction between verapamil and ritonavir-boosted nirmatrelvir: implications for the management of COVID-19 in patients with hypertension. ( Haque, OI; Hussain, S; Mahar, S; Sloane, P, 2023) |
| "Male Wistar rats were submitted to two kidneys, one clip (2K1C) model of hypertension or sham surgery and were treated with verapamil (VRP, 8 mg/kg/bid) by gavage from the second to tenth week post-surgery." | 7.96 | Verapamil decreases calpain-1 and matrix metalloproteinase-2 activities and improves hypertension-induced hypertrophic cardiac remodeling in rats. ( Blascke de Mello, MM; Castro, MM; Fazan, R; Mendes, AS; Neto-Neves, EM; Omoto, ACM; Parente, JM; Tanus-Santos, JE, 2020) |
| "to compare efficacy of verapamil and amlodipine in treatment of chronic heart failure (CHF) with preserved left ventricular (LV) ejection fraction (EF) in patients with hypertensive disease (HD)." | 7.83 | [Comparison of Verapamil and Amlodipine for Treatment of Chronic Heart Failure With Preserved Left Ventricular Ejection Fraction in Patients With Hypertensive Disease]. ( Kanorskii, SG; Sereda, AF, 2016) |
| "Renal failure patients with baseline mild hyperkalaemia are particularly liable to bradyarrhythmias with SR verapamil." | 7.78 | Junctional bradycardia with verapamil in renal failure--care required even with mild hyperkalaemia. ( Al-Mutairi, S; Aldabie, G; El Sayed, A; Hegazi, MO, 2012) |
| " We retrospectively analyzed the International Verapamil SR-Trandolapril Study, which randomized coronary artery disease patients with hypertension to either verapamil SR- or atenolol-based treatment strategies, focusing on characteristics and outcomes of 6166 previously revascularized patients compared with 16 410 nonrevascularized patients." | 7.75 | Characteristics and outcomes of revascularized patients with hypertension: an international verapamil SR-trandolapril substudy. ( Aranda, JM; Champion, A; Cooper-Dehoff, RM; Denardo, SJ; Gaxiola, E; Gong, Y; Handberg, EM; Messerli, FH; Pepine, CJ; Zhou, Q, 2009) |
| "we observe the efficacy of verapamil and amlodipine administered simultaneously in the medical treatment of endogenous hyperinsulinemic hypoglycemia." | 7.73 | [Successful pharmacological treatment of hyperinsulinemic hypoglycemia with verapamil and amlodipine--case report]. ( Owecki, M; Sowiński, J, 2005) |
| " Combination therapy of valsartan with either amlodipine or verapamil was equally effective in reducing blood pressure to valsartan monotherapy (valsartan + amlodipine 129 +/- 4 valsartan + verapamil 133 +/- 6 mmHg;) but was not as effective at reducing albuminuria." | 7.72 | Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin. ( Allen, TJ; Cao, Z; Cooper, ME; Davis, BJ; de Gasparo, M; Kawachi, H, 2003) |
| "To study the dose-ranging population pharmacokinetics of controlled release verapamil in healthy subjects and patients with angina or hypertension." | 7.71 | Pharmacokinetics of controlled-release verapamil in healthy volunteers and patients with hypertension or angina. ( Aarons, L; Gupta, S; Ho Pl, PL; Modi, NB; Sathyan, G, 2002) |
| " In young Dahl/S rats, an angiotensin-converting enzyme inhibitor, imidapril, attenuated the development of proteinuria accompanied by a decrease in blood pressure." | 7.70 | Involvement of angiotensin II in development of spontaneous nephrosis in Dahl salt-sensitive rats. ( Fujimura, H; Nishiyama, S; Ohmachi, Y; Okumura, F; Toriumi, W; Yoneda, H, 1998) |
| "Ninety patients, 50 males and 40 females, and their ages ranged between 42 and 70 years, with severe hypertension were treated by either sublingual verapamil tablets 40 mg (30 patients) or 80 mg (30 patients) or sublingual nifedipine capsules 10 mg (30 patients)." | 7.70 | Efficacy of sublingual verapamil in patients with severe essential hypertension: comparison with sublingual nifedipine. ( Al-Waili, NS; Hasan, NA, 1999) |
| "The authors examined the efficacy and safety of the combination of verapamil and nifedipine in the control of hypertension." | 7.69 | Verapamil and nifedipine in combination for the treatment of hypertension. ( Bottini, PB; Carr, AA; Kaesemeyer, WH; Prisant, LM, 1994) |
| "To describe a patient with asymptomatic bronchial asthma and hypertension who developed an acute asthma attack after receiving sustained-release verapamil." | 7.69 | Acute asthma associated with sustained-release verapamil. ( Ben-Noun, L, 1997) |
| "We sought to characterize the effects of the nonselective Ca2+ channel antagonist, verapamil, and the vascular-selective Ca2+ channel antagonist, felodipine, on obese, hypertensive, heart failure-prone, female SHHF/Mcc-fa(cp) rats." | 7.69 | Verapamil accelerates the transition to heart failure in obese, hypertensive, female SHHF/Mcc-fa(cp) rats. ( Altschuld, RA; Hensley, J; Hoepf, TM; Hohl, CM; McCune, SA; Park, S; Radin, MJ, 1997) |
| " This article describes the case of a patient affected by pheochromocytoma in whom multiple organ failure developed after contemporary administration of ergotamine, caffeine, and nimesulide." | 7.69 | Pheochromocytoma crisis caused by contemporary ergotamine, caffeine, and nimesulide administration. ( Bartoli, P; Bonechi, F; Brandinelli, A; Del Rosso, A; Fradella, G; Ieri, A; Maioli, M; Mannelli, M; Mazza, F; Russo, L; Sansoni, M; Zipoli, A, 1997) |
| "Thirty-three hypertensive patients with left ventricular hypertrophy were treated with slow-release verapamil for 1 year." | 7.69 | [Study of the mechanism of regression of left ventricular hypertrophy in hypertension treated with slow-release verapamil]. ( Li, G; Sun, M; Zhou, H, 1997) |
| "We evaluated the effect of verapamil therapy on left ventricular hypertrophy and left ventricular diastolic function in 13 patients with mild to moderate hypertension." | 7.68 | Improvement in left ventricular hypertrophy and left ventricular diastolic function following verapamil therapy in mild to moderate hypertension. ( Conte, D; Douste-Blazy, MY; Galinier, F; Granier, P; Tredez, P, 1990) |
| " (160 mg, n = 9) on the pressor effect of the unselective alpha-adrenergic agonist noradrenaline, as well as on 3H-yohimbine binding to platelet alpha 2-adrenoceptors was studied in patients with essential hypertension." | 7.67 | Effect of nifedipine and verapamil on alpha-receptor-activation in patients with essential hypertension. ( Distler, A; Fritschka, E; Kribben, A; Lenz, T; Philipp, T; Schudrowitsch, L, 1984) |
| "The effect of verapamil on different metabolic parameters has been studied after changing the treatment of hypertension from hydrochlorothiazide to verapamil monotherapy." | 7.67 | Metabolic parameters after changing from hydrochlorothiazide to verapamil treatment in hypertension. ( Gordin, A; Lehtonen, A, 1984) |
| "The effect of treatment with verapamil on cell sodium transport was studied in the leucocytes of patients with essential hypertension." | 7.67 | Reversal by verapamil of defect in sodium transport in leucocytes in essential hypertension. ( Gray, HH; Hilton, PJ; MacGregor, GA; Markandu, ND; Poston, L; Smith, SJ, 1984) |
| "Twenty-four subjects with mild to moderate essential hypertension completed this 9-wk parallel, randomized, double-blind study of the antihypertensive effects of verapamil (V) (240 to 480 mg%) and propranolol (P) (120 to 360 mg%)." | 7.67 | Verapamil and propranolol in essential hypertension. ( Cubeddu, LX; Gross, KM; Halperin, AK; Rogers, JF, 1984) |
| "In recent years the calcium antagonist verapamil has been used in the treatment of essential hypertension." | 7.67 | Hemodynamic effects of verapamil in essential hypertension at rest and during exercise. ( Lund-Johansen, P, 1984) |
| "Based on the vasodilator properties of calcium antagonists, verapamil was recently introduced into the treatment of arterial hypertension." | 7.67 | Long-term treatment of arterial hypertension with verapamil. ( Aviram, A; Blum, M; Peer, G; Soferman, G; Wigler, I, 1984) |
| "In order to try and evaluate through what prevailing mechanism verapamil (V) can induce an improvement in left ventricular (LV) diastolic early filling in mild to moderate essential hypertension, 43 properly classified essential hypertensives, aged 41-74 years (mean age 58." | 7.67 | Left ventricular diastolic filling improvement obtained by intravenous verapamil in mild to moderate essential hypertension: a complex effect. ( Bisi, G; Fabbri, G; Franchi, F; Matassi, L; Monopoli, A; Rossi, D; Strazzulla, G, 1989) |
| "This study was carried out to investigate the hypotensive mechanisms of ketanserin and Ca-antagonists (verapamil and diltiazem) in hypertension." | 7.67 | Effects of ketanserin, verapamil and diltiazem on vascular sympathetic nerve activity in hypertension. ( Masuyama, Y; Nishio, I; Tsuda, K, 1989) |
| "Fifty-two cases of hypertension were treated with verapamil." | 7.67 | [Therapeutic effect of verapamil in hypertension: an analysis of 52 cases]. ( Wang, JJ; Wen, ZB; Zong, JL, 1989) |
| "This study was designed to examine the mechanisms that contribute to the chronic hypotensive effects of verapamil during angiotensin II-induced hypertension." | 7.67 | Chronic hypotensive effects of verapamil in angiotensin hypertension are steroid independent. ( Lohmeier, TE; Montani, JP; Rushing, EL; Smith, MJ, 1989) |
| "Arterial blood pressure and central hemodynamic changes were assessed in 44 patients with essential hypertension, uncontrollable by prazosin alone, after propranolol (anaprilin), celiprolol, clonidine (clofelin) or verapamil were added to the treatment schedule." | 7.67 | [Hemodynamic effect of a combination of prazosin with cardiac depressants in the treatment of hypertension]. ( Akopian, LM; Basem, AS; Ivleva, AIa; Krasnobaeva, GM; Moiseev, VS, 1988) |
| "The effects of long-term treatment with verapamil on blood pressure, cardiac hypertrophy and collagen content, collagen concentration and prolyl hydroxylase activity were studied in spontaneously hypertensive rats (SHR)." | 7.67 | Effects of long-term verapamil treatment on blood pressure, cardiac hypertrophy and collagen metabolism in spontaneously hypertensive rats. ( Ruskoaho, HJ; Savolainen, ER, 1985) |
| "Nifedipine was used successfully in nine patients with refractory hypertension and left ventricular hypertrophy who had symptoms of congestive heart failure despite preserved left ventricular systolic function." | 7.67 | Nifedipine in severely hypertensive patients with congestive heart failure and preserved ventricular systolic function. ( Dzau, VJ; Given, BD; Lee, TH; Stone, PH, 1985) |
| "In a prospective, open study 45 patients (mean age fifty-three years) with essential hypertension were treated with verapamil for four to eight years (mean 5." | 7.67 | No metabolic side effects of long-term treatment with verapamil in hypertension. ( Hals, O; Lauve, O; Midtbø, K, 1988) |
| "A single-blind trial was carried out in 18 patients with moderately severe hypertension to investigate the efficacy of the angiotensin-converting enzyme inhibitor captopril in combination with the calcium antagonist verapamil after treatment with captopril alone had failed to achieve satisfactory control." | 7.67 | The combination of verapamil and captopril in the treatment of essential hypertension. ( Heagerty, AM; Swales, JD, 1987) |
| "The calcium antagonist verapamil was infused intravenously in 10 patients with severe postpartum gestational proteinuric hypertension." | 7.67 | Verapamil in the treatment of severe postpartum hypertension. ( Belfort, MA; Moore, PJ, 1988) |
| "Pharmacodynamic and therapeutic studies with a new slow release 240 mg verapamil formulation were performed in a total of 73 patients with essential hypertension (WHO I-II, diastolic greater than or equal to 100 mm Hg)." | 7.67 | Once a day verapamil in essential hypertension. ( Bühler, FR; Follath, F; Ha, HR; Hotz, H; Müller, FB; Schmidlin, O, 1986) |
| "The cardiovascular effects of intravenous verapamil and 3 months of oral administration of a slow-release form of verapamil (verapamil-SR) were studied in 10 patients with mild-to-moderate essential hypertension." | 7.67 | Cardiovascular effects of verapamil in patients with essential hypertension. ( Garavaglia, GE; Messerli, FH; Nunez, BD; Schmieder, RE, 1987) |
| "To characterize the hemodynamic response to exercise and the effects of calcium channel antagonism in hypertensive subjects, invasive exercise hemodynamics were performed in the baseline state after intravenous infusion of verapamil and after 5 to 7 days of oral verapamil in 10 subjects with moderate to severe hypertension." | 7.67 | Exercise hemodynamics and oxygen delivery in human hypertension. Response to verapamil. ( Cody, RJ; Covit, AB; Kubo, SH; Laragh, JH; Lopez-Ovejero, J; Müller, FB, 1986) |
| "The antihypertensive effect of twice-daily administration of verapamil hydrochloride was evaluated in 21 adult patients with mild to moderate essential hypertension." | 7.67 | Twice-daily administration of oral verapamil in the treatment of essential hypertension. ( Charlap, S; Dorsa, F; Frishman, W; Kimmel, B; Monuszko, E; Pollack, S; Saltzberg, S; Stroh, J; Weinberg, P; Wiezner, J, 1986) |
| "Thirty two patients with essential hypertension, stage I and II according to WHO classification, were treated according to the following schedule: period A--3 X 1 dragée placebo--3 weeks; period B--3 X 1 dragée placebo + 25 mg hydrochlorothiazide in the morning--6 weeks; period C--3 X 1 dragée isoptin 80 mg + 25 mg hydrochlorothiazide in the morning--6 weeks; period D--3 X 1 dragée placebo--2 weeks." | 7.67 | [Treatment of essential hypertension (hypertensive disease) with verapamil and hydrochlorothiazide]. ( Dimitrov, D, 1985) |
| "The dependency of arteriolar tone on calcium influx was studied in 11 patients with essential hypertension (EHT) and compared to 11 age-matched normotensive (NT) subjects by measuring the forearm blood flow (FAF) response to intraarterial infusion of the calcium channel blocker verapamil (Verap) and the nonspecific vasodilator sodium nitroprusside (Nip) with venous occlusion plethysmography." | 7.66 | Verapamil-induced vasodilation is enhanced in essential hypertension. ( Amann, FW; Bolli, P; Bühler, FR; Hulthén, UL; Kiowski, W, 1982) |
| "Forearm blood flow response to the calcium channel inhibitor verapamil, 1 75 micrograms/100 ml tissue, as measured by venous occlusion plethysmography, was found to be significantly greater in 11 patients with essential hypertension as compared to 11 age-matched normotensive subjects whereas there was no significant difference in increase in forearm blood flow between both groups to non-specific vasodilatation with sodium nitroprusside (1." | 7.66 | Verapamil-induced vasodilator response is enhanced in essential hypertension. ( Amann, FW; Bolli, P; Bühler, FR; Hulthén, L; Kiowski, W, 1983) |
| "The forearm resistance vessels of men with primary hypertension respond to verapamil with a greater than normal dilatation relative to that induced by sodium nitroprusside." | 7.66 | Effect of treatment with chlorthalidone and atenolol on response to dilator agents in the forearm resistance vessels of men with primary hypertension. ( Dobbs, RJ; Phillips, RJ; Robinson, BF, 1983) |
| "A 38-year-old woman with hypercalcemia, severe hypertension, and high renin levels was treated with the angiotensin-converting enzyme inhibitor captopril." | 7.66 | Hypertension in a patient with hypercalcemia: captopril and verapamil. ( Brunner, HR; Burckhardt, P; Gavras, H; Waeber, B, 1982) |
| " The response of the forearm resistance vessels to local intra-arterial infusion of verapamil and sodium nitroprusside has been assessed by a plethysmographic method in 23 men with normal arterial pressure and 35 men with primary hypertension." | 7.66 | Response of forearm resistance vessels to verapamil and sodium nitroprusside in normotensive and hypertensive men: evidence for a functional abnormality of vascular smooth muscle in primary hypertension. ( Bayley, S; Dobbs, RJ; Robinson, BF, 1982) |
| "Verapamil is a non-dihydropyridine calcium channel blocker (CCB) widely used in the treatment of hypertension, chronic stable angina, secondary prevention of reinfarction, paroxysmal supra-ventricular tachycardia and for rate control in atrial fibrillation/flutter." | 6.82 | Verapamil: prevention and treatment of cardio-renal syndromes in diabetic hypertensive patients? ( Bei, A; Calò, L; Cice, G; Di Lullo, L; Lido, P; Noce, A; Palazzetti, D; Perrone, MA; Romanello, D; Tesauro, M, 2022) |
| "Angina and hypertension are common in patients with coronary artery disease (CAD); however, the effect on mortality is unclear." | 6.78 | Mortality implications of angina and blood pressure in hypertensive patients with coronary artery disease: New data from extended follow-up of the International Verapamil/Trandolapril Study (INVEST). ( Cooper-Dehoff, RM; Gong, Y; Handberg, EM; Pepine, CJ; Winchester, DE, 2013) |
| "The aim of this study was to compare the effect of trandolapril (T) and its fixed-dose combination with verapamil (FDTV) on adiponectin levels in hypertensive type 2 diabetic patients." | 6.76 | Impact of trandolapril therapy and its combination with a calcium channel blocker on plasma adiponectin levels in patients with type 2 diabetes and hypertension. ( Castro-Serna, D; Escalante-Acosta, BA; Rodríguez-Lopez, L; Rubio-Guerra, AF; Vargas-Ayala, G; Vargas-Robles, H, 2011) |
| "Sibutramine treatment resulted in a significantly greater decrease in body weight, body mass index, and waist circumference and a significant increase in diastolic blood pressure during 24-hour blood pressure monitoring compared with placebo treatment." | 6.73 | Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. ( Grimm, E; Herrmann, D; Kintscher, U; Scholze, J; Unger, T, 2007) |
| "Trandolapril was also recommended for patients with heart failure, diabetes, or renal impairment." | 6.71 | A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. ( Bakris, GL; Bristol, HA; Cangiano, JL; Cohen, JD; Cooper-DeHoff, RM; Erdine, S; Garcia-Barreto, D; Handberg, EM; Keltai, M; Kolb, HR; Kowey, P; Mancia, G; Marks, RG; Messerli, FH; Parmley, WW; Pepine, CJ, 2003) |
| "COER-verapamil was well tolerated in both subgroups, but the incidence of constipation was significantly less in obese patients (P < 0." | 6.70 | Chronotherapeutic delivery of verapamil in obese versus non-obese patients with essential hypertension. ( Black, HR; Elliott, WJ; Johnson, MF; White, WB, 2001) |
| " After a 4-week single-blind placebo phase, patients received one of the following daily dosage regimens in a double-blind fashion for 6 weeks: placebo, 4 mg of trandolapril, 240 mg of verapamil SR, or a combination of 4 mg of trandolapril and 240 mg of verapamil SR." | 6.69 | Effects of verapamil and trandolapril in the treatment of hypertension. Trandolapril Study Group. ( Elliott, WJ; Frishman, WH; Messerli, F, 1998) |
| "alpha-Blockers and calcium antagonists are commonly used in the treatment of hypertension, but few data are available concerning first dose or steady state (SS) hemodynamic and pharmacokinetic effects of these drugs when they are used in combination therapy." | 6.68 | Combined terazosin and verapamil therapy in essential hypertension. Hemodynamic and pharmacokinetic interactions. ( Johnston, W; Laddu, AR; Lenz, ML; Pool, JL; Taylor, AA; Varghese, A, 1995) |
| " It is concluded that the combination doses tested showed a sustained and marked antihypertensive effect throughout the 24-hour dosing interval, and the starting dose (verapamil 180 mg plus trandolapril 2 mg) seems appropriate in this group of patients." | 6.68 | Once-daily fixed dose combinations of verapamil and trandolapril in black patients with mild to moderate hypertension: a new choice for first line treatment. ( Hlatswayo, Z; Radevski, I; Sareli, P; Skoularigis, J; Strugo, V, 1997) |
| "Treatment with verapamil caused significant increase of EDF from 61." | 6.67 | [Effects of verapamil and propranolol on the left-ventricular diastolic function in patients with primary arterial hypertension]. ( Markiewicz, M; Rymar, B; Trojnar, R; Wysokiński, A, 1991) |
| "Constipation was the only side-effect reported by those who completed the trial." | 6.67 | [Sustained release verapamil in essential hypertension]. ( Gibor, Y; Nusbaum, M; Yodfat, Y, 1991) |
| "The antihypertensive action of sustained release verapamil is, in the majority of cases, obtained with a dosage of 240 mg per day." | 6.67 | [Randomized double-blind study of delayed-action verapamil as a single dose versus 2 doses daily in patients with moderate hypertension]. ( Chapelon-Abric, C; Godeau, P; Villarroya, A; Wajman, A, 1991) |
| "Nifedipine was slightly, but not significantly, more potent." | 6.67 | Verapamil versus nifedipine in slow-release preparations for the treatment of mild to moderate hypertension. ( Meisel, S; Nussinovitch, N; Rosenthal, T; Shamiss, A, 1990) |
| " The overall effect is partly due to an increase in the apparent bioavailability of prazosin but may also reflect a synergistic effect on reducing peripheral vascular resistance." | 6.66 | Verapamil and prazosin in essential hypertension: evidence of a synergistic combination? ( Elliott, HL; Meredith, PA; Reid, JL, 1987) |
| "The dose-response relationship of verapamil-SR was studied in 221 hypertensive patients." | 6.66 | The relationship of dose to the antihypertensive response of verapamil-sustained release in patients with mild to moderate essential hypertension. The Verapamil-SR Study Group. ( McMahon, FG; Reder, RF, 1989) |
| " Thirty-six ambulatory patients with chronic, stable, mild to moderate hypertension (supine diastolic blood pressure of 94-116 mm Hg) received a dosage of either verapamil or diltiazem 80 mg t." | 6.66 | Comparison of equal-weight oral dosages of verapamil hydrochloride and diltiazem hydrochloride in patients with mild to moderate hypertension. ( DesChamps, M; Dickson, B; Gray, J; Heusner, JJ; Hollifield, JW; Peace, KE; Spyker, DA, 1988) |
| " Further measurements were made during a series of intensive study days, and the most important additional finding was a pharmacokinetic interaction that resulted in increased peak concentrations and bioavailability of prazosin." | 6.66 | The combination of prazosin and verapamil in the treatment of essential hypertension. ( Campbell, L; Elliott, HL; Meredith, PA; Reid, JL, 1988) |
| "Verapamil was devoid of any such effect." | 6.66 | Evaluation of verapamil in the treatment of hypertension. ( Anavekar, SN; Doyle, AE, 1986) |
| " The plasma half-life of verapamil was increased from 3." | 6.66 | Pharmacokinetics of verapamil in patients with hypertension. ( Anderson, P; Bondesson, U; de Faire, U, 1986) |
| "It is indicated for the treatment of hypertension in patients who require more than one agent to achieve blood pressure (BP) targets." | 6.43 | Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension. ( Keam, SJ; Reynolds, NA; Wagstaff, AJ, 2005) |
| " An increase in the dosage (360 mg/24 hours in two subdoses) could be made during the first month of treatment if the diastolic blood pressure remained greater than or equal to 95 mmHg." | 6.38 | [Sustained-released verapamil and ambulatory recording of blood pressure in mild to moderate essential hypertension]. ( Bernadet, P; Durand, D; Galey, C; Maarek-Charbit, M; Suc, JM, 1992) |
| "The aim of this study was to assess potential differences in the 24-h antihypertensive response to treatment with the controlled-onset, extended-release (COER) calcium antagonist, verapamil in men versus women and older versus younger patients with hypertension." | 6.19 | Gender and age effects on the ambulatory blood pressure and heart rate responses to antihypertensive therapy. ( Black, HR; Elliott, WJ; Johnson, MF; Sica, DA; White, WB, 2001) |
| "Although verapamil is a well-established treatment for angina, cardiac arrhythmias and cardiomyopathies, this review reflects current interest in calcium antagonists as anti-hypertensive agents by focusing on the role of verapamil in hypertension." | 6.16 | Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. ( McTavish, D; Sorkin, EM, 1989) |
| "Glycyrrhizin can cause pseudohyperaldosteronism and thereby result in hypertension and hypokalaemia." | 5.48 | Potassium chloride mixture may maintain hypokalaemia and hypertension. ( Borg, R; Hansen, D; Mandoe, MJ, 2018) |
| " We performed a randomized-controlled trial of lisinopril alone (an ACEI) or in combination with verapamil (a CCB) as a therapy for DN in type 2 diabetes mellitus (T2DM) patients with hypertension (HTN) and urinary albumin creatinine ratio (UACR) (30-300 mg/g) also to evaluate their effect on UACR, the angiogenic proteins: Angiopoietin 2 (Ang-2) and Endostatin (EST)." | 5.41 | Effect of Lisinopril and Verapamil on Angiopoietin 2 and Endostatin in Hypertensive Diabetic Patients with Nephropathy: A Randomized Trial. ( Abdel-Aleem, E; El-Mesallamy, HO; Salem, M; Sallam, AM, 2021) |
| " Verapamil heart tissue and plasma levels after intraperitoneal dosing of spontaneously hypertensive and normotensive rats were investigated." | 5.36 | Impaired tissue clearance of verapamil in rat cardiac hypertrophy results in transcriptional repression of ion channels. ( Borlak, J; Zwadlo, C, 2010) |
| "A clear reduction of BP values was recorded after both the first and the second month of treatment with kanrenoate, with the maximal effect obtained when the dosage titration at 100 mg/day was accomplished." | 5.35 | Menopause not aldosterone-to-renin ratio predicts blood pressure response to a mineralocorticoid receptor antagonist in primary care hypertensive patients. ( Blengio, GS; Ciacciarelli, A; Corrocher, R; Falcone, S; Olivieri, O; Pizzolo, F; Signorelli, D, 2008) |
| " Chronic administration of nitric oxide inhibitors provides a new model of hypertension with pronounced target organ damage." | 5.29 | L-NAME hypertension alters endothelial and smooth muscle function in rat aorta. Prevention by trandolapril and verapamil. ( Küng, CF; Lüscher, TF; Moreau, P; Takase, H, 1995) |
| "Verapamil pretreatment attenuated the BP and HR responses in rats." | 5.29 | Effect of verapamil on cadmium induced hypertension in rats. ( Puri, VN, 1996) |
| "Verapamil was demonstrated to produce a consistent reduction of blood pressure over most of the 24 h period studied but this was most marked during the day." | 5.27 | The role of a slow channel inhibitor, verapamil, in the management of hypertension. ( Gould, BA; Kieso, H; Mann, S; Raftery, EB; Subramanian, VB, 1984) |
| "Fifteen males with previously untreated essential hypertension in WHO stage I, aged 20-64 years were studied on an outpatient basis." | 5.27 | Haemodynamic effects of nifedipine in essential hypertension at rest and during exercise. ( Lund-Johansen, P; Omvik, P, 1983) |
| "In three patients with orthostatic hypotension successfully treated by the peripheral dopaminergic antagonist domperidone 60 mg/day, the subsequent introduction of verapamil 240 mg/day did not modify the standing-induced decrease in systolic blood pressure: 46." | 5.27 | Hypertension with orthostatic hypotension: interest of verapamil. ( Chamontin, BF; Montastruc, JL; Salvador, MJ, 1987) |
| "Verapamil HCl was chronically administered to inbred Dahl S/JR and R/JR rats maintained on a diet containing 8." | 5.27 | Calcium channel blockade with verapamil. Effects on blood pressure, renal, and myocardial adrenergic, cholinergic, and calcium channel receptors in inbred Dahl hypertension-sensitive (S/JR) and hypertension-resistant (R/JR) rats. ( Juno, CJ; McCaughran, JA, 1988) |
| "Verapamil is an effective and relatively-safe antihypertensive drug." | 5.27 | Verapamil withdrawal as a possible cause of myocardial infarction in a hypertensive woman with a normal coronary angiogram. ( Beilin, LJ; Dimmitt, SB; Hockings, BE, 1988) |
| " In 13 the dosage was decreased to 120 mg 2 times a day." | 5.27 | Short- and long-term treatment of mild to moderate hypertension with verapamil. ( Dallocchio, M; Gosse, P; Roudaut, R; Wicker, P, 1986) |
| "3." | 5.26 | The role of a slow channel inhibitor, verapamil, in the management of hypertension. ( Balasubramanian, V; Gould, BA; Kieso, H; Mann, S; Raftery, EB, 1982) |
| "The aim of this study was to compare the effects of a dihidropiridin calcium channel blocker amlodipin and a non-dihidropiridin calcium channel blocker verapamil on nephropathy and serum pigment epithelium-derived factor (PEDF) levels of type 2 diabetic patients with hypertension." | 5.20 | The effects of calcium channel blockers on nephropathy and pigment epithelium-derived factor in the treatment of hypertensive patients with type 2 diabetes mellitus. ( Çelik, H; Korkmaz, H; Oğuz, E; Sabuncu, T; Tabur, S, 2015) |
| "We utilized data from 22,576 hypertensive coronary artery disease patients, prospectively enrolled in the INternational VErapamil-Trandolapril STudy (INVEST)." | 5.16 | Comparing marginal structural models to standard methods for estimating treatment effects of antihypertensive combination therapy. ( Brumback, BA; Cooper-Dehoff, RM; Delaney, JA; Gerhard, T; Johnson, JA; Pepine, CJ; Shuster, J; Winterstein, AG, 2012) |
| "The Bergamo Nephrologic Diabetes Complications Trial-B was a multicentre, prospective, double-blind, parallel-group trial comparing renal and cardiovascular outcomes in 281 hypertensive type 2 diabetes patients with microalbuminuria randomized to at least 2-year VeraTran (verapamil/trandolapril 180 mg/2 mg daily) or trandolapril (2 mg daily, identical image) treatment." | 5.15 | Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. ( Bossi, A; Chiurchiu, C; Cravedi, P; Ene-Iordache, B; Fassi, A; Gaspari, F; Gherardi, G; Iliev, IP; Ilieva, A; Motterlini, N; Perna, A; Remuzzi, G; Rubis, N; Ruggenenti, P; Trevisan, R, 2011) |
| "In INternational VErapamil-trandolapril STudy, 22,576 CAD patients with hypertension (mean age 66 years) were randomized to verapamil-SR or atenolol-based strategies and followed for 2." | 5.14 | Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis. ( Bangalore, S; Champion, A; Franklin, SS; Mancia, G; Messerli, FH; Pepine, CJ, 2009) |
| "In hypertensive patients with prior MI, a verapamil-SR-based strategy was equivalent to a beta-blocker-based strategy for blood pressure control and prevention of cardiovascular events, with greater subjective feeling of well-being and a trend toward lower incidence of angina pectoris and stroke in the verapamil-SR-based group." | 5.13 | Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. ( Bacher, PH; Bangalore, S; Champion, A; Cohen, JD; Kowey, P; Mancia, G; Messerli, FH; Pepine, CJ; Sleight, P; Zhou, Q, 2008) |
| " STAR-LET was a 6-month extension of the Study of Trandolapril/Verapamil SR and Insulin Resistance (STAR), which assessed the effects of a fixed-dose renin-angiotensin system inhibitor (RASI)/hydrochlorothiazide (HCTZ) combination on changes in 2-hour oral glucose tolerance test (OGTT) results." | 5.13 | Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study. ( Bacher, P; Bakris, G; Champion, A; Molitch, M; Sarafidis, P; Sowers, JR; Zhou, Q, 2008) |
| " Statistical modeling from INVEST (INternational VErapamil-Trandolapril STudy), suggests an association between dual and triple therapy and decreased risk of primary outcome ([PO] first occurrence of death, nonfatal MI, or nonfatal stroke) in patients with hypertension and coronary artery disease (CAD)." | 5.12 | Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers. ( Bakris, GL; Champion, A; Cooper-Dehoff, RM; Kupfer, S; Pepine, CJ; Zhou, Q, 2007) |
| "We sought to test the hypothesis that a fixed-dose combination of trandolapril/verapamil-SR (T/V) is superior to a fixed-dose combination of losartan/hydrochlorothiazide (L/H) on glucose tolerance in hypertensive patients with impaired glucose tolerance (IGT)." | 5.12 | Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. ( Bacher, P; Bakris, G; Fakouhi, K; Hewkin, A; Kipnes, M; Molitch, M; Sarafidis, P; Sowers, J, 2006) |
| "The hypotensive and antiischemic activity of combined therapy with dihydropyridine group (amlodipine) and non-dihydropyridine group (verapamil retard) calcium antagonists (CA) as well as tolerance to this therapy were studied in 43 patients suffering from coronary heart disease (CAD) with II-III functional class exertional angina and II degree essential hypertension during 24 weeks." | 5.12 | [Evaluation of hypotensive and antiischemic effects of a combination of dihydropyridine and non-dihydropyridine calcium antagonists in patients suffering from coronary artery disease with arterial hypertension]. ( Abramova, GN; Berenshteĭn, NV; Burmistrova, LF; Iskendeerov, BG; Lokhina, TV; Shibaeva, TM, 2006) |
| " We sought to determine if the CYP3A5 genetic polymorphisms were associated with level of blood pressure (BP), risk of hypertension (HTN), and the antihypertensive response to verapamil." | 5.12 | Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil. ( Cooper-DeHoff, RM; Gong, Y; Johnson, JA; Katz, DA; Langaee, TY; Pepine, CJ; Yarandi, HN, 2007) |
| "This study evaluated the effectiveness of an escalating-dose regimen of trandolapril in subjects with stage 1 or stage 2 hypertension." | 5.12 | A 26-week, prospective, open-label, uncontrolled, multicenter study to evaluate the effect of an escalating-dose regimen of trandolapril on change in blood pressure in treatment-naive and concurrently treated adult hypertensive subjects (TRAIL). ( Assouline, L; Burgess, ED; Tytus, RH; Vanjaka, A, 2007) |
| " Therapeutic response to the angiotensin-converting enzyme inhibitor trandolapril used as add-on therapy to stable calcium channel blocker therapy with verapamil sustained release 240 mg was addressed in a racially/ethnically diverse group of 1,832 hypertensive patients with coronary artery disease." | 5.12 | Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study). ( Brunner, M; Cooper-DeHoff, RM; Gong, Y; Johnson, JA; Karnes, JH; Langaee, TY; Pepine, CJ, 2007) |
| "To use a nonparametric approach involving longitudinal splines to model the baseline blood pressure profile and investigate the impact of this modelling on the pharmacodynamic analysis for verapamil in patients with angina or hypertension." | 5.11 | Pharmacodynamics of controlled release verapamil in patients with hypertension: an analysis using spline functions. ( Aarons, L; Baxter, C; Gupta, S, 2004) |
| "In subjects with type 2 diabetes and hypertension but with normoalbuminuria, the use of trandolapril plus verapamil and trandolapril alone decreased the incidence of microalbuminuria to a similar extent." | 5.11 | Preventing microalbuminuria in type 2 diabetes. ( Arnoldi, F; Bossi, A; Bruno, S; Brusegan, V; Dodesini, AR; Ene-Iordache, B; Fassi, A; Ganeva, M; Gaspari, F; Gherardi, G; Iliev, IP; Ilieva, AP; Perna, A; Remuzzi, G; Rubis, N; Ruggenenti, P; Trevisan, R, 2004) |
| " Aim of the study was treatment of hypertension in patients with DM of both types by the ACE inhibitor trandolapril in dose of 2-4 mg, possibly in combination with the calcium channel blocker verapamil--240 mg." | 5.10 | [Treatment of hypertension in diabetics with trandolapril, an angiotensin converting enzyme inhibitor--a multicenter study]. ( Cech, F; Rosolová, H; Sefrna, F, 2002) |
| "002; multivariate analysis of variance), with 7 significant univariate treatment effects, all favoring COER-verapamil, being noted-pedal edema, polyuria, rapid heart beat or palpitations, hives, muscle cramps, abdominal cramps, and headaches." | 5.09 | Physical Symptoms Distress Index: a sensitive tool to evaluate the impact of pharmacological agents on quality of life. ( Anderson, RB; Hollenberg, NK; Williams, GH, 1999) |
| "Four hundred seventy-five patients with angina pectoris were randomized to double-blind treatment with PPR (physiological pattern release) verapamil hydrochloride, amlodipine besylate, amlodipineatenolol combination, or placebo." | 5.09 | Medical therapy, symptoms, and the distress the cause: relation to quality of life in patients with angina pectoris and/or hypertension. ( Anderson, R; Hollenberg, NK; Williams, GH, 2000) |
| "To evaluate the clinical efficacy and safety of a new antihypertensive drug combination of trandolapril/verapamil compared to monotherapy with verapamil or trandolapril, in patients with mild to moderate primary hypertension." | 5.09 | Efficacy and safety of a new long-acting drug combination, trandolapril/verapamil as compared to monotherapy in primary hypertension. Swedish TARKA trialists. ( Andrup, M; Karlberg, BE; Odén, A, 2000) |
| "The objective of this randomised open, active controlled, cross-over study was to evaluate the effect of a fixed combination of verapamil SR/trandolapril compared to captopril/hydrochlorothiazide on serum lipids, lipoproteins, and other metabolic and electrolyte parameters in patients with essential hypertension." | 5.09 | Evaluation of the effects of fixed combinations of sustained-release verapamil/trandolapril versus captopril/hydrochlorothiazide on metabolic and electrolyte parameters in patients with essential hypertension. ( Cifková, R; Compagnone, D; Hejl, Z; Nakov, R; Novozámská, E; Petrzílková, Z; Poledne, R; Stávek, P, 2000) |
| "A novel verapamil chronotherapeutic oral drug absorption system (CODAS-Verapamil) designed for bedtime dosing and with controlled onset and extended-release properties was evaluated in 257 patients with mild-to-moderate essential hypertension in an 8-week, double-blind, placebo-controlled trial." | 5.09 | A new chronotherapeutic oral drug absorption system for verapamil optimizes blood pressure control in the morning. ( Neutel, JM; Smith, DH; Weber, MA, 2001) |
| " There were no differences in the BP reached in the four therapy groups; however, proteinuria only decreased in the patients treated with trandolapril alone or in combination with verapamil." | 5.09 | Effect of strict blood pressure control on proteinuria in renal patients treated with different antihypertensive drugs. ( Dall'Anese, C; García de Vinuesa, S; Gómez-Campderá, F; Luño, J; Ridao, N; Sánchez, M; Valderrábano, F, 2001) |
| " To evaluate the effect of antihypertensive treatment on cardiac arrhythmias (CA) and transient episodes of myocardial ischemia (TEMI), we studied 46 hypertensive patients with LVH, divided into four groups randomly treated with enalapril, hydrochlorothiazide (HCTZ), atenolol, or verapamil (SR-V) for 6 months." | 5.09 | Effects of drug therapy on cardiac arrhythmias and ischemia in hypertensives with LVH. ( Abrignani, MG; Barbagallo, M; Dominguez, LJ; Nardi, E; Novo, G; Novo, S; Strano, A, 2001) |
| "We compared the effects of amlodipine and verapamil slow release on autonomic responses to a 5-min mental arithmetic test (MST) in patients with mild to moderate hypertension." | 5.09 | Less adrenergic response to mental task during verapamil compared to amlodipine treatment in hypertensive subjects. ( Eide, I; Lefrandt, JD; Rostrup, M; Sevre, K; Smit, AJ, 2001) |
| "The aim of the present study was to compare the effects of a long-acting dihydropyridine (amlodipine) and a nondihydropyridine (verapamil) on autonomic function in patients with mild to moderate hypertension." | 5.09 | The effects of dihydropyridine and phenylalkylamine calcium antagonist classes on autonomic function in hypertension: the VAMPHYRE study. ( Agabiti-Rosei, E; Castellano, M; de Kam, PJ; Fallon, M; Fluckiger, L; Hausberg, M; Heitmann, J; Lefrandt, JD; Murphy, M; Rahn, KH; Rostrup, M; Sevre, K; Smit, AJ; Urbigkeit, A; van Roon, AM; Zannad, F, 2001) |
| "The antihypertensive effects of moexipril, a new angiotensin converting enzyme inhibitor, and verapamil-SR as add-on therapy to hydrochlorothiazide (HCTZ) were investigated in patients with moderate to severe (stages II and III) essential hypertension." | 5.08 | Comparison of moexipril, a new ACE inhibitor, to verapamil-SR as add-on therapy to low dose hydrochlorothiazide in hypertensive patients. ( Chrysant, SG; Fox, AA; Stimpel, M, 1995) |
| "To evaluate the efficacy and safety of a novel delivery system of physiologic pattern release (PPR)-verapamil administered nocturnally to patients with stages I and II hypertension using ambulatory blood pressure (BP) monitoring, we performed a multicenter (17 centers), double-blind, randomized, placebo-controlled, parallel-group trial with placebo and 120, 180, 360, and 540 mg of verapamil in 287 randomized patients." | 5.08 | Nocturnal dosing of a novel delivery system of verapamil for systemic hypertension. Verapamil Study Group. ( Anders, RJ; Black, HR; MacIntyre, JM; Sica, DA; White, WB, 1995) |
| "The efficacy and safety of a low dose (120 mg) of a sustained-release capsule formulation of verapamil administered once daily in the treatment of 42 patients with mild hypertension were assessed in this clinical trial." | 5.08 | Treatment of mild hypertension with low once-daily doses of a sustained-release capsule formulation of verapamil. ( Davis, PJ; Fagan, TC; Ferdinand, KC; Levine, JH; Topmiller, MJ, 1995) |
| "The aim of the study was to evaluate the effects of verapamil sustained release (SR) 240 mg, enalapril and their combination on blood pressure (BP) and cardiac haemodynamics at rest and during exercise in 20 patients with moderate essential hypertension (seven men and 13 women, mean age +/- s." | 5.08 | Favourable interaction of calcium antagonist plus ACE inhibitor on cardiac haemodynamics in treating hypertension: rest and effort evaluation. ( Carotenuto, A; Cuocolo, A; de Divitiis, M; de Divitiis, O; Di Somma, S; Galderisi, M; Paulucci, A, 1995) |
| "To compare and contrast the antihypertensive efficacy of an angiotensin-converting enzyme (ACE) inhibitor to a calcium antagonist, 88 and 90 patients with essential hypertension were randomly assigned to receive moexipril and verapamil, respectively." | 5.08 | Moexipril in the treatment of mild to moderate essential hypertension: comparison with sustained-release verapamil. ( Abernethy, DR; Fox, AA; Stimpel, M, 1995) |
| "The VHAS (Verapamil-Hypertension Atherosclerosis Study) Investigators entered 1464 patients with essential hypertension and blood pressure (BP) values > or = 160 mmHg systolic and 95 mmHg diastolic (DBP) but excluded those with a DBP > or = 115 mmHg, and those with diabetes mellitus or previous myocardial infarction or cerebrovascular episodes." | 5.08 | Vascular complications in hypertension: the VHAS study. Verapamil-Hypertension Atherosclerosis Study. ( Zanchetti, A, 1995) |
| " Therefore, the triad of metabolic neutrality with antihypertensive and antiproteinuric efficacy supports combined verapamil-trandolapril as a potentially valuable therapy for hypertension accompanying diabetes mellitus." | 5.08 | Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low-dose chlortalidone treatment in hypertensive type 2 diabetes. ( Boehlen, L; Buechel, P; Lerch, M; Papiri, M; Risen, W; Schneider, M; Shaw, S; Weidmann, P, 1996) |
| " To test this hypothesis, thirty patients with essential hypertension were placed on 240 mg once daily of a slow release verapamil preparation for a period of one month following a one month run-in period." | 5.08 | Parathyroid hypertensive factor predicts efficacy in the treatment of essential hypertension with verapamil. ( Hamilton, PG; Lewanczuk, RZ, 1996) |
| "The antihypertensive effectiveness of moexipril, a new angiotensin-converting enzyme (ACE) inhibitor, and sustained-release verapamil (verapamil SR) in combination with low-dose hydrochlorothiazide was investigated in patients with moderate to severe (Stages II and III) essential hypertension." | 5.08 | A comparison of the antihypertensive effectiveness of a combination of moexipril or sustained-release verapamil with low-dose hydrochlorothiazide. ( Chrysant, SG; Stimpel, M, 1996) |
| "5 mg lisinopril/hydrochlorothiazide and placebo in patients with essential hypertension." | 5.08 | Comparison of different fixed antihypertensive combination drugs: a double-blind, placebo-controlled parallel group study. ( de Leeuw, PW; Notter, T; Zilles, P, 1997) |
| "The cardiovascular effects of a combination of trandolapril and verapamil were evaluated in 14 patients with mild to moderate essential hypertension." | 5.08 | Cardiovascular effects of a trandolapril/verapamil combination in patients with mild to moderate essential hypertension. ( Aepfelbacher, FC; Messerli, FH; Michalewicz, L; Nunez, E, 1997) |
| "In a placebo-controlled study of 13 subjects with systemic hypertension, sustained-release verapamil reduced the morning surge in systolic pressure by 10." | 5.08 | Effect of sustained-release Verapamil on the morning systemic arterial pressure surge during daily activity in patients with systemic hypertension. ( Gebara, OC; McKenna, CA; Muller, JE; Rosito, GA; Solomon, HS; Tofler, GH, 1997) |
| "We assessed the efficacy of monotherapy with trandolapril, an angiotensin converting enzyme (ACE) inhibitor, and of verapamil slow-release (SR), a calcium antagonist, each in a range of three doses as monotherapy, and in the nine possible combinations of therapy in patients with stage I to III diastolic hypertension." | 5.08 | Fixed-dose combination therapy with trandolapril and verapamil SR is effective in primary hypertension. Trandolapril Study Group. ( DeQuattro, V; Lee, D, 1997) |
| "In arterial hypertension, MBF during pacing tachycardia and after dipyridamole is impaired." | 5.08 | Comparative effects of enalapril and verapamil on myocardial blood flow in systemic hypertension. ( Gallopin, M; Giorgetti, A; L'Abbate, A; Marabotti, C; Neglia, D; Palombo, C; Parodi, O; Sambuceti, G; Simonetti, I, 1997) |
| "The regression of left ventricular hypertrophy in hypertensive patients was evaluated in a multicenter study with a combination therapy of verapamil 120 mg and captopril 25 mg given once or twice daily." | 5.08 | Treatment of left ventricular hypertrophy in hypertensive patients with a combination of verapamil and captopril--a multicenter study. ( Brandt, D; Hofmann, R; Magometschnigg, D; Sihorsch, K; Stoschitzky, K; Zangeneh, M; Zenker, G, 1997) |
| "A multiple drug regimen consisting of trandolapril, verapamil and hydrochlorothiazide (HCTZ) were sequentially added in an open-label evaluation of patients with severe hypertension." | 5.08 | The treatment of severe hypertension with trandolapril, verapamil, and hydrochlorothiazide. Trandolapril/Verapamil Multicenter Study Group. ( Novrit, BA; Punzi, HA, 1997) |
| "The Verapamil in Hypertension and Atherosclerosis Study (VHAS) is a prospective randomized study the objective of which was to compare the long-term effects of verapamil and chlorthalidone on the blood pressure, clinical safety, and the progression/regression of carotid wall lesions in members of a large population of hypertensive patients." | 5.08 | Clinical results of the Verapamil inHypertension and Atherosclerosis Study. VHAS Investigators. ( Dal Palù, C; Leonetti, G; Magnani, B; Pessina, A; Rosei, EA; Zanchetti, A, 1997) |
| "To investigate the dose-response relationship and contribution of verapamil SR and trandolapril given in combination once a day for the treatment of essential hypertension." | 5.08 | Verapamil SR and trandolapril combination therapy in hypertension--a clinical trial of factorial design. German Hypertension Study Group. ( Compagnone, D; Scholze, J; Zilles, P, 1998) |
| "A total of 27,000 CAD patients with hypertension will be randomized at 1,500 primary care sites to receive either a calcium antagonist-based (verapamil) or beta-blocker/diuretic-based (atenolol/hydrochlorothiazide) antihypertensive care strategy." | 5.08 | Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension. ( Conlon, M; Cooper-DeHoff, R; Handberg-Thurmond, E; Marks, RG; Pepine, CJ; Volkers, P; Zellig, P, 1998) |
| "The TEAM trial investigated the effectiveness and tolerance of a fixed combination of the ACE inhibitor and calcium channel blocker (2 mg trandolapril and 180 mg verapamil retard) (preparation Tarka) in an open multicentre prospective study of treatment of moderately severe hypertension (diastolic pressure at the end of the two-week wash-out period 100-115 mm Hg)." | 5.08 | [The TEAM study--a study of the effectiveness and tolerance of treatment of essential hypertension with a fixed combination of trandolapril and verapamil]. ( Dzúrik, R; Widimský, J, 1998) |
| " The present paper reports the principal results of the ultrasound substudy of the randomized, prospective, controlled, Verapamil in Hypertension and Atherosclerosis Study (VHAS)." | 5.08 | The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. ( Dal Palù, C; Leonetti, G; Magnani, B; Pessina, A; Rosei, EA; Zanchetti, A, 1998) |
| " In order to evaluate the changes occurring in beta-2 adrenoceptor density, 40 patients with mild to moderate hypertension received verapamil 240 mg (once a day) or captopril 20 mg (twice a day) during 30 days, in a double-blind randomized study, after a placebo run-in period." | 5.07 | Is verapamil also a non-selective beta blocker? ( Drici, MD; Iacono, P; Jacomet, Y; Lapalus, P, 1993) |
| "Forty patients with mild to moderate hypertension were divided into two groups, 20 patients (group A) received 240 mg verapamil and 20 patients (group B) received 20 mg nitrendipine daily during the first six weeks." | 5.07 | Combination therapy with verapamil and nitrendipine in patients with hypertension. ( Kiliçcioğlu, B; Nalbantgil, I; Onder, R; Türkoğlu, C, 1993) |
| "To define the influence of dietary salt intake on the antihypertensive effect of slow-release verapamil 240 mg once a day in a population with mild-to-moderate essential hypertension." | 5.07 | Antihypertensive activity of verapamil: impact of dietary sodium. The VERSAL Study Group. ( Abellán-Alemán, J; Aranda-Lara, P; de la Figuera-von Wichmann, M; Luque-Otero, M; Redón-Más, J; Rodicio-Díaz, JL; Ruilope-Urioste, LM; Velasco-Quintana, J, 1993) |
| "The effect of three calcium entry blockers--verapamil, nifedipine and felodipine--on diuresis, natriuresis, the renin-aldosterone axis, and atrial natriuretic peptide (ANP) levels was studied in 30 previously untreated patients with mild to moderate essential hypertension." | 5.07 | The role of atrial natriuretic peptide in the diuretic effect of Ca2+ entry blockers. ( Ezra, D; Peleg, E; Rosenthal, T; Shamiss, A, 1993) |
| "The antihypertensive effects of the regular immediate release formulation of verapamil (verapamil IR) and the newer sustained release formulation of verapamil (verapamil SR) were compared in Hispanic patients with untreated essential hypertension." | 5.07 | Comparative efficacy, safety and pharmacokinetics of verapamil SR vs verapamil IR in hypertensive patients. ( Cubeddu, LX; Faggin, BM; Fuenmayor, NT, 1992) |
| " The Verapamil in Hypertension Atherosclerosis Study is an ongoing multicentre randomised double-blind parallel group trial comparing the antihypertensive efficacy of verapamil SR 240 mg/day with that of chlorthalidone 25 mg/day in 1464 patients with essential hypertension aged 40 to 65 years." | 5.07 | Preliminary clinical experience with calcium antagonists in atherosclerosis. Verapamil in Hypertension Atherosclerosis Study Investigators. ( Dal Palù, C; Magnani, B; Zanchetti, A, 1992) |
| " The Verapamil in Hypertension Atherosclerosis Study (VHAS) is an ongoing randomized trial, comparing the antihypertensive efficacy of verapamil 240 mg SR with chlorthalidone 25 mg in 1,464 essential hypertensives aged 40-65 years." | 5.07 | Atherosclerosis and calcium antagonists: the VHAS. The Verapamil-Hypertension Atherosclerosis Study (VHAS) Investigators. ( Dal Palù, C; Magnani, B; Zanchetti, A, 1992) |
| "The aim of the present study was to compare the effects of slow-release verapamil (V), 240 mg and nitrendipine (N), 20 mg, administered once daily, on office (OBP) and 24-h ambulatory blood pressure (ABP) in patients with mild-to-moderate hypertension." | 5.07 | Effects of slow-release verapamil and nitrendipine on office and 24-hour ambulatory blood pressure in hypertensive patients. ( Campbell, SV; Collauto, F; Pannarale, G; Puddu, PE; Reale, A; Stazi, F, 1992) |
| "In this double-blind, parallel, multicenter study, sustained-release (SR) preparations of 2 calcium antagonists, nicardipine and verapamil, were compared for the treatment of mild to moderate systemic hypertension." | 5.07 | Comparison of sustained-release formulations of nicardipine and verapamil for mild to moderate systemic hypertension. ( Friday, KJ; Frishman, WH; Gradman, AH; Kaihlanen, PM; Wong, SC, 1992) |
| "Verapamil, the first calcium-channel blocker to be introduced for clinical use, is a major drug used for the treatment of systemic hypertension." | 5.07 | Sustained-release verapamil formulations for treating hypertension. ( Frishman, WH; Lazar, EJ, 1992) |
| "In a double-blind, crossover study, five white men with mild-to-moderate hypertension received placebo and fixed doses of atenolol, metoprolol, chlorthalidone, verapamil, and the combination of atenolol and chlorthalidone in a quasi-random order." | 5.07 | Effectiveness of antihypertensive medications in office and ambulatory settings: a placebo-controlled comparison of atenolol, metoprolol, chlorthalidone, verapamil, and an atenolol-chlorthalidone combination. ( Durel, LA; Hayashi, PJ; Schneiderman, N; Weidler, DJ, 1992) |
| "Calcium-entry blockade produced by verapamil was studied in 13 subjects with sustained essential hypertension." | 5.07 | Cardiac mass and aortic distensibility following calcium blockade in hypertension. ( Lacolley, PJ; Levy, BI; Pannier, BP; Safar, ME, 1991) |
| "In 80 patients with moderate hypertension the effects of nisoldipine 10 mg b." | 5.07 | The effects of nisoldipine, diltiazem, nifedipine, and verapamil on hemodynamic parameters and red blood cells-platelet interactions in patients with arterial hypertension. ( Belousov, Y; Kushnaryov, V, 1991) |
| "The efficacy and tolerability of hydrochlorothiazide, sustained-release verapamil, and their combination was compared in patients with mild to moderate hypertension." | 5.07 | Hydrochlorothiazide and verapamil in the treatment of hypertension. The Verapamil Versus Diuretic (VERDI) Trial Research Group. ( Distler, A; Holzgreve, H; Michaelis, J; Philipp, T; Wellek, S, 1991) |
| "A randomised, double-blind, double-placebo trial compared the efficacy and safety/acceptability of sustained release verapamil and of captopril in two parallel groups of patients with mild to moderate hypertension." | 5.07 | [Comparison of the efficacy and tolerability of sustained-release verapamil and captopril in mild to moderate essential arterial hypertension]. ( Galey-Arcangioli, C; Imbs, JL; Maarek-Charbit, M; Stephan, D; Welsch, M, 1991) |
| "This double-blind, double-dummy, randomized clinical trial, conducted in elderly patients with mild hypertension, compared adherence to treatment, efficacy, side effects, and quality of life during treatment with transdermal clonidine versus oral sustained-release verapamil (verapamil-SR)." | 5.07 | Therapeutic adherence in the elderly: transdermal clonidine compared to oral verapamil for hypertension. ( Burris, JF; Cook, ME; Papademetriou, V; Wallin, JD; Weidler, DJ, 1991) |
| "The antihypertensive efficacy and tolerability of enalapril (E) and slow-release verapamil (V) were compared in a 2-month double-blind cross-over study in 22 patients with mild to moderate essential hypertension." | 5.07 | Antihypertensive efficacy and tolerability of enalapril and slow-release verapamil in essential hypertension: a double-blind, cross-over study. ( Fagher, B; Henningsen, NC; Hulthén, UL; Katzman, P; Thulin, T, 1991) |
| "Supine office blood pressures (SOBP) and 24-hour automated ambulatory blood pressure monitorings (AABPM) showed blood pressure reductions from a stable baseline to active treatment with 120-, 240-, and 480-mg doses of a new verapamil QD capsule (solid-spheroidal-oral once-daily drug-absorption system: (SODAS) in patients with mild-to-moderately severe (diastolic blood pressures 95-119 mm Hg) essential hypertension." | 5.07 | Once-daily verapamil in the treatment of mild-to-moderate hypertension: a double-blind placebo-controlled dose-ranging study. ( Bottini, PB; Carr, AA; Devane, JG; Fisher, LD; O'Brien, DE; Prisant, LM; Rhoades, RB, 1991) |
| "The effect of chronic administration of verapamil, following a double-blind, crossover protocol, on the distensibility and cross-sectional compliance of the common carotid artery was investigated in 19 patients with essential hypertension." | 5.06 | The effect of verapamil on carotid artery distensibility and cross-sectional compliance in hypertensive patients. ( Böhm, R; Mooij, J; Rahn, KH; Reneman, RS; Smeets, FA; Van Bortel, L; Van Merode, T, 1990) |
| "Seventeen adult patients with moderate and stable bronchial asthma and established essential hypertension (WHO I or II) were evaluated in a randomized, double-blind, crossover study of the effects of captopril (50-100 mg/day) and verapamil (160-240 mg/day) on blood pressure, orthostatic reactions, respiratory function, and asthmatic symptoms." | 5.06 | Effects of captopril on blood pressure and respiratory function compared to verapamil in patients with hypertension and asthma. ( Ahonen, A; Riska, H; Salorinne, Y; Sovijärvi, AR; Stenius-Aarniala, B; Sundberg, S, 1990) |
| "The arterial vasodilator properties of the dihydropyridine calcium antagonist amlodipine were compared with the effects of vascular muscle cyclic guanosine monophosphate production by sodium nitroprusside and with the effects of a combined infusion of amlodipine and the nondihydropyridine calcium antagonist verapamil in 8 untreated patients with primary hypertension." | 5.06 | Arterial vasodilator effects of the dihydropyridine calcium antagonist amlodipine alone and in combination with verapamil in systemic hypertension. ( Bühler, FR; Erne, P; Kiowski, W; Linder, L, 1990) |
| "A double-blind, positively controlled, forced dose titration study comparing the efficacy and safety of atenolol, captopril, and verapamil sustained release as single agents in the treatment of black patients with mild to moderate hypertension (diastolic blood pressure, 95 to 114 mm Hg) was conducted." | 5.06 | A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. ( Curry, C; Gray, J; Hollifield, J; Kong, BW; Saunders, E; Schoenberger, J; Sowers, JR; Vertes, V; Weir, MR; Zemel, MB, 1990) |
| "A multicenter, randomized double-blind clinical trial was conducted among 306 black men and women with mild to moderate hypertension to determine effects of atenolol, captopril, and verapamil SR on measures of quality of life." | 5.06 | Hypertensive black men and women. Quality of life and effects of antihypertensive medications. Black Hypertension Quality of Life Multicenter Trial Group. ( Baume, RM; Croog, SH; Kong, BW; Levine, S; Saunders, E; Weir, MR, 1990) |
| "The renal, metabolic and antihypertensive effects of enalapril (E) and slow-release verapamil (V) were compared in a 2-month double-blind crossover trial in 22 patients with newly discovered essential hypertension." | 5.06 | Antihypertensive and renal effects of enalapril and slow-release verapamil in essential hypertension. A double-blind, randomized study. ( Fagher, B; Henningsen, N; Hulthén, L; Katzman, P; Thulin, T, 1990) |
| "A series of 12 adult patients with stable bronchial asthma and an established diagnosis of essential hypertension (WHO I or II) were studied in a randomized double-blind crossover study to assess the effect of captopril (50-100 mg/day) and verapamil (160-240 mg/day) on blood pressure, lung function, and asthmatic symptoms." | 5.06 | Comparison of the effects of an angiotensin converting enzyme inhibitor and a calcium channel blocker on blood pressure and respiratory function in patients with hypertension and asthma. ( Riska, H; Sovijärvi, AR; Stenius-Aarniala, B, 1987) |
| "One hundred sixty patients with mild to moderate essential hypertension entered this double-blind parallel group comparison of amlodipine, verapamil, and placebo." | 5.06 | Comparison of amlodipine and verapamil in the treatment of mild to moderate hypertension. ( Lorimer, AR; Smedsrud, T; Tyler, HM; Walker, P, 1988) |
| "The blood-pressure (BP)-lowering efficacy of sustained-release verapamil, using both clinic and ambulatory measurements, was assessed in patients with essential hypertension." | 5.06 | The efficacy and duration of action of sustained-release verapamil in essential hypertension. ( Atkins, N; Latham, AN; McCormack, PM; Mee, F; O'Brien, ET; O'Malley, K, 1989) |
| "9% female; aged 17-89 years) with mild, moderate, or severe hypertension, the antihypertensive efficacy and in particular the tolerability of verapamil slow-release (SR) 240 mg (Isoptin RR) were studied." | 5.06 | Efficacy and safety of verapamil SR 240 mg in essential hypertension: results of a multicentric phase IV study. ( Pfennigsdorf, G; Schumacher, A; Sosna, J; Speders, S, 1989) |
| "We assessed the pharmacokinetics and pharmacodynamics of immediate-release (IR) and slow-release (SR) verapamil in Hispanic patients with mild to moderate essential hypertension." | 5.06 | Comparative efficacy, safety, and kinetics of immediate- and slow-release verapamil in hispanic patients with essential hypertension. ( Cubeddu, LX; Faggin, BM; Fuenmayor, NT, 1989) |
| "A close comparative study of the hypotensive effects of verapamil and chlorthalidone was carried out on 60 patients affected with mild essential hypertension showing systemic." | 5.06 | [Effects of a calcium antagonist, verapamil, on mild-moderate essential arterial hypertension]. ( Hergueta García de Guadiana, G; Paumard Fraguas, A, 1989) |
| "To compare the efficacy and tolerability of hydrochlorothiazide, sustained release verapamil, and their combination in patients with mild to moderate hypertension." | 5.06 | Verapamil versus hydrochlorothiazide in the treatment of hypertension: results of long term double blind comparative trial. Verapamil versus Diuretic (VERDI) Trial Research Group. ( Distler, A; Holzgreve, H; Michaelis, J; Philipp, T; Wellek, S, 1989) |
| "This is a double blind parallel group comparison in patients with mild-moderate hypertension, of amlodipine, verapamil and placebo." | 5.06 | A comparison of amlodipine, verapamil and placebo in the treatment of mild to moderate hypertension. Amlodipine Study Group. ( Lorimer, AR; Smedsrud, T; Tyler, HM; Walker, P, 1989) |
| "The effects of one month's treatment with each of nifedipine, verapamil, diltiazem, propranolol and placebo, given in random order, on fasting plasma glucose, haemoglobin Alc, serum fructosamine, immunoreactive insulin, cholesterol, and triglyceride were studied in a group of 19 patients with hypertension and non-insulin dependent diabetes mellitus." | 5.06 | The effects of verapamil, diltiazem, nifedipine and propranolol on metabolic control in hypertensives with non-insulin dependent diabetes mellitus. ( Chellingsworth, MC; Kendall, MJ; Pasi, J; Singh, BM; Wright, AD, 1989) |
| "Quality of life was evaluated in a four-month randomised double-blind trial of verapamil compared with propranolol in the treatment of hypertension in 94 patients in the UK." | 5.06 | The effects of verapamil and propranolol on quality of life in hypertension. ( Bulpitt, CJ; Chester, PC; Fletcher, AE; Hawkins, CM; Latham, AN; Pike, LA, 1989) |
| "A total of 1337 patients with mild to moderate essential hypertension were included in an open, multicentre trial to assess the response rate to the diuretic etozolin (200 mg once a day) and to verify whether the addition of the calcium antagonist verapamil (120 mg twice a day) in non-responders may have a favourable effect." | 5.06 | Etozolin monotherapy and combination with verapamil in essential hypertension. ( Agabiti-Rosei, E; Muiesan, G, 1989) |
| "The antihypertensive effect of verapamil administered either two or three times daily was compared in a double blind, cross over study in 15 patients with mild to moderate essential hypertension." | 5.06 | Comparisons of verapamil administration twice and three times daily in hypertension. ( Gordin, A; Jounela, AJ; Ottoila, P; Salmela, PI; Salo, H, 1988) |
| "The efficacy, safety and toleration of sustained release verapamil (Securon SR, Knoll) and long acting propranolol (Inderal LA, ICI) in the treatment of mild to moderate hypertension were compared in a randomized, double-blind, parallel group study." | 5.06 | Verapamil SR and propranolol LA: a comparison of efficacy and side effects in the treatment of mild to moderate hypertension. ( Bochsler, JA; Chester, PC; Latham, AN; Simmons, RL; Ward, PJ, 1988) |
| "The efficacy of nitroglycerine, verapamil and nifedipine in controlling post-sternotomy hypertension was compared in four groups of 20 patients anaesthetized with fentanyl 100 micrograms kg-1 undergoing elective coronary artery surgery." | 5.06 | Comparison of nitroglycerine, verapamil and nifedipine in the management of arterial pressure during coronary artery surgery. ( Bovill, JG; Gielen, J; Hoeneveld, MH; Schuller, J; van Wezel, HB, 1986) |
| "The long-term safety and efficacy of twice-daily sustained-release verapamil were assessed compared to thrice-daily immediate-release verapamil in 25 patients with mild to moderate systemic hypertension." | 5.06 | Long-term safety and efficacy comparison of immediate-release and sustained-release oral verapamil in systemic hypertension. ( Charlap, S; Eisen, G; Frishman, WH; Strom, JA, 1987) |
| "To compare responses of blood pressure to the calcium antagonist verapamil and the beta blocker metoprolol in black compared with white diabetics with hypertension and to monitor urinary albumin excretion in relation to fall in blood pressure." | 5.06 | Treating hypertension in black compared with white non-insulin dependent diabetics: a double blind trial of verapamil and metoprolol. ( Anderson, NM; Cruickshank, JK; Jepson, E; Wadsworth, J; Young, SM, 1988) |
| "The antihypertensive effect of a single dose of 240 mg sustained-release (S-R) verapamil was investigated by ambulatory blood pressure (BP) monitoring in 13 patients with mild to moderate essential hypertension." | 5.06 | Twenty-four-hour blood pressure monitoring after a single dose of sustained-release verapamil. ( Baroni, S; Cardillo, C; Cremona, G; Folli, G; Mores, N; Musumeci, V; Tutinelli, F, 1988) |
| "A double blind, double dummy, randomized cross-over pharmacokinetic study comparing verapamil 120 mg, conventional tablets administered twice daily and verapamil 240 mg sustained release tablets once daily was performed in 12 patients with essential hypertension." | 5.06 | Pharmacokinetics of verapamil and norverapamil in patients with hypertension: a comparison of oral conventional and sustained release formulations. ( Jørgensen, NP; Walstad, RA, 1988) |
| "Plasma verapamil concentration was correlated with serial electrocardiographic P-R intervals in patients with essential hypertension receiving immediate-release (80 to 120 mg three times a day) or sustained-release (240 mg daily) verapamil." | 5.06 | Correlation between verapamil plasma concentration and P-R prolongation in essential hypertension. ( Carlson, CA; Schirger, A; Sheps, SG; Shub, C; Wolf, MK; Zachariah, PK, 1988) |
| "The effects of verapamil and bendrofluazide used singly and in combination were examined in patients with primary hypertension in a patient blind, partly observer blind placebo controlled study of parallel group design; there were ten subjects in each arm of the trial." | 5.06 | Verapamil and bendrofluazide in the treatment of hypertension: a controlled study of effectiveness alone and in combination. ( Benjamin, N; Phillips, RJ; Robinson, BF, 1988) |
| "To evaluate the hypotensive efficacy of Verapamil alone and combined with diuretic, in the treatment of essential hypertension in elderly patients, we studied 54 patients, mean age 67." | 5.06 | [Hypotensive efficacy of verapamil alone and in combination with a diuretic in the treatment of essential hypertension in geriatric patients]. ( Achilli, L; D'Amico, F; Latini, R; Lombi, V; Pierandrei, G, 1987) |
| " Exchangeable sodium, blood volume, plasma norepinephrine, renin, aldosterone, pressor responsiveness to norepinephrine, heart rate responses to isoproterenol, and lipid metabolism were studied in 15 patients with essential hypertension after 8 weeks of treatment with verapamil (348 +/- 68 (SD) mg/day)." | 5.06 | Cardiovascular effects of verapamil in essential hypertension. ( Beretta-Piccoli, C; Leonardi, L; Marone, C; Riesen, W; Städler, P; Ziegler, W, 1987) |
| "A series of 8 adult patients with stable bronchial asthma and an established diagnois of essential hypertension (WHO I and II) was studied in a randomized double-blind cross-over study to assess the effect of captopril (50-100 mg/day) and verapamil (160-240 mg/day) on blood pressure, lung function and asthmatic symptoms." | 5.06 | Comparison of the efficacy of an ACE-inhibitor and a calcium channel blocker in hypertensive asthmatics. A preliminiary report. ( Riska, H; Sovijärvi, AR; Stenius-Aaniala, B, 1986) |
| "The influences of verapamil, propranolol and their combination on blood pressure and heart rate during cold pressor testing and isometric exercise were examined in 13 patients with essential hypertension." | 5.06 | Effects of calcium antagonism and beta-blockade on haemodynamic responses to stress. ( Dargie, HJ; Findlay, IN; McInnes, GT; Murray, GD, 1987) |
| "The antihypertensive effect and possible adverse effects of verapamil were assessed in 30 Thai patients with mild to moderate hypertension." | 5.06 | A multicenter study of verapamil in systemic hypertension in Thailand. ( Intharakoses, A; Jeam-Anukulkit, N; Ngarmukos, P; Nontakanun, S; Polsi, Y; Sansanayudth, P; Sitthisook, S; Sriratanaban, A; Tanprasert, P, 1986) |
| "In a series of controlled studies for periods of 4 to 6 weeks comprising 103 patients altogether, and in 1 long-term trial for 1 year, various dosages of instant and sustained-release verapamil were administered in the treatment of mild and moderate essential hypertension." | 5.06 | Instant and sustained-release verapamil in the treatment of essential hypertension. ( Hals, O; Lauve, O; Midtbø, K; Storstein, L; van der Meer, J, 1986) |
| " Verapamil is such a drug, but its clinical role in the management of hypertension is not clear." | 5.06 | Twice-daily verapamil for hypertension: a comparison with propranolol. ( Gould, BA; Hornung, RS; Jones, RI; Raftery, EB; Sonecha, T, 1986) |
| "The antihypertensive effect of a new sustained-release matrix formulation of verapamil 200 mg was investigated in a dose-response study in patients with mild to moderate essential hypertension." | 5.06 | Sustained release verapamil in hypertension. Results from a noninvasive ambulatory blood pressure monitoring and a clinical study. ( Gordin, A; Koistinen, A; Nissinen, A; Sundberg, S; Tuomilehto, J, 1986) |
| "The study was carried out in 24 patients with mild to moderate essential hypertension to assess the antihypertensive efficiency and tolerability of a new sustained-release formulation of verapamil (tablets containing 240 mg)." | 5.06 | A new sustained-release formulation of verapamil in the treatment of hypertension. ( Hals, O; Lauve, O; Midtbo, KA, 1986) |
| "The potential antihypertensive effect of sustained-release (SR) verapamil was compared to immediate-release (IR) verapamil in a group of patients with essential hypertension." | 5.06 | Efficacy of sustained-release verapamil: automatic ambulatory blood pressure monitoring. ( Schriger, A; Sheps, SG; Zachariah, PK, 1986) |
| "The antihypertensive effects of verapamil over 24 hours were assessed on twice and thrice daily dose regimens on 12 patients (25-65 years of age; mean age 50) with essential hypertension (WHO stages I-II) in a randomised, double-blind, cross-over trial." | 5.06 | Variability of blood pressure in ambulatory hypertensive patients: effects of verapamil on twice and thrice daily dose regimens. ( de Faire, U; Forslund, L; Odén, A, 1986) |
| "In a single-blind, placebo-controlled crossover study the effects of verapamil (450 +/- 30 mg/day) and propranolol (160 +/- 20 mg/day) on endurance time during submaximal exercise were compared in eight patients with essential hypertension." | 5.06 | The effects of verapamil and propranolol on exercise tolerance in hypertensive patients. ( Böhm, R; Does, R; Mooy, J; Petri, H; Rahn, KH; van Baak, M; van Kemenade, J, 1987) |
| "The effects of graded doses of verapamil were compared with those of a combination of atenolol and hydralazine in a double-blind, randomised, crossover trial in 16 patients with essential hypertension." | 5.06 | Verapamil in essential hypertension: a comparison with atenolol plus hydralazine. ( Bailey, BP; Duggin, GG; Fletcher, PJ; Hall, B; Horvath, JS; Tiller, D, 1987) |
| " Therefore, the effects of 4-week treatment periods with verapamil and propranolol on metabolic parameters during an endurance bicycle ergometer test were studied in eight patients with mild to moderate essential hypertension." | 5.06 | Metabolic effects of verapamil and propranolol during submaximal endurance exercise in patients with essential hypertension. ( Böhm, RO; Petri, J; Rahn, KH; van Baak, MA, 1987) |
| "The antihypertensive effects of oral regular and slow-release verapamil, a calcium-channel blocking agent, were evaluated in 22 patients with mild to moderate hypertension (sitting diastolic blood pressure [DBP] 95 to 112 mm Hg)." | 5.06 | Verapamil and 24-hour ambulatory blood pressure monitoring in essential hypertension. ( O'Brien, PC; Schirger, A; Sheps, SG; Simpson, KK; Spiekerman, RE; Zachariah, PK, 1986) |
| "The relative efficacies of oral verapamil, a calcium-entry blocking drug, and propranolol, a beta-adrenergic blocking drug, were compared in 12 patients who had both stable angina pectoris and mild to moderate systemic hypertension, using a placebo-controlled, double-blind, randomized crossover protocol." | 5.05 | Comparison of oral propranolol and verapamil for combined systemic hypertension and angina pectoris. A placebo-controlled double-blind randomized crossover trial. ( Frishman, WH; Klein, NA; Klein, P; LeJemtel, TH; Pollack, S; Roth, S; Sonnenblick, EH; Strair, R; Strom, JA; Tawil, R; Wong, B, 1982) |
| "Monotherapy with the calcium antagonists verapamil, nifedipine, nitrendipine or diltiazem was shown to have a good efficacy/tolerability ratio in the treatment of patients with essential hypertension and overall blood pressure responses were comparable as well as similar to those observed with betablockers and diuretics." | 5.05 | Calcium antagonists, firstline partners for betablockers in hypertension. ( Bühler, FR, 1984) |
| "The aim of this study was to investigate and compare the effects of two calcium antagonist drugs, verapamil (VER) and nifedipine (NIF), on blood pressure (BP), heart rate (HR), plasma catecholamines (pCA), renin (PRA), plasma aldosterone (pALD), and plasma volume (PV) in a group of patients with mild to moderate essential hypertension." | 5.05 | Antihypertensive and humoral effects of verapamil and nifedipine in essential hypertension. ( Agabiti-Rosei, E; Alicandri, CL; Beschi, M; Castellano, M; Corea, L; Fariello, R; Muiesan, G; Romanelli, G, 1982) |
| "The antihypertensive efficacy of the calcium antagonist verapamil was tested in 43 patients with essential hypertension, examining relationships between age and pretreatment renin and blood pressure and comparing intraindividually the responses with those obtained using beta-blockers (n = 29) and diuretic therapy (n = 18)." | 5.05 | The place of the calcium antagonist verapamil in antihypertensive therapy. ( Bolli, P; Bühler, FR; Hulthén, UL; Kiowski, W; Müller, FB, 1982) |
| "In a double-blind, cross-over study for 6 weeks that included 28 patients with essential hypertension, WHO stage I-II, the hypotensive action of verapamil (160 mg thrice daily) was compared with nifedipine (20 mg slow release twice daily)." | 5.05 | Verapamil compared with nifedipine in the treatment of essential hypertension. ( Hals, O; Midtbø, K; van der Meer, J, 1982) |
| " Their clinical place in the management of hypertension has yet to be clearly defined, and thus we have performed an open crossover trial to compare the 24-hour profiles of blood pressure reduction after chronic therapy with propranolol and verapamil." | 5.05 | Propranolol versus verapamil for the treatment of essential hypertension. ( Gould, BA; Hornung, RS; Jones, RI; Raftery, EB; Sonecha, T, 1984) |
| " We studied the effects of two calcium antagonists, nifedipine and verapamil, on blood pressure, reactivity to exogenous noradrenaline and plasma noradrenaline concentration in 10 patients with essential hypertension." | 5.05 | Hypotensive action of calcium antagonists as related to plasma noradrenaline and reactivity to noradrenaline. ( Distler, A; Philipp, T; Reeck, S; Schwietzer, G; Thiede, HM, 1983) |
| "In 12 in-patients with moderate uncomplicated hypertension, maintained on constant sodium intake for 15 days, single-blind oral administration of verapamil 80-160 mg t." | 5.05 | Antihypertensive and renal effects of orally administered verapamil. ( Bianchini, C; Leonetti, G; Sala, C; Terzoli, L; Zanchetti, A, 1980) |
| "The antihypertensive efficacy of combination therapy with the angiotensin-converting enzyme inhibitor captopril and a diuretic or a calcium antagonist was compared in 16 patients with essential hypertension with a blood pressure of over 160/95 mm Hg having triple drug therapy." | 5.05 | Antihypertensive treatment using calcium antagonists in combination with captopril rather than diuretics. ( Bolli, P; Brouwer, RM; Bühler, FR; Conen, D; Erné, P; Kiowski, W, 1985) |
| "Renal plasma flow, glomerular filtration rate plasma angiotensin II, aldosterone and arginine vasopressin, free water clearance, blood pressure and body weight in 11 patients with mild to moderate hypertension were determined at the end of consecutive 6 week periods of administration of placebo and verapamil up to 120 mg t." | 5.05 | Effect of verapamil on renal plasma flow, glomerular filtration rate and plasma angiotensin II, aldosterone and arginine vasopressin in essential hypertension. ( Danielsen, H; Pedersen, EB; Sørensen, SS; Thomsen, OO, 1985) |
| " Extended-release nifedipine and amlodipine are the two most commonly used oral CCAs in the management of pediatric hypertension." | 4.83 | A review of calcium channel antagonists in the treatment of pediatric hypertension. ( Sahney, S, 2006) |
| " In comparative trials in the management of hypertension, trandolapril 1 to 4 mg/d was statistically indistinguishable from or superior to captopril 100 mg/d, enalapril 10 or 20 mg/d, hydrochlorothiazide (HCTZ) 25 mg/d, nifedipine ER 30 or 40 mg/d, nitrendipine 20 mg/d, perindopril 4 mg/d, and verapamil ER 120 to 240 mg/d." | 4.82 | Trandolapril: a newer angiotensin-converting enzyme inhibitor. ( Guay, DR, 2003) |
| "Calcium channel blockers (CCBs), which include both dihydropyridines such as nifedipine and amlodipine and non-dihydropyridines (verapamil and diltiazem), are among the most widely prescribed agents for the management of essential hypertension." | 4.82 | The role of existing and newer calcium channel blockers in the treatment of hypertension. ( Basile, J, 2004) |
| "In well designed studies in patients with mild to moderate hypertension, combinations of the sustained-release (SR) formulation of the nondihydropyridine calcium channel antagonist verapamil 120 to 240 mg/day and the ACE inhibitor trandolapril 0." | 4.81 | Fixed combination trandolapril/verapamil sustained-release: a review of its use in essential hypertension. ( Curran, MP; Muijsers, RB; Perry, CM, 2002) |
| "SEVERAL MECHANISMS: The progression in renal failure first implies hemodynamic mechanisms and among which angiotensin II has a central role, but also an increase in proteinuria and the induction of many inflammatory and mitogenic mediators that enhance fibrosis (TGF-beta), an effect stimulating the thrombotic mechanism." | 4.81 | [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]. ( Bernadet-Monrozies, P; Durand, D; Kamar, N; Rostaing, L, 2002) |
| "From three large, randomized, placebo-controlled, secondary prevention trials investigating verapamil or diltiazem (the first and second Danish Verapamil Infarction Trials and the Multicentre Diltiazem Post-Infarction Trial) data from a total of 1,325 hypertensive post-myocardial infarction patients (drugs = 667, placebo = 658) were pooled to assess effect of blinded therapy on mortality and event rates." | 4.81 | Heart rate-lowering calcium antagonists in hypertensive post-myocardial infarction patients. ( Boden, WE; Gibson, RS; Hansen, JF; Messerli, FH; Schechtman, KB, 2001) |
| "In all patients combined, the incidence of constipation (13% vs 2%), dizziness (6% vs 2%), and back pain (3% vs 1%) was higher in patients treated with COER verapamil than with placebo." | 4.81 | Safety of controlled-onset extended-release verapamil in middle-aged and older patients with hypertension and coronary artery disease. ( Anders, RJ; Black, HR; Elliott, WJ; Johnson, MF; White, WB, 2001) |
| "Based on over 4,000 person-years of observation, patients with acute myocardial infarction (MI) treated with verapamil had a decreased risk of nonfatal reinfarction compared with placebo (relative risk 0." | 4.80 | Verapamil use in patients with cardiovascular disease: an overview of randomized trials. ( Faich, G; Makuch, R; Pepine, CJ, 1998) |
| "To evaluate the effects of COER-verapamil on circadian blood pressure (BP) and heart rate in African-American patients with hypertension." | 4.80 | Effects of the chronotherapeutic delivery of verapamil on circadian blood pressure in African-American patients with hypertension. ( Black, HR; Fakouhi, TD; Johnson, MF; White, WB, 1999) |
| "Preclinical studies were designed to investigate whether the combination of verapamil and trandolapril was more potent than either drug alone for the treatment of hypertension and concomitant cardiovascular or metabolic diseases." | 4.79 | Preclinical considerations and results with the combination of verapamil and trandolapril: blood pressure reduction and beyond. ( Kirchengast, M, 1997) |
| "Various doses of verapamil, using the conventional and sustained release formulations, have been administered for the treatment of mild or moderate hypertension in different controlled studies for periods of 4-6 weeks, involving a total of 103 patients, and in one long-term trial for 1 year in 12 patients." | 4.77 | Studies on verapamil in the treatment of essential hypertension: a review. ( Hals, O; Lauve, O; Midtbø, K; Storstein, L; van der Meer, J, 1986) |
| "Sustained-release diltiazem (D-SR) and sustained-release verapamil (V-SR) when given twice a day have been successfully used to treat both essential hypertension and angina pectoris." | 4.77 | Treatment of angina pectoris and hypertension with sustained-release calcium channel-blocking drugs. ( Klein, MD; Weiner, DA, 1987) |
| "This review focuses on the potential use of the calcium antagonists diltiazem, nifedipine, and verapamil in the treatment of hypertensive emergencies." | 4.77 | The role of calcium entry blockers in hypertensive emergencies. ( Bauer, JH; Reams, GP, 1987) |
| " Verapamil is extremely effective in patients with supraventricular tachyarrhythmias, hypertrophic cardiomyopathy, and the various anginal syndromes, but it appears to be ineffective or possibly even deleterious in those with pulmonary hypertension, congestive heart failure of any cause, and Raynaud's phenomenon or disease." | 4.77 | Calcium antagonists in patients with cardiovascular disease. Current perspectives. ( Hillis, LD; Winniford, MD, 1985) |
| " Nifedipine and diltiazem are effective in the relief of angina, and verapamil is used in the treatment of supraventricular tachyarrhythmias." | 4.77 | Calcium channel blocking agents: physiologic basis of nursing intervention. ( Touloukian, JE, 1985) |
| " In chronic arterial hypertension, verapamil, and especially diltiazem seem to be superior to nifedipine." | 4.76 | Treatment of hypertension with calcium channel blockers: European data. ( Klein, WW, 1984) |
| "Hydralazine, doxazosin, and verapamil are currently recommended by the Endocrine Society as acceptable bridging treatment in those in whom full cessation of antihypertensive medication is infeasible during screening for primary aldosteronism (PA)." | 4.31 | The Effects of Verapamil, Hydralazine, and Doxazosin on Renin, Aldosterone, and the Ratio Thereof. ( Alnazer, RM; de Leeuw, PW; Kroon, AA; Veldhuizen, GP, 2023) |
| " Medical history was notable for hypertension, hyperlipidaemia, type 2 diabetes, and a recently diagnosed SARS-CoV-2 (COVID-19) infection for which she was prescribed ritonavir-boosted nirmatrelvir (Paxlovid) two days before the presentation." | 4.31 | Pharmacokinetic interaction between verapamil and ritonavir-boosted nirmatrelvir: implications for the management of COVID-19 in patients with hypertension. ( Haque, OI; Hussain, S; Mahar, S; Sloane, P, 2023) |
| "The US cohort of the International Verapamil SR-Trandolapril Study (INVEST), a randomized clinical trial of 16 688 patients aged 50 years or older with hypertension and coronary artery disease, was conducted between September 2, 1997, and December 15, 2000, with in-trial follow-up through February 14, 2003." | 4.02 | Association of 1-Year Blood Pressure Variability With Long-term Mortality Among Adults With Coronary Artery Disease: A Post Hoc Analysis of a Randomized Clinical Trial. ( Cooper-DeHoff, RM; Dasa, O; Gong, Y; Handberg, E; Howard, G; Pepine, CJ; Smith, SM, 2021) |
| "Male Wistar rats were submitted to two kidneys, one clip (2K1C) model of hypertension or sham surgery and were treated with verapamil (VRP, 8 mg/kg/bid) by gavage from the second to tenth week post-surgery." | 3.96 | Verapamil decreases calpain-1 and matrix metalloproteinase-2 activities and improves hypertension-induced hypertrophic cardiac remodeling in rats. ( Blascke de Mello, MM; Castro, MM; Fazan, R; Mendes, AS; Neto-Neves, EM; Omoto, ACM; Parente, JM; Tanus-Santos, JE, 2020) |
| " He was taking verapamil, clonidine, and hydralazine for hypertension." | 3.91 | Bradycardia in a Man With Hypertension. ( Drutel, RO; Glancy, DL; Payne, JR, 2019) |
| " James Women Take Heart (WTH; women without coronary disease at baseline), Women's Ischemia Syndrome Evaluation (women with signs/symptoms of ischemia at baseline), and the INternational VErapamil-Trandolapril STudy (INVEST; women with coronary artery disease and hypertension at baseline), totaling 15,108 adult women with no hypertension, non-RH (blood pressure [BP] ≥140/90 mmHg on ≤2 drugs or BP <140/90 mmHg on 1-3 drugs), or aRH (BP ≥140/90 mmHg on ≥3 drugs or anyone on ≥4 drugs) at baseline." | 3.83 | Mortality Risk Associated With Resistant Hypertension Among Women: Analysis from Three Prospective Cohorts Encompassing the Spectrum of Women's Heart Disease. ( Cooper-DeHoff, RM; Gong, Y; Gulati, M; Handberg, E; Huo, T; Merz, CN; Pepine, CJ; Smith, SM, 2016) |
| " We therefore investigated the effects of diltiazem on cardiac gene expression in normotensive and hypertensive rats with left ventricular hypertrophy and compared the results with our previous findings on verapamil and nifedipine." | 3.83 | Gene expression profiling of calcium-channel antagonists in the heart of hypertensive and normotensive rats reveals class specific effects. ( Borlak, J; Zwadlo, C, 2016) |
| "to compare efficacy of verapamil and amlodipine in treatment of chronic heart failure (CHF) with preserved left ventricular (LV) ejection fraction (EF) in patients with hypertensive disease (HD)." | 3.83 | [Comparison of Verapamil and Amlodipine for Treatment of Chronic Heart Failure With Preserved Left Ventricular Ejection Fraction in Patients With Hypertensive Disease]. ( Kanorskii, SG; Sereda, AF, 2016) |
| "Verapamil is a calcium channel blocker commonly used in treatments of hypertension." | 3.80 | A pharmacokinetic drug-drug interaction model of simvastatin and verapamil in humans. ( Chamnansua, M; Kaewdang, N; Lohitnavy, M; Methaneethorn, J, 2014) |
| "Renal failure patients with baseline mild hyperkalaemia are particularly liable to bradyarrhythmias with SR verapamil." | 3.78 | Junctional bradycardia with verapamil in renal failure--care required even with mild hyperkalaemia. ( Al-Mutairi, S; Aldabie, G; El Sayed, A; Hegazi, MO, 2012) |
| " Metabolic dysregulation is a major contributor to coronary disease; therefore, we assessed LXRA in International Verapamil Sustained Release SR Trandolapril Study Genetic Substudy (INVEST-GENES), a genetic-substudy of a large clinical trial in patients with hypertension and coronary artery disease." | 3.77 | Liver X receptor α gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study. ( Cooper-DeHoff, RM; Johnson, JA; Martin, MA; Pacanowski, MA; Pepine, CJ; Price, ET; Zineh, I, 2011) |
| "This was a post hoc analysis from the INternational VErapamil Trandolapril STudy (INVEST), which enrolled patients with hypertension and coronary artery disease." | 3.77 | Harmful effects of NSAIDs among patients with hypertension and coronary artery disease. ( Bavry, AA; Cooper-Dehoff, RM; Gong, Y; Handberg, EM; Khaliq, A; Pepine, CJ, 2011) |
| " Concomitant verapamil therapy for hypertension did not prevent the vasospastic effects of dihydroergotamine." | 3.77 | Dihydroergotamine-induced vasospastic angina in a patient taking a calcium channel blocker. ( Johnson, BD; Schenkat, DH; Schulz, LT, 2011) |
| " The pharmacokinetics of verapamil and of one of its metabolites, norverapamil, is changed after multiple oral dosing as has been described in patients with supraventricular tachyarrhythmias, angina pectoris or in patients with essential hypertension." | 3.76 | Pharmacokinetics of calcium channel blocking agents. ( Anderson, P, 1986) |
| " After receiving a nonselective slow infusion of verapamil, the patient developed an episode of extreme hypertension." | 3.75 | Near-complete resolution of angiographic cerebral vasospasm after extreme elevation of mean arterial pressure: case report. ( Dacey, RG; Derdeyn, CP; Diringer, MN; Moran, CJ; Ray, WZ; Zipfel, GJ, 2009) |
| " We retrospectively analyzed the International Verapamil SR-Trandolapril Study, which randomized coronary artery disease patients with hypertension to either verapamil SR- or atenolol-based treatment strategies, focusing on characteristics and outcomes of 6166 previously revascularized patients compared with 16 410 nonrevascularized patients." | 3.75 | Characteristics and outcomes of revascularized patients with hypertension: an international verapamil SR-trandolapril substudy. ( Aranda, JM; Champion, A; Cooper-Dehoff, RM; Denardo, SJ; Gaxiola, E; Gong, Y; Handberg, EM; Messerli, FH; Pepine, CJ; Zhou, Q, 2009) |
| "7-year follow-up, compared a calcium antagonist-led strategy (verapamil SR plus trandolapril) with a beta-blocker-led strategy (atenolol plus hydrochlorothiazide) for hypertension treatment and prevention of cardiovascular outcomes in coronary artery disease patients." | 3.75 | INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study. ( Champion, A; Cooper-DeHoff, RM; Handberg, EM; Legler, UF; Mancia, G; Pepine, CJ; Zhou, Q, 2009) |
| " Administration of verapamil, an L-type calcium channel blocker which was effective for hypertension in SHRSP rats, prevented the decrease in plasma protein expression." | 3.74 | Proteomic identification of haptoglobin as a stroke plasma biomarker in spontaneously hypertensive stroke-prone rats. ( Goto, H; Hayashi, K; Kiga, C; Saiki, I; Sakurai, H; Shimada, Y, 2008) |
| "Results of several clinical trials have shown that verapamil is effective in reducing blood pressure (BP) in African Americans, a population at high risk for hypertension and target-organ damage." | 3.73 | Chronotherapeutic oral drug absorption system verapamil is effective in reducing morning blood pressure in African Americans: a post hoc analysis of the chrono trial. ( Black, HR; Prisant, LM; Weber, M, 2005) |
| "we observe the efficacy of verapamil and amlodipine administered simultaneously in the medical treatment of endogenous hyperinsulinemic hypoglycemia." | 3.73 | [Successful pharmacological treatment of hyperinsulinemic hypoglycemia with verapamil and amlodipine--case report]. ( Owecki, M; Sowiński, J, 2005) |
| "To understand the effects of single- and multiple-drug combinations for hypertension on the risk of adverse clinical outcomes, the authors analyzed data from the International Verapamil SR/Trandolapril Study (INVEST)." | 3.73 | A drug dose model for predicting clinical outcomes in hypertensive coronary disease patients. ( Cooper-DeHoff, R; Elliott, WJ; Hewkin, AC; Kupfer, S; Pepine, CJ, 2005) |
| " A verapamil SR strategy is an alternative to an atenolol strategy for the treatment of Hispanic patients with hypertension and CAD and can reduce the risk of new-onset diabetes." | 3.73 | Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients--findings from the International Verapamil SR/Trandolapril Study (INVEST). ( Aranda, JM; Cangiano, JL; Conti, CR; Cooper-DeHoff, RM; Garcia-Barreto, D; Gaxiola, E; Hewkin, A; Pepine, CJ, 2006) |
| " Combination therapy of valsartan with either amlodipine or verapamil was equally effective in reducing blood pressure to valsartan monotherapy (valsartan + amlodipine 129 +/- 4 valsartan + verapamil 133 +/- 6 mmHg;) but was not as effective at reducing albuminuria." | 3.72 | Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin. ( Allen, TJ; Cao, Z; Cooper, ME; Davis, BJ; de Gasparo, M; Kawachi, H, 2003) |
| "Population pharmacokinetic analyses were performed on data from 186 patients with hypertension, coronary artery disease, or supraventricular arrhythmias who were receiving long-term sustained-release oral racemic verapamil (Covera SR in 105 patients, Calan SR in 67 patients, and other formulations in 14 patients; mean +/- SD dose, 280 +/- 139 mg) for clinical care or as a part of phase III efficacy studies." | 3.72 | Population analyses of sustained-release verapamil in patients: effects of sex, race, and smoking. ( Gupta, SK; Kang, D; Krecic-Shepard, ME; Modi, NB; Schwartz, JB; Verotta, D, 2003) |
| "We investigated the potential of chronic administration of an oral daily dose (10 mg/kg) of the dietary flavonoid quercetin to prevent hypertension and oxidative stress induced by deoxycorticosterone acetate (DOCA)-salt in rats." | 3.72 | Effects of chronic quercetin treatment on antioxidant defence system and oxidative status of deoxycorticosterone acetate-salt-hypertensive rats. ( Duarte, J; Galisteo, M; García-Saura, MF; Jiménez, R; Vargas, F; Villar, IC; Zarzuelo, A, 2004) |
| " A second combination compound including verapamil 180 mg and trandolapril 2 mg daily was added 5 days prior to hospitalisation due to insufficient control of arterial hypertension." | 3.72 | [Lethal polypharmacy in a patient with arterial hypertension]. ( Diethelm, M; Joerger, M, 2004) |
| "To study the dose-ranging population pharmacokinetics of controlled release verapamil in healthy subjects and patients with angina or hypertension." | 3.71 | Pharmacokinetics of controlled-release verapamil in healthy volunteers and patients with hypertension or angina. ( Aarons, L; Gupta, S; Ho Pl, PL; Modi, NB; Sathyan, G, 2002) |
| "We compared the chronic effects in spontaneously hypertensive rats (SHR) of low doses of an angiotensin converting enzyme inhibitor, trandolapril, a Ca2+ channel antagonist, verapamil, and their combination (trandolapril-verapamil), on arterial mechanical properties, arterial wall hypertrophy and extracellular matrix proteins." | 3.70 | Prevention of arterial structural alterations with verapamil and trandolapril and consequences for mechanical properties in spontaneously hypertensive rats. ( Benetos, A; Kirchengaast, M; Koffi, I; Lacolley, P; Laurent, S; Pomiès, JP, 1998) |
| " In young Dahl/S rats, an angiotensin-converting enzyme inhibitor, imidapril, attenuated the development of proteinuria accompanied by a decrease in blood pressure." | 3.70 | Involvement of angiotensin II in development of spontaneous nephrosis in Dahl salt-sensitive rats. ( Fujimura, H; Nishiyama, S; Ohmachi, Y; Okumura, F; Toriumi, W; Yoneda, H, 1998) |
| "Ninety patients, 50 males and 40 females, and their ages ranged between 42 and 70 years, with severe hypertension were treated by either sublingual verapamil tablets 40 mg (30 patients) or 80 mg (30 patients) or sublingual nifedipine capsules 10 mg (30 patients)." | 3.70 | Efficacy of sublingual verapamil in patients with severe essential hypertension: comparison with sublingual nifedipine. ( Al-Waili, NS; Hasan, NA, 1999) |
| "To analyse the effects of endothelin-1 and vasopressin on the sympathetic vasoconstriction during hypertension." | 3.70 | Impaired potentiation by endothelin-1 and vasopressin of sympathetic contraction in tail artery from hypertensive rats. ( Diéguez, G; Fernández, N; García-Villalón, AL; Gómez, B; Martínez, MA; Monge, L; Sánchez, MA, 2000) |
| "We assessed the effect of 240 mg/day sustained released verapamil on blood pressure and heart rate, measured in the office and at home, in 1395 hypertensive outpatients with mild-to-moderate hypertension, who were using an Omron HEM 705 CP automatic device for self-measurement." | 3.70 | Effect of verapamil on home self-measurement of blood pressure and heart rate by hypertensive patients. Verapamil-Frequency Research Group. ( de La Figuera, M; Fernández-González, R; Gabriel, R; Gómez-Pajuelo, C; Moreno, E, 2000) |
| " The atherogenic significance of Ca ions and arterial Ca overload was examined under the influence of nicotine, oxidatively modified low-density lipoproteins, spontaneous hypertension, and an elevated extracellular Ca concentration or vitamin D3." | 3.69 | Experimental vasoprotection by calcium antagonists against calcium-mediated arteriosclerotic alterations. ( Czirfuzs, A; Fleckenstein-Grün, G; Frey, M; Matyas, S; Thimm, F, 1994) |
| "The authors examined the efficacy and safety of the combination of verapamil and nifedipine in the control of hypertension." | 3.69 | Verapamil and nifedipine in combination for the treatment of hypertension. ( Bottini, PB; Carr, AA; Kaesemeyer, WH; Prisant, LM, 1994) |
| "To describe a patient with asymptomatic bronchial asthma and hypertension who developed an acute asthma attack after receiving sustained-release verapamil." | 3.69 | Acute asthma associated with sustained-release verapamil. ( Ben-Noun, L, 1997) |
| "We sought to characterize the effects of the nonselective Ca2+ channel antagonist, verapamil, and the vascular-selective Ca2+ channel antagonist, felodipine, on obese, hypertensive, heart failure-prone, female SHHF/Mcc-fa(cp) rats." | 3.69 | Verapamil accelerates the transition to heart failure in obese, hypertensive, female SHHF/Mcc-fa(cp) rats. ( Altschuld, RA; Hensley, J; Hoepf, TM; Hohl, CM; McCune, SA; Park, S; Radin, MJ, 1997) |
| " This article describes the case of a patient affected by pheochromocytoma in whom multiple organ failure developed after contemporary administration of ergotamine, caffeine, and nimesulide." | 3.69 | Pheochromocytoma crisis caused by contemporary ergotamine, caffeine, and nimesulide administration. ( Bartoli, P; Bonechi, F; Brandinelli, A; Del Rosso, A; Fradella, G; Ieri, A; Maioli, M; Mannelli, M; Mazza, F; Russo, L; Sansoni, M; Zipoli, A, 1997) |
| "Thirty-three hypertensive patients with left ventricular hypertrophy were treated with slow-release verapamil for 1 year." | 3.69 | [Study of the mechanism of regression of left ventricular hypertrophy in hypertension treated with slow-release verapamil]. ( Li, G; Sun, M; Zhou, H, 1997) |
| "Hypothalamic inhibitory factor (HIF) is an endogenous high-affinity inhibitor of Na+,K(+)-ATPase with ouabain-like properties and has been implicated in the pathogenesis of genetic systemic hypertension." | 3.68 | Hypothalamic Na+,K(+)-ATPase inhibitor constricts pulmonary arteries of spontaneously hypertensive rats. ( Hales, CA; Haupert, GT; Janssens, SP; Kachoris, C; Parker, WL, 1993) |
| " The purpose of the present study was to investigate the effects of Ca(2+)-antagonists (verapamil and diltiazem) on dopamine release in the central nervous system in hypertension." | 3.68 | Effects of verapamil and diltiazem on dopamine release in the central nervous system of spontaneously hypertensive rats. ( Goldstein, M; Masuyama, Y; Tsuda, K; Tsuda, S, 1993) |
| "Cadmium, a trace element from natural and industrial sources, may contribute to the pathogenesis of arterial hypertension." | 3.68 | Verapamil prevents the acute hypertensive response to intracerebroventricular cadmium in conscious normotensive rats. ( Anania, V; Demontis, MP; Fattaccio, MC; Madeddu, P; Palmieri, A; Varoni, MV, 1993) |
| "The calcium antagonist verapamil has been demonstrated to be effective in reducing hypertension in patients in whom sodium intake was not restricted." | 3.68 | The antihypertensive effect of verapamil in patients with chronic renal failure. ( Alcazar, JM; Rodicio, JL; Ruilope, LM, 1992) |
| "The effects of verapamil or diltiazem on pressor responses to posterior hypothalamic stimulation, injected noradrenaline or tyramine were studied in urethane-anaesthetized normotensive, deoxycorticosterone acetate (DOCA), renal and spontaneously hypertensive rats at the early and established phases of hypertension." | 3.68 | Failure of verapamil and diltiazem to attenuate the pressor response to hypothalamic stimulation: a possible mechanism. ( Eferakeya, AE; Osunkwo, UA, 1992) |
| "We performed two sets of experiments in order to prevent or to regress cardiac and vascular hypertrophy, using antihypertensive and subantihypertensive doses of the angiotensin converting enzyme inhibitor zabicipril." | 3.68 | Cardiac and vascular effects of chronic angiotensin converting enzyme inhibition at subantihypertensive doses. ( Gohlke, P; Lamberty, V; Mall, G; Martorana, P; Mattfeld, T; Stoll, M; Unger, T; van Even, P, 1992) |
| "The aim of the present study was to define the protective effects of verapamil and nifedipine on mechanical performance and energy and substrate metabolism of the postischemically reperfused myocardium in a chronic pressure overload cardiac hypertrophy model." | 3.68 | Protective effects of calcium antagonists on energy and substrate metabolism during ischemia and reperfusion in hypertensive myocardial hypertrophy. ( Buser, PT; Higgins, CB; Wagner, S; Wikman-Coffelt, J; Wu, S, 1991) |
| "The influence of age on the pharmacokinetics of verapamil at steady state has been studied in 74 individuals, age range 19-79 years, including healthy normotensive volunteers and patients with essential hypertension." | 3.68 | The influence of age on the pharmacokinetics of verapamil. ( Ahmed, JH; Elliott, HL; Meredith, PA, 1991) |
| "As many as 98 patients suffering from essential hypertension (EH) were examined for the effects of verapamil and nifedipine." | 3.68 | [The hemodynamic reactions of hypertension patients taking the calcium antagonists finoptin and korinfar]. ( Geller, AL; Goldabin, VI; Goloshchapov, OA; Mashin, AA, 1990) |
| " In order to precise the molecular cause of the phenomenon and the eventual action of calcium channel blockers on the development of this organic characteristic of hypertension, we have compared the responses of cultured cells from both SH and WKY rats to various agents in the absence or presence of verapamil." | 3.68 | [Role of external calcium on the growth of aortic smooth muscle cells in SHR]. ( Baudouin-Legros, M; Brunelle, G; Donnadieu, E; Meyer, P; Paquet, JL, 1990) |
| "We evaluated the effect of verapamil therapy on left ventricular hypertrophy and left ventricular diastolic function in 13 patients with mild to moderate hypertension." | 3.68 | Improvement in left ventricular hypertrophy and left ventricular diastolic function following verapamil therapy in mild to moderate hypertension. ( Conte, D; Douste-Blazy, MY; Galinier, F; Granier, P; Tredez, P, 1990) |
| "The effects of caffeine on aortic smooth muscle contractility during hypertension were studied in SHR and WKY control rats." | 3.68 | In vitro caffeine induced aortic smooth muscle reactivity in rat. ( Bennett, T; Mangroo, T; Neves, M; Rahmani, MA, 1990) |
| "The antihypertensive efficacy of the calcium entry blocker nitrendipine administered as monotherapy (20-80 mg; mean, 36/day) on the average for 144 days to 46 patients with essential hypertension (WHO I and II) was investigated in relation to age, pretreatment blood pressure, and plasma renin activity." | 3.67 | Antihypertensive therapy with the long-acting calcium antagonist nitrendipine. ( Block, LH; Bolli, P; Bühler, FR; Erne, P; Kiowski, W; Müller, FB, 1984) |
| " (160 mg, n = 9) on the pressor effect of the unselective alpha-adrenergic agonist noradrenaline, as well as on 3H-yohimbine binding to platelet alpha 2-adrenoceptors was studied in patients with essential hypertension." | 3.67 | Effect of nifedipine and verapamil on alpha-receptor-activation in patients with essential hypertension. ( Distler, A; Fritschka, E; Kribben, A; Lenz, T; Philipp, T; Schudrowitsch, L, 1984) |
| " In the second study the leucocyte sodium content of 14 patients with essential hypertension was investigated before and after treatment with the calcium antagonist verapamil." | 3.67 | Cellular sodium concentration and vasoconstrictor state in hypertension. ( Crowther, A; Dittrich, HC; Gray, HH; Hilton, PJ; MacGregor, GA; Poston, L; Webb-Peploe, MM, 1984) |
| "In fifteen patients with uncomplicated essential hypertension verapamil reduced systolic as well as diastolic blood pressure by virtue of a decrease in total peripheral vascular resistance." | 3.67 | Effects of verapamil in hypertensive patients. ( Birkenhäger, WH; de Leeuw, PW, 1984) |
| "The effect of verapamil on different metabolic parameters has been studied after changing the treatment of hypertension from hydrochlorothiazide to verapamil monotherapy." | 3.67 | Metabolic parameters after changing from hydrochlorothiazide to verapamil treatment in hypertension. ( Gordin, A; Lehtonen, A, 1984) |
| "The effect of treatment with verapamil on cell sodium transport was studied in the leucocytes of patients with essential hypertension." | 3.67 | Reversal by verapamil of defect in sodium transport in leucocytes in essential hypertension. ( Gray, HH; Hilton, PJ; MacGregor, GA; Markandu, ND; Poston, L; Smith, SJ, 1984) |
| "Twenty-four subjects with mild to moderate essential hypertension completed this 9-wk parallel, randomized, double-blind study of the antihypertensive effects of verapamil (V) (240 to 480 mg%) and propranolol (P) (120 to 360 mg%)." | 3.67 | Verapamil and propranolol in essential hypertension. ( Cubeddu, LX; Gross, KM; Halperin, AK; Rogers, JF, 1984) |
| "In recent years the calcium antagonist verapamil has been used in the treatment of essential hypertension." | 3.67 | Hemodynamic effects of verapamil in essential hypertension at rest and during exercise. ( Lund-Johansen, P, 1984) |
| "Based on the vasodilator properties of calcium antagonists, verapamil was recently introduced into the treatment of arterial hypertension." | 3.67 | Long-term treatment of arterial hypertension with verapamil. ( Aviram, A; Blum, M; Peer, G; Soferman, G; Wigler, I, 1984) |
| "In stroke-prone spontaneously hypertensive rats, oral long-term treatment with verapamil, propranolol, hydrochlorothiazide, and dihydralazine attenuated the development of hypertension." | 3.67 | Development of hypertension and life span in stroke-prone spontaneously hypertensive rats during oral long-term treatment with various antihypertensive drugs. ( Gries, J; Kretzschmar, R; Neumann, BW, 1989) |
| "The interference by two unrelated calcium entry blockers, nicardipine and verapamil, with the forearm vascular response to graded exogenous norepinephrine was evaluated in two groups (n = 6 each) of patients with uncomplicated hypertension." | 3.67 | Calcium entry blockade and alpha-adrenergic vascular reactivity in human beings: differences between nicardipine and verapamil. ( Pedrinelli, R; Salvetti, A; Taddei, S, 1989) |
| "As many as 52 patients with essential hypertension aggravated by circulatory failure were examined for the clinical, hemodynamic and neurohumoral parameters during furosemide stimulation." | 3.67 | [The efficacy of calcium antagonists in circulatory failure in elderly patients with hypertension]. ( Orynchak, MA, 1989) |
| "In order to try and evaluate through what prevailing mechanism verapamil (V) can induce an improvement in left ventricular (LV) diastolic early filling in mild to moderate essential hypertension, 43 properly classified essential hypertensives, aged 41-74 years (mean age 58." | 3.67 | Left ventricular diastolic filling improvement obtained by intravenous verapamil in mild to moderate essential hypertension: a complex effect. ( Bisi, G; Fabbri, G; Franchi, F; Matassi, L; Monopoli, A; Rossi, D; Strazzulla, G, 1989) |
| "This study was carried out to investigate the hypotensive mechanisms of ketanserin and Ca-antagonists (verapamil and diltiazem) in hypertension." | 3.67 | Effects of ketanserin, verapamil and diltiazem on vascular sympathetic nerve activity in hypertension. ( Masuyama, Y; Nishio, I; Tsuda, K, 1989) |
| "Fifty-two cases of hypertension were treated with verapamil." | 3.67 | [Therapeutic effect of verapamil in hypertension: an analysis of 52 cases]. ( Wang, JJ; Wen, ZB; Zong, JL, 1989) |
| " In our study, we used enalapril, furosemide and verapamil for treatment of arterial hypertension in cardiac transplant recipients and investigated the influence of these drugs on ciclosporin whole blood trough levels." | 3.67 | [Effect of enalapril, furosemide and verapamil on cyclosporin concentration in whole blood]. ( Angermann, CE; Anthuber, M; Kemkes, BM; Spes, CH; Theisen, K, 1988) |
| " Calcium antagonists, including verapamil, are now used widely in the management of patients with hypertension." | 3.67 | Calcium antagonists and hypertension. ( Dillon, JS; Nayler, WG; Sturrock, WJ, 1988) |
| "This study was designed to examine the mechanisms that contribute to the chronic hypotensive effects of verapamil during angiotensin II-induced hypertension." | 3.67 | Chronic hypotensive effects of verapamil in angiotensin hypertension are steroid independent. ( Lohmeier, TE; Montani, JP; Rushing, EL; Smith, MJ, 1989) |
| "Arterial blood pressure and central hemodynamic changes were assessed in 44 patients with essential hypertension, uncontrollable by prazosin alone, after propranolol (anaprilin), celiprolol, clonidine (clofelin) or verapamil were added to the treatment schedule." | 3.67 | [Hemodynamic effect of a combination of prazosin with cardiac depressants in the treatment of hypertension]. ( Akopian, LM; Basem, AS; Ivleva, AIa; Krasnobaeva, GM; Moiseev, VS, 1988) |
| "The effects of long-term treatment with verapamil on blood pressure, cardiac hypertrophy and collagen content, collagen concentration and prolyl hydroxylase activity were studied in spontaneously hypertensive rats (SHR)." | 3.67 | Effects of long-term verapamil treatment on blood pressure, cardiac hypertrophy and collagen metabolism in spontaneously hypertensive rats. ( Ruskoaho, HJ; Savolainen, ER, 1985) |
| "Based on their previous observations of the stimulating action of verapamil on the secretory reserve of cortisol after one-week oral administration to healthy volunteers, the author investigated the effect of this calcium entry blocker on the adrenocortical function (cortisol and aldosterone secretion) during therapeutic administration to patients with mild arterial hypertension and normotensive patients suffering from Raynaud's syndrome." | 3.67 | The effect of long-term verapamil treatment on the secretion of cortisol and aldosterone in subjects with normal and high blood pressure. ( Zofková, I, 1985) |
| "The effects of 2 calcium antagonist drugs, verapamil and nifedipine, on blood pressure, heart rate (HR), plasma catecholamines, plasma renin activity and some echocardiographic indexes of left ventricular anatomy and function were studied in 67 patients with essential hypertension." | 3.67 | Adrenergic activity and left ventricular function during treatment of essential hypertension with calcium antagonists. ( Agabiti-Rosei, E; Beschi, M; Castellano, M; Muiesan, G; Muiesan, ML; Romanelli, G, 1986) |
| " Due to uncontrolled hypertension, sustained-release (SR) verapamil 240 mg/d was added with no change in cyclosporine levels." | 3.67 | Increased cyclosporine blood concentrations due to verapamil administration. ( Bartels, DW; Maggio, TG, 1988) |
| "Nifedipine was used successfully in nine patients with refractory hypertension and left ventricular hypertrophy who had symptoms of congestive heart failure despite preserved left ventricular systolic function." | 3.67 | Nifedipine in severely hypertensive patients with congestive heart failure and preserved ventricular systolic function. ( Dzau, VJ; Given, BD; Lee, TH; Stone, PH, 1985) |
| "A 56-year-old female patient on verapamil for hypertension experienced two episodes of jaundice, pruritus and upper abdominal pain with transaminase elevated up to six-fold and alkaline phosphatase up to four-fold when inadvertently re-challenged with the drug." | 3.67 | Liver injury due to verapamil. ( Abernethy, DR; Burgunder, JM; Lauterburg, BH, 1988) |
| "In a prospective, open study 45 patients (mean age fifty-three years) with essential hypertension were treated with verapamil for four to eight years (mean 5." | 3.67 | No metabolic side effects of long-term treatment with verapamil in hypertension. ( Hals, O; Lauve, O; Midtbø, K, 1988) |
| "Verapamil, a calcium-entry blocker, and sodium nitroprusside, a non-specific vasodilator, were infused into the blood-perfused hindlimbs of New Zealand genetically hypertensive rats (NZGH) and spontaneously hypertensive rats (SHR), two genetic models of hypertension, and their normotensive controls, New Zealand normotensive rats and Wistar-Kyoto rats (WKY)." | 3.67 | Effect of verapamil and sodium nitroprusside on hindlimb vascular resistance in New Zealand genetically hypertensive and Japanese spontaneously hypertensive rats. ( Phelan, EL; Simpson, FO, 1988) |
| "A single-blind trial was carried out in 18 patients with moderately severe hypertension to investigate the efficacy of the angiotensin-converting enzyme inhibitor captopril in combination with the calcium antagonist verapamil after treatment with captopril alone had failed to achieve satisfactory control." | 3.67 | The combination of verapamil and captopril in the treatment of essential hypertension. ( Heagerty, AM; Swales, JD, 1987) |
| "The calcium antagonist verapamil was infused intravenously in 10 patients with severe postpartum gestational proteinuric hypertension." | 3.67 | Verapamil in the treatment of severe postpartum hypertension. ( Belfort, MA; Moore, PJ, 1988) |
| "Pharmacodynamic and therapeutic studies with a new slow release 240 mg verapamil formulation were performed in a total of 73 patients with essential hypertension (WHO I-II, diastolic greater than or equal to 100 mm Hg)." | 3.67 | Once a day verapamil in essential hypertension. ( Bühler, FR; Follath, F; Ha, HR; Hotz, H; Müller, FB; Schmidlin, O, 1986) |
| "The cardiovascular effects of intravenous verapamil and 3 months of oral administration of a slow-release form of verapamil (verapamil-SR) were studied in 10 patients with mild-to-moderate essential hypertension." | 3.67 | Cardiovascular effects of verapamil in patients with essential hypertension. ( Garavaglia, GE; Messerli, FH; Nunez, BD; Schmieder, RE, 1987) |
| "The pressor effects of a single infusion of calcium gluconate (1375 mg) were measured in 20 patients, aged 31-63 years, with mild and moderate essential hypertension, being on long-term treatment with the slow calcium channel blocker verapamil." | 3.67 | Can blood pressure reduction induced by slow calcium channel blockade (verapamil) be reversed by calcium infusion? ( Hals, O; Midtbø, K, 1987) |
| "In 20 patients with mild to moderate essential hypertension, serum ionized calcium was determined before and after four weeks of treatment with 240 mg verapamil sustained release bid." | 3.67 | Serum ionized calcium--a predictor of therapeutic response to slow calcium channel blockade in essential hypertension. ( Hals, O; Midtbø, K, 1987) |
| " In this study, we evaluated the hemodynamic response to the prototypic calcium-channel antagonist, verapamil, in patients with moderate-to-severe hypertension." | 3.67 | The hemodynamics of calcium-channel antagonists in hypertension: vascular and myocardial responses. ( Cody, RJ, 1987) |
| "To characterize the hemodynamic response to exercise and the effects of calcium channel antagonism in hypertensive subjects, invasive exercise hemodynamics were performed in the baseline state after intravenous infusion of verapamil and after 5 to 7 days of oral verapamil in 10 subjects with moderate to severe hypertension." | 3.67 | Exercise hemodynamics and oxygen delivery in human hypertension. Response to verapamil. ( Cody, RJ; Covit, AB; Kubo, SH; Laragh, JH; Lopez-Ovejero, J; Müller, FB, 1986) |
| "A solution of verapamil in sequential intravenous infusion was used in patients with severe arterial hypertension who were resistant to various antihypertensive drug regimens." | 3.67 | Efficacy of verapamil in patients resistant to other antihypertensive therapy. ( Carrasco, RM; Luna, RL, 1986) |
| "The antihypertensive effect of twice-daily administration of verapamil hydrochloride was evaluated in 21 adult patients with mild to moderate essential hypertension." | 3.67 | Twice-daily administration of oral verapamil in the treatment of essential hypertension. ( Charlap, S; Dorsa, F; Frishman, W; Kimmel, B; Monuszko, E; Pollack, S; Saltzberg, S; Stroh, J; Weinberg, P; Wiezner, J, 1986) |
| " The forearm resistance vessels of men with primary hypertension respond to verapamil with larger-than-normal dilatation compared with that induced by nitroprusside." | 3.67 | Functional differences in blood vessels determined from studies with calcium-channel blockers. Functional changes in forearm resistance vessels of men with primary hypertension. ( Robinson, BF, 1985) |
| "The antihypertensive effect of finoptin (verapamil) and corinfar (nifedipin) and their impact on the hemodynamics and the repolarization complex of the ECG were studied in 52 patients with essential hypertension and 48 patients with secondary arterial hypertension." | 3.67 | [Treatment of arterial hypertension with calcium antagonists]. ( Grigorian, TZ; Gurgenian, SV; Mikaelian, ES; Nikogosian, KG; Tatinian, NG, 1985) |
| "Thirty two patients with essential hypertension, stage I and II according to WHO classification, were treated according to the following schedule: period A--3 X 1 dragée placebo--3 weeks; period B--3 X 1 dragée placebo + 25 mg hydrochlorothiazide in the morning--6 weeks; period C--3 X 1 dragée isoptin 80 mg + 25 mg hydrochlorothiazide in the morning--6 weeks; period D--3 X 1 dragée placebo--2 weeks." | 3.67 | [Treatment of essential hypertension (hypertensive disease) with verapamil and hydrochlorothiazide]. ( Dimitrov, D, 1985) |
| "The dependency of arteriolar tone on calcium influx was studied in 11 patients with essential hypertension (EHT) and compared to 11 age-matched normotensive (NT) subjects by measuring the forearm blood flow (FAF) response to intraarterial infusion of the calcium channel blocker verapamil (Verap) and the nonspecific vasodilator sodium nitroprusside (Nip) with venous occlusion plethysmography." | 3.66 | Verapamil-induced vasodilation is enhanced in essential hypertension. ( Amann, FW; Bolli, P; Bühler, FR; Hulthén, UL; Kiowski, W, 1982) |
| "The acute effects of two calcium channel blockers, nifedipine and verapamil, were compared in eight normotensive subjects and eight patients with essential hypertension." | 3.66 | Comparison of cardiovascular, renal, and humoral effects of acute administration of two calcium channel blockers in normotensive and hypertensive subjects. ( Cuspidi, C; Leonetti, G; Sampieri, L; Terzoli, L; Zanchetti, A, 1982) |
| "Forearm blood flow response to the calcium channel inhibitor verapamil, 1 75 micrograms/100 ml tissue, as measured by venous occlusion plethysmography, was found to be significantly greater in 11 patients with essential hypertension as compared to 11 age-matched normotensive subjects whereas there was no significant difference in increase in forearm blood flow between both groups to non-specific vasodilatation with sodium nitroprusside (1." | 3.66 | Verapamil-induced vasodilator response is enhanced in essential hypertension. ( Amann, FW; Bolli, P; Bühler, FR; Hulthén, L; Kiowski, W, 1983) |
| "The forearm vascular resistance (FVR) following intra-arterial infusions of the calcium influx inhibitors nicardipine and verapamil and sodium nitroprusside was compared to that following 10 min arterial occlusion in 10 normotensive (NT) individuals aged 45 +/- 12 years, 12 patients with mild essential hypertension (EH) aged 42 +/- 14 years and 11 patients with moderate EH aged 49 +/- 11 years." | 3.66 | Calcium influx mediated vasoconstriction: studies in patients with mild and moderate essential hypertension. ( Bolli, P; Bühler, FR; Hulthén, UL, 1983) |
| "The forearm resistance vessels of men with primary hypertension respond to verapamil with a greater than normal dilatation relative to that induced by sodium nitroprusside." | 3.66 | Effect of treatment with chlorthalidone and atenolol on response to dilator agents in the forearm resistance vessels of men with primary hypertension. ( Dobbs, RJ; Phillips, RJ; Robinson, BF, 1983) |
| "The calcium antagonists nicardipin and verapamil were used to demonstrate enhanced calcium influx dependent vasoconstriction in the forearm circulation of patients with essential hypertension (n = 11) as compared to normotensive subjects (n = 10) while non-specific vasodilatory responses were comparable." | 3.66 | [Calcium antagonists: a potent vasodilatory principle and alternative basic antihypertensive therapy]. ( Bolli, P; Bühler, FR; Erne, P, 1983) |
| "The hypotensive effects of intravenous injection and infusion of diltiazem, l- and d-verapamil were investigated in conscious and anaesthetized rats with spontaneous hypertension (SHR) and normal blood pressure (NT-WKY)." | 3.66 | Exaggerated hypotensive responses to calcium antagonists in spontaneously hypertensive rats. ( Hutchinson, JS; Takata, Y, 1983) |
| "Verapamil, a known Ca++ antagonist, has vasodilator properties and is of use in the management of mild to moderate hypertension." | 3.66 | Modification of anti-hypertensive action of verapamil by inhibition of endogenous prostaglandin synthesis. ( Das, UN, 1982) |
| "A 38-year-old woman with hypercalcemia, severe hypertension, and high renin levels was treated with the angiotensin-converting enzyme inhibitor captopril." | 3.66 | Hypertension in a patient with hypercalcemia: captopril and verapamil. ( Brunner, HR; Burckhardt, P; Gavras, H; Waeber, B, 1982) |
| " The response of the forearm resistance vessels to local intra-arterial infusion of verapamil and sodium nitroprusside has been assessed by a plethysmographic method in 23 men with normal arterial pressure and 35 men with primary hypertension." | 3.66 | Response of forearm resistance vessels to verapamil and sodium nitroprusside in normotensive and hypertensive men: evidence for a functional abnormality of vascular smooth muscle in primary hypertension. ( Bayley, S; Dobbs, RJ; Robinson, BF, 1982) |
| "Verapamil is a non-dihydropyridine calcium channel blocker (CCB) widely used in the treatment of hypertension, chronic stable angina, secondary prevention of reinfarction, paroxysmal supra-ventricular tachycardia and for rate control in atrial fibrillation/flutter." | 2.82 | Verapamil: prevention and treatment of cardio-renal syndromes in diabetic hypertensive patients? ( Bei, A; Calò, L; Cice, G; Di Lullo, L; Lido, P; Noce, A; Palazzetti, D; Perrone, MA; Romanello, D; Tesauro, M, 2022) |
| "Angina and hypertension are common in patients with coronary artery disease (CAD); however, the effect on mortality is unclear." | 2.78 | Mortality implications of angina and blood pressure in hypertensive patients with coronary artery disease: New data from extended follow-up of the International Verapamil/Trandolapril Study (INVEST). ( Cooper-Dehoff, RM; Gong, Y; Handberg, EM; Pepine, CJ; Winchester, DE, 2013) |
| "The aim of this study was to compare the effect of trandolapril (T) and its fixed-dose combination with verapamil (FDTV) on adiponectin levels in hypertensive type 2 diabetic patients." | 2.76 | Impact of trandolapril therapy and its combination with a calcium channel blocker on plasma adiponectin levels in patients with type 2 diabetes and hypertension. ( Castro-Serna, D; Escalante-Acosta, BA; Rodríguez-Lopez, L; Rubio-Guerra, AF; Vargas-Ayala, G; Vargas-Robles, H, 2011) |
| "Sibutramine use has raised concerns regarding a potential increase in subjects' blood pressure and heart rate." | 2.73 | Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients. ( Elisaf, MS; Filippatos, TD; Kiortsis, DN; Liberopoulos, EN; Mikhailidis, DP; Nakou, E; Tselepis, AD, 2008) |
| " The aim of this study was to compare the effect of trandolapril (T) and its fixed-dose combination with verapamil (FDTV) on SAM levels in hypertensive type-2 diabetic patients." | 2.73 | The effect of trandolapril and its fixed-dose combination with verapamil on circulating adhesion molecules levels in hypertensive patients with type 2 diabetes. ( Escalante-Acosta, BA; Rodriguez-Lopez, L; Rubio-Guerra, AF; Vargas-Ayala, G; Vargas-Robles, H, 2008) |
| "Sibutramine treatment resulted in a significantly greater decrease in body weight, body mass index, and waist circumference and a significant increase in diastolic blood pressure during 24-hour blood pressure monitoring compared with placebo treatment." | 2.73 | Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. ( Grimm, E; Herrmann, D; Kintscher, U; Scholze, J; Unger, T, 2007) |
| "Established hypertension is characterized by increased peripheral vascular resistance and endothelial dysfunction, features that may underlie the reduced exercise-induced vasodilatation seen in hypertensive patients." | 2.73 | Phosphodiesterase type 5 inhibition reverses impaired forearm exercise-induced vasodilatation in hypertensive patients. ( Attinà, TM; Malatino, LS; Maxwell, SR; Padfield, PL; Webb, DJ, 2008) |
| "Trandolapril was also recommended for patients with heart failure, diabetes, or renal impairment." | 2.71 | A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. ( Bakris, GL; Bristol, HA; Cangiano, JL; Cohen, JD; Cooper-DeHoff, RM; Erdine, S; Garcia-Barreto, D; Handberg, EM; Keltai, M; Kolb, HR; Kowey, P; Mancia, G; Marks, RG; Messerli, FH; Parmley, WW; Pepine, CJ, 2003) |
| "We studied the effects of a chronotherapeutic delivery system of verapamil (controlled-onset extended release [COER]-24 system) dosed at bedtime versus conventional morning administration of both enalapril and losartan on the blood pressure (BP), heart rate, and the heart rate systolic BP product during the first 4 hours after awakening in a placebo-controlled, forced-titration trial." | 2.70 | Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising. ( Anders, RJ; Calhoun, D; Mansoor, GA; Sica, DA; White, WB, 2002) |
| "COER-verapamil was well tolerated in both subgroups, but the incidence of constipation was significantly less in obese patients (P < 0." | 2.70 | Chronotherapeutic delivery of verapamil in obese versus non-obese patients with essential hypertension. ( Black, HR; Elliott, WJ; Johnson, MF; White, WB, 2001) |
| " After a 4-week single-blind placebo phase, patients received one of the following daily dosage regimens in a double-blind fashion for 6 weeks: placebo, 4 mg of trandolapril, 240 mg of verapamil SR, or a combination of 4 mg of trandolapril and 240 mg of verapamil SR." | 2.69 | Effects of verapamil and trandolapril in the treatment of hypertension. Trandolapril Study Group. ( Elliott, WJ; Frishman, WH; Messerli, F, 1998) |
| "A total of 898 men and women with type 2 diabetes mellitus and hypertension, receiving antihypertensive treatment with one single drug and whose BP was > 140 and/or 90 mmHg." | 2.69 | Prospective comparison of therapeutical attitudes in hypertensive type 2 diabetic patients uncontrolled on monotherapy. A randomized trial: the EDICTA study. ( Coca, A; de la Cámara, AG; de la Figuera, M; de la Sierra, A; Fernández, R; Garrido, J; Luque-Otero, M; Moreno, E; Ruilope, LM, 1999) |
| "Left ventricular hypertrophy is very frequent when determined by echocardiography and all three drugs produced regression of left ventricular hypertrophy in a different way with respect to left ventricle geometry, an effect which could have potential therapeutic implications." | 2.68 | [Effect of 3 hypertensive++ agents on ventricular geometry and function]. ( Gómez Pajuelo, C; Gómez Sánchez, MA; Lombera Romero, F; Marín Ruiz, R; Sáenz de la Calzada, C; Sanz Julve, M; Tascón Pérez, J, 1995) |
| "alpha-Blockers and calcium antagonists are commonly used in the treatment of hypertension, but few data are available concerning first dose or steady state (SS) hemodynamic and pharmacokinetic effects of these drugs when they are used in combination therapy." | 2.68 | Combined terazosin and verapamil therapy in essential hypertension. Hemodynamic and pharmacokinetic interactions. ( Johnston, W; Laddu, AR; Lenz, ML; Pool, JL; Taylor, AA; Varghese, A, 1995) |
| "Verapamil treatment statistically significantly reduced (p < 0." | 2.68 | [Evaluation of the antihypertensive efficacy and safety of using sustained release verapamil in elderly subjects using ambulatory blood pressure monitoring]. ( Bednarz, S; Janicki, K; Jasiński, T; Klima, M; Pieniazek, W, 1996) |
| " Patients whose conventionally measured diastolic blood pressure after 4 weeks' treatment was not normalised (diastolic blood pressure < 90 mmHg) received the higher dosage (verapamil SR/trandolapril 180/2 mg o." | 2.68 | Antihypertensive efficacy of a once a day verapamil SR/trandolapril combination. ( Oren, S; Viskoper, JR; Zilles, P, 1996) |
| " In the last 4 hours of the dosing interval (6 PM to 10 PM), verapamil COER-24 caused significantly greater (p < 0." | 2.68 | Novel delivery system for verapamil designed to achieve maximal blood pressure control during the early morning. ( Alderman, M; Anders, RJ; Neutel, JM; Weber, MA, 1996) |
| "Moreover, in individuals with diabetic nephropathy, antihypertensive agents that provide sustained reductions in proteinuria slow the rate of decline in renal function compared with agents without this antiproteinuric effect." | 2.68 | Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. ( Bakris, GL; Copley, JB; Mangrum, A; Sadler, R; Vicknair, N, 1997) |
| " It is concluded that the combination doses tested showed a sustained and marked antihypertensive effect throughout the 24-hour dosing interval, and the starting dose (verapamil 180 mg plus trandolapril 2 mg) seems appropriate in this group of patients." | 2.68 | Once-daily fixed dose combinations of verapamil and trandolapril in black patients with mild to moderate hypertension: a new choice for first line treatment. ( Hlatswayo, Z; Radevski, I; Sareli, P; Skoularigis, J; Strugo, V, 1997) |
| "The pharmacokinetic actions, bioequivalence, and cardiovascular effects of two verapamil products were studied in a randomized, double-blind, crossover study in eight elderly hypertensive patients (median age, 69." | 2.68 | Postabsorption concentration peaks with brand-name and generic verapamil: a double-blind, crossover study in elderly hypertensive patients. ( Barnette, DJ; Bauman, JL; Carter, BL; Porter, JA; Saseen, JJ; Zajac, EJ, 1997) |
| "Captopril-treated patients reported a positive change in well being compared with placebo, although there was no overall difference between the drugs in any of the ten quality of life measurements." | 2.67 | Comparison of verapamil and captopril in elderly hypertensive subjects: results of a randomized, double-blind, crossover study. ( Ben-Ishay, D; Bursztyn, M; Fidel, J; Ghanem, J; Kobrin, I, 1993) |
| "It is now recognized that left ventricular hypertrophy (LVH), often associated with hypertension, is itself a risk factor for coronary disease in the elderly." | 2.67 | Left ventricular mass regression in elderly hypertensives. ( Gerstenblith, G, 1992) |
| "Renal hemodynamics, albuminuria and metabolic parameters were evaluated for a period of one year." | 2.67 | Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. ( Bakris, GL; Barnhill, BW; Sadler, R, 1992) |
| "plus captopril 50 mg b." | 2.67 | Antihypertensive effects of verapamil, captopril and their combination at rest and during dynamic exercise. ( Carotenuto, A; De Divitiis, O; Di Somma, S; Liguori, V; Paulucci, A; Petitto, M, 1992) |
| "Treatment with verapamil caused significant increase of EDF from 61." | 2.67 | [Effects of verapamil and propranolol on the left-ventricular diastolic function in patients with primary arterial hypertension]. ( Markiewicz, M; Rymar, B; Trojnar, R; Wysokiński, A, 1991) |
| "In hypertensive patients with NIDDM, a diuretic-free therapy based on the Ca2+ antagonist verapamil and/or the ACE inhibitor enalapril can effectively decrease blood pressure without adversely affecting carbohydrate and lipid metabolism." | 2.67 | Antihypertensive therapy with Ca2+. Antagonist verapamil and/or ACE inhibitor enalapril in NIDDM patients. ( Beretta-Piccoli, C; Ferrari, P; Ferrier, C; Keller, U; Riesen, WF; Weidmann, P, 1991) |
| "Constipation was the only side-effect reported by those who completed the trial." | 2.67 | [Sustained release verapamil in essential hypertension]. ( Gibor, Y; Nusbaum, M; Yodfat, Y, 1991) |
| "The antihypertensive action of sustained release verapamil is, in the majority of cases, obtained with a dosage of 240 mg per day." | 2.67 | [Randomized double-blind study of delayed-action verapamil as a single dose versus 2 doses daily in patients with moderate hypertension]. ( Chapelon-Abric, C; Godeau, P; Villarroya, A; Wajman, A, 1991) |
| "Atenolol did not produce a reduction in the left-ventricular-mass index (109 +/- 9 g per square meter before treatment vs." | 2.67 | The effects of antihypertensive therapy on left ventricular mass in elderly patients. ( Becker, LC; Gerstenblith, G; Gottlieb, SO; Schulman, SP; Weisfeldt, ML; Weiss, JL; Woodruff, KM, 1990) |
| "We studied the dose-response relationship for hydrochlorothiazide + triameterene and verapamil, comparing monotherapy with combined treatment in 216 hypertensive patients over 3 weeks of active treatment following a 2-week washout period with placebo." | 2.67 | Dose-response curves in antihypertensive combination therapy: results of a controlled clinical trial. ( Bluemner, E; Letzel, H, 1990) |
| "Nifedipine was slightly, but not significantly, more potent." | 2.67 | Verapamil versus nifedipine in slow-release preparations for the treatment of mild to moderate hypertension. ( Meisel, S; Nussinovitch, N; Rosenthal, T; Shamiss, A, 1990) |
| " The overall effect is partly due to an increase in the apparent bioavailability of prazosin but may also reflect a synergistic effect on reducing peripheral vascular resistance." | 2.66 | Verapamil and prazosin in essential hypertension: evidence of a synergistic combination? ( Elliott, HL; Meredith, PA; Reid, JL, 1987) |
| "The dose-response relationship of verapamil-SR was studied in 221 hypertensive patients." | 2.66 | The relationship of dose to the antihypertensive response of verapamil-sustained release in patients with mild to moderate essential hypertension. The Verapamil-SR Study Group. ( McMahon, FG; Reder, RF, 1989) |
| "SR verapamil and placebo were administered every 12 h for 6 consecutive weeks." | 2.66 | Effect of sustained-release verapamil therapy on the blood pressure at rest and on the pressor response to isometric exertion in hypertensive patients. ( Cardillo, C; Folli, G; Guardigli, R; Mores, N; Musumeci, V; Savi, L, 1988) |
| "3." | 2.66 | Changes in calcium metabolic indices during long-term treatment of patients with essential hypertension. ( Bergström, R; Hvarfner, A; Lithell, H; Ljunghall, S; Mörlin, C; Wide, L, 1988) |
| " Thirty-six ambulatory patients with chronic, stable, mild to moderate hypertension (supine diastolic blood pressure of 94-116 mm Hg) received a dosage of either verapamil or diltiazem 80 mg t." | 2.66 | Comparison of equal-weight oral dosages of verapamil hydrochloride and diltiazem hydrochloride in patients with mild to moderate hypertension. ( DesChamps, M; Dickson, B; Gray, J; Heusner, JJ; Hollifield, JW; Peace, KE; Spyker, DA, 1988) |
| " Further measurements were made during a series of intensive study days, and the most important additional finding was a pharmacokinetic interaction that resulted in increased peak concentrations and bioavailability of prazosin." | 2.66 | The combination of prazosin and verapamil in the treatment of essential hypertension. ( Campbell, L; Elliott, HL; Meredith, PA; Reid, JL, 1988) |
| "Verapamil was devoid of any such effect." | 2.66 | Evaluation of verapamil in the treatment of hypertension. ( Anavekar, SN; Doyle, AE, 1986) |
| " The plasma half-life of verapamil was increased from 3." | 2.66 | Pharmacokinetics of verapamil in patients with hypertension. ( Anderson, P; Bondesson, U; de Faire, U, 1986) |
| "Verapamil treatment was associated with a significant reduction in diastolic blood pressure (P = 0." | 2.66 | Influence of oral verapamil on glucoregulatory hormones in man. ( Baylor, P; Charlap, S; Frishman, WH; Kambosos, D; Plawes, S; Shamoon, H, 1985) |
| "Verapamil was devoid of any such effect." | 2.65 | A double-blind comparison of verapamil and labetalol in hypertensive patients with coexisting chronic obstructive airways disease. ( Adam, WR; Anavekar, SN; Barter, C; Doyle, AE, 1982) |
| "Verapamil was discontinued in 2 patients who developed severe dyspnea at rest after 3-4 days of continued oral treatment." | 2.65 | Clinical use of calcium channel blockers as ventricular unloading agents. ( Agostoni, PG; Cipolla, C; Fabbiocchi, F; Guazzi, MD; Pepi, M; Sganzerla, P, 1983) |
| "Verapamil was evaluated as an antihypertensive agent in a pilot study." | 2.64 | Does verapamil have a clinically significant antihypertensive effect? ( Pedersen, OL, 1978) |
| "Hypertension is a risk factor for PAD." | 2.45 | Treatment of hypertension in peripheral arterial disease. ( Lane, DA; Lip, GY, 2009) |
| " In spite of the low dose ingested, the postmortem cardiac blood verapamil level was clearly toxic (6000 ng/mL, or 6 mg/L)." | 2.44 | Verapamil toxicity: an unusual case report and review of the literature. ( Batalis, NI; Harley, RA; Schandl, CA, 2007) |
| " To achieve BP target a combination of antihypertensives will be needed, and the use of long-acting drugs that are able to provide 24-hour efficacy with a once-daily dosing confers the noteworthy advantages of compliance improvement and BP variation lessening." | 2.44 | Trandolapril/verapamil combination in hypertensive diabetic patients. ( García Donaire, JA; Ruilope, LM, 2007) |
| "Pharmacological treatment of hypertension is effective in preventing cardiovascular and renal complications." | 2.44 | Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension. ( Feihl, F; Gojanovic, B; Liaudet, L; Waeber, B, 2008) |
| "Both drugs are used to treat hypertension, but only verapamil can be used to produce atrioventricular block in patients with atrial fibrillation." | 2.43 | Mechanism of tissue-selective drug action in the cardiovascular system. ( Barrett, TD; Maurice, DH; Triggle, DJ; Walker, MJ, 2005) |
| "It is indicated for the treatment of hypertension in patients who require more than one agent to achieve blood pressure (BP) targets." | 2.43 | Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension. ( Keam, SJ; Reynolds, NA; Wagstaff, AJ, 2005) |
| "Therefore, treatment for hypertension must be compatible with the symptoms of PAD." | 2.42 | Treatment of hypertension in peripheral arterial disease. ( Lip, GY; Makin, AJ, 2003) |
| "Although end-stage renal disease (ESRD) currently affects only a small percentage (<0." | 2.42 | Calcium channel blockers and the kidney. ( Sica, D, 2004) |
| "She had coronary atherosclerosis, liver cirrhosis and bradycardia-tachycardia syndrome." | 2.41 | Cardiogenic shock triggered by verapamil and atenolol: a case report of therapeutic experience with intravenous calcium. ( Hattori, K; Hirakawa, Y; Ichihashi, R; Kei, M; Matsubara, K; Saburi, Y; Sakurai, H; Tsukamoto, H; Yokouchi, K, 2000) |
| " Verapamil SR/trandolapril 180/2 mg combination produces the best dose-response ratio of different dose combinations of these two drugs." | 2.41 | The fixed combination of verapamil SR/trandolapril. ( Widimský, J, 2000) |
| " These differences can be attributed at least in part to the low catecholamine profile of verapamil and the marked rapid adrenergic activation with short-acting nifedipine, which could also explain the adverse effects found when this agent is given to patients with acute coronary syndromes." | 2.40 | Calcium channel blockers for hypertension: dissecting the evidence for adverse effects. ( Opie, LH, 1997) |
| " However, at least as important is a consideration of adverse reactions and the safety of the combination compared to monotherapy." | 2.40 | Safety profile of the combination of verapamil and trandolapril. ( Holzgreve, H, 1997) |
| " In addition, combination therapy enhances tolerability because one drug of fixed combination can antagonize some of the adverse effects of the second drug." | 2.40 | [Fixed-dose combination therapy: reduction of side effects with enhanced tolerance and antihypertensive efficacy]. ( Gómez Guindal, JA; González Lama, I; González Maqueda, I, 1999) |
| "Hypertension is a potentially life-threatening condition that can lead to heart failure, stroke, and kidney disease." | 2.39 | Management of the hypertensive patient: a case report. ( Barry, JM; Bolt, TR; Smith, CJ, 1995) |
| " Most antihypertensives can be given once or twice daily without the need for sustained-release dosage forms." | 2.39 | Selected factors that influence responses to antihypertensives. Choosing therapy for the uncomplicated patient. ( Carter, BL; Elliott, WJ; Frohlich, ED; Mann, RJ; Moore, MA; Roberts, RW, 1994) |
| " Antihypertensive therapy has been traditionally dosed in the morning after awakening, and in recent years most of the newly developed antihypertensive agents have been once-daily, long-acting preparations." | 2.39 | A chronotherapeutic approach to the management of hypertension. ( White, WB, 1996) |
| "Verapamil was associated with constipation." | 2.38 | Quality of life in the treatment of hypertension. The effect of calcium antagonists. ( Bulpitt, C; Fletcher, A, 1992) |
| "Untreated hypertension has a variety of serious consequences, such as stroke, congestive heart failure and coronary heart disease, the incidences of which escalate sharply in the presence of other risk factors." | 2.38 | Primary prevention potential of the calcium antagonists. Effects on blood pressure and lipid pattern. ( Midtbø, K, 1992) |
| " An increase in the dosage (360 mg/24 hours in two subdoses) could be made during the first month of treatment if the diastolic blood pressure remained greater than or equal to 95 mmHg." | 2.38 | [Sustained-released verapamil and ambulatory recording of blood pressure in mild to moderate essential hypertension]. ( Bernadet, P; Durand, D; Galey, C; Maarek-Charbit, M; Suc, JM, 1992) |
| " In experimental chronic renal failure, the long-term administration of verapamil protects against renal dysfunction and damage, independent of any effect on systemic mean arterial pressure." | 2.38 | Role of calcium channel blockers in protection against experimental renal injury. ( Schrier, RW, 1991) |
| " Another side effect is constipation, which is frequent after verapamil." | 2.38 | Calcium antagonists--assessment of side effects. ( Thulin, T, 1990) |
| "Verapamil was more often associated with conduction problems (up to 9%) and dyspnea or heart failure (up to 8%)." | 2.37 | Review of the cardiovascular adversity of the calcium antagonist beta-blocker combination: implications for antihypertensive therapy. ( Brouwer, RM; Bühler, FR; Follath, F, 1985) |
| "Diltiazem may increase glomerular filtration rate via attenuation of the intrarenal effects of angiotensin II or norepinephrine." | 2.37 | Effects of calcium entry blockers on renin-angiotensin-aldosterone system, renal function and hemodynamics, salt and water excretion and body fluid composition. ( Bauer, JH; Reams, G; Sunderrajan, S, 1985) |
| " The elimination half-life of all 3 prototypical calcium antagonists is probably significantly prolonged during long-term dosing with clinically effective regimens." | 2.37 | Kinetics and dynamics of calcium entry antagonists in systemic hypertension. ( Hamann, SR; McAllister, RG; Schloemer, GL, 1986) |
| "Nifedipine generally has little depressant action in this setting and usually improves cardiac function, especially if the sympathetic reflexes are intact." | 2.37 | Use of calcium antagonists in ventricular dysfunction. ( Josephson, MA; Singh, BN, 1985) |
| "Treatment with nifedipine can safely be combined with administration of a beta receptor blocking agent." | 2.36 | Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem. ( Henry, PD, 1980) |
| "Clinical experience in the treatment of hypertension with this class of agents is confined to verapamil, nifedipine, and diltiazem." | 2.36 | Calcium antagonists. Clinical use in the treatment of systemic hypertension. ( Frishman, WH; Ocken, S; Spivack, C, 1983) |
| " The activation of the adrenergic and renin angiotension systems seen after nifedipine administration is less pronounced after chronic administration of the drug and is nearly absent after verapamil and diltiazem." | 2.36 | [Calcium antagonists in the therapy of hypertension]. ( Heidbreder, E; Heidland, A; Hörl, WH; Schäfer, RM, 1983) |
| "Amiodarone is an extremely potent drug which is effective for both supraventricular as well as ventricular arrhythmias." | 2.36 | New antiarrhythmic drugs. ( Hess, DS; Scheinman, MM, 1983) |
| "Verapamil was the first of a class of agents known as calcium entry blockers to be released for clinical use in the United States." | 2.36 | The clinical use of verapamil. ( Holmes, DR; McGoon, MD; Osborn, JE; Vlietstra, RE, 1982) |
| "Verapamil is a novel antiarrhythmic and antianginal agent which, although introduced in 1962, has only recently gained prominence not only as a significant agent in cardiovascular therapeutics but also as a powerful tool to examine the nature of some of the biophysical phenomena at the membrane of cardiac and other excitable tissues." | 2.36 | Verapamil: a review of its pharmacological properties and therapeutic use. ( Ellrodt, G; Peter, CT; Singh, BN, 1978) |
| "Glycyrrhizin can cause pseudohyperaldosteronism and thereby result in hypertension and hypokalaemia." | 1.48 | Potassium chloride mixture may maintain hypokalaemia and hypertension. ( Borg, R; Hansen, D; Mandoe, MJ, 2018) |
| "Arterial hypertension is an important risk factor for cerebrovascular diseases, such as transient ischemic attacks or stroke, and represents a major global health issue." | 1.39 | Multimodal imaging in rats reveals impaired neurovascular coupling in sustained hypertension. ( Buck, A; Calcinaghi, N; Fritschy, JM; Jolivet, R; Keller, AL; Matter, CM; Singh, A; Weber, B; Winnik, S; Wyss, MT, 2013) |
| "0-10 mg/mL relaxed high K+ (80 mM) and phenylephrine (PE, 1 μM)-induced contractions and shifted Ca++ dose-response curves to right, similar to that caused by verapamil." | 1.38 | Hypotensive effect of Gentiana floribunda is mediated through Ca++ antagonism pathway. ( Khan, AU; Murugan, DD; Mustafa, MR, 2012) |
| " Chronic administration (45 days) produced no toxic effects in vital organs and systems of Wistar rats and ISIAH rats." | 1.37 | Glycidipine, a promising hypotensive and cardioprotective agent. ( Belenichev, IF; Bryzgalov, AO; Khvostov, MV; Pavlov, SV; Tolstikova, TG, 2011) |
| " Verapamil heart tissue and plasma levels after intraperitoneal dosing of spontaneously hypertensive and normotensive rats were investigated." | 1.36 | Impaired tissue clearance of verapamil in rat cardiac hypertrophy results in transcriptional repression of ion channels. ( Borlak, J; Zwadlo, C, 2010) |
| "A clear reduction of BP values was recorded after both the first and the second month of treatment with kanrenoate, with the maximal effect obtained when the dosage titration at 100 mg/day was accomplished." | 1.35 | Menopause not aldosterone-to-renin ratio predicts blood pressure response to a mineralocorticoid receptor antagonist in primary care hypertensive patients. ( Blengio, GS; Ciacciarelli, A; Corrocher, R; Falcone, S; Olivieri, O; Pizzolo, F; Signorelli, D, 2008) |
| "Data regarding use of CCBs in human polycystic kidney disease (PKD) are limited and mixed." | 1.35 | Calcium, cyclic AMP, and MAP kinases: dysregulation in polycystic kidney disease. ( Cowley, BD, 2008) |
| "Potassium bromide was added to each TV capsule." | 1.35 | Bromide as marker for drug adherence in hypertensive patients. ( Braam, RL; Lenders, JW; Thien, T; van Uum, SH, 2008) |
| "To formulate and evaluate a pharmacodynamic model that characterizes the effects of S-verapamil on the circadian 24-hour ambulatory blood pressure (ABP)." | 1.33 | A pharmacodynamic model of the effects of controlled-onset extended-release verapamil on 24-hour ambulatory blood pressure. ( Beasley, BN; Johnson, JA; Lima, JJ; Parker, RB, 2005) |
| "Propranolol pretreatment (4 microg/0." | 1.33 | Cardiovascular excitatory effect on rats of a fraction isolated from the eyestalk of shrimp: Peneaus vanameii. ( Antequera, R; Cedeño, J; Estrada, O; León, L; Romero-Vecchione, E; Rosa, F; Vásquez, J, 2006) |
| "Essential hypertension is a common disease caused by a combination of genetic and environmental factors." | 1.32 | Low urinary kallikrein rats: different sensitivity of verapamil on hypertensive response to central acute cadmium administration. ( Anania, V; Palomba, D; Satta, M; Varoni, MV, 2003) |
| "Quercetin and verapamil treatments reduced the endothelium-independent hyper-reactivity to KCl observed in the aorta of DOCA-salt-hypertensive rats, but only quercetin increased the contractile responses to angiotensin II, improved endothelial dysfunction and restored basal aortic Cu/Zn SOD expression, altered in DOCA-salt-treated rats." | 1.32 | Effects of quercetin treatment on vascular function in deoxycorticosterone acetate-salt hypertensive rats. Comparative study with verapamil. ( Duarte, J; Galisteo, M; García-Saura, MF; Jiménez, R; Vargas, F; Villar, IC; Wangensteen, R; Zarzuelo, A, 2004) |
| "Verapamil treatment seems to ameliorate the renal effects of exercise on GFR in these patients, and this may in part be mediated via a stimulatory effect on ANP." | 1.31 | Effect of light exercise on renal hemodynamics in patients with hypertension and chronic renal disease. ( Iversen, BM; Myking, O; Ofstad, J; Svarstad, E, 2002) |
| "We conclude that the treatment of hypertension by combined therapy leads to a better normalisation of structural, contractile, and metabolic parameters in the SHR, than either treatment alone and that metabolic changes with the pathology are resolved with appropriate therapy." | 1.31 | The effects of anti-hypertensive therapy on the structural, mechanical and metabolic properties of the rat aorta. ( Boehm, EA; Clark, JF; Radda, GK, 2000) |
| "For the treatment of hypertension, this idea has the potential for a therapeutic paradigm shift." | 1.31 | Hypertension and chronotherapy: shifting the treatment paradigm. ( Prisant, LM, 2001) |
| "Verapamil and veratran were more effective than trandolapril at reducing lamina media cross-sectional area." | 1.30 | Antihypertensive action of trandolapril and verapamil in spontaneously hypertensive rats after unilateral nephrectomy. ( Carrón, R; Flores, O; López-Hernández, FJ; López-Novoa, JM; Montero, MJ, 1998) |
| " Chronic administration of low-dose candesartan, captopril, or verapamil prevented the arterial hypertension and improved renal hemodynamics, but these levels were not completely normalized." | 1.30 | Pressure natriuresis in nitric oxide-deficient hypertensive rats: effect of antihypertensive treatments. ( Atucha, NM; Cachofeiro, V; Fortepiani, LA; García-Estañ, J; Lahera, V; Ortíz, MC; Rodrigo, E; Ruilope, LM, 1999) |
| "Hydralazine treatment and sodium deprivation did not significantly modify the pressure-independence of renin release by LH rat kidneys." | 1.29 | Pressure control of renal renin release in Lyon hypertensive rats. ( Bertolino, S; Medeiros, IA; Sassard, J; Zhang, BL, 1994) |
| " Chronic administration of nitric oxide inhibitors provides a new model of hypertension with pronounced target organ damage." | 1.29 | L-NAME hypertension alters endothelial and smooth muscle function in rat aorta. Prevention by trandolapril and verapamil. ( Küng, CF; Lüscher, TF; Moreau, P; Takase, H, 1995) |
| "Nifedipine was the most efficient drug in inhibiting the rise in intracellular calcium ion concentration ([Ca2+]i) when added in vitro and in neutrophils of patients receiving this drug, whereas verapamil had no significant effect." | 1.29 | Inhibited neutrophil functions in patients treated with nifedipine but not with verapamil or diltiazem. ( Levy, R; Nagauker-Shriker, O; Schlaeffer, F, 1996) |
| "Verapamil pretreatment attenuated the BP and HR responses in rats." | 1.29 | Effect of verapamil on cadmium induced hypertension in rats. ( Puri, VN, 1996) |
| "Verapamil was more effective than nifedipine in improving natriuresis and ANP release to saline load and in lowering the albumin excretion rate." | 1.28 | Effects of angiotensin converting enzyme inhibitors and calcium antagonists on atrial natriuretic peptide release and action and on albumin excretion rate in hypertensive insulin-dependent diabetic patients. ( Abaterusso, C; Brocco, E; Carraro, A; Cipollina, MR; Fioretto, P; Frigato, F; Muollo, B; Riva, F; Trevisan, M; Velussi, M, 1992) |
| "Spontaneous motor activity was measured in six baboons during chronic oral dosing with a diuretic (hydrochlorothiazide/triamterene), a calcium channel blocker (verapamil), and a combination of the two drugs." | 1.28 | Chronic hydrochlorothiazide and verapamil effects on motor activity in hypertensive baboons. ( Allen, RP; Hienz, RD; Turkkan, JS, 1992) |
| "Four hypertensive patients with chronic renal insufficiency or end-stage renal disease who were treated with sustained-release verapamil hydrochloride subsequently developed acute toxic effects." | 1.28 | Acute toxic effects of sustained-release verapamil in chronic renal failure. ( Bierman, MH; Hammeke, MD; Pritza, DR, 1991) |
| "Verapamil treatment of the aortic constricted hearts prevented the rise in intracellular calcium, and attenuated phosphomonoester sugar accumulation." | 1.28 | Calcium inhibition of glycolysis contributes to ischaemic injury. ( Auffermann, W; Buser, P; Parmley, WW; Wagner, S; Wikman-Coffelt, J; Wu, S, 1990) |
| " Patients treated with cyclosporine and prednisone alone had their cyclosporine dosage adjusted to maintain their cyclosporine level between 400 and 900 ng/mL between 1 and 6 months following transplantation." | 1.28 | The effect of calcium channel blockers on the cyclosporine dose requirement in renal transplant recipients. ( Babcock, S; Chan, L; Howard, RL; Shapiro, JI, 1990) |
| "Verapamil clearances were calculated according to different dialysis methods." | 1.28 | Verapamil in antihypertensive treatment of patients on renal replacement therapy--clinical implications and pharmacokinetics. ( Beyerlein, C; Csaszar, G; Hollmann, M; Schumacher, A, 1990) |
| "Verapamil and diltiazem were equally potent (ie, similar EC50s) in relaxing potassium-contracted aortas of spontaneously hypertensive (SHR) and normotensive Wistar-Kyoto (WKY) rats." | 1.28 | Effect of calcium antagonists on aortae isolated from normotensive and hypertensive rats: relaxation and calcium influx blockade. ( Cattaneo, EA; Cingolani, HE; Rinaldi, GJ, 1990) |
| "Verapamil was demonstrated to produce a consistent reduction of blood pressure over most of the 24 h period studied but this was most marked during the day." | 1.27 | The role of a slow channel inhibitor, verapamil, in the management of hypertension. ( Gould, BA; Kieso, H; Mann, S; Raftery, EB; Subramanian, VB, 1984) |
| " It is therefore concluded that continuous control of water intake and analysis of the stability of the drug is essential for the establishment of proper dose-response relationships." | 1.27 | Drinking water and drug dosage in rat studies. ( Jakobsen, P; Jespersen, LT; Mikkelsen, EO; Pedersen, OL, 1983) |
| "Fifteen males with previously untreated essential hypertension in WHO stage I, aged 20-64 years were studied on an outpatient basis." | 1.27 | Haemodynamic effects of nifedipine in essential hypertension at rest and during exercise. ( Lund-Johansen, P; Omvik, P, 1983) |
| "Hydralazine was discontinued and replaced by placebo during 3 weeks and after this period, verapamil was instituted at increasing doses." | 1.27 | Hypotensive action of verapamil in a group of hydralazine-dependent hypertensive patients. ( Gamio-Capestany, F; García-Barreto, D; González-Gómez, A, 1983) |
| "They also have great potential for the treatment of hypertension, cerebrovascular disorders, and Raynaud's phenomenon." | 1.27 | Calcium channel blocking drugs. Part II: Clinical applications. ( Brill, DM; Fozzard, HA, 1985) |
| "Verapamil (0." | 1.27 | Verapamil pharmacodynamics and disposition in obese hypertensive patients. ( Abernethy, DR; Schwartz, JB, 1988) |
| "In three patients with orthostatic hypotension successfully treated by the peripheral dopaminergic antagonist domperidone 60 mg/day, the subsequent introduction of verapamil 240 mg/day did not modify the standing-induced decrease in systolic blood pressure: 46." | 1.27 | Hypertension with orthostatic hypotension: interest of verapamil. ( Chamontin, BF; Montastruc, JL; Salvador, MJ, 1987) |
| "Enalapril treatment (5 mg/kg/day, n = 11) or felodipine (30 mg/kg/day, n = 11) reduced systolic blood pressure to a comparable degree." | 1.27 | Disparate effects of angiotensin converting enzyme inhibitor and calcium blocker treatment on the preservation of renal structure and function following subtotal nephrectomy or streptozotocin-induced diabetes in the rat. ( Cubela, R; Debrevi, L; Jackson, B; Johnston, CI; Whitty, M, 1987) |
| "Verapamil HCl was chronically administered to inbred Dahl S/JR and R/JR rats maintained on a diet containing 8." | 1.27 | Calcium channel blockade with verapamil. Effects on blood pressure, renal, and myocardial adrenergic, cholinergic, and calcium channel receptors in inbred Dahl hypertension-sensitive (S/JR) and hypertension-resistant (R/JR) rats. ( Juno, CJ; McCaughran, JA, 1988) |
| " Cumulative dose-response curves to intra-arterial methoxamine or B-HT 933 were obtained during saline or two different rates of verapamil infusion (0." | 1.27 | Verapamil antagonizes forearm vasoconstriction mediated by selective alpha 1- and alpha 2-agonists in hypertensive patients. ( Graziadei, L; Panarace, G; Pedrinelli, R; Salvetti, A; Taddei, S, 1986) |
| "Verapamil is an effective and relatively-safe antihypertensive drug." | 1.27 | Verapamil withdrawal as a possible cause of myocardial infarction in a hypertensive woman with a normal coronary angiogram. ( Beilin, LJ; Dimmitt, SB; Hockings, BE, 1988) |
| "Verapamil treatment resulted in a significant decrease in systolic and diastolic blood pressure and a reduction in maximum left ventricular pressure." | 1.27 | Effect of calcium blocking agent verapamil on blood pressure, ventricular contractility, parathyroid hormone, calcium and phosphorus in plasma, catecholamines, corticosterone and plasma renin activity in spontaneously hypertensive rats. ( Ancov, V; Grigorova, R; Ilieva, T; Lolov, R; Nicolov, N; Petkova, M; Sheitanova, S; Todorova, M; Tzoncheva, A; Velkov, Z, 1988) |
| "When verapamil or nifedipine were added prior to and during Ca2+ repletion, the force developed was reduced to 25% of that of uninhibited contraction." | 1.27 | Ca2+ influx in spontaneously hypertensive rats is sensitive to calcium antagonists. ( Heinle, H; Lindner, V, 1987) |
| "Verapamil disposition was also age related." | 1.27 | Verapamil pharmacodynamics and disposition in young and elderly hypertensive patients. Altered electrocardiographic and hypotensive responses. ( Abernethy, DR; Luchi, R; Schwartz, JB; Snow, E; Todd, EL, 1986) |
| "Verapamil is a racemic mixture of two optical isomers, the (-)-form being the more active component." | 1.27 | Pharmacokinetics of conventional and slow-release verapamil. ( Bühler, F; Follath, F; Ha, HR; Schütz, E, 1986) |
| " In 13 the dosage was decreased to 120 mg 2 times a day." | 1.27 | Short- and long-term treatment of mild to moderate hypertension with verapamil. ( Dallocchio, M; Gosse, P; Roudaut, R; Wicker, P, 1986) |
| " Norverapamil concentrations were higher than those of the parent drug throughout the entire dosage interval." | 1.26 | Serum concentration and antihypertensive effect of slow-release verapamil. ( Bühler, FR; Follath, F; Ha, HR; Schütz, E, 1982) |
| "3." | 1.26 | The role of a slow channel inhibitor, verapamil, in the management of hypertension. ( Balasubramanian, V; Gould, BA; Kieso, H; Mann, S; Raftery, EB, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 472 (46.37) | 18.7374 |
| 1990's | 324 (31.83) | 18.2507 |
| 2000's | 168 (16.50) | 29.6817 |
| 2010's | 45 (4.42) | 24.3611 |
| 2020's | 9 (0.88) | 2.80 |
| Authors | Studies |
|---|---|
| Shanklin, JR | 1 |
| Johnson, CP | 1 |
| Proakis, AG | 1 |
| Barrett, RJ | 2 |
| Kurokawa, M | 1 |
| Sato, F | 1 |
| Fujiwara, I | 1 |
| Hatano, N | 1 |
| Honda, Y | 2 |
| Yoshida, T | 1 |
| Naruto, S | 1 |
| Mastumoto, J | 1 |
| Uno, H | 1 |
| Carson, JR | 1 |
| Almond, HR | 1 |
| Brannan, MD | 1 |
| Carmosin, RJ | 1 |
| Flaim, SF | 1 |
| Gill, A | 1 |
| Gleason, MM | 1 |
| Keely, SL | 1 |
| Ludovici, DW | 1 |
| Pitis, PM | 1 |
| Veldhuizen, GP | 1 |
| Alnazer, RM | 1 |
| de Leeuw, PW | 6 |
| Kroon, AA | 1 |
| Lido, P | 1 |
| Romanello, D | 1 |
| Tesauro, M | 1 |
| Bei, A | 1 |
| Perrone, MA | 1 |
| Palazzetti, D | 1 |
| Noce, A | 1 |
| Di Lullo, L | 1 |
| Calò, L | 1 |
| Cice, G | 1 |
| Bibi, R | 1 |
| Salma, U | 1 |
| Bashir, K | 1 |
| Khan, T | 1 |
| Shah, AJ | 1 |
| Haque, OI | 1 |
| Mahar, S | 1 |
| Hussain, S | 1 |
| Sloane, P | 1 |
| Sava, RI | 1 |
| Chen, YE | 1 |
| Smith, SM | 4 |
| Gong, Y | 18 |
| Cooper-DeHoff, RM | 30 |
| Keeley, EC | 1 |
| Pepine, CJ | 40 |
| Handberg, EM | 10 |
| Drutel, RO | 1 |
| Payne, JR | 1 |
| Glancy, DL | 1 |
| Scantlebury, DC | 1 |
| Morris, RL | 1 |
| Mendes, AS | 1 |
| Blascke de Mello, MM | 1 |
| Parente, JM | 1 |
| Omoto, ACM | 1 |
| Neto-Neves, EM | 1 |
| Fazan, R | 1 |
| Tanus-Santos, JE | 1 |
| Castro, MM | 1 |
| Dasa, O | 1 |
| Howard, G | 1 |
| Handberg, E | 4 |
| Salem, M | 1 |
| Sallam, AM | 1 |
| Abdel-Aleem, E | 1 |
| El-Mesallamy, HO | 1 |
| Wokhlu, A | 1 |
| Elgendy, IY | 2 |
| Bavry, AA | 4 |
| Magvanjav, O | 1 |
| McDonough, CW | 3 |
| Chapman, AB | 2 |
| Turner, ST | 2 |
| Gums, JG | 2 |
| Bailey, KR | 3 |
| Boerwinkle, E | 2 |
| Beitelshees, AL | 3 |
| Tanaka, T | 2 |
| Kubo, M | 2 |
| Johnson, JA | 14 |
| Carvalho, DS | 1 |
| de Almeida, AA | 1 |
| Borges, AF | 1 |
| Vannucci Campos, D | 1 |
| El Rouby, N | 1 |
| McClure, LA | 1 |
| Mitchell, BD | 1 |
| Horenstein, RB | 1 |
| Talbert, RL | 1 |
| Crawford, DC | 1 |
| Gitzendanner, MA | 1 |
| Takahashi, A | 1 |
| Benavente, OR | 1 |
| Shuldiner, AR | 1 |
| Mandoe, MJ | 1 |
| Borg, R | 1 |
| Hansen, D | 1 |
| Fu, YS | 1 |
| Lue, SI | 1 |
| Lin, SY | 1 |
| Luo, CL | 1 |
| Chou, CC | 1 |
| Weng, CF | 1 |
| Padmanabhan, S | 1 |
| Burkley, B | 1 |
| Langaee, TY | 6 |
| Melander, O | 1 |
| Dominiczak, AF | 1 |
| Winchester, DE | 1 |
| Calcinaghi, N | 1 |
| Wyss, MT | 1 |
| Jolivet, R | 1 |
| Singh, A | 1 |
| Keller, AL | 1 |
| Winnik, S | 1 |
| Fritschy, JM | 1 |
| Buck, A | 1 |
| Matter, CM | 1 |
| Weber, B | 1 |
| Sorajja, P | 1 |
| Ommen, SR | 1 |
| Nishimura, RA | 1 |
| Tabur, S | 1 |
| Oğuz, E | 1 |
| Sabuncu, T | 1 |
| Korkmaz, H | 1 |
| Çelik, H | 1 |
| Methaneethorn, J | 1 |
| Chamnansua, M | 1 |
| Kaewdang, N | 1 |
| Lohitnavy, M | 1 |
| Denardo, SJ | 2 |
| Farsang, C | 1 |
| Keltai, M | 2 |
| Szirmai, L | 1 |
| Messerli, FH | 14 |
| Mancia, G | 11 |
| Huo, T | 1 |
| Gulati, M | 1 |
| Merz, CN | 1 |
| De Mello, W | 1 |
| Zwadlo, C | 2 |
| Borlak, J | 2 |
| Kanorskii, SG | 1 |
| Sereda, AF | 1 |
| Nakou, E | 1 |
| Filippatos, TD | 1 |
| Liberopoulos, EN | 1 |
| Tselepis, AD | 1 |
| Kiortsis, DN | 1 |
| Mikhailidis, DP | 1 |
| Elisaf, MS | 1 |
| Olivieri, O | 1 |
| Pizzolo, F | 1 |
| Ciacciarelli, A | 1 |
| Corrocher, R | 1 |
| Signorelli, D | 1 |
| Falcone, S | 1 |
| Blengio, GS | 1 |
| Pacanowski, MA | 3 |
| Schork, NJ | 2 |
| Shriver, MD | 2 |
| Bangalore, S | 3 |
| Cohen, JD | 2 |
| Bacher, PH | 2 |
| Sleight, P | 5 |
| Kowey, P | 2 |
| Zhou, Q | 9 |
| Champion, A | 11 |
| Volkov, VE | 1 |
| Babaev, FZ | 1 |
| Pshenitsin, AI | 2 |
| Zhezheva, FM | 1 |
| Mazur, NA | 4 |
| Kiga, C | 1 |
| Sakurai, H | 2 |
| Goto, H | 1 |
| Hayashi, K | 1 |
| Shimada, Y | 1 |
| Saiki, I | 1 |
| Rubio-Guerra, AF | 3 |
| Vargas-Robles, H | 2 |
| Vargas-Ayala, G | 3 |
| Rodriguez-Lopez, L | 3 |
| Escalante-Acosta, BA | 3 |
| Nguan, CY | 1 |
| Sener, A | 1 |
| Karnik, V | 1 |
| Caumartin, Y | 1 |
| House, AA | 1 |
| McAlister, VC | 1 |
| Luke, PP | 1 |
| Ostroumova, OD | 1 |
| Zhukova, OV | 1 |
| Abakumov, IuE | 1 |
| Paukov, SV | 1 |
| Otdelenov, AV | 1 |
| Versari, D | 1 |
| Virdis, A | 1 |
| Ghiadoni, L | 1 |
| Daghini, E | 1 |
| Duranti, E | 1 |
| Masi, S | 1 |
| Magagna, A | 1 |
| Taddei, S | 5 |
| Ray, WZ | 1 |
| Moran, CJ | 1 |
| Derdeyn, CP | 1 |
| Diringer, MN | 1 |
| Dacey, RG | 1 |
| Zipfel, GJ | 1 |
| Ball, CJ | 1 |
| Wilson, DP | 1 |
| Turner, SP | 1 |
| Saint, DA | 1 |
| Beltrame, JF | 1 |
| Gaxiola, E | 4 |
| Aranda, JM | 2 |
| Cohen, V | 1 |
| Jellinek, SP | 1 |
| Fancher, L | 1 |
| Sangwan, G | 1 |
| Wakslak, M | 1 |
| Marquart, E | 1 |
| Farahani, C | 1 |
| Khezheva, FM | 1 |
| Franklin, SS | 1 |
| Zineh, I | 3 |
| Godfraind, T | 1 |
| Vaja, V | 1 |
| Ochodnicky, P | 1 |
| Krenek, P | 1 |
| Klimas, J | 1 |
| Bajuszova, Z | 1 |
| Kyselovic, J | 1 |
| Gerhard, T | 2 |
| Ried, LD | 1 |
| Chen, X | 1 |
| Yang, D | 1 |
| Ma, S | 1 |
| He, H | 2 |
| Luo, Z | 1 |
| Feng, X | 1 |
| Cao, T | 1 |
| Ma, L | 1 |
| Yan, Z | 1 |
| Liu, D | 1 |
| Tepel, M | 1 |
| Zhu, Z | 1 |
| Kullmann, S | 1 |
| Binner, P | 1 |
| Rackebrandt, K | 1 |
| Huge, A | 1 |
| Haltern, G | 1 |
| Lankisch, M | 1 |
| Füth, R | 1 |
| von Hodenberg, E | 1 |
| Bestehorn, HP | 1 |
| Scheffold, T | 1 |
| Lane, DA | 1 |
| Lip, GY | 3 |
| Bakris, GL | 6 |
| Kupfer, S | 4 |
| Legler, UF | 2 |
| Gilani, AH | 1 |
| Mandukhail, SU | 1 |
| Iqbal, J | 1 |
| Yasinzai, M | 1 |
| Aziz, N | 1 |
| Khan, A | 1 |
| Iskenderov, BG | 4 |
| Sisina, ON | 2 |
| Gridneva, EV | 1 |
| Lokhina, TV | 4 |
| Zou, Z | 1 |
| Xu, FY | 1 |
| Wang, L | 1 |
| An, MM | 1 |
| Zhang, H | 1 |
| Shi, XY | 1 |
| Chytil, L | 1 |
| Strauch, B | 1 |
| Cvačka, J | 1 |
| Marešová, V | 1 |
| Widimský, J | 3 |
| Holaj, R | 1 |
| Slanař, O | 1 |
| Weber, MA | 7 |
| Chatterjee, N | 1 |
| Domoto-Reilly, K | 1 |
| Fecci, PE | 1 |
| Schwamm, LH | 1 |
| Singhal, AB | 1 |
| Tkachenko, EY | 1 |
| Kozyreva, TV | 1 |
| Bălan, H | 1 |
| Ruggenenti, P | 4 |
| Fassi, A | 2 |
| Ilieva, A | 1 |
| Iliev, IP | 2 |
| Chiurchiu, C | 1 |
| Rubis, N | 2 |
| Gherardi, G | 2 |
| Ene-Iordache, B | 3 |
| Gaspari, F | 2 |
| Perna, A | 3 |
| Cravedi, P | 1 |
| Bossi, A | 2 |
| Trevisan, R | 2 |
| Motterlini, N | 1 |
| Remuzzi, G | 4 |
| Price, ET | 1 |
| Martin, MA | 1 |
| Lambertucci, L | 1 |
| Di Serio, C | 1 |
| Castellani, S | 1 |
| Torrini, M | 1 |
| Lotti, E | 1 |
| Cristofari, C | 1 |
| Masotti, G | 1 |
| Marchionni, N | 1 |
| Ungar, A | 1 |
| Khaliq, A | 1 |
| Burmistrova, LF | 4 |
| Schenkat, DH | 1 |
| Schulz, LT | 1 |
| Johnson, BD | 1 |
| Castro-Serna, D | 1 |
| Halna du Fretay, X | 1 |
| Blanchard-Lemoine, B | 1 |
| Schnebert, B | 1 |
| Viossat, J | 1 |
| Brito, JP | 1 |
| Singh, E | 1 |
| Basu, A | 1 |
| Tolstikova, TG | 1 |
| Khvostov, MV | 1 |
| Bryzgalov, AO | 1 |
| Belenichev, IF | 1 |
| Pavlov, SV | 1 |
| Hegazi, MO | 1 |
| Aldabie, G | 1 |
| Al-Mutairi, S | 1 |
| El Sayed, A | 1 |
| Delaney, JA | 1 |
| Shuster, J | 1 |
| Brumback, BA | 1 |
| Winterstein, AG | 1 |
| Khan, AU | 2 |
| Mustafa, MR | 1 |
| Murugan, DD | 1 |
| Vandell, AG | 1 |
| Lobmeyer, MT | 1 |
| Gawronski, BE | 1 |
| Liggett, SB | 1 |
| Kasprzak, JD | 1 |
| Stępińska, J | 1 |
| Wożakowska Kapłon, B | 1 |
| Drożdż, J | 1 |
| Grajek, S | 1 |
| Opolski, G | 1 |
| Rynkiewicz, A | 1 |
| Tykarski, A | 1 |
| Filipiak, KJ | 1 |
| Efimova, IIu | 1 |
| Kalashnikova, TP | 1 |
| Lishmanov, IuB | 1 |
| Kahn, DF | 1 |
| Duffy, SJ | 1 |
| Tomasian, D | 1 |
| Holbrook, M | 1 |
| Rescorl, L | 1 |
| Russell, J | 1 |
| Gokce, N | 1 |
| Loscalzo, J | 1 |
| Vita, JA | 1 |
| Cheung, BM | 1 |
| Kumana, CR | 1 |
| White, WB | 12 |
| Sica, DA | 4 |
| Calhoun, D | 1 |
| Mansoor, GA | 1 |
| Anders, RJ | 6 |
| Muijsers, RB | 1 |
| Curran, MP | 1 |
| Perry, CM | 1 |
| Rosolová, H | 1 |
| Cech, F | 1 |
| Sefrna, F | 1 |
| Quiñones-Galvan, A | 2 |
| Pucciarelli, A | 2 |
| Ciociaro, D | 1 |
| Masoni, A | 1 |
| Franzoni, F | 2 |
| Natali, A | 2 |
| Ferrannini, E | 2 |
| Bernadet-Monrozies, P | 1 |
| Rostaing, L | 1 |
| Kamar, N | 1 |
| Durand, D | 2 |
| Mandarim-de-Lacerda, CA | 2 |
| Madeira, AC | 1 |
| Pereira, LM | 1 |
| Davis, BJ | 1 |
| Cao, Z | 1 |
| de Gasparo, M | 1 |
| Kawachi, H | 1 |
| Cooper, ME | 1 |
| Allen, TJ | 1 |
| Kang, D | 1 |
| Verotta, D | 1 |
| Krecic-Shepard, ME | 1 |
| Modi, NB | 2 |
| Gupta, SK | 1 |
| Schwartz, JB | 3 |
| Rosa Brito-Zurita, O | 1 |
| Posadas-Romero, C | 1 |
| Hermosillo, AG | 1 |
| Zamora-González, J | 1 |
| Hernández-Ono, A | 1 |
| Cardoso-Saldaña, G | 1 |
| Torres-Tamayo, M | 1 |
| Svarstad, E | 1 |
| Myking, O | 1 |
| Ofstad, J | 2 |
| Iversen, BM | 2 |
| Sekiguchi, F | 1 |
| Kawata, K | 1 |
| Komori, M | 1 |
| Sunano, S | 2 |
| Holzgreve, H | 6 |
| Nakov, R | 2 |
| Beck, K | 1 |
| Janka, HU | 1 |
| Bertolucci, A | 1 |
| Latkany, RA | 1 |
| Gentile, RC | 1 |
| Rosen, RB | 1 |
| Walczak, IM | 1 |
| Guay, DR | 1 |
| Varoni, MV | 3 |
| Palomba, D | 2 |
| Satta, M | 1 |
| Anania, V | 3 |
| Lopatin, IuM | 1 |
| Kirakozov, DA | 1 |
| Statsenko, ME | 1 |
| HOFFMANN, P | 1 |
| BECKER, G | 1 |
| SCHNEIDER, KW | 1 |
| JACOB, KO | 1 |
| Gianorso, S | 1 |
| Macías-Núñez, JF | 2 |
| Fernández, R | 4 |
| Calvo, C | 1 |
| Grande, J | 1 |
| Herrera, J | 1 |
| Bustamante, J | 1 |
| Garay, R | 1 |
| Robles, R | 1 |
| López-Novoa, JM | 5 |
| Makin, AJ | 1 |
| Marks, RG | 2 |
| Cangiano, JL | 2 |
| Garcia-Barreto, D | 5 |
| Erdine, S | 2 |
| Bristol, HA | 1 |
| Kolb, HR | 1 |
| Parmley, WW | 2 |
| Little, WC | 1 |
| Wesley-Farrington, DJ | 1 |
| Hoyle, J | 1 |
| Brucks, S | 1 |
| Robertson, S | 1 |
| Kitzman, DW | 1 |
| Cheng, CP | 1 |
| Yu, XC | 1 |
| Wu, S | 3 |
| Chen, CF | 1 |
| Pang, KT | 1 |
| Wong, TM | 1 |
| Lehfeld, LS | 1 |
| Silveira, LA | 1 |
| Ghini, B | 1 |
| Lopes de Faria, JB | 1 |
| Galisteo, M | 2 |
| García-Saura, MF | 2 |
| Jiménez, R | 2 |
| Villar, IC | 2 |
| Wangensteen, R | 1 |
| Zarzuelo, A | 2 |
| Vargas, F | 2 |
| Duarte, J | 2 |
| Ruilope, LM | 6 |
| Usan, L | 1 |
| Segura, J | 1 |
| Liebson, PR | 1 |
| Martynov, AI | 1 |
| Zadionchenko, VS | 1 |
| Shestakova, MV | 1 |
| Sidorenko, BA | 1 |
| Ugriumova, MO | 1 |
| Muñoz Díaz, AB | 1 |
| Aguilar, P | 1 |
| Zeltser, D | 1 |
| Justo, D | 1 |
| Halkin, A | 1 |
| Rosso, R | 1 |
| Ish-Shalom, M | 1 |
| Hochenberg, M | 1 |
| Viskin, S | 1 |
| Aarons, L | 2 |
| Baxter, C | 1 |
| Gupta, S | 2 |
| Conti, CR | 4 |
| Romero, M | 1 |
| Sánchez, I | 1 |
| Pujol, MD | 1 |
| Cooper-DeHoff, R | 3 |
| Ilieva, AP | 1 |
| Bruno, S | 1 |
| Brusegan, V | 1 |
| Arnoldi, F | 1 |
| Ganeva, M | 2 |
| Dodesini, AR | 1 |
| Basile, J | 1 |
| Joerger, M | 1 |
| Diethelm, M | 1 |
| Handler, J | 1 |
| Logan, A | 1 |
| Gurevich, MA | 1 |
| Prisant, LM | 6 |
| Weber, M | 1 |
| Black, HR | 11 |
| Henry, A | 1 |
| Charpiat, B | 1 |
| Vial, T | 1 |
| Franchini, S | 1 |
| Cuilleret, FJ | 1 |
| Milon, H | 1 |
| Barrett, TD | 1 |
| Triggle, DJ | 3 |
| Walker, MJ | 1 |
| Maurice, DH | 1 |
| Elliott, WJ | 12 |
| Grandits, G | 2 |
| Grambsch, P | 2 |
| Lucente, T | 1 |
| Neaton, JD | 2 |
| Grimm, RH | 2 |
| Hansson, L | 2 |
| Lacourcière, Y | 3 |
| Muller, JE | 3 |
| Williams, GH | 4 |
| Wittes, J | 2 |
| Zanchetti, A | 14 |
| Sica, D | 2 |
| Kim, J | 2 |
| Lee, YR | 1 |
| Lee, CH | 1 |
| Choi, WH | 1 |
| Lee, CK | 1 |
| Bae, YM | 1 |
| Cho, S | 2 |
| Kim, B | 1 |
| Hjemdahl, P | 1 |
| Eriksson, SV | 1 |
| Held, C | 1 |
| Forslund, L | 2 |
| Näsman, P | 1 |
| Rehnqvist, N | 1 |
| Lima, JJ | 1 |
| Beasley, BN | 1 |
| Parker, RB | 2 |
| Wessel, TR | 1 |
| Arant, CB | 1 |
| Geiser, EA | 1 |
| Reynolds, NA | 1 |
| Wagstaff, AJ | 1 |
| Keam, SJ | 1 |
| Vakina, TN | 1 |
| Bogdanova, SR | 1 |
| Owecki, M | 1 |
| Sowiński, J | 1 |
| Hewkin, AC | 3 |
| Karpov, IuA | 1 |
| Fomin, VV | 1 |
| Moiseev, SV | 2 |
| Nitschmann, S | 1 |
| Zhu, F | 1 |
| Huang, B | 1 |
| Hu, CY | 1 |
| Jiang, QY | 1 |
| Lu, ZG | 1 |
| Lu, M | 1 |
| Wang, MH | 1 |
| Gong, M | 1 |
| Qiao, CP | 1 |
| Chen, W | 1 |
| Huang, PH | 1 |
| Kowey, PR | 1 |
| Kolloch, RE | 1 |
| Benetos, A | 7 |
| Coca, A | 3 |
| Tavazzi, L | 1 |
| Hewkin, A | 2 |
| Kolloch, R | 2 |
| Kosicka, T | 1 |
| Kara-Perz, H | 1 |
| Głuszek, J | 1 |
| Perz, S | 1 |
| Rosa, F | 1 |
| Cedeño, J | 1 |
| León, L | 1 |
| Estrada, O | 1 |
| Romero-Vecchione, E | 1 |
| Vásquez, J | 1 |
| Antequera, R | 1 |
| Lozano-Nuevo, JJ | 1 |
| Ramos-Brizuela, LM | 1 |
| Glassock, RJ | 1 |
| Bakris, G | 4 |
| Molitch, M | 2 |
| Kipnes, M | 1 |
| Sarafidis, P | 2 |
| Fakouhi, K | 1 |
| Bacher, P | 2 |
| Sowers, J | 1 |
| Sahney, S | 1 |
| Iskendeerov, BG | 1 |
| Berenshteĭn, NV | 2 |
| Abramova, GN | 1 |
| Shibaeva, TM | 1 |
| Yarandi, HN | 1 |
| Katz, DA | 1 |
| Scholze, J | 2 |
| Grimm, E | 1 |
| Herrmann, D | 1 |
| Unger, T | 2 |
| Kintscher, U | 1 |
| Tytus, RH | 1 |
| Burgess, ED | 1 |
| Assouline, L | 1 |
| Vanjaka, A | 1 |
| Batalis, NI | 1 |
| Harley, RA | 1 |
| Schandl, CA | 1 |
| Brunner, M | 1 |
| Karnes, JH | 1 |
| Messerli, F | 4 |
| Frishman, WH | 13 |
| García Donaire, JA | 1 |
| Ozkul, Y | 1 |
| Wang, D | 1 |
| Sadee, W | 1 |
| Knot, HJ | 1 |
| Uretsky, S | 1 |
| Ural, E | 1 |
| Kozdag, G | 1 |
| Kilic, T | 1 |
| Ural, D | 1 |
| Sahin, T | 1 |
| Celebi, O | 1 |
| Komsuoglu, B | 1 |
| Sharma, SK | 1 |
| Cowley, BD | 1 |
| Braam, RL | 1 |
| van Uum, SH | 1 |
| Lenders, JW | 1 |
| Thien, T | 1 |
| Attinà, TM | 1 |
| Malatino, LS | 1 |
| Maxwell, SR | 1 |
| Padfield, PL | 1 |
| Webb, DJ | 1 |
| Sowers, JR | 2 |
| González-Castro, A | 1 |
| Suberviola Cañas, B | 1 |
| Burón Mediavilla, FJ | 1 |
| San José, JM | 1 |
| González, C | 1 |
| Vázquez de Prada, JA | 1 |
| Gojanovic, B | 1 |
| Feihl, F | 1 |
| Liaudet, L | 1 |
| Waeber, B | 5 |
| Yildiz, A | 1 |
| Yigit, Z | 1 |
| Okcun, B | 1 |
| Baskurt, M | 1 |
| Ortak, K | 1 |
| Kaya, A | 1 |
| Kucukoglu, S | 1 |
| Müller, FB | 8 |
| Bolli, P | 13 |
| Erne, P | 8 |
| Block, LH | 1 |
| Kiowski, W | 11 |
| Bühler, FR | 20 |
| Stone, KS | 1 |
| Scordo, KA | 1 |
| Massie, BM | 2 |
| Hirsch, AT | 1 |
| Inouye, IK | 1 |
| Tubau, JF | 1 |
| Fritschka, E | 1 |
| Distler, A | 4 |
| Lenz, T | 1 |
| Kribben, A | 1 |
| Schudrowitsch, L | 1 |
| Philipp, T | 5 |
| Opie, LH | 2 |
| Lampa, E | 1 |
| Rossi, F | 1 |
| Aliperta, A | 1 |
| Giordano, L | 1 |
| Perna, D | 1 |
| Catena, E | 1 |
| Marmo, E | 2 |
| Lewis, GR | 5 |
| Iaina, A | 1 |
| Eliahou, HE | 1 |
| Wheatley, D | 1 |
| Klein, NA | 1 |
| Klein, P | 1 |
| Strom, JA | 2 |
| Tawil, R | 1 |
| Strair, R | 1 |
| Wong, B | 1 |
| Roth, S | 1 |
| LeJemtel, TH | 1 |
| Pollack, S | 2 |
| Sonnenblick, EH | 2 |
| Krikler, DM | 1 |
| Rowland, E | 2 |
| Anand, MP | 1 |
| Brandt, D | 3 |
| MacAlpin, R | 1 |
| Ellrodt, AG | 2 |
| Singh, BN | 4 |
| Hulthén, UL | 9 |
| Rahn, KH | 8 |
| Tsuda, K | 7 |
| Kuchii, M | 3 |
| Kusuyama, Y | 3 |
| Hano, T | 2 |
| Nishio, I | 6 |
| Masuyama, Y | 8 |
| Lederballe Pedersen, C | 1 |
| Mikkelsen, E | 1 |
| Jespersen, LT | 2 |
| Amann, FW | 2 |
| Leonetti, G | 11 |
| Cuspidi, C | 5 |
| Sampieri, L | 6 |
| Terzoli, L | 3 |
| Muiesan, G | 5 |
| Agabiti-Rosei, E | 6 |
| Castellano, M | 5 |
| Alicandri, CL | 1 |
| Corea, L | 4 |
| Fariello, R | 1 |
| Beschi, M | 3 |
| Romanelli, G | 3 |
| Schütz, E | 2 |
| Ha, HR | 3 |
| Follath, F | 5 |
| Midtbø, K | 8 |
| Hals, O | 7 |
| van der Meer, J | 3 |
| Gould, BA | 7 |
| Hornung, RS | 4 |
| Mann, S | 4 |
| Balasubramanian, V | 2 |
| Raftery, EB | 9 |
| Anavekar, SN | 2 |
| Barter, C | 1 |
| Adam, WR | 1 |
| Doyle, AE | 5 |
| Poston, L | 3 |
| Gray, HH | 3 |
| Crowther, A | 1 |
| Dittrich, HC | 1 |
| Hilton, PJ | 3 |
| Webb-Peploe, MM | 1 |
| MacGregor, GA | 4 |
| Sloan, RW | 1 |
| Karlsberg, RP | 2 |
| Aronow, WS | 1 |
| Guazzi, MD | 6 |
| Cipolla, C | 2 |
| Sganzerla, P | 2 |
| Agostoni, PG | 2 |
| Fabbiocchi, F | 2 |
| Pepi, M | 3 |
| Loaldi, A | 2 |
| Fiorentini, C | 3 |
| Grazi, S | 1 |
| Della Bella, P | 2 |
| Henry, PD | 1 |
| Horwitz, DL | 1 |
| Ewy, GA | 1 |
| Nami, R | 1 |
| Martinelli, M | 1 |
| Lo Monaco, B | 1 |
| Pizzuti, M | 1 |
| Nardi, PL | 1 |
| D'Ascenzo, G | 1 |
| Gennari, C | 1 |
| Hulthén, L | 3 |
| van Soest, GA | 1 |
| Birkenhäger, WH | 3 |
| Johnston, WE | 1 |
| Lowenstein, E | 1 |
| Ambrose, JE | 1 |
| Johnston, CI | 2 |
| Covinsky, JO | 1 |
| Hamburger, SC | 1 |
| Tullio, D | 1 |
| Valerio, A | 1 |
| D'Agostino, F | 1 |
| Spivack, C | 2 |
| Ocken, S | 2 |
| Hedbäck, B | 2 |
| Parment, K | 1 |
| Heidland, A | 2 |
| Heidbreder, E | 2 |
| Hörl, WH | 2 |
| Schäfer, RM | 1 |
| Gelman, A | 1 |
| de Albuquerque, EM | 1 |
| Reynaldo Stella, S | 1 |
| Draibe, SA | 1 |
| Ajzen, H | 1 |
| Scannapieco, G | 1 |
| Pauletto, P | 1 |
| Semplicini, A | 1 |
| Dario, C | 1 |
| Vescovo, G | 1 |
| Mazzucato, A | 1 |
| Angelini, A | 1 |
| Pessina, AC | 1 |
| Ottander, C | 1 |
| Lipe, S | 1 |
| Moulds, RF | 3 |
| Montorsi, P | 1 |
| Jones, RI | 2 |
| Sonecha, T | 2 |
| Klein, WW | 1 |
| Lehtonen, A | 3 |
| Gordin, A | 4 |
| Schwietzer, G | 1 |
| Reeck, S | 1 |
| Thiede, HM | 1 |
| Maclean, D | 1 |
| Feely, J | 1 |
| Scheinman, MM | 1 |
| Hess, DS | 1 |
| Smith, SJ | 1 |
| Markandu, ND | 2 |
| Weinberg, P | 2 |
| Peled, HB | 1 |
| Kimmel, B | 3 |
| Charlap, S | 8 |
| Beer, N | 1 |
| Zofková, I | 2 |
| Hampl, R | 1 |
| Roztocil, K | 1 |
| Lafleur, C | 1 |
| Bufalino, C | 1 |
| Taubert, KA | 1 |
| Halperin, AK | 3 |
| Gross, KM | 1 |
| Rogers, JF | 1 |
| Cubeddu, LX | 5 |
| Vasquez, EC | 2 |
| Mill, JG | 3 |
| Cabral, AM | 2 |
| Kondo, N | 1 |
| Shibata, S | 1 |
| Rossi, LP | 1 |
| Antman, EM | 1 |
| Lund-Johansen, P | 4 |
| Kieso, H | 4 |
| Subramanian, VB | 2 |
| Hermann, LS | 1 |
| Pasotti, C | 1 |
| Ferrari, GP | 1 |
| Raine, AE | 1 |
| Roberts, AF | 1 |
| Manley, BS | 1 |
| Jones, JV | 1 |
| Ledingham, JG | 1 |
| Robinson, BF | 8 |
| Benjamin, N | 3 |
| Phillips, RJ | 3 |
| Pedersen, OL | 3 |
| Mikkelsen, EO | 1 |
| Jakobsen, P | 1 |
| Dobbs, RJ | 2 |
| Omvik, P | 2 |
| Wigler, I | 1 |
| Peer, G | 2 |
| Soferman, G | 1 |
| Blum, M | 1 |
| Aviram, A | 1 |
| Kaburagi, T | 1 |
| Yokoyama, S | 1 |
| Agapova, EN | 1 |
| Denisova, TP | 1 |
| Eliseeva, LN | 1 |
| Schäfer, R | 1 |
| Candau, LA | 2 |
| Pereira, LS | 1 |
| Scherr, C | 2 |
| Brunner, HR | 4 |
| Reves, JG | 1 |
| Kissin, I | 1 |
| Lell, WA | 1 |
| Tosone, S | 1 |
| Chlewicka, I | 2 |
| Wasowska, T | 1 |
| Wajngarten, M | 1 |
| Solorzano, J | 1 |
| Godoy, M | 1 |
| Barretto, AC | 2 |
| Pileggi, F | 2 |
| Manfroi, WC | 1 |
| Vieira, SR | 1 |
| Ludwig, R | 1 |
| Hemb, R | 1 |
| de Azevedo, DF | 1 |
| de Freitas, FM | 1 |
| Faraco, EZ | 1 |
| Dipalma, JR | 1 |
| Friesen, RM | 1 |
| Bonet, JF | 1 |
| Zaret, GM | 1 |
| González-Gómez, A | 3 |
| Gamio-Capestany, F | 1 |
| Nash, DT | 1 |
| Feer, TD | 1 |
| Aguas, AP | 1 |
| Nickerson, PA | 1 |
| Raczka, A | 1 |
| Azuma, T | 1 |
| Ohhashi, T | 1 |
| Takata, Y | 1 |
| Hutchinson, JS | 1 |
| Das, UN | 2 |
| Levy, JV | 3 |
| Lehmann, HU | 2 |
| Hochrein, H | 2 |
| Sala, C | 2 |
| Bianchini, C | 3 |
| Schamroth, L | 2 |
| Penna, M | 1 |
| Pescio, S | 1 |
| Dargie, H | 2 |
| Krikler, D | 2 |
| Ruedy, J | 1 |
| Burckhardt, P | 1 |
| Gavras, H | 1 |
| de Oliveira, JM | 3 |
| Maciel, RM | 1 |
| Spritzer, N | 2 |
| Spritzer, TS | 2 |
| Abichequer, MB | 1 |
| Bar-Andziak, E | 1 |
| McGoon, MD | 2 |
| Vlietstra, RE | 2 |
| Holmes, DR | 1 |
| Osborn, JE | 1 |
| Merz, B | 1 |
| Nghiem, C | 2 |
| Swamy, VC | 2 |
| Krebs, R | 1 |
| Graefe, KH | 1 |
| Ziegler, R | 1 |
| Bayley, S | 1 |
| Anshelevich, IuV | 1 |
| Dumesh, SZ | 1 |
| Slaĭdyn', AK | 1 |
| Sporan, VG | 1 |
| Vasques, EC | 1 |
| Moysés, MR | 2 |
| da Silva, FD | 1 |
| da Costa, MB | 1 |
| Caldas, JG | 1 |
| Cabral, Ade M | 1 |
| Vassalo, DV | 1 |
| Sau, F | 2 |
| Pisano, MR | 1 |
| Pirisi, R | 1 |
| Seguro, C | 2 |
| Ledda, M | 1 |
| Raffo, M | 1 |
| Cherchi, A | 2 |
| Zanolli, MB | 1 |
| Herdoiza, GL | 1 |
| Padolan, E | 1 |
| Mulinari, AS | 1 |
| Lassitte, A | 1 |
| Branco, BP | 1 |
| Marks, SC | 1 |
| Rocha de Carvalho, JG | 1 |
| Mourão, AM | 1 |
| Reinert, MI | 1 |
| Peixoto, RL | 1 |
| de Moraes, CA | 1 |
| Pimentel Filho, P | 1 |
| Talano, JV | 1 |
| Feerst, D | 1 |
| Pang, CC | 1 |
| Sutter, MC | 1 |
| Novo, S | 4 |
| Riolo, F | 1 |
| Pinto, A | 1 |
| Davì, G | 1 |
| Botindari, C | 1 |
| Nayler, WG | 2 |
| Tasca, R | 1 |
| Carvalho, DM | 1 |
| Carrasco, RM | 5 |
| da Rocha, MM | 1 |
| Luna, RL | 6 |
| Talberg, J | 1 |
| Fernandes, EO | 1 |
| Chequer, CV | 1 |
| Latreca, CE | 1 |
| Reis, NB | 1 |
| de Melo Junior, MG | 2 |
| Carvalho, Mde A | 2 |
| de Couto, AA | 1 |
| dos Reis, LM | 1 |
| Aloan, L | 2 |
| Carneiro, RD | 2 |
| Osterne, EC | 1 |
| de Alencar, JE | 1 |
| da Fonseca, AA | 1 |
| Fleckenstein, A | 1 |
| Fleckenstein-Grün, G | 2 |
| Bender, F | 3 |
| Asano, M | 3 |
| Nomura, Y | 3 |
| Ito, K | 2 |
| Uyama, Y | 2 |
| Imaizumi, Y | 2 |
| Watanabe, M | 2 |
| Kokkinos, PF | 2 |
| Narayan, P | 2 |
| Colleran, JA | 1 |
| Pittaras, A | 1 |
| Notargiacomo, A | 1 |
| Reda, D | 1 |
| Papademetriou, V | 3 |
| von Manteuffel, GE | 1 |
| Rakette, S | 1 |
| Woll, EM | 1 |
| Reinfrank, J | 3 |
| Schiemann, J | 1 |
| Howley, JW | 1 |
| Formolo, JM | 1 |
| Penney, DG | 2 |
| Janssens, SP | 1 |
| Kachoris, C | 1 |
| Parker, WL | 1 |
| Hales, CA | 1 |
| Haupert, GT | 1 |
| Lal, KJ | 1 |
| Dakshinamurti, K | 1 |
| Libretti, A | 2 |
| Catalano, M | 2 |
| Hansen, JF | 4 |
| Bragato, R | 4 |
| Comerio, G | 2 |
| Arita, M | 2 |
| Horinaka, S | 1 |
| Komatsu, K | 1 |
| Frohlich, ED | 2 |
| Medeiros, IA | 1 |
| Zhang, BL | 1 |
| Bertolino, S | 1 |
| Sassard, J | 1 |
| Rubio-Luengo, MA | 1 |
| Maldonado-Martín, A | 1 |
| Gil-Extremera, B | 1 |
| González-Gómez, L | 1 |
| Luna del Castillo, JD | 1 |
| Tobias, JD | 1 |
| Moreau, P | 3 |
| Takase, H | 3 |
| Küng, CF | 3 |
| van Rooijen, MM | 1 |
| Schaffner, T | 1 |
| Lüscher, TF | 7 |
| Padrell, MD | 1 |
| Navarro, M | 1 |
| Faura, CC | 1 |
| Horga, JF | 1 |
| Kong, BW | 3 |
| Bean, JA | 1 |
| Stephens, D | 1 |
| Kailasam, MT | 1 |
| Parmer, RJ | 1 |
| Cervenka, JH | 1 |
| Wu, RA | 1 |
| Ziegler, MG | 1 |
| Kennedy, BP | 1 |
| Adegbile, IA | 1 |
| O'Connor, DT | 1 |
| Chrysant, SG | 2 |
| Fox, AA | 2 |
| Stimpel, M | 3 |
| MacIntyre, JM | 1 |
| Levine, JH | 2 |
| Ferdinand, KC | 2 |
| Cargo, P | 2 |
| Laine, H | 1 |
| Lefkowitz, M | 2 |
| Bursztyn, M | 2 |
| Ghanem, J | 2 |
| Kobrin, I | 1 |
| Fidel, J | 1 |
| Ben-Ishay, D | 2 |
| Gómez Pajuelo, C | 2 |
| Gómez Sánchez, MA | 1 |
| Marín Ruiz, R | 1 |
| Lombera Romero, F | 1 |
| Sanz Julve, M | 1 |
| Tascón Pérez, J | 1 |
| Sáenz de la Calzada, C | 1 |
| Houston, MC | 1 |
| Weir, M | 1 |
| Gray, J | 4 |
| Ginsberg, D | 1 |
| Szeto, C | 1 |
| Kaihlenen, PM | 1 |
| Sugimoto, D | 1 |
| Runde, M | 1 |
| Klaus, D | 1 |
| Davis, PJ | 1 |
| Fagan, TC | 1 |
| Topmiller, MJ | 1 |
| Redón, J | 2 |
| Lozano, JV | 1 |
| de la Figuera, M | 3 |
| Rodriguez, JC | 1 |
| Garrido, J | 5 |
| Alés-Martínez, JE | 1 |
| Alvarez-Cantalapiedra, I | 1 |
| Velasco-Quintana, J | 2 |
| Lenz, ML | 1 |
| Pool, JL | 2 |
| Laddu, AR | 1 |
| Varghese, A | 1 |
| Johnston, W | 1 |
| Taylor, AA | 1 |
| Barry, JM | 1 |
| Smith, CJ | 1 |
| Bolt, TR | 1 |
| Ferner, RE | 1 |
| Di Somma, S | 2 |
| Carotenuto, A | 2 |
| de Divitiis, M | 1 |
| Paulucci, A | 2 |
| Galderisi, M | 1 |
| Cuocolo, A | 2 |
| de Divitiis, O | 2 |
| Lee, DW | 1 |
| Cohan, B | 1 |
| Huelmos, A | 1 |
| Alegría, E | 2 |
| Vázquez, C | 1 |
| Cantor, A | 2 |
| Gilutz, H | 2 |
| Meyer, T | 1 |
| Arabidze, GG | 2 |
| Dmitriev, VV | 2 |
| Rogoza, AN | 2 |
| Jovanović, L | 1 |
| Novosel, D | 1 |
| Lang, MG | 1 |
| Noll, G | 3 |
| Thimm, F | 1 |
| Czirfuzs, A | 1 |
| Matyas, S | 1 |
| Frey, M | 1 |
| Cedro, K | 1 |
| Dłuzniewski, M | 1 |
| Szpytma, M | 1 |
| Knypl, K | 1 |
| Brym, E | 1 |
| Wacławek-Maczkowska, J | 1 |
| Carter, BL | 3 |
| Moore, MA | 1 |
| Mann, RJ | 1 |
| Roberts, RW | 1 |
| Weinberger, MH | 1 |
| Wagner, UL | 1 |
| Fineberg, NS | 1 |
| Cléroux, J | 2 |
| Beaulieu, M | 2 |
| Kouamé, N | 1 |
| Rinaldi, G | 1 |
| Cingolani, H | 1 |
| Conrad, K | 1 |
| Barbee, RW | 1 |
| Maymind, M | 1 |
| Zimmerman, R | 1 |
| Crocker, JF | 1 |
| Renton, KW | 1 |
| LeVatte, TL | 1 |
| McLellan, DH | 1 |
| Clements, IP | 1 |
| Zachariah, PK | 5 |
| Petrella, RJ | 2 |
| Nichol, PM | 1 |
| Cunningham, DA | 2 |
| Paterson, DH | 2 |
| Alvau, MD | 1 |
| Pargentino, E | 1 |
| Vulpis, V | 2 |
| Seccia, TM | 1 |
| Ricci, S | 1 |
| Nazzaro, P | 2 |
| Pirrelli, A | 3 |
| Ding, YA | 1 |
| Chou, TC | 1 |
| Lin, KC | 1 |
| Antonicelli, R | 2 |
| Savonitto, S | 1 |
| Tomassini, PF | 2 |
| Gambini, C | 2 |
| Sardina, M | 2 |
| Paciaroni, E | 2 |
| González-Juanatey, JR | 1 |
| García-Acuña, JM | 1 |
| Calvo Gómez, C | 1 |
| Amaro Cendón, A | 2 |
| Fernández-López, JA | 1 |
| Gil de la Peña, M | 2 |
| Qian, XX | 1 |
| Chen, AH | 1 |
| Deng, JY | 1 |
| Tang, XM | 1 |
| Liu, YF | 1 |
| Li, ZL | 1 |
| Ou, SB | 1 |
| Wu, ZN | 1 |
| Wang, KR | 1 |
| Drici, MD | 2 |
| Jacomet, Y | 1 |
| Iacono, P | 1 |
| Lapalus, P | 2 |
| Madsen, JK | 1 |
| Schohn, D | 1 |
| Maarek, M | 1 |
| Jahn, H | 1 |
| Porter-Field, LM | 1 |
| Kaesemeyer, WH | 2 |
| Carr, AA | 4 |
| Bottini, PB | 3 |
| Steele, RM | 1 |
| Schuna, AA | 1 |
| Schreiber, RT | 1 |
| Icenogle, MV | 1 |
| Kapsner, CO | 1 |
| Chick, TW | 1 |
| Roehnert, J | 1 |
| Murata, GH | 1 |
| Lograno, MD | 1 |
| Daniele, E | 1 |
| Bocciolone, M | 4 |
| Lonati, L | 4 |
| Boselli, L | 4 |
| Lemieux, SC | 1 |
| Deniel Rosanas, J | 2 |
| Jespersen, CM | 1 |
| Tomás, S | 1 |
| Duaso, E | 1 |
| Llibre, J | 1 |
| Weiner, DA | 3 |
| Daroca Pérez, R | 1 |
| Alfaro Olea, A | 1 |
| San Román Lazcano, FJ | 1 |
| Jiménez Santolaya, C | 1 |
| Soltis, EE | 1 |
| Newman, PS | 1 |
| Trowbridge, JL | 1 |
| Tsuda, S | 2 |
| Goldstein, M | 1 |
| Sasaki, F | 1 |
| Osugi, S | 2 |
| Shimamura, K | 1 |
| Feldman, RD | 1 |
| Freeman, DJ | 1 |
| Bierbrier, GS | 1 |
| Anthony, SE | 1 |
| Brown, JE | 1 |
| Carmona, J | 1 |
| Amado, P | 1 |
| Castanheira, J | 1 |
| Nazaré, J | 1 |
| Araújo, V | 1 |
| Glotov, MN | 1 |
| Malov, AG | 1 |
| Metelitsa, TV | 1 |
| Domba, GIu | 1 |
| Sitina, VK | 1 |
| Tamborini, G | 3 |
| Susini, G | 1 |
| Salvi, L | 1 |
| Nalbantgil, I | 1 |
| Onder, R | 1 |
| Kiliçcioğlu, B | 1 |
| Türkoğlu, C | 1 |
| Nose, I | 1 |
| Kataoka, T | 1 |
| Yamada, T | 1 |
| Ikeno, A | 1 |
| Fukuya, F | 1 |
| Minato, H | 1 |
| Takeyama, K | 1 |
| Hosoki, K | 1 |
| Karasawa, T | 1 |
| Redón-Más, J | 1 |
| Abellán-Alemán, J | 1 |
| Aranda-Lara, P | 1 |
| de la Figuera-von Wichmann, M | 1 |
| Luque-Otero, M | 2 |
| Rodicio-Díaz, JL | 1 |
| Ruilope-Urioste, LM | 1 |
| Vasdev, S | 1 |
| Gupta, IP | 1 |
| Sampson, CA | 1 |
| Longerich, L | 1 |
| Parai, S | 1 |
| Madeddu, P | 2 |
| Demontis, MP | 1 |
| Fattaccio, MC | 1 |
| Palmieri, A | 1 |
| Mora-Macià, J | 1 |
| Ocón Pujadas, J | 1 |
| Fernández Vidal, P | 1 |
| Garrido García, J | 1 |
| Velasco Quintana, J | 1 |
| del Río Pérez, G | 1 |
| Shamiss, A | 2 |
| Peleg, E | 1 |
| Rosenthal, T | 3 |
| Ezra, D | 1 |
| Saelens, DA | 1 |
| Zawada, ET | 1 |
| Peterson, J | 1 |
| Lembke, JM | 1 |
| van Zwieten, PA | 2 |
| Pfaffendorf, M | 1 |
| Abernethy, DR | 4 |
| Neutel, JM | 3 |
| Smith, DH | 3 |
| Lefkowitz, MP | 1 |
| Alemayehu, D | 1 |
| Tijssen, JG | 1 |
| Lie, KI | 1 |
| Blackshear, JL | 1 |
| Kopecky, SL | 1 |
| Litin, SC | 1 |
| Safford, RE | 1 |
| Hammill, SC | 1 |
| Manzari, M | 1 |
| Merlo, M | 1 |
| Triggiani, R | 1 |
| Scarano, AM | 1 |
| Lasciarrea, A | 1 |
| Doggrell, SA | 2 |
| Surman, AJ | 1 |
| Gebara, OC | 2 |
| Jimenez, AH | 1 |
| McKenna, C | 1 |
| Mittleman, MA | 1 |
| Xu, P | 1 |
| Lipinska, I | 1 |
| Tofler, GH | 2 |
| Saseen, JJ | 2 |
| Brown, TE | 1 |
| Gromyko, GL | 1 |
| Münter, K | 1 |
| Hergenröder, S | 1 |
| Jochims, K | 1 |
| Kirchengast, M | 2 |
| Jasiński, T | 1 |
| Janicki, K | 1 |
| Klima, M | 1 |
| Pieniazek, W | 1 |
| Bednarz, S | 1 |
| Schneider, M | 1 |
| Lerch, M | 1 |
| Papiri, M | 1 |
| Buechel, P | 1 |
| Boehlen, L | 1 |
| Shaw, S | 2 |
| Risen, W | 1 |
| Weidmann, P | 4 |
| Levy, R | 1 |
| Nagauker-Shriker, O | 1 |
| Schlaeffer, F | 1 |
| Oren, S | 2 |
| Viskoper, JR | 1 |
| Zilles, P | 4 |
| Chen, S | 1 |
| Monteith, GR | 1 |
| Roufogalis, BD | 1 |
| Lewanczuk, RZ | 2 |
| Hamilton, PG | 1 |
| Alderman, M | 1 |
| Notter, T | 2 |
| Mangrum, A | 1 |
| Copley, JB | 1 |
| Vicknair, N | 1 |
| Sadler, R | 2 |
| Iabichella, ML | 1 |
| Dell'Omo, G | 1 |
| Melillo, E | 1 |
| Pedrinelli, R | 6 |
| Aepfelbacher, FC | 1 |
| Nunez, E | 1 |
| Michalewicz, L | 1 |
| DeQuattro, V | 2 |
| Lee, D | 2 |
| Horiuchi, K | 1 |
| Tomohiro, A | 1 |
| Aki, Y | 1 |
| Kimura, S | 1 |
| Tamaki, T | 2 |
| Abe, Y | 1 |
| Bitar, R | 2 |
| Martín, B | 1 |
| Skoularigis, J | 1 |
| Strugo, V | 1 |
| Radevski, I | 2 |
| Hlatswayo, Z | 1 |
| Sareli, P | 3 |
| Ben-Noun, L | 1 |
| Rosito, GA | 2 |
| McKenna, CA | 1 |
| Solomon, HS | 1 |
| Fletcher, RD | 1 |
| Tsagadopoulos, D | 1 |
| Erlich, Y | 1 |
| Rosenmann, E | 1 |
| Cohen, A | 1 |
| Porter, JA | 1 |
| Barnette, DJ | 1 |
| Bauman, JL | 1 |
| Zajac, EJ | 1 |
| Omboni, S | 2 |
| Grassi, G | 1 |
| Park, S | 1 |
| McCune, SA | 1 |
| Radin, MJ | 1 |
| Hoepf, TM | 1 |
| Hensley, J | 1 |
| Hohl, CM | 1 |
| Altschuld, RA | 1 |
| Puri, VN | 1 |
| Parodi, O | 2 |
| Neglia, D | 2 |
| Palombo, C | 2 |
| Sambuceti, G | 2 |
| Giorgetti, A | 1 |
| Marabotti, C | 2 |
| Gallopin, M | 1 |
| Simonetti, I | 1 |
| L'Abbate, A | 1 |
| Mehrotra, DV | 1 |
| Fakouhi, TD | 4 |
| Gralec, M | 1 |
| Piusińska-Macoch, A | 1 |
| Cholewa, M | 1 |
| Sułek, K | 1 |
| Magometschnigg, D | 1 |
| Hofmann, R | 1 |
| Sihorsch, K | 1 |
| Stoschitzky, K | 1 |
| Zangeneh, M | 1 |
| Zenker, G | 1 |
| Punzi, HA | 1 |
| Novrit, BA | 1 |
| Mikawa, K | 2 |
| Nishina, K | 1 |
| Takao, Y | 1 |
| Shiga, M | 1 |
| Maekawa, N | 2 |
| Obara, H | 2 |
| Rosei, EA | 2 |
| Dal Palù, C | 4 |
| Magnani, B | 4 |
| Pessina, A | 2 |
| Pitt, B | 1 |
| Young, ME | 1 |
| Clark, JF | 2 |
| Leighton, B | 1 |
| Grossman, E | 1 |
| Espina Ordeix, J | 1 |
| Molina Gallardo, S | 1 |
| Casellas Criballés, E | 1 |
| Del Rosso, A | 1 |
| Fradella, G | 1 |
| Russo, L | 1 |
| Bartoli, P | 1 |
| Bonechi, F | 1 |
| Brandinelli, A | 1 |
| Maioli, M | 2 |
| Mazza, F | 1 |
| Sansoni, M | 1 |
| Zipoli, A | 1 |
| Mannelli, M | 1 |
| Ieri, A | 1 |
| Oken, RJ | 1 |
| Streier, K | 1 |
| Molinero, E | 1 |
| Murga, N | 1 |
| Sagastagoitia, JD | 1 |
| Bryzinski, B | 1 |
| Pargger, H | 1 |
| Kaufmann, MA | 1 |
| Drop, LJ | 1 |
| Conlin, PR | 1 |
| Odeh, M | 1 |
| Oliven, A | 1 |
| Liang, LC | 1 |
| Antonios, TF | 1 |
| d'Uscio, LV | 1 |
| Barton, M | 1 |
| Pierdomenico, SD | 1 |
| Bucci, A | 1 |
| Costantini, F | 1 |
| Lapenna, D | 1 |
| Cuccurullo, F | 1 |
| Mezzetti, A | 1 |
| Compagnone, D | 3 |
| Lacoucière, Y | 1 |
| Muller, J | 1 |
| Williams, G | 1 |
| López-Hernández, FJ | 3 |
| Flores, O | 3 |
| Montero, MJ | 3 |
| Carrón, R | 3 |
| Giovannini, L | 1 |
| Migliori, M | 1 |
| Taccola, D | 1 |
| Panichi, V | 1 |
| Andreini, B | 1 |
| De Pietro, S | 1 |
| Filippi, C | 1 |
| Del Ry, S | 1 |
| Andreassi, MG | 1 |
| Colombo, MG | 1 |
| Biagini, A | 1 |
| Giannessi, D | 1 |
| Palla, R | 1 |
| Breithaupt-Grögler, K | 1 |
| Gerhardt, G | 1 |
| Lehmann, G | 1 |
| Belz, GG | 2 |
| Kvam, FI | 1 |
| Faich, G | 1 |
| Makuch, R | 1 |
| Handberg-Thurmond, E | 1 |
| Conlon, M | 1 |
| Volkers, P | 1 |
| Zellig, P | 1 |
| Dzúrik, R | 1 |
| Koffi, I | 2 |
| Lacolley, P | 2 |
| Kirchengaast, M | 1 |
| Pomiès, JP | 1 |
| Laurent, S | 1 |
| Makolkin, VI | 1 |
| Podzolkov, VI | 1 |
| Yoneda, H | 1 |
| Toriumi, W | 1 |
| Ohmachi, Y | 1 |
| Okumura, F | 1 |
| Fujimura, H | 1 |
| Nishiyama, S | 1 |
| Fortepiani, LA | 2 |
| Rodrigo, E | 1 |
| Ortíz, MC | 2 |
| Cachofeiro, V | 1 |
| Atucha, NM | 2 |
| Lahera, V | 2 |
| García-Estañ, J | 2 |
| Li, G | 1 |
| Sun, M | 1 |
| Zhou, H | 1 |
| Anderson, RB | 1 |
| Hollenberg, NK | 2 |
| Arévalo, MA | 1 |
| Topouchian, J | 1 |
| Asmar, R | 2 |
| Sayegh, F | 1 |
| Rudnicki, A | 1 |
| Bacri, AM | 1 |
| Safar, ME | 3 |
| Al-Waili, NS | 1 |
| Hasan, NA | 1 |
| Petretta, M | 2 |
| Canonico, V | 2 |
| Madrid, A | 1 |
| Mickiewicz, M | 1 |
| Spinelli, L | 1 |
| Marciano, F | 1 |
| Vetrano, A | 1 |
| Signorini, A | 1 |
| Bonaduce, D | 2 |
| Labat, C | 1 |
| Mourad, JJ | 1 |
| Hilleman, DE | 1 |
| Ryschon, KL | 1 |
| Mohiuddin, SM | 1 |
| Wurdeman, RL | 1 |
| Loeb, ED | 1 |
| Diamond, JA | 3 |
| Krakoff, LR | 2 |
| Phillips, RA | 3 |
| Johnson, MF | 5 |
| González Maqueda, I | 1 |
| Gómez Guindal, JA | 1 |
| González Lama, I | 1 |
| Smeda, JS | 3 |
| VanVliet, BN | 1 |
| King, SR | 1 |
| de la Sierra, A | 1 |
| Moreno, E | 2 |
| de la Cámara, AG | 1 |
| García-Villalón, AL | 1 |
| Monge, L | 1 |
| Fernández, N | 1 |
| Sánchez, MA | 1 |
| Martínez, MA | 1 |
| Gómez, B | 1 |
| Diéguez, G | 1 |
| Lee, BH | 1 |
| Shin, HS | 1 |
| Lee, CO | 1 |
| Park, SH | 1 |
| Yoo, SE | 1 |
| Yi, KY | 1 |
| Jung, NP | 1 |
| Choi, SU | 1 |
| Fernández-González, R | 1 |
| Gómez-Pajuelo, C | 1 |
| Gabriel, R | 1 |
| Anderson, R | 1 |
| Meirelles Pereira, LM | 1 |
| Guize, L | 1 |
| Rudnichi, A | 1 |
| Safar, M | 1 |
| Bean, K | 1 |
| Karlberg, BE | 1 |
| Andrup, M | 1 |
| Odén, A | 2 |
| Cifková, R | 1 |
| Novozámská, E | 1 |
| Hejl, Z | 1 |
| Petrzílková, Z | 1 |
| Poledne, R | 1 |
| Stávek, P | 1 |
| Glasser, SP | 1 |
| Frishman, W | 2 |
| Stone, P | 1 |
| Ortega, KC | 1 |
| Santello, JL | 1 |
| Nobre, F | 1 |
| Kohlman Júnior, O | 1 |
| Jardim, PC | 1 |
| da Costa, LS | 1 |
| Raposo Filho, JJ | 1 |
| Oigman, W | 1 |
| Mion Júnior, D | 1 |
| Radda, GK | 1 |
| Boehm, EA | 1 |
| Sun, N | 1 |
| Hong, T | 1 |
| Zhang, R | 1 |
| Yang, X | 1 |
| Kei, M | 1 |
| Matsubara, K | 1 |
| Yokouchi, K | 1 |
| Hattori, K | 1 |
| Ichihashi, R | 1 |
| Hirakawa, Y | 1 |
| Tsukamoto, H | 1 |
| Saburi, Y | 1 |
| Schussheim, AE | 1 |
| Ruiz-Marcos, FM | 1 |
| Nadal, FJ | 1 |
| Nguyen, BN | 1 |
| Noujedehi, M | 1 |
| Sullivan, JM | 1 |
| Reverte, M | 1 |
| Macías, JF | 1 |
| Goldman, A | 1 |
| Coplan, N | 1 |
| Gharavi, A | 1 |
| Martin, K | 1 |
| Goldsmith, R | 1 |
| Henzlova, MJ | 1 |
| Machac, J | 1 |
| Radevski, IV | 1 |
| Valtchanova, ZP | 1 |
| Libhaber, E | 2 |
| Candy, GP | 1 |
| Den Hond, E | 1 |
| Libhaber, C | 1 |
| Skudicky, D | 2 |
| Wang, JG | 2 |
| Staessen, JA | 2 |
| Williams, LS | 1 |
| Hill, D | 1 |
| Davis, J | 1 |
| Lowenthal, DT | 2 |
| García de Vinuesa, S | 1 |
| Luño, J | 1 |
| Gómez-Campderá, F | 1 |
| Ridao, N | 1 |
| Sánchez, M | 1 |
| Dall'Anese, C | 1 |
| Valderrábano, F | 1 |
| Gibson, RS | 1 |
| Schechtman, KB | 1 |
| Boden, WE | 1 |
| Ruschitzka, F | 1 |
| Quaschning, T | 1 |
| deGottardi, A | 1 |
| Rossier, MF | 1 |
| Enseleit, F | 1 |
| Hürlimann, D | 1 |
| Shaw, SG | 1 |
| Abrignani, MG | 2 |
| Novo, G | 1 |
| Nardi, E | 1 |
| Dominguez, LJ | 1 |
| Strano, A | 3 |
| Barbagallo, M | 1 |
| Sevre, K | 3 |
| Lefrandt, JD | 3 |
| Eide, I | 1 |
| Smit, AJ | 3 |
| Rostrup, M | 3 |
| Fratta-Pasini, A | 1 |
| Garbin, U | 1 |
| Galetta, F | 1 |
| Cominacini, L | 1 |
| Perk, G | 1 |
| Aamar, S | 1 |
| Heitmann, J | 2 |
| Hausberg, M | 2 |
| Fallon, M | 2 |
| Fluckiger, L | 1 |
| Urbigkeit, A | 2 |
| Murphy, M | 2 |
| Zannad, F | 2 |
| de Kam, PJ | 2 |
| van Roon, AM | 1 |
| Laurent, D | 1 |
| Poirier, K | 1 |
| Wasvary, J | 1 |
| Rudin, M | 1 |
| Puig, JG | 1 |
| Rodríguez-Pérez, JC | 1 |
| Ram, V | 1 |
| Fagan, T | 1 |
| Vaitkus, PT | 1 |
| Candy, G | 1 |
| Valtchanova, Z | 1 |
| Tshele, E | 1 |
| Thijs, L | 1 |
| Sathyan, G | 1 |
| Ho Pl, PL | 1 |
| Binggeli, C | 1 |
| Corti, R | 1 |
| Sudano, I | 1 |
| Schwab, M | 1 |
| Oetzel, C | 1 |
| Mörike, K | 1 |
| Jägle, C | 1 |
| Gleiter, CH | 1 |
| Eichelbaum, M | 1 |
| Goicolea, I | 1 |
| Fernández González, R | 1 |
| Piniés, J | 1 |
| Martínez, JM | 1 |
| Armenteros, S | 1 |
| Moreno Carretero, E | 1 |
| Estrada, J | 1 |
| Cott, R | 1 |
| Witt, E | 1 |
| Morley, KD | 2 |
| Maslowski, AH | 1 |
| Bones, PJ | 2 |
| Johnstone, M | 1 |
| Sernesi, L | 1 |
| Oates, HF | 1 |
| Vohra, JK | 1 |
| Meneghelo, RS | 1 |
| Duprat, R | 1 |
| Batlouni, M | 1 |
| Severino, CA | 1 |
| Armaganijan, D | 1 |
| Magalhães, HM | 1 |
| Feher, J | 1 |
| Ellrodt, G | 1 |
| Peter, CT | 1 |
| Lewis, BM | 1 |
| Johansson, BW | 2 |
| Labriola, E | 2 |
| Marlettini, MG | 2 |
| Platè, L | 1 |
| Salomone, T | 2 |
| De Novellis, M | 1 |
| Trisolino, G | 1 |
| Lenzi, T | 2 |
| Capelli, M | 1 |
| Minero, R | 1 |
| Ortiz, J | 2 |
| Barreto, AC | 1 |
| Savioli, RM | 1 |
| Barbato, AJ | 1 |
| Netto, MP | 1 |
| Monaco, CA | 2 |
| Del Nero Júnior, E | 1 |
| Tranchesi, J | 1 |
| Ribeiro, LC | 1 |
| Albanesi, FM | 1 |
| Albuquerque, DC | 1 |
| Rocha, PJ | 1 |
| Benchimol, CB | 1 |
| Schlesinger, P | 1 |
| Benchimol, AB | 1 |
| Rocha, MC | 1 |
| Mochizuki, A | 1 |
| Yamamoto, Y | 1 |
| Kondo, S | 1 |
| Aoki, K | 2 |
| Mizuno, T | 1 |
| Hotta, K | 1 |
| Tkaczewski, W | 1 |
| Goch, JH | 1 |
| Sivkova, SK | 1 |
| Mikhailov, AA | 1 |
| Sumarokov, AV | 1 |
| Tatsievskiĭ, VA | 1 |
| Arata, L | 2 |
| Di Renzi, L | 2 |
| Giannico, S | 1 |
| Fedele, F | 2 |
| Pastore, LR | 2 |
| Penco, M | 2 |
| Agati, L | 2 |
| Nicita-Mauro, V | 3 |
| Barbera, N | 2 |
| Savica, V | 1 |
| Frisina, N | 3 |
| Ceruso, D | 1 |
| Gargari, T | 1 |
| Freitas, AM | 1 |
| Francischetti, EA | 1 |
| Cardoso, MS | 1 |
| Abraham, R | 1 |
| Menezes, CR | 1 |
| Bruni, EJ | 1 |
| Silva, DM | 1 |
| Mazza, ZC | 1 |
| Vichi, FL | 1 |
| Mazotti, L | 1 |
| Capucci de Oliveira, AF | 1 |
| Dráusio Martins, J | 1 |
| Bernardes, J | 1 |
| Buemi, M | 1 |
| Squadrito, G | 1 |
| Saitta, A | 1 |
| Scamardi, R | 1 |
| Cucinotta, D | 1 |
| Gushi, N | 1 |
| Mateos, DA | 2 |
| Magaldi, JB | 1 |
| Bachour, G | 1 |
| Wessels, F | 1 |
| Losse, H | 1 |
| Haas, Th | 1 |
| Denkl, P | 1 |
| Tsuzuki, S | 1 |
| Nakiri, K | 1 |
| Bittencourt, D | 1 |
| Zerbini, EJ | 1 |
| Addarii, F | 1 |
| Bogoliubov, VM | 2 |
| Lyskova, MN | 2 |
| Gribkova, IN | 1 |
| Kruglova, ZG | 1 |
| Das, AM | 1 |
| Harris, DA | 1 |
| Fuenmayor, NT | 2 |
| Faggin, BM | 2 |
| Mallion, JM | 1 |
| Maitre, A | 1 |
| de Gaudemaris, R | 1 |
| Siché, JP | 1 |
| Tremel, F | 1 |
| Fletcher, A | 3 |
| Bulpitt, C | 3 |
| Ravogli, A | 1 |
| Frattola, A | 1 |
| Villani, A | 1 |
| Donato, L | 1 |
| Ferrier, C | 2 |
| Ferrari, P | 2 |
| Keller, U | 2 |
| Beretta-Piccoli, C | 3 |
| Riesen, WF | 2 |
| Cislaghi, C | 1 |
| Carzaniga, G | 1 |
| Aronica, A | 1 |
| Seregni, R | 1 |
| Casal, MC | 1 |
| Guerrero, L | 1 |
| Alcázar, JM | 2 |
| Férnandez, ML | 1 |
| Rodicio, JL | 2 |
| Gerstenblith, G | 4 |
| Boutarin, J | 1 |
| Maarek-Charbit, M | 4 |
| Aupetit, JF | 1 |
| Galey-Arcangioli, C | 3 |
| Ritz, B | 1 |
| Angermann, CE | 3 |
| Spes, CH | 3 |
| Dominiak, P | 2 |
| Weil, J | 1 |
| Gerzer, R | 1 |
| Stempfle, HU | 1 |
| Kemkes, BM | 3 |
| Theisen, K | 4 |
| Barnhill, BW | 1 |
| Yaku, H | 1 |
| Eferakeya, AE | 1 |
| Osunkwo, UA | 1 |
| Panarace, G | 3 |
| Spessot, M | 2 |
| Salvetti, A | 5 |
| Pannarale, G | 1 |
| Puddu, PE | 1 |
| Campbell, SV | 1 |
| Collauto, F | 1 |
| Stazi, F | 1 |
| Reale, A | 1 |
| Pang, PK | 1 |
| Benishin, CG | 1 |
| Harder, S | 2 |
| Thürmann, P | 2 |
| Siewert, M | 1 |
| Blume, H | 1 |
| Rietbrock, N | 1 |
| vander Kleijn, J | 1 |
| Gierend, M | 1 |
| Goloshchapov, OA | 3 |
| Goldabin, VI | 3 |
| Geller, AL | 2 |
| Mashin, AA | 2 |
| Rud', SS | 1 |
| Gohlke, P | 1 |
| Stoll, M | 1 |
| Lamberty, V | 1 |
| Mattfeld, T | 1 |
| Mall, G | 1 |
| van Even, P | 1 |
| Martorana, P | 1 |
| Moiseev, VS | 2 |
| Fioretto, P | 1 |
| Frigato, F | 1 |
| Velussi, M | 1 |
| Riva, F | 1 |
| Muollo, B | 1 |
| Carraro, A | 1 |
| Brocco, E | 1 |
| Cipollina, MR | 1 |
| Abaterusso, C | 1 |
| Trevisan, M | 1 |
| Gradman, AH | 1 |
| Kaihlanen, PM | 1 |
| Wong, SC | 1 |
| Friday, KJ | 1 |
| Chernoguz, LS | 1 |
| Zanozdra, NS | 1 |
| Kupchinskaia, EG | 1 |
| Bertel, O | 1 |
| Bernadet, P | 1 |
| Suc, JM | 1 |
| Galey, C | 1 |
| Turkkan, JS | 1 |
| Allen, RP | 1 |
| Hienz, RD | 1 |
| Lazar, EJ | 1 |
| Petitto, M | 1 |
| Liguori, V | 1 |
| Pfennigsdorf, G | 2 |
| Borgia, MC | 1 |
| De Paola, G | 1 |
| Calpicchio, A | 1 |
| Gonski, PN | 1 |
| Karpov, RS | 1 |
| Tkachenko, OG | 1 |
| Trissvetova, EL | 1 |
| Krylov, AL | 1 |
| Shapovalova, ON | 1 |
| Durel, LA | 1 |
| Hayashi, PJ | 1 |
| Weidler, DJ | 3 |
| Schneiderman, N | 1 |
| Vanhees, L | 1 |
| Fagard, R | 1 |
| Lijnen, P | 1 |
| Amery, A | 1 |
| Sever, PS | 1 |
| Van Merode, T | 3 |
| Van Bortel, L | 1 |
| Smeets, FA | 3 |
| Böhm, R | 2 |
| Mooij, J | 1 |
| Reneman, RS | 3 |
| Riska, H | 3 |
| Sovijärvi, AR | 3 |
| Ahonen, A | 1 |
| Salorinne, Y | 1 |
| Sundberg, S | 2 |
| Stenius-Aarniala, B | 2 |
| Wright, KF | 1 |
| Allen, AD | 1 |
| Taylor, DR | 1 |
| Yu, Z | 1 |
| McNeill, JH | 1 |
| Pannier, BP | 1 |
| Lacolley, PJ | 1 |
| Levy, BI | 1 |
| Buser, PT | 1 |
| Wagner, S | 2 |
| Higgins, CB | 1 |
| Wikman-Coffelt, J | 2 |
| Ashida, T | 1 |
| Kawano, Y | 1 |
| Yoshimi, H | 1 |
| Akabane, S | 1 |
| Kuramochi, M | 1 |
| Omae, T | 2 |
| Belousov, Y | 1 |
| Kushnaryov, V | 1 |
| Michaelis, J | 2 |
| Wellek, S | 2 |
| Rhoades, RB | 2 |
| Katz, A | 1 |
| Gold, B | 1 |
| Stephan, D | 1 |
| Welsch, M | 1 |
| Imbs, JL | 1 |
| Trojnar, R | 2 |
| Rymar, B | 2 |
| Wysokiński, A | 2 |
| Markiewicz, M | 2 |
| Palmer, A | 2 |
| Hamilton, G | 2 |
| Muriss, S | 2 |
| Teboul, B | 1 |
| Morand, P | 1 |
| Atlan, JP | 1 |
| Bouche, JM | 1 |
| Ceccaldi, JP | 1 |
| Giacomoni, S | 1 |
| Halimi, G | 1 |
| Passeron-Seître, M | 1 |
| Iruela, LM | 1 |
| Ibañez-Rojo, V | 1 |
| Gurgenian, SV | 2 |
| Mikaelian, ES | 2 |
| Dzhandzhapanian, AZ | 1 |
| Babaian, AS | 1 |
| Traub, YM | 1 |
| Ayache, AS | 1 |
| Groshar, D | 1 |
| Schwinger, RH | 1 |
| Böhm, M | 1 |
| Erdmann, E | 1 |
| Thom, CM | 1 |
| Willems, S | 1 |
| Pritza, DR | 1 |
| Bierman, MH | 1 |
| Hammeke, MD | 1 |
| Burris, JF | 1 |
| Wallin, JD | 1 |
| Cook, ME | 1 |
| Zeng, B | 1 |
| Dai, GZ | 1 |
| Brunner, FP | 1 |
| Bock, HA | 1 |
| Hermle, M | 1 |
| Thiel, G | 1 |
| Mihatsch, MJ | 1 |
| Fagher, B | 2 |
| Katzman, P | 2 |
| Henningsen, NC | 1 |
| Thulin, T | 3 |
| Wright, BA | 1 |
| Jarrett, DB | 1 |
| Yodfat, Y | 1 |
| Nusbaum, M | 1 |
| Gibor, Y | 1 |
| Ahmed, JH | 2 |
| Meredith, PA | 5 |
| Elliott, HL | 4 |
| Andrushchenko, EV | 1 |
| Chmir, VP | 1 |
| Krasovskaia, EA | 1 |
| Malanchuk, TA | 1 |
| Polishchuk, II | 1 |
| Iashchenko, OB | 1 |
| Fisher, LD | 1 |
| Devane, JG | 1 |
| O'Brien, DE | 1 |
| Jacques, RM | 1 |
| Cox, SJ | 1 |
| Van Bortel, LM | 3 |
| Böhm, RO | 4 |
| Schrier, RW | 1 |
| Chapelon-Abric, C | 1 |
| Wajman, A | 2 |
| Villarroya, A | 1 |
| Godeau, P | 1 |
| Osipov, MA | 1 |
| Bashchinskiĭ, SE | 1 |
| Bart, BIa | 1 |
| Bentivoglio, M | 2 |
| Berioli, S | 1 |
| Savino, K | 2 |
| De Caprio, L | 1 |
| Nicolino, A | 1 |
| Forgione, L | 1 |
| Rengo, F | 1 |
| Middeke, M | 1 |
| Verma, SK | 1 |
| Dosi, R | 1 |
| Kaushik, SK | 1 |
| Bordia, A | 1 |
| Soria, F | 1 |
| Valdés, M | 1 |
| García, A | 1 |
| Vicente, T | 1 |
| Castello, MJ | 1 |
| Paquet, JL | 1 |
| Brunelle, G | 1 |
| Donnadieu, E | 1 |
| Baudouin-Legros, M | 1 |
| Meyer, P | 1 |
| de la Figuera von Wichmann, M | 1 |
| Fein, FS | 1 |
| Zola, BE | 1 |
| Malhotra, A | 1 |
| Factor, SM | 1 |
| Scheuer, J | 1 |
| Schulman, SP | 2 |
| Weiss, JL | 1 |
| Becker, LC | 1 |
| Gottlieb, SO | 1 |
| Woodruff, KM | 1 |
| Weisfeldt, ML | 1 |
| Auffermann, W | 1 |
| Buser, P | 1 |
| Robinson, MC | 1 |
| Linder, L | 2 |
| Galletti, P | 1 |
| Marini, M | 1 |
| Amadio, L | 1 |
| Schiffers, PM | 1 |
| Mooij, JM | 2 |
| Struyker Boudier, HA | 1 |
| Granier, P | 1 |
| Douste-Blazy, MY | 1 |
| Tredez, P | 1 |
| Conte, D | 1 |
| Galinier, F | 1 |
| Nitta, Y | 1 |
| Shimizu, M | 1 |
| Kita, Y | 1 |
| Konishi, K | 1 |
| Kawagoshi, H | 1 |
| Umeda, K | 1 |
| Takeda, R | 1 |
| Bunko, H | 1 |
| Hisada, K | 1 |
| Genda, A | 1 |
| Andreeva, TN | 1 |
| Prabha, PS | 1 |
| Koratkar, R | 1 |
| Sagar, PS | 1 |
| Ramesh, G | 1 |
| Souviron Rodríguez, A | 2 |
| Kreuter, U | 1 |
| Mühlemann, M | 1 |
| Vogt, E | 1 |
| Wohlwend, MC | 1 |
| Kahn, JC | 1 |
| Pathé, M | 1 |
| Adibaev, OA | 1 |
| Aleĭnikov, VK | 1 |
| Veber, VR | 1 |
| Kazymov, MS | 1 |
| Saunders, E | 2 |
| Weir, MR | 2 |
| Hollifield, J | 1 |
| Vertes, V | 1 |
| Zemel, MB | 1 |
| Curry, C | 1 |
| Schoenberger, J | 1 |
| Croog, SH | 1 |
| Levine, S | 1 |
| Baume, RM | 1 |
| Howard, RL | 1 |
| Shapiro, JI | 1 |
| Babcock, S | 1 |
| Chan, L | 1 |
| Midtbø, KA | 1 |
| Burnier, M | 1 |
| Nussberger, J | 2 |
| Letzel, H | 1 |
| Bluemner, E | 1 |
| Meisel, S | 1 |
| Nussinovitch, N | 1 |
| Henningsen, N | 1 |
| Beyerlein, C | 1 |
| Csaszar, G | 1 |
| Hollmann, M | 1 |
| Schumacher, A | 2 |
| Sjödén, G | 1 |
| Rosenqvist, M | 1 |
| Kriegholm, E | 1 |
| Nordenström, J | 1 |
| Björkhem, I | 1 |
| Mironova, MI | 1 |
| Paskhina, OE | 1 |
| Reams, GP | 2 |
| Bauer, JH | 3 |
| Ashmore, RC | 1 |
| Corkadel, LK | 1 |
| Green, CL | 1 |
| Horwitz, LD | 1 |
| Pfisterer, M | 1 |
| Burkart, F | 1 |
| Rahmani, MA | 1 |
| Neves, M | 1 |
| Mangroo, T | 1 |
| Bennett, T | 1 |
| Hefti, F | 1 |
| Clozel, JP | 1 |
| Osterrieder, W | 1 |
| Cattaneo, EA | 1 |
| Rinaldi, GJ | 1 |
| Cingolani, HE | 1 |
| Fránquiz, J | 1 |
| Blank, I | 1 |
| Baudisch, W | 1 |
| Burmeister, J | 1 |
| Franz, U | 1 |
| Brouwer, RM | 2 |
| Ram, CV | 2 |
| Brill, DM | 1 |
| Fozzard, HA | 1 |
| Reid, JL | 3 |
| Chamontin, BF | 1 |
| Montastruc, JL | 3 |
| Salvador, MJ | 1 |
| Jackson, B | 1 |
| Cubela, R | 1 |
| Debrevi, L | 1 |
| Whitty, M | 1 |
| Dessì-Fulgheri, P | 1 |
| Pacifico, A | 1 |
| Bandiera, F | 1 |
| Rubattu, S | 1 |
| Glorioso, N | 1 |
| Delitala, G | 1 |
| Tomasi, P | 1 |
| Rappelli, A | 1 |
| Cruickshank, JK | 2 |
| Anderson, NM | 2 |
| Wadsworth, J | 2 |
| Young, SM | 2 |
| Jepson, E | 2 |
| McCaughran, JA | 1 |
| Juno, CJ | 1 |
| Lorimer, AR | 2 |
| Smedsrud, T | 2 |
| Walker, P | 2 |
| Tyler, HM | 2 |
| Donnelly, R | 1 |
| Cardillo, C | 4 |
| Musumeci, V | 4 |
| Mores, N | 4 |
| Folli, G | 4 |
| McCormack, PM | 1 |
| Latham, AN | 3 |
| Mee, F | 2 |
| Atkins, N | 2 |
| O'Brien, ET | 2 |
| O'Malley, K | 2 |
| Alaimo, G | 1 |
| Longo, B | 1 |
| Muratore, G | 1 |
| Meric, M | 1 |
| Adalet, K | 1 |
| Erzengin, F | 1 |
| Korkut, F | 1 |
| Okur, O | 1 |
| Büyüköztürk, K | 1 |
| Böhmer, F | 1 |
| Barousch, R | 2 |
| Speders, S | 1 |
| Sosna, J | 1 |
| Pérez Naranjo, J | 1 |
| Ruiz Martínez, I | 1 |
| Hosie, J | 1 |
| Hosie, G | 1 |
| Katzman, PL | 1 |
| Rodrigues, R | 1 |
| Hollifield, JW | 2 |
| Heusner, JJ | 2 |
| DesChamps, MK | 1 |
| Fiasconaro, G | 1 |
| Saviolo, R | 1 |
| Gries, J | 1 |
| Kretzschmar, R | 1 |
| Neumann, BW | 1 |
| Dustan, HP | 1 |
| Hergueta García de Guadiana, G | 1 |
| Paumard Fraguas, A | 1 |
| Lehmann, M | 2 |
| Dürr, H | 1 |
| Keul, J | 2 |
| Cellamare, G | 1 |
| Poppa, E | 1 |
| Sgobba, G | 1 |
| Bianco, G | 1 |
| Miilunpalo, S | 1 |
| Saarinen, R | 1 |
| Marniemi, J | 1 |
| Conen, D | 1 |
| Mehmel, HC | 1 |
| Baba, A | 1 |
| Burtsev, EM | 1 |
| Savkov, VS | 1 |
| Vogler, AC | 1 |
| Silber, S | 1 |
| Vogel, M | 1 |
| Rudyk, BI | 1 |
| Iarema, NI | 1 |
| Metelitsa, VI | 1 |
| Slastnikova, ID | 1 |
| Matsevich, SIu | 1 |
| Kokurina, EV | 1 |
| Piotrovskiĭ, VK | 1 |
| Resnick, LM | 4 |
| Nicholson, JP | 4 |
| Laragh, JH | 7 |
| Orynchak, MA | 3 |
| Chellingsworth, MC | 1 |
| Kendall, MJ | 2 |
| Wright, AD | 1 |
| Singh, BM | 1 |
| Pasi, J | 1 |
| Fletcher, AE | 1 |
| Chester, PC | 2 |
| Hawkins, CM | 1 |
| Pike, LA | 1 |
| Bulpitt, CJ | 1 |
| McTavish, D | 1 |
| Sorkin, EM | 1 |
| Wallis, DE | 1 |
| McMahon, FG | 1 |
| Reder, RF | 1 |
| Titov, VN | 1 |
| Nazerov, EA | 1 |
| Iudaev, AE | 1 |
| Franchi, F | 2 |
| Fabbri, G | 2 |
| Monopoli, A | 2 |
| Rossi, D | 2 |
| Matassi, L | 2 |
| Strazzulla, G | 1 |
| Bisi, G | 2 |
| Nishikawa, T | 1 |
| Namiki, A | 1 |
| Brush, JE | 1 |
| Udelson, JE | 1 |
| Bacharach, SL | 1 |
| Cannon, RO | 1 |
| Leon, MB | 1 |
| Rumble, TF | 1 |
| Bonow, RO | 1 |
| Chen, YS | 1 |
| Li, JL | 1 |
| Zong, JL | 1 |
| Wang, JJ | 1 |
| Wen, ZB | 1 |
| Som, P | 1 |
| Oster, ZH | 1 |
| Kubota, K | 1 |
| Goodman, MM | 1 |
| Knapp, FF | 1 |
| Sacker, DF | 1 |
| Weber, DA | 1 |
| Minatogawa, Y | 2 |
| Shima, H | 2 |
| Yoshikawa, H | 1 |
| Kido, R | 2 |
| Anthuber, M | 1 |
| Dillon, JS | 1 |
| Sturrock, WJ | 1 |
| McInnes, GT | 3 |
| Findlay, IN | 2 |
| Murray, G | 2 |
| Cleland, JG | 1 |
| Dargie, HJ | 5 |
| Shub, C | 2 |
| Agarwal, OP | 1 |
| Murphy, MB | 1 |
| Kuznetsov, VN | 1 |
| Rebanal, P | 1 |
| Piontek, M | 1 |
| Nademanee, K | 1 |
| Morgan, T | 1 |
| Anderson, A | 1 |
| Wilson, D | 1 |
| Myers, J | 1 |
| Murphy, J | 1 |
| Nowson, C | 1 |
| Beard, TC | 1 |
| Cooke, HM | 1 |
| Gray, WR | 1 |
| Wild, P | 1 |
| Graziadei, L | 1 |
| McLenachan, JM | 1 |
| Henderson, E | 1 |
| Herrick, AL | 1 |
| Merkelbach, H | 1 |
| Gastmann, U | 1 |
| Jackson, SH | 1 |
| Thoolen, MJ | 1 |
| Miller, CR | 1 |
| Chiu, AT | 1 |
| Timmermans, PB | 1 |
| Lohmeier, TE | 1 |
| Montani, JP | 1 |
| Smith, MJ | 1 |
| Rushing, EL | 1 |
| Fadayomi, MO | 1 |
| Sunderrajan, S | 1 |
| Reams, G | 1 |
| Chamontin, B | 1 |
| Villeneuve, A | 1 |
| Berlan, M | 1 |
| Salvador, M | 1 |
| Anderson, P | 3 |
| Spacek, R | 1 |
| Kozák, P | 1 |
| Stárek, A | 1 |
| Hes, I | 1 |
| Skalníková, V | 1 |
| Ivleva, AIa | 1 |
| Akopian, LM | 1 |
| Krasnobaeva, GM | 1 |
| Basem, AS | 1 |
| Custro, N | 1 |
| Scafidi, V | 1 |
| Ruskoaho, HJ | 1 |
| Savolainen, ER | 1 |
| Muiesan, ML | 2 |
| Koster, M | 1 |
| Salmela, PI | 1 |
| Salo, H | 2 |
| Ottoila, P | 1 |
| Jounela, AJ | 1 |
| Maggio, TG | 1 |
| Bartels, DW | 1 |
| Bochsler, JA | 1 |
| Simmons, RL | 1 |
| Ward, PJ | 1 |
| Cox, JP | 1 |
| O'Boyle, CA | 1 |
| Kelly, J | 1 |
| Coakley, D | 1 |
| van Wezel, HB | 1 |
| Bovill, JG | 1 |
| Schuller, J | 1 |
| Gielen, J | 1 |
| Hoeneveld, MH | 1 |
| Lombard, JH | 1 |
| Madden, JA | 1 |
| Harder, DR | 2 |
| Eisen, G | 1 |
| Brigden, GS | 1 |
| Caruana, MP | 1 |
| Heber, ME | 1 |
| Silke, B | 1 |
| Singer, DR | 1 |
| Baroni, S | 1 |
| Cremona, G | 1 |
| Tutinelli, F | 1 |
| Pasanisi, F | 1 |
| Ferrara, AL | 1 |
| Marotta, T | 1 |
| Thibonnier, M | 1 |
| Given, BD | 1 |
| Lee, TH | 1 |
| Stone, PH | 1 |
| Dzau, VJ | 1 |
| Edmonds, D | 2 |
| Förster, E | 1 |
| Wehling, M | 1 |
| Siegenthaler, W | 1 |
| Vetter, W | 2 |
| Savi, L | 2 |
| Guardigli, R | 1 |
| Dimmitt, SB | 1 |
| Beilin, LJ | 1 |
| Hockings, BE | 1 |
| Burgunder, JM | 1 |
| Lauterburg, BH | 1 |
| Jørgensen, NP | 1 |
| Walstad, RA | 1 |
| Lauve, O | 4 |
| Cires Pujols, M | 1 |
| Gamio Capestany, F | 1 |
| Rodriguez de la Vega, A | 1 |
| Julien, J | 1 |
| Jeunemaitre, X | 1 |
| Pagny, JY | 1 |
| Plouin, PF | 1 |
| Corvol, P | 1 |
| Petty, MA | 1 |
| Mir, AK | 1 |
| Karasawa, A | 1 |
| Kubo, K | 1 |
| Oka, T | 1 |
| Nakamizo, N | 1 |
| Suzuki, T | 1 |
| Lee, JY | 1 |
| Krueger, AD | 1 |
| Walsh, GM | 1 |
| Mettimano, M | 1 |
| Costalunga, A | 1 |
| Guerrera, G | 1 |
| Melina, D | 1 |
| Sheps, SG | 4 |
| Schirger, A | 3 |
| Wolf, MK | 1 |
| Carlson, CA | 1 |
| Phelan, EL | 1 |
| Simpson, FO | 1 |
| Arslanian, L | 1 |
| de Souza, EM | 1 |
| de Oliveira, PS | 1 |
| Hvarfner, A | 1 |
| Bergström, R | 1 |
| Lithell, H | 1 |
| Mörlin, C | 1 |
| Wide, L | 1 |
| Ljunghall, S | 1 |
| Busse, JC | 1 |
| Materson, BJ | 1 |
| DesChamps, M | 1 |
| Spyker, DA | 1 |
| Peace, KE | 1 |
| Dickson, B | 1 |
| Waeber, G | 1 |
| Beck, G | 1 |
| Bidiville, J | 1 |
| Campbell, L | 1 |
| Nicolov, N | 1 |
| Todorova, M | 1 |
| Ilieva, T | 1 |
| Velkov, Z | 1 |
| Lolov, R | 1 |
| Petkova, M | 1 |
| Ancov, V | 1 |
| Sheitanova, S | 1 |
| Tzoncheva, A | 1 |
| Grigorova, R | 1 |
| Featherston, WE | 1 |
| Kolesova, MA | 1 |
| Orlov, VM | 1 |
| González Juanatey, JR | 1 |
| Pose Reino, A | 1 |
| Heagerty, AM | 1 |
| Swales, JD | 1 |
| Latini, R | 1 |
| Pierandrei, G | 1 |
| Achilli, L | 1 |
| Lombi, V | 1 |
| D'Amico, F | 1 |
| Eckardt, A | 1 |
| Hahn, KJ | 1 |
| Bailo, M | 1 |
| Folli, A | 1 |
| Galli, C | 2 |
| Maltagliati, A | 1 |
| Tosi, E | 2 |
| Städler, P | 1 |
| Leonardi, L | 1 |
| Riesen, W | 1 |
| Ziegler, W | 1 |
| Marone, C | 1 |
| Stenius-Aaniala, B | 1 |
| Murray, GD | 1 |
| Oshrain, C | 1 |
| Stein, WJ | 1 |
| Fogelman, J | 1 |
| Viskoper, R | 1 |
| Laszt, A | 1 |
| Modan, M | 1 |
| Atakhanov, ShE | 1 |
| Tkhostova, EB | 1 |
| Iurenev, AP | 1 |
| Men'shikov, MIu | 1 |
| Mazaev, AV | 1 |
| Hill, AC | 1 |
| Schecter, WP | 1 |
| Mori, H | 1 |
| Stevens, MB | 1 |
| Husseni, W | 1 |
| Lim, RC | 1 |
| Hoffman, JI | 1 |
| Belfort, MA | 1 |
| Moore, PJ | 1 |
| Chiba, S | 1 |
| Tsukada, M | 1 |
| Katsuyama, Y | 1 |
| Tada, A | 1 |
| Zenda, H | 1 |
| Burgess, CD | 1 |
| Baez, MA | 1 |
| Alvarez, CR | 1 |
| Montastruc, P | 1 |
| Valet, P | 1 |
| Dang Tran, L | 1 |
| Gaillard, G | 1 |
| Nontakanun, S | 1 |
| Ngarmukos, P | 1 |
| Sitthisook, S | 1 |
| Jeam-Anukulkit, N | 1 |
| Intharakoses, A | 1 |
| Tanprasert, P | 1 |
| Sansanayudth, P | 1 |
| Sriratanaban, A | 1 |
| Polsi, Y | 1 |
| McAllister, RG | 1 |
| Schloemer, GL | 1 |
| Hamann, SR | 1 |
| Goldberger, J | 1 |
| Phillippides, G | 1 |
| Klein, N | 1 |
| Escudero, J | 1 |
| Hernandez, H | 1 |
| Martinez, F | 1 |
| Storstein, L | 2 |
| Klein, MD | 2 |
| Kellett, MA | 1 |
| Cleland, J | 1 |
| Findlay, I | 1 |
| McInnes, G | 1 |
| Cashman, PM | 1 |
| Larach, DR | 1 |
| Zelis, R | 1 |
| Michelson, EL | 1 |
| Hotz, H | 1 |
| Schmidlin, O | 1 |
| Nissinen, A | 1 |
| Koistinen, A | 1 |
| Tuomilehto, J | 1 |
| Loeb, AL | 1 |
| Bean, BL | 1 |
| Midtbo, KA | 1 |
| Schriger, A | 1 |
| Laragh, JA | 1 |
| de Faire, U | 2 |
| Bazzato, G | 1 |
| Coli, U | 1 |
| Landini, S | 1 |
| Fracasso, A | 1 |
| Morachiello, P | 1 |
| Righetto, F | 1 |
| Scanferla, F | 1 |
| Genchi, R | 1 |
| Del Turco, M | 1 |
| Mooy, J | 1 |
| van Baak, M | 1 |
| Does, R | 1 |
| Petri, H | 1 |
| van Kemenade, J | 1 |
| Schmieder, RE | 1 |
| Garavaglia, GE | 1 |
| Nunez, BD | 1 |
| Lo Sapio, P | 1 |
| Malfanti, PL | 1 |
| Horvath, JS | 1 |
| Fletcher, PJ | 1 |
| Bailey, BP | 1 |
| Duggin, GG | 1 |
| Hall, B | 1 |
| Tiller, D | 1 |
| Lindner, V | 1 |
| Heinle, H | 1 |
| Caruana, M | 1 |
| Heber, M | 1 |
| Brigden, G | 1 |
| Hughes, GS | 1 |
| Cowart, TD | 1 |
| Conradi, EC | 1 |
| van Baak, MA | 1 |
| Petri, J | 1 |
| Baños, G | 1 |
| Ramírez González, MD | 1 |
| Zaldívar, HM | 1 |
| Sánchez Torres, G | 1 |
| Barrera, J | 1 |
| Korzets, A | 1 |
| Levtov, O | 1 |
| Cubberley, RB | 1 |
| Todd, EL | 1 |
| Luchi, R | 1 |
| Snow, E | 1 |
| Sokolov, AM | 2 |
| Ivanova, GA | 2 |
| Suloeva, MN | 2 |
| Norris, MC | 1 |
| Rose, JC | 1 |
| Dewan, DM | 1 |
| Bühler, F | 1 |
| Golikov, AP | 1 |
| Riabinin, VA | 1 |
| Cody, RJ | 4 |
| Cannon, R | 1 |
| Hotz, M | 1 |
| Kubo, SH | 3 |
| Covit, AB | 2 |
| Feldschuh, J | 1 |
| Bondesson, U | 2 |
| Furuya, S | 1 |
| Ueda, E | 1 |
| Betocchi, S | 1 |
| Pace, L | 1 |
| Chiariello, M | 1 |
| Trimarco, B | 1 |
| Alfano, B | 1 |
| Ricciardelli, B | 1 |
| Salvatore, M | 1 |
| Condorelli, M | 1 |
| Verdecchia, P | 1 |
| Mattiasson, I | 1 |
| Winniford, MD | 1 |
| Hillis, LD | 1 |
| Josephson, MA | 1 |
| Shamoon, H | 1 |
| Baylor, P | 1 |
| Kambosos, D | 1 |
| Plawes, S | 1 |
| Bergmans, MG | 1 |
| Jonker, GJ | 1 |
| Kock, HC | 1 |
| Horton, RC | 1 |
| Touloukian, JE | 1 |
| Herpin, D | 1 |
| Amiel, A | 1 |
| Boutaud, P | 1 |
| Demange, J | 1 |
| Minors, DS | 1 |
| Spies, G | 1 |
| Zaslavskaia, RM | 1 |
| Budenova, LA | 1 |
| Vilkovyskiĭ, FA | 1 |
| Malkin, LM | 1 |
| Olevskiĭ, IKh | 1 |
| Chamma Neto, M | 1 |
| Pinto, MJ | 1 |
| Rojas, RI | 1 |
| Santos, LM | 1 |
| Glitz, T | 1 |
| Blume, Ldo R | 1 |
| Quintino, E | 1 |
| Michelotto, PV | 1 |
| Maranhão, MF | 1 |
| Sobrinho, MI | 1 |
| Gerber, A | 1 |
| Laederach, K | 1 |
| Taylor, SH | 1 |
| Kenny, J | 1 |
| Ault, MJ | 1 |
| Blok, WL | 1 |
| van Es, PN | 1 |
| Tchang, PT | 1 |
| De Cesare, N | 1 |
| Salvioni, A | 1 |
| Lopez-Ovejero, J | 1 |
| Matsumoto, A | 1 |
| Spiekerman, RE | 1 |
| O'Brien, PC | 1 |
| Simpson, KK | 1 |
| Wicker, P | 1 |
| Roudaut, R | 1 |
| Gosse, P | 1 |
| Dallocchio, M | 1 |
| Saltzberg, S | 1 |
| Stroh, J | 1 |
| Monuszko, E | 1 |
| Wiezner, J | 1 |
| Dorsa, F | 1 |
| Tatinian, NG | 1 |
| Grigorian, TZ | 1 |
| Nikogosian, KG | 1 |
| MacLaughlin, M | 1 |
| de Mello Aires, M | 1 |
| Malnic, G | 1 |
| Steele, TH | 1 |
| Challoner-Hue, L | 1 |
| McLean, AJ | 1 |
| Knight, R | 1 |
| Harrison, PM | 1 |
| Harper, RW | 1 |
| Baumgart, P | 1 |
| Tenschert, W | 1 |
| Vetter, H | 1 |
| Smeda, J | 1 |
| Lombard, J | 1 |
| Rotolo, V | 1 |
| Lombardo, F | 1 |
| Cicuttini, L | 1 |
| Moratti, P | 1 |
| Dimitrov, D | 1 |
| Sotobata, I | 1 |
| Yamauchi, K | 1 |
| Tsuzuki, M | 1 |
| Noda, S | 1 |
| Hatano, K | 1 |
| Ito, E | 1 |
| Sørensen, SS | 1 |
| Thomsen, OO | 1 |
| Danielsen, H | 1 |
| Pedersen, EB | 1 |
| Arsov, D | 1 |
| Serafimova, E | 1 |
| Nast, HP | 1 |
| Morris, R | 3 |
| Levy, L | 1 |
| Andersen, ED | 1 |
| Andreasen, PB | 1 |
| De Liperi, E | 1 |
| Coli, R | 1 |
| Brunori, F | 1 |
| Singer, MT | 1 |
| Heinrich, F | 1 |
| Schultis, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| INternational VErapamil SR Trandolapril STudy[NCT00133692] | Phase 4 | 22,000 participants | Interventional | 1997-09-30 | Completed | ||
| Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)[NCT00246519] | Phase 4 | 1,701 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Qianyangyuyin Formula Prevent and Treat for Early Renal Injury in Hypertensive Patients[NCT04078711] | Phase 2/Phase 3 | 520 participants (Anticipated) | Interventional | 2019-09-10 | Not yet recruiting | ||
| A Two-Phase Study for Primary and Secondary Prevention of Diabetic Nephropathy by Combined ACE Inhibition and Calcium Channel Blockade (BENEDICT)[NCT00235014] | Phase 4 | 1,204 participants (Actual) | Interventional | 1997-03-31 | Completed | ||
| A Phase IV, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Hyzaar® on Glucose Tolerance in Subjects With Metabolic Syndrome[NCT00234858] | Phase 4 | 280 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| Comparison of Single and Combination Diuretics in Low-Renin Hypertension[NCT02351973] | Phase 4 | 423 participants (Actual) | Interventional | 2009-11-30 | Active, not recruiting | ||
| A Study of the Effects of Dapagliflozin on Ambulatory Aortic Pressure, Arterial Stiffness and Urine Albumin Excretion in Patients With Type 2 Diabetes[NCT02887677] | Phase 4 | 85 participants (Actual) | Interventional | 2016-10-31 | Terminated (stopped due to On February 2019 Astra-Zeneca Greece decided to stop the financial support of the study.) | ||
| Effects of Artificial Intelligence Assisted Follow-up Strategy Based on a New Remote Contactless Sleep Monitoring System on Secondary Prevention in Patients Received Coronary Artery Bypass Grafting Surgery[NCT04636996] | 200 participants (Anticipated) | Interventional | 2021-01-01 | Not yet recruiting | |||
| A Single Centre, Retrospective Cohort Study on Post Analysis on the Link Between the Clinical Heart Rate and Outcomes During PCI[NCT02351674] | 15,000 participants (Anticipated) | Observational | 2015-01-31 | Not yet recruiting | |||
| The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension[NCT01996449] | Phase 2 | 14 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| Verapamil as Adjunctive Seizure Therapy for Children and Young Adults With Dravet Syndrome[NCT01607073] | Phase 2 | 2 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00246519)
Timeframe: baseline to 18 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| Atenolol +HCTZ Arm | -12.06 |
| HCTZ + Atenolol | -13.33 |
measurement of sympathetic nerve activity by microneurography (intraneural microelectrodes) (NCT01996449)
Timeframe: 8 weeks post treatment initiation
| Intervention | bursts/minute (Mean) |
|---|---|
| Amlodipine | 41 |
| Eplerenone | 43.8 |
measurement of sympathetic nerve activity by microneurography (intraneural microelectrodes) during arm cycling exercise (NCT01996449)
Timeframe: 8 weeks post treatment initiation
| Intervention | bursts/minute (Mean) |
|---|---|
| Amlodipine | 47 |
| Eplerenone | 51 |
The secondary outcome measure is the change in number of absence seizures from Week 8 (Baseline) to Week 12 (NCT01607073)
Timeframe: Week 8 to Week 12
| Intervention | Abscence seizures (Number) |
|---|---|
| Week 8 Baseline | 165 |
| Week 12 Verapamil 4mg/kg/Day | 101 |
The primary study endpoint is the change in number of seizures from baseline. Since we only had one participant finish the study, the endpoint was changed to Week 12 visit. Participants were on verapamil for 4 weeks at Week 12. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12
| Intervention | General tonic-clonic seizures (Number) |
|---|---|
| Week 8 Baseline | 39 |
| Week 12 Verapamil 4mg/kg/Day | 14 |
The secondary outcome is the change in number of myoclonic seizures between baseline Week 8 visit and Week 12 visit. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12
| Intervention | Myoclonic seizures (Number) |
|---|---|
| Week 8 Baseline | 116 |
| Week 12 Verapamil 4mg/kg/Day | 175 |
134 reviews available for verapamil and Hypertension
| Article | Year |
|---|---|
Verapamil: prevention and treatment of cardio-renal syndromes in diabetic hypertensive patients?
Topics: Cardio-Renal Syndrome; Diabetes Mellitus; Diabetic Nephropathies; Female; Heart Failure; Humans; Hyp | 2022 |
Treatments for diabetes mellitus type II: New perspectives regarding the possible role of calcium and cAMP interaction.
Topics: Adjuvants, Pharmaceutic; Animals; Calcium; Calcium Channel Blockers; Cardiovascular Diseases; Cyclic | 2018 |
[Clinical application of verapamil in patients with supraventricular cardiac rhythm disturbances and arterial hypertension].
Topics: Blood Pressure; Calcium Channel Blockers; Heart Rate; Humans; Hypertension; Tachycardia, Supraventri | 2008 |
Tarka® (trandolapril/verapamil hydrochloride extended-release) overdose.
Topics: Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Co | 2011 |
Treatment of hypertension in peripheral arterial disease.
Topics: Antihypertensive Agents; Humans; Hypertension; Intermittent Claudication; Perindopril; Peripheral Va | 2009 |
Antihypertensive and renoprotective effects of trandolapril/verapamil combination: a meta-analysis of randomized controlled trials.
Topics: Albuminuria; Antihypertensive Agents; Drug Therapy, Combination; Female; Humans; Hypertension; Indol | 2011 |
Fixed combination trandolapril/verapamil sustained-release: a review of its use in essential hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Area Under Curve; Blood Pressure; Calcium Channel Blockers | 2002 |
[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito | 2002 |
Trandolapril: a newer angiotensin-converting enzyme inhibitor.
Topics: Acute Disease; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as | 2003 |
Treatment of hypertension in peripheral arterial disease.
Topics: Antihypertensive Agents; Humans; Hypertension; Intermittent Claudication; Perindopril; Peripheral Va | 2003 |
New advances in the field of calcium channel antagonists: cardiovascular effects and structure-activity relationships.
Topics: Angina Pectoris; Animals; Calcium Channel Blockers; Calcium Channels; Cardiovascular System; Diltiaz | 2003 |
The role of existing and newer calcium channel blockers in the treatment of hypertension.
Topics: Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Humans; Hypertension; Nifedipine; Nit | 2004 |
Mechanism of tissue-selective drug action in the cardiovascular system.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Binding Sites; Calcium Channels; Cardiovascular System; Chemist | 2005 |
Calcium channel blockers and the kidney.
Topics: Black or African American; Calcium Channel Blockers; Diabetic Nephropathies; Dihydropyridines; Dilti | 2004 |
Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug C | 2005 |
[Ischemic heart disease combined with hypertension: peculiarities of course and selection of therapy].
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2005 |
[Hypertension combined with atherosclerotic lesions in carotid arteries: should angiotensin converting enzyme inhibitors be prescribed?].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Ant | 2005 |
[Indications for calcium channel antagonist therapy according to the latest large clinical trials].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Antihypertensive Agents; Calcium Channel Blockers; Cli | 2005 |
A review of calcium channel antagonists in the treatment of pediatric hypertension.
Topics: Amiodarone; Calcium Channel Blockers; Child; Felodipine; Humans; Hypertension; Isradipine; Nicardipi | 2006 |
Verapamil toxicity: an unusual case report and review of the literature.
Topics: Accidents; Antihypertensive Agents; Calcium Channel Blockers; Drug Combinations; Drug Overdose; Fema | 2007 |
Trandolapril/verapamil combination in hypertensive diabetic patients.
Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Drug T | 2007 |
Managing hypertension in diabetic patients--focus on trandolapril/verapamil combination.
Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetic Angiopathies; Drug Thera | 2007 |
Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension.
Topics: Adult; Aged; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Calcium Channel Blo | 2008 |
Understanding the calcium channel blockers.
Topics: Action Potentials; Angina Pectoris; Animals; Arrhythmias, Cardiac; Arteriosclerosis; Calcium; Calciu | 1984 |
Calcium channel blockers as antihypertensive agents.
Topics: Blood Pressure; Calcium Channel Blockers; Cardiomegaly; Clinical Trials as Topic; Coronary Disease; | 1984 |
From beta blockers to Ca2+ blockers in hypertension: a review.
Topics: Adrenergic beta-Antagonists; Calcium Channel Blockers; Coronary Circulation; Drug Therapy, Combinati | 1982 |
Clinical value of calcium antagonists in treatment of cardiovascular disorders.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina Pectoris, Variant; Arrhythmias, Cardiac; Calciu | 1983 |
Hypertension--drug management.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Calcium Channel Blockers; Captopril; Diaz | 1982 |
Treatment of vasospastic angina.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Anemia; Angina Pectoris, Variant; | 1983 |
Clinical applications of slow channel blocking compounds.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Blood Platelets; Blood Vessels; Calcium | 1983 |
Calcium influx blockers in the treatment of essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aging; Animals; Drug Therapy, Combination; Forearm; Humans | 1984 |
Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem.
Topics: Angina Pectoris; Angina Pectoris, Variant; Animals; Arrhythmias, Cardiac; Benzazepines; Calcium; Car | 1980 |
Calcium channel blocking drugs.
Topics: Anesthesia; Angina Pectoris; Animals; Calcium; Calcium Channel Blockers; Cardiomyopathy, Hypertrophi | 1983 |
Hypertension: calcium-blocking agents in treatment.
Topics: Animals; Blood Pressure; Calcium; Calcium Channel Blockers; Diltiazem; Heart Rate; Humans; Hypertens | 1984 |
Slow channel blockers.
Topics: Angina Pectoris; Arrhythmias, Cardiac; Calcium Channel Blockers; Chemical Phenomena; Chemistry; Cons | 1983 |
[Calcium antagonists in cardiology].
Topics: Arrhythmias, Cardiac; Calcium Channel Blockers; Cardiomyopathy, Hypertrophic; Coronary Disease; Dilt | 1983 |
Calcium antagonists. Clinical use in the treatment of systemic hypertension.
Topics: Angina Pectoris; Calcium Channel Blockers; Diltiazem; Humans; Hypertension; Nifedipine; Verapamil | 1983 |
[Calcium antagonists in the therapy of hypertension].
Topics: Biological Transport; Blood Pressure; Calcium; Calcium Channel Blockers; Diltiazem; Humans; Hyperten | 1983 |
Calcium, drug action and hypertension.
Topics: Animals; Arteries; Calcium; Chelating Agents; Humans; Hydralazine; Hypertension; Lanthanum; Muscle C | 1983 |
Treatment of hypertension with calcium channel blockers: European data.
Topics: Age Factors; Blood Pressure; Calcium Channel Blockers; Coronary Disease; Diltiazem; Europe; Humans; | 1984 |
Calcium entry blockers as vasodilators in man.
Topics: Calcium Channel Blockers; Humans; Hypertension; Nicardipine; Nifedipine; Nitroprusside; Vascular Res | 1984 |
New antiarrhythmic drugs.
Topics: Amiodarone; Angina Pectoris; Anti-Arrhythmia Agents; Blood Circulation; Bradycardia; Diltiazem; Half | 1983 |
Hypertension and calcium antagonists.
Topics: Airway Resistance; Antihypertensive Agents; Calcium Channel Blockers; Humans; Hypertension; Labetalo | 1982 |
Calcium antagonists in the treatment of hypertension.
Topics: Blood Pressure; Calcium; Calcium Channel Blockers; Diltiazem; Heart Rate; Humans; Hypertension; Nife | 1982 |
[New therapeutic approaches to arterial hypertension].
Topics: Angiotensin II; Benzothiadiazines; Calcium; Calcium Channel Blockers; Captopril; Diuretics; Drug The | 1982 |
Calcium entry blockers: uses and implications for anesthesiologists.
Topics: Anesthesia, General; Animals; Arrhythmias, Cardiac; Biotransformation; Calcium Channel Blockers; Cor | 1982 |
[Indications for use of calcium antagonists].
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium; Cardiotonic Agents; Coronary Disease | 1980 |
The clinical use of intravenous verapamil.
Topics: Angina Pectoris, Variant; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Atrioventricula | 1980 |
[Pharmacological aspects and therapeutic uses of verapamil and related calcium antagonists (author's transl)].
Topics: Animals; Arrhythmias, Cardiac; Calcium; Coronary Circulation; Coronary Disease; Electrocardiography; | 1980 |
Role of calcium antagonists in cardiovascular therapy.
Topics: Angina Pectoris; Arrhythmias, Cardiac; Blood Vessels; Calcium; Calcium Channel Blockers; Cardiomyopa | 1981 |
Verapamil.
Topics: Action Potentials; Angina Pectoris; Animals; Calcium; Cardiovascular System; Heart Diseases; Hemodyn | 1981 |
Calcium blockade as a therapeutic principle in arterial hypertension. Clinical aspects and experimental studies on isolated vessels from spontaneously hypertensive rats and normotensive man.
Topics: Animals; Biological Transport; Blood Pressure; Blood Vessels; Calcium; Calcium Channel Blockers; Fem | 1981 |
The clinical use of verapamil.
Topics: Administration, Oral; Adult; Animals; Arrhythmias, Cardiac; Biological Availability; Calcium; Cardio | 1982 |
Effect of verapamil on atherosclerosis.
Topics: Animals; Arteriosclerosis; Humans; Hypertension; Prospective Studies; Retrospective Studies; Verapam | 1993 |
Management of the hypertensive patient: a case report.
Topics: Adult; Antihypertensive Agents; Blood Pressure Determination; Dental Care for Chronically Ill; Glome | 1995 |
Poisoning with anti-hypertensive drugs: calcium antagonists.
Topics: Age Factors; Antihypertensive Agents; Calcium; Diltiazem; Drug Overdose; Humans; Hypertension; Nifed | 1995 |
Refractory cardiogenic shock and complete heart block after verapamil SR and metoprolol treatment. A case report.
Topics: Aged; Delayed-Action Preparations; Drug Therapy, Combination; Emergencies; Female; Heart Block; Huma | 1995 |
[The toxicity of slow-release verapamil and chronic kidney disease].
Topics: Aged; Delayed-Action Preparations; Drug Overdose; Female; Humans; Hypertension; Kidney Failure, Chro | 1994 |
Selected factors that influence responses to antihypertensives. Choosing therapy for the uncomplicated patient.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Ant | 1994 |
Similarities and differences between calcium antagonists: pharmacological aspects.
Topics: Angina Pectoris; Antihypertensive Agents; Calcium Channel Blockers; Dihydropyridines; Diltiazem; Hum | 1993 |
Management of atrial fibrillation in adults: prevention of thromboembolism and symptomatic treatment.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Anti-Arrhythmia Agents; Aspirin; Atrial Fibri | 1996 |
A chronotherapeutic approach to the management of hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Humans; Hypertension; Isoquinolines; Quin | 1996 |
Calcium channel blockers for hypertension: dissecting the evidence for adverse effects.
Topics: Calcium Channel Blockers; Catecholamines; Cerebrovascular Disorders; Drug Evaluation; Gastrointestin | 1997 |
Preclinical considerations and results with the combination of verapamil and trandolapril: blood pressure reduction and beyond.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Coronary Disease; Diabet | 1997 |
Safety profile of the combination of verapamil and trandolapril.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Drug Therapy, Combination; Humans; Hypertension; | 1997 |
Combination treatment in hypertension: the VeraTran Study.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Drug Co | 1997 |
Diversity of calcium antagonists.
Topics: Angina Pectoris; Arteriosclerosis; Benzimidazoles; Calcium Channel Blockers; Diltiazem; Humans; Hype | 1997 |
Use of calcium channel blockers in hypertension.
Topics: Antihypertensive Agents; Benzimidazoles; Blood Pressure; Calcium Channel Blockers; Case-Control Stud | 1998 |
Some similarities and differences between verapamil and the dihydropyridines.
Topics: Antihypertensive Agents; Arrhythmias, Cardiac; Calcium Channel Blockers; Coronary Disease; Dihydropy | 1998 |
Verapamil use in patients with cardiovascular disease: an overview of randomized trials.
Topics: Angina Pectoris; Calcium Channel Blockers; Cardiovascular Diseases; Female; Humans; Hypertension; Ma | 1998 |
Fixed-dose combination vs monotherapy in hypertension: a meta-analysis evaluation.
Topics: Amlodipine; Antihypertensive Agents; Benzazepines; Drug Combinations; Humans; Hypertension; Lisinopr | 1999 |
Effects of the chronotherapeutic delivery of verapamil on circadian blood pressure in African-American patients with hypertension.
Topics: Black or African American; Blood Pressure; Calcium Channel Blockers; Chronotherapy; Heart Rate; Hype | 1999 |
[Fixed-dose combination therapy: reduction of side effects with enhanced tolerance and antihypertensive efficacy].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 1999 |
Circadian heart rate response to chronotherapy versus conventional therapy in patients with hypertension and myocardial ischemia.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Amlodipine; Atenolol; Blood Pressure; C | 2000 |
Cardiogenic shock triggered by verapamil and atenolol: a case report of therapeutic experience with intravenous calcium.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Atrial Fibrillation; Bradycardia; Calcium Channel Block | 2000 |
The fixed combination of verapamil SR/trandolapril.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel B | 2000 |
Heart rate-lowering calcium antagonists in hypertensive post-myocardial infarction patients.
Topics: Aged; Calcium Channel Blockers; Diltiazem; Female; Heart Rate; Humans; Hypertension; Lung Diseases; | 2001 |
Safety of controlled-onset extended-release verapamil in middle-aged and older patients with hypertension and coronary artery disease.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Back Pain; Constipation; Delayed-Action Preparation | 2001 |
Gender and age effects on the ambulatory blood pressure and heart rate responses to antihypertensive therapy.
Topics: Adult; Age Factors; Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blo | 2001 |
[Calcium antagonists in cardiology].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Arrhythmias, Cardiac; Calcium; Coronary Disease; Human | 1978 |
Clinical use of verapamil.
Topics: Angina Pectoris; Arrhythmias, Cardiac; Atrial Fibrillation; Heart Conduction System; Hemodynamics; H | 1977 |
Verapamil: a review of its pharmacological properties and therapeutic use.
Topics: Angina Pectoris; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Circulation; Corona | 1978 |
Clinical aspects of Ca-blocking agents.
Topics: Angina Pectoris; Animals; Arrhythmias, Cardiac; Calcium; Coronary Disease; Cricetinae; Humans; Hyper | 1978 |
Quality of life in the treatment of hypertension. The effect of calcium antagonists.
Topics: Calcium Channel Blockers; Captopril; Humans; Hypertension; Male; Nifedipine; Propranolol; Quality of | 1992 |
Ambulatory blood pressure monitoring.
Topics: Blood Pressure Monitors; Double-Blind Method; Enalapril; Humans; Hypertension; Nitrendipine; Verapam | 1992 |
Regional myocardial blood flow and coronary reserve in hypertensive patients. The effect of therapy.
Topics: Adult; Coronary Circulation; Enalapril; Female; Hemodynamics; Humans; Hypertension; Male; Middle Age | 1992 |
Primary prevention potential of the calcium antagonists. Effects on blood pressure and lipid pattern.
Topics: Blood Pressure; Coronary Artery Disease; Humans; Hypertension; Lipids; Verapamil | 1992 |
[Verapamil--on the 30th anniversary of its clinical use].
Topics: Arrhythmias, Cardiac; Arteriosclerosis; History, 20th Century; Humans; Hypertension; Myocardial Isch | 1992 |
[Sustained-released verapamil and ambulatory recording of blood pressure in mild to moderate essential hypertension].
Topics: Aged; Ambulatory Care; Analysis of Variance; Blood Pressure Determination; Delayed-Action Preparatio | 1992 |
Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 1991 |
New drugs for hypertension--variations on old themes.
Topics: Amlodipine; Antihypertensive Agents; Delayed-Action Preparations; Dihydropyridines; Doxazosin; Human | 1991 |
Role of calcium channel blockers in protection against experimental renal injury.
Topics: Acute Kidney Injury; Animals; Calcium; Disease Models, Animal; Dogs; Glomerular Filtration Rate; Hum | 1991 |
Calcium antagonists--assessment of side effects.
Topics: Benzodiazepines; Calcium Channel Blockers; Cardiovascular Diseases; Dihydropyridines; Health Status; | 1990 |
[Verapamil: a primary care antihypertensive].
Topics: Antihypertensive Agents; Cardiovascular Diseases; Humans; Hypertension; Primary Health Care; Risk Fa | 1990 |
[Verapamil: an antihypertensive drug of first choice].
Topics: Humans; Hypertension; Verapamil | 1990 |
Effects of long-term verapamil therapy on serum lipids and other metabolic parameters.
Topics: Blood Pressure; Cholesterol, HDL; Female; Heart Rate; Humans; Hypertension; Lipids; Longitudinal Stu | 1990 |
Effects of calcium antagonists on the hypertensive kidney.
Topics: Calcium Channel Blockers; Dihydropyridines; Diltiazem; Humans; Hypertension; Kidney; Kidney Function | 1990 |
Review of the cardiovascular adversity of the calcium antagonist beta-blocker combination: implications for antihypertensive therapy.
Topics: Adrenergic beta-Antagonists; Calcium Channel Blockers; Cardiovascular Diseases; Diltiazem; Drug Ther | 1985 |
Calcium antagonists in the treatment of hypertension.
Topics: Biological Transport, Active; Calcium; Calcium Channel Blockers; Captopril; Diltiazem; Diuretics; Dr | 1985 |
Calcium channel blockers. Potential medical benefits and side effects.
Topics: Blood Pressure; Calcium Channel Blockers; Diltiazem; Exercise; Humans; Hypertension; Nifedipine; Uni | 1989 |
Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.
Topics: Clinical Trials as Topic; Humans; Hypertension; Verapamil | 1989 |
Calcium-channel blockers in the management of essential hypertension.
Topics: Calcium Channel Blockers; Dihydropyridines; Diltiazem; Humans; Hypertension; Verapamil | 1989 |
[Calcium antagonists in the treatment of moderate arterial hypertension].
Topics: Calcium Channel Blockers; Heart; Hemodynamics; Humans; Hypertension; Nifedipine; Verapamil | 1989 |
[Verapamil: a 1st choice antihypertensive agent].
Topics: Coronary Disease; Diabetes Complications; Humans; Hypertension; Sodium, Dietary; Verapamil | 1989 |
Calcium-entry blocking agents in the treatment of systemic hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Calcium Channel Blockers; Diuretics; Drug Ther | 1985 |
Selection of optimal drug therapy for the patient with angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Arrhythmias, Cardiac; Blood Pressure; Calcium Channel | 1985 |
Antihypertensive therapy with calcium-channel blockers: comparison with beta blockers.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Clinical Tri | 1985 |
[Calcium antagonists in the treatment of arterial hypertension].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Calcium Channel Blockers; Diltiazem; Diuretics | 1985 |
Combination therapy with beta-adrenoceptor blockers and calcium antagonists.
Topics: Adrenergic beta-Antagonists; Calcium Channel Blockers; Humans; Hypertension; Nifedipine; Verapamil | 1986 |
Clinical trials of verapamil: comparative studies of verapamil with beta-blockers and nifedipine.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Humans; Hypertension; Nifedipine; Verapamil | 1988 |
Comparison of calcium antagonists with other antihypertensive agents.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Calcium Channel Blockers; Humans; Hypertension | 1985 |
Effects of calcium entry blockers on renin-angiotensin-aldosterone system, renal function and hemodynamics, salt and water excretion and body fluid composition.
Topics: Animals; Blood Pressure; Body Fluids; Calcium Channel Blockers; Diltiazem; Diuresis; Glomerular Filt | 1985 |
Pharmacokinetics of calcium channel blocking agents.
Topics: Administration, Oral; Angina Pectoris; Atrial Fibrillation; Biological Availability; Cardiomegaly; C | 1986 |
[Calcium antagonists in arterial hypertension].
Topics: Calcium Channel Blockers; Diltiazem; Drug Interactions; Heart Diseases; Hemodynamics; Humans; Hypert | 1988 |
Geriatric hypertension: the growing use of calcium-channel blockers.
Topics: Aged; Calcium; Calcium Channel Blockers; Diltiazem; Humans; Hypertension; Nifedipine; Verapamil | 1988 |
Calcium antagonists in the treatment of hypertension. An overview.
Topics: Calcium Channel Blockers; Humans; Hypertension; Nifedipine; Verapamil | 1988 |
[Dynamic behavior of arterial pressure during exertion. Effects of treatment with 2 different calcium blockers: nifedipine and verapamil].
Topics: Adult; Blood Pressure; Exercise Test; Humans; Hypertension; Male; Middle Aged; Nifedipine; Physical | 1988 |
The role of calcium channel blockers in the treatment of hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Diltiaz | 1986 |
Kinetics and dynamics of calcium entry antagonists in systemic hypertension.
Topics: Administration, Oral; Animals; Calcium Channel Blockers; Diltiazem; Half-Life; Hemodynamics; Humans; | 1986 |
Advances in calcium blocker therapy.
Topics: Arrhythmias, Cardiac; Arteriosclerosis; Asthma; Blood Platelet Disorders; Calcium; Calcium Channel B | 1986 |
Calcium channel blockers in systemic hypertension.
Topics: Animals; Calcium Channel Blockers; Delayed-Action Preparations; Diltiazem; Drug Interactions; Humans | 1986 |
Studies on verapamil in the treatment of essential hypertension: a review.
Topics: Delayed-Action Preparations; Humans; Hypertension; Physical Exertion; Verapamil | 1986 |
Racial difference in response to antihypertensive drugs. A focus on verapamil.
Topics: Antihypertensive Agents; Black People; Clinical Trials as Topic; Humans; Hypertension; Male; Potassi | 1986 |
Treatment of angina pectoris and hypertension with sustained-release calcium channel-blocking drugs.
Topics: Angina Pectoris; Biological Availability; Calcium Channel Blockers; Delayed-Action Preparations; Dil | 1987 |
The role of calcium entry blockers in hypertensive emergencies.
Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diltiazem; Emergencies; Humans; H | 1987 |
Calcium antagonists in patients with cardiovascular disease. Current perspectives.
Topics: Angina Pectoris; Angina Pectoris, Variant; Atrial Fibrillation; Atrial Flutter; Benzazepines; Cardio | 1985 |
Use of calcium antagonists in ventricular dysfunction.
Topics: Calcium Channel Blockers; Diltiazem; Heart Diseases; Heart Ventricles; Hemodynamics; Humans; Hyperte | 1985 |
Fetal supraventricular tachycardia. Review of the literature.
Topics: Adult; Cesarean Section; Digitalis; Drug Therapy, Combination; Electric Countershock; Electrocardiog | 1985 |
Are calcium antagonists cardioprotective?
Topics: Angina Pectoris; Animals; Blood Viscosity; Calcium Channel Blockers; Clinical Trials as Topic; Coron | 1985 |
Calcium channel blocking agents: physiologic basis of nursing intervention.
Topics: Angina Pectoris; Angina Pectoris, Variant; Atrioventricular Node; Calcium; Calcium Channel Blockers; | 1985 |
Chronobiology: its importance in clinical medicine.
Topics: Airway Resistance; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Asthma; Biological Cloc | 1985 |
Calcium-channel blockers and systemic hypertension.
Topics: Acute Disease; Angina Pectoris; Animals; Calcium Channel Blockers; Chronic Disease; Diltiazem; Drug | 1985 |
Calcium antagonists in the treatment of hypertension: a critical overview.
Topics: Aldosterone; Blood Pressure; Calcium; Calcium Channel Blockers; Cardiac Output; Catecholamines; Hear | 1985 |
Calcium channel blocking agents and the heart.
Topics: Angina Pectoris; Arrhythmias, Cardiac; Calcium Channel Blockers; Coronary Vasospasm; Digoxin; Diltia | 1985 |
362 trials available for verapamil and Hypertension
| Article | Year |
|---|---|
Effect of Lisinopril and Verapamil on Angiopoietin 2 and Endostatin in Hypertensive Diabetic Patients with Nephropathy: A Randomized Trial.
Topics: Angiotensin-Converting Enzyme Inhibitors; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic | 2021 |
Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/β-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) Trials.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aldehyde Dehydrogenase 1 Family; Angiotensin-C | 2017 |
Genome-wide association analysis of common genetic variants of resistant hypertension.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Female; Genome-Wide Association Study; Hispanic or La | 2019 |
Pharmacogenomic association of nonsynonymous SNPs in SIGLEC12, A1BG, and the selectin region and cardiovascular outcomes.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers; Cardiovasc | 2013 |
Mortality implications of angina and blood pressure in hypertensive patients with coronary artery disease: New data from extended follow-up of the International Verapamil/Trandolapril Study (INVEST).
Topics: Age Factors; Aged; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agent | 2013 |
The effects of calcium channel blockers on nephropathy and pigment epithelium-derived factor in the treatment of hypertensive patients with type 2 diabetes mellitus.
Topics: Aged; Albuminuria; Amlodipine; Blood Pressure; Calcium Channel Blockers; Creatinine; Diabetes Mellit | 2015 |
Effects of verapamil SR and atenolol on 24-hour blood pressure and heart rate in hypertension patients with coronary artery disease: an international verapamil SR-trandolapril ambulatory monitoring substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Coronary Artery Disease; Drug Therapy, Comb | 2015 |
Long-Term Mortality in Hypertensive Patients With Coronary Artery Disease: Results From the US Cohort of the International Verapamil (SR)/Trandolapril Study.
Topics: Aged; Blood Pressure Determination; Cause of Death; Comorbidity; Coronary Artery Disease; Dose-Respo | 2016 |
Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients.
Topics: Adult; Antihypertensive Agents; Appetite Depressants; Blood Pressure; Body Weights and Measures; C-R | 2008 |
beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Confidence Intervals; Coronary Disease; Dose-Response R | 2008 |
Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Atenol | 2008 |
The effect of trandolapril and its fixed-dose combination with verapamil on circulating adhesion molecules levels in hypertensive patients with type 2 diabetes.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; C | 2008 |
Effect of verapamil, trandolapril and their combination on vascular function and structure in essential hypertensive patients.
Topics: Acetylcholine; Adult; Antihypertensive Agents; Case-Control Studies; Endothelium, Vascular; Female; | 2009 |
Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Coronary Artery Disease; Coronary Disease; | 2009 |
Genetic and pharmacogenetic associations between NOS3 polymorphisms, blood pressure, and cardiovascular events in hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Coronary Artery Disease; Female; Humans; Hy | 2009 |
Systolic blood pressure and subjective well-being in patients with coronary artery disease.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Coronary Artery Disease; Drug Therapy, Comb | 2009 |
Variation in the human soluble epoxide hydrolase gene and risk of restenosis after percutaneous coronary intervention.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Calcium Channel Blockers; Case-Control Studies; Coronar | 2009 |
Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers.
Topics: Adrenergic beta-Antagonists; Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; A | 2007 |
[Comparative efficiency of indapamide combinations with various derivaties of calcium antagonists in patients with arterial hypertension].
Topics: Adult; Aged; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Bloc | 2010 |
Bedtime versus at awakening administration of BP lowering drugs--is it the way to success?
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Cohort Studies; Drug Chronotherapy; Female; Humans | 2009 |
Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial.
Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channe | 2011 |
Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial.
Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channe | 2011 |
Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial.
Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channe | 2011 |
Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial.
Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channe | 2011 |
Trandolapril, but not verapamil nor their association, restores the physiological renal hemodynamic response to adrenergic activation in essential hypertension.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; F | 2011 |
Impact of trandolapril therapy and its combination with a calcium channel blocker on plasma adiponectin levels in patients with type 2 diabetes and hypertension.
Topics: Adiponectin; Aged; Analysis of Variance; Antihypertensive Agents; Blood Pressure; Calcium Channel Bl | 2011 |
Comparing marginal structural models to standard methods for estimating treatment effects of antihypertensive combination therapy.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Confounding Factors, Epidemiologic; Coronary Artery D | 2012 |
[The impact of antihypertensive therapy on cerebral hemodynamics in patients with metabolic syndrome].
Topics: Antihypertensive Agents; Biological Availability; Blood Pressure Monitoring, Ambulatory; Brain; Cere | 2012 |
Effects of black race on forearm resistance vessel function.
Topics: Adult; Analysis of Variance; Antioxidants; Ascorbic Acid; Black People; Brachial Artery; Bronchocons | 2002 |
Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising.
Topics: Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Delayed-Action Preparations; Double-Blind | 2002 |
[Treatment of hypertension in diabetics with trandolapril, an angiotensin converting enzyme inhibitor--a multicenter study].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Diabete | 2002 |
Metabolic effects of combined antihypertensive treatment in patients with essential hypertension.
Topics: Antihypertensive Agents; Atenolol; Blood Glucose; Cholesterol; Double-Blind Method; Drug Administrat | 2002 |
Estrogen effect on heart rate variability in hypertensive postmenopausal women.
Topics: Aged; Calcium Channel Blockers; Double-Blind Method; Electrocardiography, Ambulatory; Estrogen Repla | 2003 |
Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2003 |
Verapamil reverts acute renal functional impairment induced by angiotensin II converting enzyme inhibitors.
Topics: Acute Kidney Injury; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Creatinine; | 2003 |
A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents | 2003 |
Effect of candesartan and verapamil on exercise tolerance in diastolic dysfunction.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Calcium Channel Blocker | 2004 |
Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResión Arterial en DIabéticos tipo Dos) study.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biomarkers; Blood Pressure; | 2004 |
Pharmacodynamics of controlled release verapamil in patients with hypertension: an analysis using spline functions.
Topics: Adult; Aged; Blood Pressure; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-B | 2004 |
Preventing microalbuminuria in type 2 diabetes.
Topics: Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium | 2004 |
BENEDICT in the treatment of hypertension.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood Pressure; Calcium Channe | 2005 |
Results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial by geographical region.
Topics: Aged; Blood Pressure; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Patient | 2005 |
Favourable long term prognosis in stable angina pectoris: an extended follow up of the angina prognosis study in Stockholm (APSIS).
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Calcium Channel Blockers; Death, Sudden, Cardiac; Diab | 2006 |
Global differences in blood pressure control and clinical outcomes in the INternational VErapamil SR-Trandolapril STudy (INVEST).
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Body Mass I | 2005 |
Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cause of Death; Coronary Artery Disease; Di | 2006 |
Efficacy of a fixed-dose combination of trandolapril-verapamil in obese hypertensive patients resistant to monotherapy.
Topics: Aged; Antihypertensive Agents; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance; | 2006 |
Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calc | 2006 |
Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Body Mass Index; Body Size; Body Weight; Drug Therapy | 2006 |
Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Body Mass Index; Body Size; Body Weight; Drug Therapy | 2006 |
Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Body Mass Index; Body Size; Body Weight; Drug Therapy | 2006 |
Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Body Mass Index; Body Size; Body Weight; Drug Therapy | 2006 |
Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Body Mass Index; Body Size; Body Weight; Drug Therapy | 2006 |
Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Body Mass Index; Body Size; Body Weight; Drug Therapy | 2006 |
Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Body Mass Index; Body Size; Body Weight; Drug Therapy | 2006 |
Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Body Mass Index; Body Size; Body Weight; Drug Therapy | 2006 |
Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Body Mass Index; Body Size; Body Weight; Drug Therapy | 2006 |
[Evaluation of hypotensive and antiischemic effects of a combination of dihydropyridine and non-dihydropyridine calcium antagonists in patients suffering from coronary artery disease with arterial hypertension].
Topics: Adult; Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Coronary Circulation; Drug Therap | 2006 |
Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil.
Topics: Adult; Aged; Black People; Blood Pressure; Calcium Channel Blockers; Cohort Studies; Cytochrome P-45 | 2007 |
Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study.
Topics: Adult; Aged; Antihypertensive Agents; Appetite Depressants; Blood Pressure; Body Weight; Cyclobutane | 2007 |
A 26-week, prospective, open-label, uncontrolled, multicenter study to evaluate the effect of an escalating-dose regimen of trandolapril on change in blood pressure in treatment-naive and concurrently treated adult hypertensive subjects (TRAIL).
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; B | 2007 |
Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study).
Topics: Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2007 |
Antihypertensive properties of a high-dose combination of trandolapril and verapamil-SR.
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers; Double-Blind Met | 2007 |
Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study.
Topics: Aged; Blood Pressure Determination; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug | 2007 |
KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST).
Topics: Aged; Antihypertensive Agents; Base Sequence; Calcium Channel Blockers; DNA Primers; Female; Genotyp | 2007 |
Obesity paradox in patients with hypertension and coronary artery disease.
Topics: Age Distribution; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Causality; Cohort Studie | 2007 |
[Hypotensive efficacy and tolerability of combination of dihydropyridine and non-dihydropyridine calcium antagonists in the treatment of patients with arterial hypertension].
Topics: Adult; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Dihydropyridines; Dose-Response Relation | 2007 |
Phosphodiesterase type 5 inhibition reverses impaired forearm exercise-induced vasodilatation in hypertensive patients.
Topics: Adult; Aged; Case-Control Studies; Exercise; Female; Forearm; Humans; Hypertension; Male; Middle Age | 2008 |
Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study.
Topics: Analysis of Variance; Chi-Square Distribution; Diabetes Mellitus; Diuretics; Female; Glucose Toleran | 2008 |
Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST).
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Heart Rate; Humans; Hypertension; Indole | 2008 |
Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST).
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Heart Rate; Humans; Hypertension; Indole | 2008 |
Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST).
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Heart Rate; Humans; Hypertension; Indole | 2008 |
Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST).
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Heart Rate; Humans; Hypertension; Indole | 2008 |
Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST).
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Heart Rate; Humans; Hypertension; Indole | 2008 |
Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST).
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Heart Rate; Humans; Hypertension; Indole | 2008 |
Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST).
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Heart Rate; Humans; Hypertension; Indole | 2008 |
Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST).
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Heart Rate; Humans; Hypertension; Indole | 2008 |
Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST).
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Heart Rate; Humans; Hypertension; Indole | 2008 |
Comparison of rate and rhythm control in hypertension patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting E | 2008 |
Calcium channel blockers as antihypertensive agents.
Topics: Blood Pressure; Calcium Channel Blockers; Cardiomegaly; Clinical Trials as Topic; Coronary Disease; | 1984 |
Verapamil in the management of chronic hypertension.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Cardiac Output; Chronic Disease; Clinical Trials as Top | 1980 |
The value of anti-anxiety drugs in the management of cardiac disease.
Topics: Anti-Anxiety Agents; Antihypertensive Agents; Anxiety; Clinical Trials as Topic; Clorazepate Dipotas | 1982 |
Comparison of oral propranolol and verapamil for combined systemic hypertension and angina pectoris. A placebo-controlled double-blind randomized crossover trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; | 1982 |
Calcium antagonists, firstline partners for betablockers in hypertension.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Dil | 1984 |
Antihypertensive and humoral effects of verapamil and nifedipine in essential hypertension.
Topics: Adult; Aldosterone; Antihypertensive Agents; Blood Pressure; Blood Volume; Calcium Channel Blockers; | 1982 |
The place of the calcium antagonist verapamil in antihypertensive therapy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Calcium Channel Blockers; Diuretics; Drug | 1982 |
Verapamil compared with nifedipine in the treatment of essential hypertension.
Topics: Adult; Body Weight; Calcium Channel Blockers; Creatinine; Double-Blind Method; Electrocardiography; | 1982 |
A double-blind comparison of verapamil and labetalol in hypertensive patients with coexisting chronic obstructive airways disease.
Topics: Aged; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Double-Blind Method; Ethan | 1982 |
Calcium channel blockers: indications and limitations 2. Use in angina and other cardiac disorders.
Topics: Administration, Oral; Angina Pectoris; Angina Pectoris, Variant; Calcium Channel Blockers; Cardiomeg | 1982 |
Clinical use of calcium channel blockers as ventricular unloading agents.
Topics: Adult; Aged; Antihypertensive Agents; Calcium Channel Blockers; Cardiomegaly; Clinical Trials as Top | 1983 |
Calcium channel blocking agents.
Topics: Benzazepines; Calcium; Calcium Channel Blockers; Cardiomegaly; Clinical Trials as Topic; Coronary Di | 1981 |
The antihypertensive effect of verapamil on twice and thrice daily dose regimens. A randomized, double-blind, crossover trial.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Hypertension; Male; Midd | 1983 |
[Clinical evaluation of the effect of verapamil in hypertensive patients].
Topics: Adult; Aged; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Drug Therapy, Combination; Fe | 1983 |
[Verapamil - an alternative in hypertension therapy].
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Age | 1983 |
Disparate unloading efficacy of the calcium channel blockers, verapamil and nifedipine, on the failing hypertensive left ventricle.
Topics: Cardiac Output; Clinical Trials as Topic; Echocardiography; Female; Heart Failure; Heart Ventricles; | 1984 |
Propranolol versus verapamil for the treatment of essential hypertension.
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Exercise Test; Female; Heart Rate; Humans; Hyperten | 1984 |
Hypotensive action of calcium antagonists as related to plasma noradrenaline and reactivity to noradrenaline.
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Female; Heart Rate; Humans; Hypertension; Male; Nif | 1983 |
Antihypertensive effect of verapamil in patients with newly discovered mild to moderate essential hypertension.
Topics: Adult; Aged; Constipation; Diastole; Double-Blind Method; Female; Heart Rate; Humans; Hypertension; | 1984 |
Verapamil and propranolol: a comparison of two antihypertensive agents.
Topics: Adult; Aged; Blood Pressure; Double-Blind Method; Electrocardiography; Female; Heart Rate; Humans; H | 1984 |
[Comparative study of the combination of chlorthalidone with verapamil and metoprolol in arterial hypertension: evaluation by cycloergometrics].
Topics: Adult; Chlorthalidone; Clinical Trials as Topic; Drug Therapy, Combination; Exercise Test; Hemodynam | 1981 |
[Calcium antagonists in the treatment of arterial hypertension].
Topics: Benzazepines; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Diltiazem; Humans; | 1982 |
[Treatment of arterial hypertension in patients refractory to therapeutic diuretics. Comparative study of verapamil and propranolol].
Topics: Adult; Chlorthalidone; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Hyperten | 1982 |
[Immediate effect of verapamil in hypertensive cardiopathy].
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Female; Hemodynamics; Humans; Hypertension; M | 1982 |
[Treatment of hypertension with verapamil (Isoptin)].
Topics: Calcium Channel Blockers; Humans; Hypertension; Verapamil | 1983 |
Antihypertensive and renal effects of orally administered verapamil.
Topics: Adult; Blood Pressure; Female; Heart Rate; Humans; Hypertension; Kidney; Male; Middle Aged; Physical | 1980 |
[Verapamil-hydrochlorothiazide vs. metoprolol-hydrochlorothiazide. Trial in hypertensive patients].
Topics: Adult; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertensio | 1981 |
[Treatment of diuretic-resistant arterial hypertension - crossed comparative study of verapamil and clonidine].
Topics: Calcium; Clinical Trials as Topic; Clonidine; Female; Humans; Hypertension; Male; Sodium; Verapamil | 1981 |
Calcium blockers: more than angina.
Topics: Calcium Channel Blockers; Clinical Trials as Topic; Double-Blind Method; Humans; Hypertension; Muscl | 1982 |
Effects of regular exercise on blood pressure and left ventricular hypertrophy in African-American men with severe hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Black People; Blood Pressure; Combined Modality Therapy; Exerc | 1995 |
[Effectiveness and tolerance of combined verapamil retard and hydrochlorothiazide. Results of a double-blind, randomized study].
Topics: Adult; Aged; Antihypertensive Agents; Austria; Delayed-Action Preparations; Double-Blind Method; Fem | 1995 |
Structural and functional myocardial responses to chronic treatment with the Ca2+ blocker verapamil (Calan-SR) in hypertensive patients.
Topics: Blood Pressure; Delayed-Action Preparations; Echocardiography; Electrocardiography; Female; Humans; | 1993 |
Lipid profile during antihypertensive treatment. The SLIP Study Group. Study on Lipids with Isoptin Press.
Topics: Aged; Analysis of Variance; Antihypertensive Agents; Blood Pressure; Delayed-Action Preparations; Dr | 1993 |
Postinfarct treatment with verapamil. Effect of verapamil in patients with hypertension.
Topics: Cerebrovascular Disorders; Death, Sudden, Cardiac; Denmark; Double-Blind Method; Follow-Up Studies; | 1993 |
Variations in magnesium and zinc in hypertensive patients receiving different treatments.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Captopril; Cholesterol, HDL; Erythrocytes; | 1995 |
Assessment of the Vital Signs Quality of Life Questionnaire in three studies on hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans | 1995 |
Divergent effects of dihydropyridine and phenylalkylamine calcium channel antagonist classes on autonomic function in human hypertension.
Topics: Aldosterone; Analysis of Variance; Autonomic Nervous System; Baroreflex; Calcium Channel Blockers; C | 1995 |
Comparison of moexipril, a new ACE inhibitor, to verapamil-SR as add-on therapy to low dose hydrochlorothiazide in hypertensive patients.
Topics: Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Delayed-Action Preparat | 1995 |
Nocturnal dosing of a novel delivery system of verapamil for systemic hypertension. Verapamil Study Group.
Topics: Blood Pressure; Blood Pressure Monitors; Circadian Rhythm; Data Interpretation, Statistical; Diastol | 1995 |
Additive effects of verapamil and enalapril in the treatment of mild to moderate hypertension.
Topics: Adult; Aged; Analysis of Variance; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; E | 1995 |
Comparison of verapamil and captopril in elderly hypertensive subjects: results of a randomized, double-blind, crossover study.
Topics: Aged; Analysis of Variance; Blood Pressure; Captopril; Double-Blind Method; Female; Heart Rate; Huma | 1993 |
[Effect of 3 hypertensive++ agents on ventricular geometry and function].
Topics: Atenolol; Female; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Midd | 1995 |
The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil.
Topics: Adolescent; Adult; Aged; Blood Pressure; Double-Blind Method; Drug Interactions; Female; Humans; Hyp | 1995 |
Treatment of mild hypertension with low once-daily doses of a sustained-release capsule formulation of verapamil.
Topics: Adult; Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Capsules; Chemistry, Pharmaceuti | 1995 |
Do changes in dietary salt influence blood pressure of hypertensive patients pharmacologically controlled with verapamil? The Salt-Switching-Study (SSS).
Topics: Adult; Aged; Analysis of Variance; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cross-Over | 1995 |
Combined terazosin and verapamil therapy in essential hypertension. Hemodynamic and pharmacokinetic interactions.
Topics: Adult; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Female; Heart Rate; Humans; H | 1995 |
Favourable interaction of calcium antagonist plus ACE inhibitor on cardiac haemodynamics in treating hypertension: rest and effort evaluation.
Topics: Adult; Aged; Blood Pressure; Drug Combinations; Drug Interactions; Enalapril; Exercise; Female; Hear | 1995 |
[A new approach to the evaluation of the effectiveness of antihypertensive therapy in patients with mild and moderate arterial hypertension based on the example of isoptin retard].
Topics: Blood Pressure; Delayed-Action Preparations; Electrocardiography; Heart; Humans; Hypertension; Male; | 1994 |
[Tests for efficacy and tolerance of isoptin SR 240 in treatment of hypertension--BISON].
Topics: Age Factors; Aged; Delayed-Action Preparations; Female; Humans; Hypertension; Male; Middle Aged; Tre | 1993 |
[Use of isoptin SR-240 in treatment of hypertension].
Topics: Adult; Delayed-Action Preparations; Female; Humans; Hypertension; Male; Middle Aged; Treatment Outco | 1993 |
Salt sensitivity and the blood pressure response to verapamil.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Female; Humans; Hyp | 1994 |
Comparative effects of quinapril, atenolol, and verapamil on blood pressure and forearm hemodynamics during handgrip exercise.
Topics: Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood Pressure; Cross-Over Studies; Double-Blind | 1994 |
Effects of exercise and therapy on ventricular emptying and filling in mildly hypertensive patients.
Topics: Adult; Blood Pressure; Cardiac Output; Double-Blind Method; Exercise; Female; Heart Rate; Humans; Hy | 1994 |
Verapamil improves left ventricular filling and exercise performance in hypertensive and normotensive elderly individuals.
Topics: Adult; Age Factors; Aged; Blood Pressure; Diastole; Echocardiography, Doppler; Exercise; Female; Hum | 1994 |
Study on antihypertensive efficacy of slow-release verapamil: pharmacokinetic and noninvasive hemodynamic profile.
Topics: Adult; Antihypertensive Agents; Delayed-Action Preparations; Hemodynamics; Humans; Hypertension; Mid | 1993 |
Effects of long-acting propranolol and verapamil on blood pressure, platelet function, metabolic and rheological properties in hypertension.
Topics: Adult; Aged; beta-Thromboglobulin; Blood Flow Velocity; Blood Platelets; Blood Pressure; Dose-Respon | 1994 |
Hemodynamic effects of cadralazine or chlorthalidone in verapamil-treated elderly hypertensives.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Double-Blind Method; Drug Therapy, Co | 1994 |
[Effect of verapamil and nitrendipine on the left ventricular mass and function (systolic and diastolic) in arterial hypertension].
Topics: Double-Blind Method; Echocardiography, Doppler; Follow-Up Studies; Heart Ventricles; Humans; Hyperte | 1994 |
Is verapamil also a non-selective beta blocker?
Topics: Adrenergic beta-Antagonists; Blood Pressure; Captopril; Cell Membrane; Double-Blind Method; Heart Ra | 1993 |
Mortality of patients excluded from the Danish Verapamil Infarction Trail II. The DAVIT-II Study Group.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Calcium Channel Blockers; Clinical Protocols; Clinical Tri | 1993 |
[Effects of sustained-release verapamil on hemodynamics and renal function of patients with moderate to severe chronic renal failure].
Topics: Adult; Aged; Delayed-Action Preparations; Female; Glomerular Filtration Rate; Hemodynamics; Humans; | 1993 |
Calcium antagonist-induced gingival hyperplasia.
Topics: Adult; Aged; Calcium Channel Blockers; Cross-Sectional Studies; Diltiazem; Gingival Hyperplasia; Hum | 1994 |
A comparison of the effects of nifedipine and verapamil on exercise performance in patients with mild to moderate hypertension.
Topics: Double-Blind Method; Exercise Test; Hemodynamics; Hormones; Humans; Hypertension; Male; Middle Aged; | 1993 |
Antihypertensive and humoral effects of verapamil and lacidipine in combination in hypertensive patients.
Topics: Adult; Aldosterone; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydropyridi | 1993 |
Effects of quinapril and verapamil versus atenolol on blood pressure during dynamic leg exercise.
Topics: Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood Pressure; Double-Blind Method; Exercise; H | 1993 |
Effect of verapamil on reinfarction and cardiovascular events in patients with arterial hypertension included in the Danish Verapamil Infarction Trial II. The Danish Study Group on Verapamil in Myocardial Infarction.
Topics: Aged; Blood Pressure; Cardiovascular System; Denmark; Double-Blind Method; Female; Humans; Hypertens | 1994 |
Beta-adrenergic responsiveness is regulated selectively in hypertension.
Topics: Adult; Blood Pressure; Diet, Sodium-Restricted; Humans; Hydrochlorothiazide; Hypertension; Male; Mid | 1993 |
Combination therapy with verapamil and nitrendipine in patients with hypertension.
Topics: Blood Pressure; Drug Therapy, Combination; Heart Rate; Humans; Hypertension; Nitrendipine; Verapamil | 1993 |
Antihypertensive activity of verapamil: impact of dietary sodium. The VERSAL Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Diet, Sodium-Re | 1993 |
[A clinical study of the verapamil and captopril combination in hypertensive patients uncontrolled by monotherapy. An evaluation by recording the 24-hour ambulatory blood pressure].
Topics: Adult; Aged; Analysis of Variance; Blood Pressure; Blood Pressure Monitors; Captopril; Circadian Rhy | 1993 |
The role of atrial natriuretic peptide in the diuretic effect of Ca2+ entry blockers.
Topics: Adult; Aged; Aldosterone; Atrial Natriuretic Factor; Blood Pressure; Calcium Channel Blockers; Diure | 1993 |
Moexipril in the treatment of mild to moderate essential hypertension: comparison with sustained-release verapamil.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Ch | 1995 |
Hypertension in the elderly: 24 h ambulatory blood pressure results from a placebo-controlled trial.
Topics: Aged; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Delayed-Action Preparations; | 1995 |
Vascular complications in hypertension: the VHAS study. Verapamil-Hypertension Atherosclerosis Study.
Topics: Adult; Aged; Antihypertensive Agents; Arteriosclerosis; Blood Pressure; Chlorthalidone; Double-Blind | 1995 |
Antihypertensive treatment with verapamil and amlodipine. Their effect on the functional autonomic and cardiovascular stress responses.
Topics: Adult; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Hemodynamics; Humans; Hyperten | 1995 |
Stress-induced hemodynamic and hemostatic changes in patients with systemic hypertension: effect of verapamil.
Topics: Adenosine Diphosphate; Adult; Blood Pressure; Calcium Channel Blockers; Collagen; Cross-Over Studies | 1996 |
Comparison of nifedipine alone and with diltiazem or verapamil in hypertension.
Topics: Adult; Blood Pressure; Calcium Channel Blockers; Data Interpretation, Statistical; Diltiazem; Double | 1996 |
[Evaluation of the antihypertensive efficacy and safety of using sustained release verapamil in elderly subjects using ambulatory blood pressure monitoring].
Topics: Aged; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Circadian Rhythm; Delayed-Act | 1996 |
Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low-dose chlortalidone treatment in hypertensive type 2 diabetes.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Carbohydrate Metabolism; Chlortha | 1996 |
Antihypertensive efficacy of a once a day verapamil SR/trandolapril combination.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure Monitoring, Ambulatory; Calciu | 1996 |
Parathyroid hypertensive factor predicts efficacy in the treatment of essential hypertension with verapamil.
Topics: Adult; Aged; Antihypertensive Agents; Biological Factors; Drug Administration Schedule; Female; Huma | 1996 |
A comparison of the antihypertensive effectiveness of a combination of moexipril or sustained-release verapamil with low-dose hydrochlorothiazide.
Topics: Adult; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Delaye | 1996 |
Novel delivery system for verapamil designed to achieve maximal blood pressure control during the early morning.
Topics: Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Delayed-Action Preparations | 1996 |
Comparison of different fixed antihypertensive combination drugs: a double-blind, placebo-controlled parallel group study.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Chlorthalidone; Delayed-Action Prepa | 1997 |
Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Black People; Blood Pressure; Calcium Channel Blockers; | 1997 |
Calcium channel blockers blunt postural cutaneous vasoconstriction in hypertensive patients.
Topics: Adult; Aged; Calcium Channel Blockers; Cross-Over Studies; Female; Foot; Humans; Hypertension; Laser | 1997 |
Cardiovascular effects of a trandolapril/verapamil combination in patients with mild to moderate essential hypertension.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; C | 1997 |
Efficacy of combination therapy with trandolapril and verapamil sr in primary hypertension: a 4 x 4 trial design. The Trandolapril Study Group.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calc | 1997 |
Once-daily fixed dose combinations of verapamil and trandolapril in black patients with mild to moderate hypertension: a new choice for first line treatment.
Topics: Adult; Aged; Antihypertensive Agents; Black People; Blood Pressure; Blood Pressure Monitoring, Ambul | 1997 |
Effects of verapamil SR, trandolapril, and their fixed combination on 24-h blood pressure: the Veratran Study.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pr | 1997 |
Effect of sustained-release Verapamil on the morning systemic arterial pressure surge during daily activity in patients with systemic hypertension.
Topics: Adult; Analysis of Variance; Blood Pressure; Circadian Rhythm; Delayed-Action Preparations; Double-B | 1997 |
Postabsorption concentration peaks with brand-name and generic verapamil: a double-blind, crossover study in elderly hypertensive patients.
Topics: Aged; Calcium Channel Blockers; Cross-Over Studies; Double-Blind Method; Female; Hemodynamics; Human | 1997 |
Fixed-dose combination therapy with trandolapril and verapamil SR is effective in primary hypertension. Trandolapril Study Group.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; B | 1997 |
Combination treatment in hypertension: the VeraTran Study.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Drug Co | 1997 |
Comparative effects of enalapril and verapamil on myocardial blood flow in systemic hypertension.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Cardiac Pacing, Artificial; Coronary Circulation; | 1997 |
Effects of controlled-onset extended-release verapamil on nocturnal blood pressure (dippers versus nondippers). COER-Verapamil Study Group.
Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Co | 1997 |
[Changes in the quality of life influenced by treatment of primary arterial hypertension].
Topics: Adult; Antihypertensive Agents; Atenolol; Enalapril; Humans; Hypertension; Male; Middle Aged; Qualit | 1997 |
Treatment of left ventricular hypertrophy in hypertensive patients with a combination of verapamil and captopril--a multicenter study.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Ch | 1997 |
The treatment of severe hypertension with trandolapril, verapamil, and hydrochlorothiazide. Trandolapril/Verapamil Multicenter Study Group.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers; Diu | 1997 |
Attenuation of cardiovascular responses to tracheal extubation: comparison of verapamil, lidocaine, and verapamil-lidocaine combination.
Topics: Adult; Anesthetics, Local; Anti-Arrhythmia Agents; Calcium Channel Blockers; Dose-Response Relations | 1997 |
Clinical results of the Verapamil inHypertension and Atherosclerosis Study. VHAS Investigators.
Topics: Adult; Aged; Arteriosclerosis; Blood Pressure; Calcium Channel Blockers; Chlorthalidone; Double-Blin | 1997 |
Treatment of diastolic dysfunction in hypertensive patients without left ventricular hypertrophy.
Topics: Adult; Aged; Amiloride; Anti-Arrhythmia Agents; Antihypertensive Agents; Diuretics; Drug Therapy, Co | 1998 |
Comparison of effects of controlled onset extended release verapamil at bedtime and nifedipine gastrointestinal therapeutic system on arising on early morning blood pressure, heart rate, and the heart rate-blood pressure product.
Topics: Analysis of Variance; Blood Pressure; Chronotherapy; Delayed-Action Preparations; Double-Blind Metho | 1998 |
Effects of verapamil and trandolapril in the treatment of hypertension. Trandolapril Study Group.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel B | 1998 |
Circadian blood pressure changes and myocardial ischemia in hypertensive patients with coronary artery disease.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian | 1998 |
Verapamil SR and trandolapril combination therapy in hypertension--a clinical trial of factorial design. German Hypertension Study Group.
Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dose-Response Relationship, Drug; | 1998 |
Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cerebrovascular Disorders; Double- | 1998 |
Blood pressure and aortic elastic properties--verapamil SR/trandolapril compared to a metoprolol/hydrochlorothiazide combination therapy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Coronary | 1998 |
[The TEAM study--a study of the effectiveness and tolerance of treatment of essential hypertension with a fixed combination of trandolapril and verapamil].
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Drug Combi | 1998 |
The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness.
Topics: Adult; Anti-Arrhythmia Agents; Antihypertensive Agents; Arteriosclerosis; Basal Metabolism; Blood Pr | 1998 |
Verapamil SR/trandolapril combination therapy for the elderly hypertensive patient. German VeraTran Hypertension Study Group.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel B | 1999 |
Exercise gas transport determinants in elderly normotensive and hypertensive humans.
Topics: Adult; Aged; Aging; Biological Transport; Calcium Channel Blockers; Echocardiography, Doppler; Exerc | 1999 |
Physical Symptoms Distress Index: a sensitive tool to evaluate the impact of pharmacological agents on quality of life.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Calcium Channel Blockers; Constipation; Dou | 1999 |
Changes in arterial structure and function under trandolapril-verapamil combination in hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Aorta, Abdominal; Blood Pressure; Brachial Artery; Carotid Art | 1999 |
Comparison of verapamil versus felodipine on heart rate variability in hypertensive patients.
Topics: Aged; Blood Pressure; Calcium Channel Blockers; Delayed-Action Preparations; Felodipine; Female; Hea | 1999 |
Sex difference in response of blood pressure to calcium antagonism in the treatment of moderate-to-severe hypertension.
Topics: Blood Pressure; Calcium Channel Blockers; Diastole; Female; Humans; Hypertension; Male; Nifedipine; | 1999 |
Prospective comparison of therapeutical attitudes in hypertensive type 2 diabetic patients uncontrolled on monotherapy. A randomized trial: the EDICTA study.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Attitude to Health; Blood P | 1999 |
Medical therapy, symptoms, and the distress the cause: relation to quality of life in patients with angina pectoris and/or hypertension.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Amlodipine; Angina Pectoris | 2000 |
Efficacy and safety of a new long-acting drug combination, trandolapril/verapamil as compared to monotherapy in primary hypertension. Swedish TARKA trialists.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; B | 2000 |
Evaluation of the effects of fixed combinations of sustained-release verapamil/trandolapril versus captopril/hydrochlorothiazide on metabolic and electrolyte parameters in patients with essential hypertension.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2000 |
[Single daily dose of verapamil (COER-24 180/24 mg) in mild and moderate hypertension evaluated by ambulatory blood pressure monitoring].
Topics: Adult; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Drug Administration Schedule | 2000 |
The effects of verapamil SR and bisoprolol on reducing the sympathetic nervous system's activity.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Bisoprolol; Blood Pressure; Calcium Channel Blockers; Endo | 2000 |
A new chronotherapeutic oral drug absorption system for verapamil optimizes blood pressure control in the morning.
Topics: Absorption; Administration, Oral; Adult; Blood Pressure; Blood Pressure Determination; Blood Pressur | 2001 |
Beneficial effect of verapamil added to chronic ACE inhibitor treatment on renal function in hypertensive elderly patients.
Topics: Adolescent; Adult; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Bloc | 2000 |
Comparison of two calcium blockers on hemodynamics, left ventricular mass, and coronary vasodilatory in advanced hypertension.
Topics: Blood Pressure; Calcium Channel Blockers; Coronary Circulation; Coronary Vessels; Diastole; Echocard | 2001 |
Efficacy of different drug classes used to initiate antihypertensive treatment in black subjects: results of a randomized trial in Johannesburg, South Africa.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black Pe | 2001 |
Chronotherapeutic delivery of verapamil in obese versus non-obese patients with essential hypertension.
Topics: Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Body Mass Index; Calcium Channel Blocke | 2001 |
Effects of fosinopril or sustained-release verapamil on blood pressure and serum catecholamine concentrations in elderly hypertensive men.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Delayed-Action Preparat | 2000 |
Effect of strict blood pressure control on proteinuria in renal patients treated with different antihypertensive drugs.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2001 |
Effects of drug therapy on cardiac arrhythmias and ischemia in hypertensives with LVH.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Blood | 2001 |
Less adrenergic response to mental task during verapamil compared to amlodipine treatment in hypertensive subjects.
Topics: Adrenergic Agents; Adult; Aged; Amlodipine; Antihypertensive Agents; Baroreflex; Blood Pressure; Cal | 2001 |
Effective blood pressure treatment improves LDL-cholesterol susceptibility to oxidation in patients with essential hypertension.
Topics: Adult; Antihypertensive Agents; Atenolol; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combi | 2001 |
The effects of dihydropyridine and phenylalkylamine calcium antagonist classes on autonomic function in hypertension: the VAMPHYRE study.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Autonomic Nervous System; Baroreflex; Blood Pressu | 2001 |
Contrasting effects of verapamil and amlodipine on cardiovascular stress responses in hypertension.
Topics: Adult; Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Cross-Over Studies; Double-Blind | 2001 |
Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study.
Topics: Aged; Albuminuria; Analysis of Variance; Antihypertensive Agents; Diabetes Mellitus, Type 2; Double- | 2001 |
Gender and age effects on the ambulatory blood pressure and heart rate responses to antihypertensive therapy.
Topics: Adult; Age Factors; Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blo | 2001 |
A comparative trial of controlled-onset, extended-release verapamil, enalapril, and losartan on blood pressure and heart rate changes.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Delayed-Action Preparations; Doubl | 2002 |
Relationship between treatment-induced changes in left ventricular mass and blood pressure in black african hypertensive patients: results of the Baragwanath Trial.
Topics: Angiotensin-Converting Enzyme Inhibitors; Black People; Blood Pressure; Body Mass Index; Calcium Cha | 2002 |
Effects of chronic calcium channel blockade on sympathetic nerve activity in hypertension.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Delayed-Action Prepar | 2002 |
[Effect of antihypertensive combinations on arterial pressure, albuminuria, and glycemic control in patients with type II diabetic nephropathy: a randomized study].
Topics: Aged; Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antih | 2002 |
[Cycloergometric evaluation of the effects of verapamil in chronic coronary insufficiency].
Topics: Administration, Oral; Adult; Aged; Body Weight; Chronic Disease; Clinical Trials as Topic; Coronary | 1977 |
Does verapamil have a clinically significant antihypertensive effect?
Topics: Administration, Oral; Adult; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Hear | 1978 |
The treatment of hypertension with verapamil.
Topics: Adult; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Female; Huma | 1978 |
[Effects of verapamil on the ergometric test in patients with sustained diastolic hypertension. Preliminary study].
Topics: Clinical Trials as Topic; Diastole; Double-Blind Method; Exercise Test; Humans; Hypertension; Myocar | 1979 |
[Clinical use of verapamil in hypertensive crisis].
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Hypertension; Inje | 1976 |
[Oral treatment of hypertension using the calcium-antagonist verapamil].
Topics: Administration, Oral; Calcium; Clinical Trials as Topic; Humans; Hypertension; Verapamil | 1976 |
Comparative efficacy, safety and pharmacokinetics of verapamil SR vs verapamil IR in hypertensive patients.
Topics: Blood Pressure; Delayed-Action Preparations; Heart Rate; Hispanic or Latino; Humans; Hypertension; V | 1992 |
Use of ambulatory blood pressure monitoring in the management of antihypertensive therapy.
Topics: Blood Pressure Monitors; Delayed-Action Preparations; Diabetes Complications; Double-Blind Method; H | 1992 |
Preliminary clinical experience with calcium antagonists in atherosclerosis. Verapamil in Hypertension Atherosclerosis Study Investigators.
Topics: Adult; Aged; Arteriosclerosis; Blood Pressure; Carotid Arteries; Chlorthalidone; Delayed-Action Prep | 1992 |
Regional myocardial blood flow and coronary reserve in hypertensive patients. The effect of therapy.
Topics: Adult; Coronary Circulation; Enalapril; Female; Hemodynamics; Humans; Hypertension; Male; Middle Age | 1992 |
Swiss hypertension treatment programme with verapamil and/or enalapril in diabetic patients.
Topics: Adolescent; Adult; Aged; Blood Glucose; Blood Pressure; Creatinine; Diabetes Complications; Drug The | 1992 |
Effects of treatment with verapamil SR and captopril on the lipid profile of hypertensive patients.
Topics: Blood Pressure; Captopril; Delayed-Action Preparations; Double-Blind Method; Female; Heart Rate; Hum | 1992 |
Sodium intake does not influence the effect of verapamil in hypertensive patients with mild renal insufficiency.
Topics: Blood Pressure; Delayed-Action Preparations; Humans; Hypertension; Kidney; Kidney Failure, Chronic; | 1992 |
Left ventricular mass regression in elderly hypertensives.
Topics: Aging; Atenolol; Blood Pressure; Coronary Circulation; Delayed-Action Preparations; Echocardiography | 1992 |
Atherosclerosis and calcium antagonists: the VHAS. The Verapamil-Hypertension Atherosclerosis Study (VHAS) Investigators.
Topics: Arteriosclerosis; Calcium Channel Blockers; Carotid Arteries; Goals; Humans; Hypertension; Research | 1992 |
[Efficacy and tolerability of isoptine LP in mild to moderate hypertension. A multicenter study with 50 patients].
Topics: Adult; Aged; Delayed-Action Preparations; Female; Humans; Hypertension; Male; Middle Aged; Time Fact | 1992 |
Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection.
Topics: Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Dipeptides; Drug Combinations; | 1992 |
Effect of verapamil on the cardiovascular responses to tracheal intubation.
Topics: Adult; Anesthesia, General; Blood Pressure; Double-Blind Method; Female; Heart Rate; Humans; Hyperte | 1992 |
Effects of slow-release verapamil and nitrendipine on office and 24-hour ambulatory blood pressure in hypertensive patients.
Topics: Adult; Blood Pressure; Delayed-Action Preparations; Electrocardiography, Ambulatory; Female; Heart R | 1992 |
Comparison of sustained-release formulations of nicardipine and verapamil for mild to moderate systemic hypertension.
Topics: Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hype | 1992 |
Sustained-release verapamil formulations for treating hypertension.
Topics: Administration, Oral; Delayed-Action Preparations; Hemodynamics; Humans; Hypertension; Verapamil | 1992 |
Antihypertensive effects of verapamil, captopril and their combination at rest and during dynamic exercise.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Captopril; Dose-Response Relationship, Drug; Double-B | 1992 |
Effectiveness of antihypertensive medications in office and ambulatory settings: a placebo-controlled comparison of atenolol, metoprolol, chlorthalidone, verapamil, and an atenolol-chlorthalidone combination.
Topics: Adult; Ambulatory Care; Antihypertensive Agents; Atenolol; Blood Pressure; Blood Pressure Determinat | 1992 |
Effect of antihypertensive medication on endurance exercise capacity in hypertensive sportsmen.
Topics: Adult; Antihypertensive Agents; Atenolol; Double-Blind Method; Enalapril; Exercise Test; Humans; Hyp | 1991 |
Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 1991 |
The effect of verapamil on carotid artery distensibility and cross-sectional compliance in hypertensive patients.
Topics: Adult; Aged; Blood Pressure; Carotid Arteries; Double-Blind Method; Female; Humans; Hypertension; Ma | 1990 |
Effects of captopril on blood pressure and respiratory function compared to verapamil in patients with hypertension and asthma.
Topics: Aged; Asthma; Blood Pressure; Captopril; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged | 1990 |
Cardiac mass and aortic distensibility following calcium blockade in hypertension.
Topics: Adult; Aorta; Clinical Trials as Topic; Echocardiography; Female; Hemodynamics; Humans; Hypertension | 1991 |
The effects of nisoldipine, diltiazem, nifedipine, and verapamil on hemodynamic parameters and red blood cells-platelet interactions in patients with arterial hypertension.
Topics: Adult; Aged; Arteries; Blood Platelets; Blood Pressure; Calcium Channel Blockers; Diltiazem; Erythro | 1991 |
Hydrochlorothiazide and verapamil in the treatment of hypertension. The Verapamil Versus Diuretic (VERDI) Trial Research Group.
Topics: Adult; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochloroth | 1991 |
Variability of indirect methods used to determine blood pressure. Office vs mean 24-hour automated blood pressures.
Topics: Ambulatory Care; Blood Pressure Determination; Confidence Intervals; Double-Blind Method; Electrocar | 1992 |
[Comparison of the efficacy and tolerability of sustained-release verapamil and captopril in mild to moderate essential arterial hypertension].
Topics: Adult; Captopril; Delayed-Action Preparations; Double-Blind Method; Drug Evaluation; Drug Therapy, C | 1991 |
[Effects of verapamil and propranolol on the left-ventricular diastolic function in patients with primary arterial hypertension].
Topics: Adult; Blood Flow Velocity; Diastole; Echocardiography, Doppler; Female; Humans; Hypertension; Male; | 1991 |
Antihypertensive therapy with Ca2+. Antagonist verapamil and/or ACE inhibitor enalapril in NIDDM patients.
Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enalapril; Fema | 1991 |
[A comparison of the effects of verapamil and nifedipine on the quality of life].
Topics: Adult; Affect; Aged; Blood Pressure; Cognition; Delayed-Action Preparations; Double-Blind Method; Fe | 1991 |
[Comparative efficacy of sustained release verapamil and captopril in mild to moderate arterial hypertension by ambulatory measurement and occasional measurement].
Topics: Adult; Aged; Ambulatory Care; Blood Pressure Determination; Blood Pressure Monitors; Captopril; Dela | 1991 |
The effect of enalapril and calcium antagonists on blood pressure and cerebral perfusion in elderly hypertensives.
Topics: Aged; Blood Pressure; Cerebrovascular Circulation; Enalapril; Female; Humans; Hypertension; Male; Mi | 1991 |
Effect of acute and chronic administration of verapamil on cardiac structure and function in essential hypertension without left ventricular hypertrophy.
Topics: Blood Pressure; Double-Blind Method; Echocardiography; Female; Heart; Humans; Hypertension; Male; Mi | 1991 |
Cardiac structure and function before and after acute and chronic verapamil administration in hypertensive patients.
Topics: Adult; Blood Flow Velocity; Blood Pressure; Cardiomegaly; Echocardiography, Doppler; Female; Hemodyn | 1991 |
Therapeutic adherence in the elderly: transdermal clonidine compared to oral verapamil for hypertension.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Blood Pressure; Clonidine; Double-Blind Metho | 1991 |
Antihypertensive efficacy and tolerability of enalapril and slow-release verapamil in essential hypertension: a double-blind, cross-over study.
Topics: Adult; Age Factors; Aged; Blood Pressure; Delayed-Action Preparations; Double-Blind Method; Electroc | 1991 |
[Effects of acute and chronic administration of verapamil on the anatomy and function of the left ventricle in essential hypertensive patients ].
Topics: Adult; Female; Heart Ventricles; Humans; Hypertension; Male; Middle Aged; Ventricular Function, Left | 1991 |
[Sustained release verapamil in essential hypertension].
Topics: Blood Pressure; Constipation; Delayed-Action Preparations; Female; Humans; Hypertension; Male; Quali | 1991 |
Once-daily verapamil in the treatment of mild-to-moderate hypertension: a double-blind placebo-controlled dose-ranging study.
Topics: Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; | 1991 |
[Randomized double-blind study of delayed-action verapamil as a single dose versus 2 doses daily in patients with moderate hypertension].
Topics: Delayed-Action Preparations; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; V | 1991 |
Verapamil 240 SR versus verapamil 120 SR in arterial hypertension. A randomized double-blind, placebo-controlled study with 24-hour ambulatory blood pressure monitoring.
Topics: Adult; Aged; Blood Pressure; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-B | 1990 |
Concomitant considerations in long-term antihypertensive treatment.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Drug Therapy | 1990 |
[The prevalence of arrhythmias and repolarization changes in patients with mild or moderate essential hypertension undergoing an exercise test. Their variations with different antihypertensive treatments].
Topics: Adult; Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Drug Evaluation; Echocardiogra | 1990 |
The effects of antihypertensive therapy on left ventricular mass in elderly patients.
Topics: Atenolol; Blood Pressure; Cardiomegaly; Double-Blind Method; Echocardiography; Gated Blood-Pool Imag | 1990 |
Arterial vasodilator effects of the dihydropyridine calcium antagonist amlodipine alone and in combination with verapamil in systemic hypertension.
Topics: Amlodipine; Calcium Channel Blockers; Drug Therapy, Combination; Female; Forearm; Humans; Hypertensi | 1990 |
Influence of left ventricular mass regression on cardiac function in hypertensive elderly individuals.
Topics: Aged; Atenolol; Cardiomegaly; Double-Blind Method; Humans; Hypertension; Middle Aged; Physical Exert | 1990 |
Age-related antihypertensive and haemodynamic effects of verapamil SR: clinical results and effects on atrial natriuretic peptide.
Topics: Age Factors; Aged; Atrial Natriuretic Factor; Blood Pressure; Delayed-Action Preparations; Female; H | 1990 |
The influence of chronic treatment with verapamil on plasma atrial natriuretic peptide levels in young and elderly hypertensive patients.
Topics: Adult; Aged; Atrial Natriuretic Factor; Blood Pressure; Double-Blind Method; Humans; Hypertension; M | 1990 |
Special considerations in the elderly patient.
Topics: Age Factors; Aged; Aging; Atenolol; Blood Pressure; Cardiac Output; Cardiomegaly; Chlorthalidone; Do | 1990 |
[Verapamil and hypertension--(multicenter study of the efficacy and tolerance of delayed-action verapamil in the treatment of essential hypertension)].
Topics: Adult; Delayed-Action Preparations; Female; Hemodynamics; Humans; Hypertension; Male; Middle Aged; M | 1990 |
[Efficacy and tolerability of verapamil in mild to moderate hypertension].
Topics: Adult; Aged; Drug Evaluation; Female; Humans; Hypertension; Male; Middle Aged; Multicenter Studies a | 1990 |
[Comparative evaluation of the effects of isoptin and obsidan on central and cerebral hemodynamics in patients with hypertension during physical exercise].
Topics: Adult; Cerebrovascular Circulation; Clinical Trials as Topic; Exercise; Exercise Test; Female; Hemod | 1990 |
A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks.
Topics: Adult; Aged; Atenolol; Black People; Captopril; Delayed-Action Preparations; Dose-Response Relations | 1990 |
Hypertensive black men and women. Quality of life and effects of antihypertensive medications. Black Hypertension Quality of Life Multicenter Trial Group.
Topics: Age Factors; Antihypertensive Agents; Atenolol; Black or African American; Black People; Captopril; | 1990 |
A comparison of verapamil and nifedipine on quality of life.
Topics: Adult; Aged; Blood Pressure; Cognition; Double-Blind Method; Female; Humans; Hypertension; Male; Mid | 1990 |
Trials using a crossover design and ambulatory blood pressure recordings to determine the efficacy of antihypertensive agents in individual patients.
Topics: Ambulatory Care; Betaxolol; Blood Pressure; Delayed-Action Preparations; Drug Administration Schedul | 1990 |
Dose-response curves in antihypertensive combination therapy: results of a controlled clinical trial.
Topics: Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Drug | 1990 |
Verapamil versus nifedipine in slow-release preparations for the treatment of mild to moderate hypertension.
Topics: Adult; Aged; Blood Pressure; Delayed-Action Preparations; Drug Tolerance; Female; Humans; Hypertensi | 1990 |
Antihypertensive and renal effects of enalapril and slow-release verapamil in essential hypertension. A double-blind, randomized study.
Topics: Adult; Aldosterone; Angiotensin II; Blood Pressure; Delayed-Action Preparations; Double-Blind Method | 1990 |
Verapamil increases serum alkaline phosphatase in hypertensive patients.
Topics: Alkaline Phosphatase; Bone Development; Calcium; Female; Homeostasis; Humans; Hypertension; Male; Mi | 1990 |
[The results of a clinical study of the preparation kardil].
Topics: Coronary Disease; Diltiazem; Dose-Response Relationship, Drug; Humans; Hypertension; Nifedipine; USS | 1990 |
Verapamil but not nifedipine impairs left ventricular function during exercise in hypertensive patients.
Topics: Blood Pressure; Exercise; Female; Gated Blood-Pool Imaging; Heart Rate; Humans; Hypertension; Male; | 1990 |
Central hemodynamic changes of calcium antagonists at rest and during exercise in essential hypertension.
Topics: Adult; Calcium Channel Blockers; Female; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Nife | 1987 |
Verapamil and prazosin in essential hypertension: evidence of a synergistic combination?
Topics: Adult; Biological Availability; Blood Pressure; Drug Synergism; Drug Therapy, Combination; Female; H | 1987 |
Effect of nifedipine and verapamil on carbohydrate metabolism in hypertensive patients with impaired glucose tolerance.
Topics: Adult; Arginine; Blood Glucose; Carbohydrate Metabolism; Glucose Tolerance Test; Growth Hormone; Hum | 1987 |
Comparison of the effects of an angiotensin converting enzyme inhibitor and a calcium channel blocker on blood pressure and respiratory function in patients with hypertension and asthma.
Topics: Aged; Asthma; Blood Pressure; Captopril; Double-Blind Method; Electrocardiography; Female; Forced Ex | 1987 |
Treating hypertensive diabetics: a comparison of verapamil and metoprolol in black and white patients.
Topics: Albuminuria; Black People; Blood Glucose; Blood Pressure; Cholesterol; Diabetes Complications; Diabe | 1987 |
Comparison of amlodipine and verapamil in the treatment of mild to moderate hypertension.
Topics: Adolescent; Adult; Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Clinical Trials as To | 1988 |
Factors determining the response to calcium antagonists in hypertension.
Topics: Adult; Aged; Blood Pressure; Calcium Channel Blockers; Dose-Response Relationship, Drug; Female; Hum | 1988 |
Effects of sustained-release verapamil on 24-hour ambulatory blood pressure and on pressor response to isometric exertion in hypertensive patients.
Topics: Adult; Blood Pressure; Delayed-Action Preparations; Exercise; Humans; Hypertension; Male; Middle Age | 1989 |
The efficacy and duration of action of sustained-release verapamil in essential hypertension.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Met | 1989 |
The effects of slow-release verapamil on blood pressure and cardiovascular system in essential hypertension.
Topics: Adult; Blood Pressure; Cardiovascular System; Clinical Trials as Topic; Delayed-Action Preparations; | 1989 |
Treatment of isolated systolic hypertension in the elderly with verapamil slow-release 240 mg.
Topics: Aged; Aging; Blood Pressure; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Met | 1989 |
Efficacy and safety of verapamil SR 240 mg in essential hypertension: results of a multicentric phase IV study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Pressure; Clinical Trials as Topic; Delayed-Action | 1989 |
Comparative efficacy, safety, and kinetics of immediate- and slow-release verapamil in hispanic patients with essential hypertension.
Topics: Adult; Blood Pressure; Delayed-Action Preparations; Female; Heart Rate; Humans; Hypertension; Male; | 1989 |
The effects of age on the pharmacodynamics and pharmacokinetics of two formulations of verapamil.
Topics: Aged; Aging; Blood Pressure; Delayed-Action Preparations; Female; Humans; Hypertension; Male; Middle | 1989 |
A double-blind, randomized, crossover comparison of equivalent (by weight) oral doses of verapamil and diltiazem in patients with mild to moderate hypertension.
Topics: Blood Pressure; Clinical Trials as Topic; Diltiazem; Double-Blind Method; Heart Rate; Humans; Hypert | 1989 |
Calcium channel blockers. Potential medical benefits and side effects.
Topics: Blood Pressure; Calcium Channel Blockers; Diltiazem; Exercise; Humans; Hypertension; Nifedipine; Uni | 1989 |
[Effects of a calcium antagonist, verapamil, on mild-moderate essential arterial hypertension].
Topics: Aged; Chlorthalidone; Female; Humans; Hypertension; Male; Middle Aged; Verapamil | 1989 |
Verapamil versus hydrochlorothiazide in the treatment of hypertension: results of long term double blind comparative trial. Verapamil versus Diuretic (VERDI) Trial Research Group.
Topics: Adult; Aged; Blood Pressure; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-B | 1989 |
A comparison of amlodipine, verapamil and placebo in the treatment of mild to moderate hypertension. Amlodipine Study Group.
Topics: Adult; Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Double-Blind Method; Female; Huma | 1989 |
Verapamil and nebivolol improve carotid artery distensibility in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Benzopyrans; Carotid Arteries; Do | 1989 |
Antihypertensive treatment using calcium antagonists in combination with captopril rather than diuretics.
Topics: Adult; Aged; Amiloride; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Captopril | 1985 |
The effects of verapamil, diltiazem, nifedipine and propranolol on metabolic control in hypertensives with non-insulin dependent diabetes mellitus.
Topics: Aged; Blood Glucose; Blood Pressure; Cholesterol; Diabetes Mellitus, Type 2; Diltiazem; Female; Fruc | 1989 |
The effects of verapamil and propranolol on quality of life in hypertension.
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Humans; Hypertension; Middle Aged; Patient Dropouts | 1989 |
Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.
Topics: Clinical Trials as Topic; Humans; Hypertension; Verapamil | 1989 |
The relationship of dose to the antihypertensive response of verapamil-sustained release in patients with mild to moderate essential hypertension. The Verapamil-SR Study Group.
Topics: Blood Pressure; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; | 1989 |
Etozolin monotherapy and combination with verapamil in essential hypertension.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Diuretics; Drug Therapy, Combination; Female; Heart R | 1989 |
Attenuation of the pressor response to laryngoscopy and tracheal intubation with intravenous verapamil.
Topics: Adolescent; Adult; Aged; Anesthesia, General; Blood Pressure; Female; Heart Rate; Humans; Hypertensi | 1989 |
Cardiovascular responses to verapamil and propranolol in hypertensive patients.
Topics: Adult; Aged; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Female; Hemodynamics; H | 1985 |
Antihypertensive therapy with calcium-channel blockers: comparison with beta blockers.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Clinical Tri | 1985 |
Calcium antagonists and beta blockers in the control of mild to moderate systemic hypertension, with particular reference to verapamil and propranolol.
Topics: Adrenergic beta-Antagonists; Atrioventricular Node; Calcium Channel Blockers; Clinical Trials as Top | 1986 |
Calcium antagonists and the second drug for hypertensive therapy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; | 1986 |
Celiprolol and verapamil in the treatment of essential hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Celiprolol; Clinical Trials as Topic | 1988 |
Age, race, blood pressure and renin: predictors for antihypertensive treatment with calcium antagonists.
Topics: Adolescent; Adult; Age Factors; Aged; Black People; Blood Pressure; Calcium Channel Blockers; Female | 1985 |
Pharmacokinetics of calcium channel blocking agents.
Topics: Administration, Oral; Angina Pectoris; Atrial Fibrillation; Biological Availability; Cardiomegaly; C | 1986 |
[Effects of chronic administration of several calcium antagonists on pituitary release of TSH].
Topics: Adult; Atenolol; Calcium Channel Blockers; Clinical Trials as Topic; Coronary Disease; Humans; Hyper | 1987 |
Comparisons of verapamil administration twice and three times daily in hypertension.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Female; Heart Rate; Huma | 1988 |
Verapamil SR and propranolol LA: a comparison of efficacy and side effects in the treatment of mild to moderate hypertension.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Met | 1988 |
The antihypertensive efficacy of verapamil in the elderly evaluated by ambulatory blood pressure measurement.
Topics: Aged; Ambulatory Care; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Female; Glomer | 1988 |
Comparison of nitroglycerine, verapamil and nifedipine in the management of arterial pressure during coronary artery surgery.
Topics: Blood Pressure; Coronary Vessels; Electrocardiography; Hemodynamics; Humans; Hypertension; Intraoper | 1986 |
Long-term safety and efficacy comparison of immediate-release and sustained-release oral verapamil in systemic hypertension.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Clinical Trials as Topic; Delayed-Action Preparat | 1987 |
Treating hypertension in black compared with white non-insulin dependent diabetics: a double blind trial of verapamil and metoprolol.
Topics: Aged; Albuminuria; Black or African American; Clinical Trials as Topic; Diabetes Mellitus, Type 2; D | 1988 |
Studies with sustained-release verapamil in essential hypertension.
Topics: Adult; Aged; Clinical Trials as Topic; Delayed-Action Preparations; Female; Humans; Hypertension; Ma | 1988 |
Twenty-four-hour blood pressure monitoring after a single dose of sustained-release verapamil.
Topics: Adult; Blood Pressure; Delayed-Action Preparations; Humans; Hypertension; Middle Aged; Monitoring, P | 1988 |
[Verapamil and nitrendipine in beta blocker-resistant hypertensive patients].
Topics: Atenolol; Calcium Channel Blockers; Drug Resistance; Female; Humans; Hypertension; Male; Middle Aged | 1985 |
Effect of sustained-release verapamil therapy on the blood pressure at rest and on the pressor response to isometric exertion in hypertensive patients.
Topics: Adult; Blood Pressure; Delayed-Action Preparations; Exercise; Female; Heart Rate; Humans; Hypertensi | 1988 |
Pharmacokinetics of verapamil and norverapamil in patients with hypertension: a comparison of oral conventional and sustained release formulations.
Topics: Administration, Oral; Biological Availability; Delayed-Action Preparations; Double-Blind Method; Hum | 1988 |
Casual versus 24-hour ambulatory blood pressure recording in the evaluation of chronic administration of sustained-release verapamil.
Topics: Adult; Blood Pressure; Delayed-Action Preparations; Female; Humans; Hypertension; Male; Middle Aged; | 1988 |
Correlation between verapamil plasma concentration and P-R prolongation in essential hypertension.
Topics: Delayed-Action Preparations; Electrocardiography; Female; Heart Rate; Humans; Hypertension; Male; Mi | 1988 |
Changes in calcium metabolic indices during long-term treatment of patients with essential hypertension.
Topics: Adult; Bendroflumethiazide; Blood Pressure; Calcium; Fatty Acids, Nonesterified; Female; Humans; Hyp | 1988 |
Comparison of equal-weight oral dosages of verapamil hydrochloride and diltiazem hydrochloride in patients with mild to moderate hypertension.
Topics: Aged; Aged, 80 and over; Blood Pressure; Clinical Trials as Topic; Diltiazem; Double-Blind Method; E | 1988 |
Comparison of betaxolol with verapamil in hypertensive patients: discrepancy between office and ambulatory blood pressures.
Topics: Adult; Aged; Betaxolol; Blood Pressure; Blood Pressure Determination; Clinical Trials as Topic; Fema | 1988 |
The combination of prazosin and verapamil in the treatment of essential hypertension.
Topics: Adult; Aldosterone; Blood Pressure; Catecholamines; Drug Therapy, Combination; Female; Heart Rate; H | 1988 |
[Comparative evaluation of the hypotensive effects of finoptin and corinfar after their sublingual administration].
Topics: Administration, Sublingual; Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Calciu | 1988 |
Verapamil and bendrofluazide in the treatment of hypertension: a controlled study of effectiveness alone and in combination.
Topics: Adult; Bendroflumethiazide; Blood Pressure; Body Weight; Clinical Trials as Topic; Double-Blind Meth | 1988 |
[Hypotensive efficacy of verapamil alone and in combination with a diuretic in the treatment of essential hypertension in geriatric patients].
Topics: Aged; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Delayed-Action Preparations; Drug Th | 1987 |
Verapamil SR 240 mg as a contribution to compliance in long-term treatment of hypertension.
Topics: Clinical Trials as Topic; Delayed-Action Preparations; Female; Humans; Hypertension; Male; Middle Ag | 1987 |
Changes in systemic and pulmonary vascular reactivity in hypertension following nifedipine and verapamil.
Topics: Adult; Blood Circulation; Blood Pressure; Clinical Trials as Topic; Cognition; Cold Temperature; Hem | 1987 |
Cardiovascular effects of verapamil in essential hypertension.
Topics: Adult; Aged; Blood Pressure; Cardiovascular System; Clinical Trials as Topic; Delayed-Action Prepara | 1987 |
Comparison of the efficacy of an ACE-inhibitor and a calcium channel blocker in hypertensive asthmatics. A preliminiary report.
Topics: Aged; Asthma; Captopril; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Hypertension | 1986 |
Effects of calcium antagonism and beta-blockade on haemodynamic responses to stress.
Topics: Adult; Aged; Arousal; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, C | 1987 |
Antihypertensive efficacy of sustained-release verapamil.
Topics: Blood Pressure; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Drug Adm | 1987 |
Effects of the non-steroidal anti-inflammatory drugs, piroxicam or sulindac, on the antihypertensive actions of propranolol and verapamil.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Double-Blind Method; | 1987 |
The role of calcium channel blockers in the treatment of hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Diltiaz | 1986 |
A multicenter study of verapamil in systemic hypertension in Thailand.
Topics: Adult; Aged; Blood Pressure; Bradycardia; Clinical Trials as Topic; Constipation; Female; Humans; Hy | 1986 |
Calcium-channel blockers for combined angina pectoris and systemic hypertension.
Topics: Adult; Aged; Angina Pectoris; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Chr | 1986 |
Long-term results with verapamil in essential hypertension and its influence on serum lipids.
Topics: Blood Pressure; Clinical Trials as Topic; Constipation; Double-Blind Method; Hemodynamics; Humans; H | 1986 |
Comparative study of the antihypertensive effect of verapamil and atenolol.
Topics: Adult; Aged; Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Echocardiograp | 1986 |
Instant and sustained-release verapamil in the treatment of essential hypertension.
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; E | 1986 |
Regular formulation and sustained-release verapamil therapy in normotension and in mild to moderate hypertension.
Topics: Angina Pectoris; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Drug Ad | 1986 |
Combination of verapamil and beta blockers in systemic hypertension.
Topics: Adult; Aged; Atrioventricular Node; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; D | 1986 |
Twice-daily verapamil for hypertension: a comparison with propranolol.
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Drug Administration Schedule; Female; Heart Rate; H | 1986 |
An evaluation of self-recorded blood pressure during drug trials.
Topics: Adult; Aged; Blood Pressure; Blood Pressure Determination; Clinical Trials as Topic; Evaluation Stud | 1986 |
Sustained release verapamil in hypertension. Results from a noninvasive ambulatory blood pressure monitoring and a clinical study.
Topics: Adult; Aged; Blood Pressure Determination; Clinical Trials as Topic; Delayed-Action Preparations; Do | 1986 |
A new sustained-release formulation of verapamil in the treatment of hypertension.
Topics: Adult; Clinical Trials as Topic; Delayed-Action Preparations; Electrocardiography; Female; Heart Rat | 1986 |
Efficacy of sustained-release verapamil: automatic ambulatory blood pressure monitoring.
Topics: Adult; Aged; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Female; Hea | 1986 |
The impact of dietary sodium intake on the hypotensive response of verapamil in essential hypertension.
Topics: Clinical Trials as Topic; Diet, Sodium-Restricted; Humans; Hypertension; Random Allocation; Renin; S | 1986 |
Racial difference in response to antihypertensive drugs. A focus on verapamil.
Topics: Antihypertensive Agents; Black People; Clinical Trials as Topic; Humans; Hypertension; Male; Potassi | 1986 |
Evaluation of verapamil in the treatment of hypertension.
Topics: Adult; Benzothiadiazines; Clinical Trials as Topic; Diuretics; Drug Therapy, Combination; Female; He | 1986 |
Variability of blood pressure in ambulatory hypertensive patients: effects of verapamil on twice and thrice daily dose regimens.
Topics: Adult; Aged; Ambulatory Care; Blood Pressure; Circadian Rhythm; Clinical Trials as Topic; Double-Bli | 1986 |
Calcium antagonists in the treatment of arterial hypertension in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Calcium Channel Blockers; Clinical Trials as Topic; Female; Hu | 1986 |
Calcium-channel blockers for combined systemic hypertension and myocardial ischemia.
Topics: Angina Pectoris; Calcium Channel Blockers; Chronic Disease; Clinical Trials as Topic; Coronary Disea | 1987 |
The effects of verapamil and propranolol on exercise tolerance in hypertensive patients.
Topics: Adult; Clinical Trials as Topic; Humans; Hypertension; Male; Middle Aged; Physical Endurance; Propra | 1987 |
The antihypertensive effect of verapamil at extremes of dietary sodium intake.
Topics: Adult; Blood Pressure; Combined Modality Therapy; Diet, Sodium-Restricted; Female; Humans; Hypertens | 1987 |
Verapamil in essential hypertension: a comparison with atenolol plus hydralazine.
Topics: Adult; Aged; Atenolol; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Echocardiogra | 1987 |
Metabolic effects of verapamil and propranolol during submaximal endurance exercise in patients with essential hypertension.
Topics: Adult; Blood Glucose; Blood Pressure; Glycerol; Heart Rate; Humans; Hypertension; Lactates; Male; Mi | 1987 |
Pharmacokinetics of verapamil in patients with hypertension.
Topics: Administration, Oral; Adult; Double-Blind Method; Drug Administration Schedule; Female; Half-Life; H | 1986 |
Influence of oral verapamil on glucoregulatory hormones in man.
Topics: Adult; Blood Glucose; Catecholamines; Female; Glucagon; Growth Hormone; Humans; Hydrocortisone; Hype | 1985 |
Are calcium antagonists cardioprotective?
Topics: Angina Pectoris; Animals; Blood Viscosity; Calcium Channel Blockers; Clinical Trials as Topic; Coron | 1985 |
[Controlled study on the treatment of hypertension with verapamil in retard form].
Topics: Blood Pressure; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Electroc | 1985 |
[Effect of isoptin on hemodynamics in patients with hypertension and ischemic heart disease].
Topics: Adult; Clinical Trials as Topic; Coronary Disease; Female; Hemodynamics; Humans; Hypertension; Injec | 1985 |
[Verapamil in the hypertensive crisis].
Topics: Adolescent; Adult; Aged; Blood Pressure; Clinical Trials as Topic; Female; Heart Rate; Humans; Hyper | 1985 |
Verapamil and beta-blockers in hypertension: a beneficial drug interaction?
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Human | 1985 |
[Nifedipine as a vasodilator antihypertensive with a rapid action].
Topics: Adrenal Gland Neoplasms; Antihypertensive Agents; Brain Diseases; Cardiomyopathies; Emergencies; Hem | 1985 |
Verapamil and 24-hour ambulatory blood pressure monitoring in essential hypertension.
Topics: Administration, Oral; Blood Pressure; Delayed-Action Preparations; Double-Blind Method; Drug Adminis | 1986 |
Effect of verapamil on renal plasma flow, glomerular filtration rate and plasma angiotensin II, aldosterone and arginine vasopressin in essential hypertension.
Topics: Adult; Aldosterone; Angiotensin II; Arginine Vasopressin; Blood Pressure; Body Weight; Female; Glome | 1985 |
534 other studies available for verapamil and Hypertension
| Article | Year |
|---|---|
Synthesis, calcium-channel-blocking activity, and antihypertensive activity of 4-(diarylmethyl)-1-[3-(aryloxy)propyl]piperidines and structurally related compounds.
Topics: Animals; Antihypertensive Agents; Aorta; Calcium; Calcium Channel Blockers; Hypertension; Male; Mole | 1991 |
A new class of calcium antagonists. 2. Synthesis and biological activity of 11-[[4-[4-(4-fluorophenyl)-1-piperazinyl]butyryl]amino]-6,11- dihydrodibenzo[b,e]-thiepin maleate and related compounds.
Topics: Animals; Aorta, Thoracic; Calcium; Calcium Channel Blockers; Chemical Phenomena; Chemistry; Chemistr | 1991 |
2-Ethynylbenzenealkanamines. A new class of calcium entry blockers.
Topics: Alkynes; Amines; Animals; Calcium Channel Blockers; Coronary Circulation; Guinea Pigs; Hypertension; | 1988 |
The Effects of Verapamil, Hydralazine, and Doxazosin on Renin, Aldosterone, and the Ratio Thereof.
Topics: Aldosterone; Antihypertensive Agents; Doxazosin; Humans; Hydralazine; Hyperaldosteronism; Hypertensi | 2023 |
Antihypertensive Activity of Sauromatum guttatum Mediated by Vasorelaxation and Myocardial Depressant Effects.
Topics: Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Atropine Derivatives; Blood Pressure; Calc | 2021 |
Pharmacokinetic interaction between verapamil and ritonavir-boosted nirmatrelvir: implications for the management of COVID-19 in patients with hypertension.
Topics: Bradycardia; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Type 2; Female; Humans; Hypertens | 2023 |
Risk and Blood Pressure Control Rates Across the Spectrum of Coronary Artery Disease in Hypertensive Women: An Analysis from The INternational VErapamil SR-Trandolapril STudy (INVEST).
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Cha | 2020 |
Bradycardia in a Man With Hypertension.
Topics: Calcium Channel Blockers; Electrocardiography; Heart Rate; Humans; Hypertension; Male; Middle Aged; | 2019 |
Hypertension and Coronary Artery Disease in Women: Is Aggressive Blood Pressure Control Appropriate?
Topics: Blood Pressure; Coronary Artery Disease; Female; Humans; Hypertension; Indoles; Verapamil | 2020 |
Verapamil decreases calpain-1 and matrix metalloproteinase-2 activities and improves hypertension-induced hypertrophic cardiac remodeling in rats.
Topics: Animals; Calpain; Cardiomegaly; Gene Expression Regulation; Hypertension; Male; Matrix Metalloprotei | 2020 |
Association of 1-Year Blood Pressure Variability With Long-term Mortality Among Adults With Coronary Artery Disease: A Post Hoc Analysis of a Randomized Clinical Trial.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Coronary Artery Disease; Female; Humans; Hy | 2021 |
Mortality implications of lower DBP with lower achieved systolic pressures in coronary artery disease: long-term mortality results from the INternational VErapamil-trandolapril STudy US cohort.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Coronary Artery Disease; Diastole; | 2018 |
Potassium chloride mixture may maintain hypokalaemia and hypertension.
Topics: Diagnosis, Differential; Female; Glycyrrhiza; Glycyrrhizic Acid; Humans; Hyperaldosteronism; Hyperte | 2018 |
Topics: Administration, Oral; Animals; Blood Pressure; Disease Models, Animal; Drug Administration Schedule; | 2019 |
Multimodal imaging in rats reveals impaired neurovascular coupling in sustained hypertension.
Topics: Animals; Antihypertensive Agents; Calcium Channel Blockers; Cerebrovascular Circulation; Disease Mod | 2013 |
Symptomatic obstructive hypertrophic cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Aged; Cardiomyopathy, Hypertrophic; Diagnosis, Differential; Disease-Fr | 2013 |
A pharmacokinetic drug-drug interaction model of simvastatin and verapamil in humans.
Topics: Adult; Antihypertensive Agents; Area Under Curve; Calcium Channel Blockers; Cross-Over Studies; Doub | 2014 |
Mortality Risk Associated With Resistant Hypertension Among Women: Analysis from Three Prospective Cohorts Encompassing the Spectrum of Women's Heart Disease.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Artery Disease; Drug Resistance; Fema | 2016 |
Intracellular renin increases the inward calcium current in smooth muscle cells of mesenteric artery of SHR. Implications for hypertension and vascular remodeling.
Topics: Amides; Angiotensin II; Animals; Calcium; Calcium Signaling; Disease Models, Animal; Fumarates; Huma | 2016 |
Gene expression profiling of calcium-channel antagonists in the heart of hypertensive and normotensive rats reveals class specific effects.
Topics: Animals; Calcium Channel Blockers; Diltiazem; Gene Expression Profiling; Gene Expression Regulation; | 2016 |
[Comparison of Verapamil and Amlodipine for Treatment of Chronic Heart Failure With Preserved Left Ventricular Ejection Fraction in Patients With Hypertensive Disease].
Topics: Aged; Amlodipine; Antihypertensive Agents; Echocardiography; Exercise Tolerance; Female; Heart Failu | 2016 |
Menopause not aldosterone-to-renin ratio predicts blood pressure response to a mineralocorticoid receptor antagonist in primary care hypertensive patients.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aldosterone; Blood Pressure; Canrenoic Acid; Female; Huma | 2008 |
Proteomic identification of haptoglobin as a stroke plasma biomarker in spontaneously hypertensive stroke-prone rats.
Topics: Animals; Biomarkers; Blood Proteins; Haptoglobins; Hypertension; Male; Proteomics; Rats; Rats, Inbre | 2008 |
Perfusion of renal allografts with verapamil improves graft function.
Topics: ABO Blood-Group System; Adult; Calcium Channel Blockers; Cohort Studies; Creatinine; Drug Therapy, C | 2008 |
[Effectiveness and safety of administration of trandolapril/verapamil combination preparation as initial therapy in patients with arterial hypertension and thickening of intima-media complex of carotid arteries].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; C | 2008 |
Near-complete resolution of angiographic cerebral vasospasm after extreme elevation of mean arterial pressure: case report.
Topics: Calcium Channel Blockers; Cerebral Angiography; Cerebral Arteries; Cerebrovascular Circulation; Fema | 2009 |
Heterogeneity of L- and T-channels in the vasculature: rationale for the efficacy of combined L- and T-blockade.
Topics: Animals; Aorta; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; Dihydr | 2009 |
Characteristics and outcomes of revascularized patients with hypertension: an international verapamil SR-trandolapril substudy.
Topics: Aged; Angioplasty, Balloon, Coronary; Antihypertensive Agents; Blood Pressure; Calcium Channel Block | 2009 |
[Effect of hypotensive therapy on metalloproteinase activity of the blood in patients with arterial hypertension].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Enz | 2009 |
Is combined L- and T-channel blockade better than L-channel blockade in therapy?
Topics: Animals; Aorta; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; Dihydr | 2009 |
Rapid large artery remodeling following the administration and withdrawal of calcium channel blockers in spontaneously hypertensive rats.
Topics: Animals; Aorta; Blood Pressure; Calcium Channel Blockers; Diltiazem; Endothelium; Hypertension; Male | 2009 |
Increased rhythmicity in hypertensive arterial smooth muscle is linked to transient receptor potential canonical channels.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Arterioles; Benzimidazoles; Benzoates; | 2010 |
INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Coro | 2009 |
Antispasmodic and vasodilator activities of Morinda citrifolia root extract are mediated through blockade of voltage dependent calcium channels.
Topics: Animals; Aorta, Thoracic; Calcium; Calcium Channels; Diarrhea; Dose-Response Relationship, Drug; Gui | 2010 |
Impaired tissue clearance of verapamil in rat cardiac hypertrophy results in transcriptional repression of ion channels.
Topics: Animals; Calcium Channel Blockers; Calcium Channels; Calmodulin; Calsequestrin; Cardiomegaly; Cytosk | 2010 |
Determination of doxazosin and verapamil in human serum by fast LC-MS/MS: application to document non-compliance of patients.
Topics: Antihypertensive Agents; Chromatography, Liquid; Doxazosin; Humans; Hypertension; Patient Compliance | 2010 |
Hypertension: BP reduction in patients with diabetes--uncertainties remain.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Blockers; Coronary Artery Disease | 2010 |
Licorice-associated reversible cerebral vasoconstriction with PRES.
Topics: Administration, Oral; Brain; Cerebral Angiography; Cerebrovascular Circulation; Cerebrovascular Diso | 2010 |
Mechanisms of modulation of thermoregulatory reactions during cooling in hypertensive rats by the sympathetic nervous system.
Topics: Adrenergic Antagonists; Animals; Body Temperature Regulation; Cold Temperature; Hypertension; Propra | 2010 |
Liver X receptor α gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study.
Topics: Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Channel Blockers; Case-Control Stu | 2011 |
Harmful effects of NSAIDs among patients with hypertension and coronary artery disease.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Celec | 2011 |
[Selection of rational combinations of indapamide with various of calcium antagonists in patients with arterial hypertension].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulat | 2011 |
Dihydroergotamine-induced vasospastic angina in a patient taking a calcium channel blocker.
Topics: Angina Pectoris; Calcium Channel Blockers; Coronary Vasospasm; Dihydroergotamine; Drug Interactions; | 2011 |
[Variant angina: what to think in 2011?].
Topics: Adrenergic beta-Antagonists; Angina Pectoris, Variant; Coronary Angiography; Diagnosis, Differential | 2011 |
Iatrogenic heart block during treatment of a patient with Cushing's syndrome: report of a case.
Topics: Aged, 80 and over; Alkalosis; Antihypertensive Agents; Cushing Syndrome; Cytochrome P-450 CYP3A; Cyt | 2012 |
Glycidipine, a promising hypotensive and cardioprotective agent.
Topics: Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Cardiotonic Agents; Drug Combinations; Dru | 2011 |
Junctional bradycardia with verapamil in renal failure--care required even with mild hyperkalaemia.
Topics: Aged; Bradycardia; Calcium Channel Blockers; Delayed-Action Preparations; Female; Humans; Hyperkalem | 2012 |
Hypotensive effect of Gentiana floribunda is mediated through Ca++ antagonism pathway.
Topics: Animals; Antihypertensive Agents; Aorta, Thoracic; Arginine; Atropine; Blood Pressure; Calcium; Card | 2012 |
G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Bloc | 2012 |
[Optimum heart rate - the current goal of cardiovascular therapy. Position statement of the Polish Cardiac Society Working Group on Cardiovascular Drug Therapy].
Topics: Adrenergic beta-Agonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzazepines; Di | 2012 |
Calcium channel blockers revisited.
Topics: Angina Pectoris; Antihypertensive Agents; Arrhythmias, Cardiac; Calcium Channel Blockers; China; Cli | 2002 |
Cardiomyocyte volume-weighted nuclear volume and spironolactone therapy in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Cell Nucleus; Dose-Response Relationship, Drug; Enalapril; Hypertension; Ma | 2002 |
Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin.
Topics: Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood P | 2003 |
Population analyses of sustained-release verapamil in patients: effects of sex, race, and smoking.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Coronary Disease | 2003 |
Effect of light exercise on renal hemodynamics in patients with hypertension and chronic renal disease.
Topics: Adult; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Pressure; Captopril; Enalapril; Exe | 2002 |
Caffeine-induced contracture in oesophageal striated muscle of normotensive and hypertensive rats.
Topics: Animals; Blood Pressure; Body Weight; Caffeine; Calcium; Calcium Channel Blockers; Central Nervous S | 2003 |
Hemi-retinal artery occlusion associated with sexual activity and sildenafil citrate (Viagra).
Topics: Calcium Channel Blockers; Coitus; Erectile Dysfunction; Humans; Hypertension; Male; Middle Aged; Pho | 2003 |
Diabetes technology news. Calcium antagonists aid high blood pressure control.
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers; Diabetic Angiopa | 2003 |
Low urinary kallikrein rats: different sensitivity of verapamil on hypertensive response to central acute cadmium administration.
Topics: Acetates; Animals; Blood Pressure; Cadmium; Calcium Channel Blockers; Disease Models, Animal; Dose-R | 2003 |
[Heart rate variability in patients with hypertension and type 2 diabetes treated with long acting calcium antagonists].
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Calcium Channel Bl | 2003 |
[TREATMENT OF CORONARY CIRCULATORY DISORDERS WITH ISOPTIN IN GENERAL PRACTICE].
Topics: Angina Pectoris; Anti-Arrhythmia Agents; Coronary Disease; Drug Therapy; Electrocardiography; Genera | 1964 |
[CHANGES IN RENAL HEMODYNAMICS UNDER THE INFLUENCE OF D-365 AND USING I-131-LABELED HIPPURAN AS AN INDICATOR].
Topics: Blood Circulation; Blood Volume Determination; Hemodynamics; Hypertension; Hypertension, Renal; Iodi | 1965 |
Cadmium as an environmental factor of hypertension in animals: new perspectives on mechanisms.
Topics: Animals; Blood Pressure; Cadmium; Calcium Channel Blockers; Environmental Pollutants; Humans; Hypert | 2003 |
Antihypertensive and anti-arrhythmic effects of an extract of Radix Stephaniae Tetrandrae in the rat.
Topics: Alkaloids; Animals; Arrhythmias, Cardiac; Arterial Occlusive Diseases; Benzylisoquinolines; Calcium | 2004 |
Early blood pressure normalization independent of the class of antihypertensive agent prevents augmented renal fibronectin and albuminuria in experimental diabetic nephropathy.
Topics: Albuminuria; Amlodipine; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weigh | 2004 |
Effects of quercetin treatment on vascular function in deoxycorticosterone acetate-salt hypertensive rats. Comparative study with verapamil.
Topics: Animals; Antihypertensive Agents; Aorta; Blood Pressure; Desoxycorticosterone; Disease Models, Anima | 2004 |
Effects of chronic quercetin treatment on antioxidant defence system and oxidative status of deoxycorticosterone acetate-salt-hypertensive rats.
Topics: Administration, Oral; Animals; Blood Pressure; Cardiomegaly; Catalase; Desoxycorticosterone; Glutath | 2004 |
VISP and INVEST.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; | 2004 |
[Antihypertensive drug tarka (trandolapril plus verapamil) - unique fixed dose combination].
Topics: Aged; Drug Administration Schedule; Drug Combinations; Female; Humans; Hypertension; Indoles; Male; | 2004 |
[Idiopathic membranous nephropathy associated with anti-calcineurin toxicity. Prognosis and other immunosuppressive treatments].
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcineurin Inhibitors; Ca | 2004 |
Drug-induced atrioventricular block: prognosis after discontinuation of the culprit drug.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Calcium Channel Blockers; Diltiazem; Electroca | 2004 |
Managing hypertension in European patients with coronary artery disease: design, results, and clinical implications of INVEST.
Topics: Antihypertensive Agents; Coronary Disease; Drug Therapy, Combination; Europe; Humans; Hypertension; | 2004 |
Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents | 2004 |
[Lethal polypharmacy in a patient with arterial hypertension].
Topics: Aged; Aged, 80 and over; Amiloride; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agent | 2004 |
Case studies in hypertension. Dihydropyridine/nondihydropyridine calcium channel blocker combination therapy.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Calcium Channel Blockers; Dihydropyridines; Diltia | 2005 |
Adult hypertension: reducing cardiovascular morbidity and mortality.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Alcohol Drinking | 2005 |
[Characteristic features of the pathogenesis and treatment of coronary heart diseases, heart failure and arterial hypertension in patients with diabetes mellitus].
Topics: Adrenergic beta-Antagonists; Adult; Aspirin; Blood Glucose; Calcium Channel Blockers; Clinical Trial | 2005 |
Chronotherapeutic oral drug absorption system verapamil is effective in reducing morning blood pressure in African Americans: a post hoc analysis of the chrono trial.
Topics: Administration, Oral; Aged; Black People; Calcium Channel Blockers; Chronotherapy; Female; Humans; H | 2005 |
Pheochromocytoma unmasked by amisulpride and tiapride.
Topics: Adult; Amisulpride; Antipsychotic Agents; Calcium Channel Blockers; Headache; Humans; Hypertension; | 2005 |
Mitogen-activated protein kinase contributes to elevated basal tone in aortic smooth muscle from hypertensive rats.
Topics: Amides; Animals; Aorta, Thoracic; Blood Pressure; Desoxycorticosterone; Dose-Response Relationship, | 2005 |
A pharmacodynamic model of the effects of controlled-onset extended-release verapamil on 24-hour ambulatory blood pressure.
Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; De | 2005 |
[Efficacy of and tolerance to combined therapy with dihydropyridine and non-dihydropyridine Ca antagonists in patients with moderate arterial hypertension].
Topics: Adult; Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Dose-R | 2005 |
[Successful pharmacological treatment of hyperinsulinemic hypoglycemia with verapamil and amlodipine--case report].
Topics: Aged, 80 and over; Amlodipine; Calcium Channel Blockers; Female; Humans; Hyperinsulinism; Hypertensi | 2005 |
A drug dose model for predicting clinical outcomes in hypertensive coronary disease patients.
Topics: Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Chi-Square Distribution; Coronary Disea | 2005 |
[Prevention of microalbuminuria in type 2 diabetes. BENEDICT study].
Topics: Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium | 2006 |
Effects of total flavonoids of Hippophae rhamnoides L. on intracellular free calcium in cultured vascular smooth muscle cells of spontaneously hypertensive rats and Wistar-Kyoto rats.
Topics: Angiotensin II; Animals; Calcium; Cells, Cultured; Flavonoids; Flavonols; Hippophae; Hypertension; M | 2005 |
Predictors of adverse outcome among patients with hypertension and coronary artery disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium | 2006 |
Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients--findings from the International Verapamil SR/Trandolapril Study (INVEST).
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Case-Control Studies; Cohort Studies; Coron | 2006 |
Cardiovascular excitatory effect on rats of a fraction isolated from the eyestalk of shrimp: Peneaus vanameii.
Topics: Animal Structures; Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Blood Pressure; Calcium | 2006 |
Prevention of microalbuminuria in type 2 diabetes: millimeters or milligrams?
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Bloc | 2006 |
Hypertension treatment: how important is consistency of effect?
Topics: Antihypertensive Agents; Atenolol; Blood Pressure Determination; Cardiovascular Diseases; Cohort Stu | 2007 |
Influence of calcium channel blocker drugs in neuromuscular transmission.
Topics: Adult; Amlodipine; Calcium Channel Blockers; Electromyography; Female; Fingers; Humans; Hypertension | 2007 |
The effect of Ramadan fasting on ambulatory blood pressure in hypertensive patients using combination drug therapy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure; Blood P | 2008 |
Predicting stroke risk in hypertensive patients with coronary artery disease: a report from the INVEST.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Black People; Coronary Artery Disease; D | 2008 |
Calcium, cyclic AMP, and MAP kinases: dysregulation in polycystic kidney disease.
Topics: Animals; Calcium; Calcium Channel Blockers; Cell Proliferation; Contraindications; Cyclic AMP; Disea | 2008 |
Bromide as marker for drug adherence in hypertensive patients.
Topics: Adolescent; Aged; Antihypertensive Agents; Blood Pressure; Bromides; Calcium Channel Blockers; Femal | 2008 |
[Severe intoxication with verapamil].
Topics: Cardiopulmonary Resuscitation; Electrocardiography; Humans; Hypertension; Male; Middle Aged; Vasodil | 2008 |
Antihypertensive therapy with the long-acting calcium antagonist nitrendipine.
Topics: Adult; Aged; Blood Pressure; Body Weight; Calcium Channel Blockers; Female; Heart Rate; Humans; Hype | 1984 |
Effect of nifedipine and verapamil on alpha-receptor-activation in patients with essential hypertension.
Topics: Adult; Aged; Blood Platelets; Dose-Response Relationship, Drug; Drug Evaluation; Drug Interactions; | 1984 |
Drugs and the heart. III. Calcium antagonists.
Topics: Angina Pectoris; Aniline Compounds; Arrhythmias, Cardiac; Calcium; Cardiomegaly; Diuretics; Heart Di | 1980 |
A study on the effects of some drugs on DOCA induced hypertension in the rat.
Topics: Adrenergic alpha-Agonists; Animals; Blood Pressure; Cardiomegaly; Desoxycorticosterone; Diuretics; H | 1980 |
Calcium antagonists in hypertension.
Topics: Calcium; Calcium Channel Blockers; Cell Membrane; Hemodynamics; Humans; Hypertension; Nifedipine; Ve | 1982 |
[Calcium antagonists in the treatment of chronic arterial hypertension and hypertensive crisis].
Topics: Acute Disease; Adrenergic beta-Antagonists; Blood Pressure; Calcium Channel Blockers; Heart Rate; Hu | 1983 |
[Calcium antagonists in the therapy of hypertension].
Topics: Adrenergic beta-Antagonists; Calcium Channel Blockers; Diuretics; Drug Synergism; Headache; Humans; | 1984 |
Neurotransmitter release and vascular reactivity in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Calcium; Catecholamines; Electric Stimulation; Guanethidine; Hypertension; | 1984 |
Treatment with verapamil reduces blood pressure and tends to normalize vascular responsiveness and ion transport in the spontaneously hypertensive rat.
Topics: Animals; Aorta; Blood Pressure; Calcium; Hypertension; Male; Muscle Contraction; Muscle, Smooth, Vas | 1982 |
Verapamil-induced vasodilation is enhanced in essential hypertension.
Topics: Adult; Angiotensin II; Blood Pressure; Calcium Channel Blockers; Epinephrine; Female; Heart Rate; Hu | 1982 |
Comparison of cardiovascular, renal, and humoral effects of acute administration of two calcium channel blockers in normotensive and hypertensive subjects.
Topics: Blood Pressure; Calcium Channel Blockers; Catecholamines; Heart Rate; Hemodynamics; Humans; Hyperten | 1982 |
Serum concentration and antihypertensive effect of slow-release verapamil.
Topics: Adult; Aged; Biotransformation; Blood Pressure; Calcium Channel Blockers; Delayed-Action Preparation | 1982 |
Slow channel inhibitors verapamil and nifedipine in the management of hypertension.
Topics: Adult; Blood Pressure; Calcium Channel Blockers; Female; Humans; Hypertension; Isometric Contraction | 1982 |
Cellular sodium concentration and vasoconstrictor state in hypertension.
Topics: Adult; Aged; Female; Forearm; Humans; Hypertension; Leukocytes; Male; Middle Aged; Sodium; Vascular | 1984 |
Atrial fibrillation.
Topics: Age Factors; Aged; Atrial Fibrillation; Cardiomegaly; Digoxin; Electric Countershock; Electrocardiog | 1982 |
Cardiac rhythm in hypertension assessed through 24 hour ambulatory electrocardiographic monitoring. Effects of load manipulation with atenolol, verapamil, and nifedipine.
Topics: Adult; Atenolol; Cardiomegaly; Echocardiography; Electrocardiography; Female; Heart Conduction Syste | 1983 |
Left ventricular unloading with calcium antagonists.
Topics: Cardiac Output; Cardiomegaly; Drug Evaluation; Hemodynamics; Humans; Hypertension; Myocardial Contra | 1984 |
Calcium channels in the heart.
Topics: Angina Pectoris; Arrhythmias, Cardiac; Diltiazem; Electric Conductivity; Heart; Hypertension; Ion Ch | 1981 |
[Effects of calcium antagonists (verapamil and nifedipine) on blood levels of calcium and cyclic AMP in humans].
Topics: Adult; Calcium; Coronary Disease; Cyclic AMP; Electrocardiography; Electrolytes; Female; Heart; Huma | 1981 |
Calcium channel blockers for cardiovascular disorders.
Topics: Angina Pectoris; Angina Pectoris, Variant; Arrhythmias, Cardiac; Calcium; Calcium Channel Blockers; | 1982 |
Calcium channel blockers: a pathophysiologically based antihypertensive treatment concept for the future?
Topics: Calcium Channel Blockers; Humans; Hypertension; Ion Channels; Nifedipine; Vascular Resistance; Verap | 1982 |
Aldosterone response to antihypertensive treatment.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Antihypertensive Agents; Atenolol; Blood Pressure; Dipepti | 1982 |
New antihypertensive drugs. Angiotensin converting enzyme inhibitors and calcium antagonists.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Captopr | 1984 |
Verapamil-induced vasodilator response is enhanced in essential hypertension.
Topics: Adult; Angiotensin II; Calcium; Epinephrine; Female; Forearm; Humans; Hypertension; Middle Aged; Nit | 1983 |
[Evaluation of the efficacy of various hypotensive drugs in broad-breasted white turkeys as an experimental model of arterial hypertension with high catecholamine levels].
Topics: Animals; Antihypertensive Agents; Captopril; Catecholamines; Disease Models, Animal; Furosemide; Hyp | 1983 |
Effects of verapamil in hypertensive patients.
Topics: Adult; Angiotensin II; Blood Pressure; Humans; Hypertension; Middle Aged; Plasma Volume; Renal Circu | 1984 |
Use of calcium antagonists as monotherapy in the management of hypertension.
Topics: Calcium; Calcium Channel Blockers; Humans; Hypertension; Nicardipine; Nifedipine; Nitroprusside; Pra | 1984 |
Metabolic parameters after changing from hydrochlorothiazide to verapamil treatment in hypertension.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; C-Peptide; Creatinine; Fatty Acids, Nonesterified; Femal | 1984 |
Calcium antagonists, nitrates, and new antianginal drugs.
Topics: Angina Pectoris; Calcium Channel Blockers; Humans; Hypertension; Isosorbide Dinitrate; Lidoflazine; | 1983 |
Calcium antagonists in hypertension.
Topics: Humans; Hypertension; Leukocytes; Sodium; Verapamil | 1984 |
Reversal by verapamil of defect in sodium transport in leucocytes in essential hypertension.
Topics: Adult; Aged; Biological Transport, Active; Female; Humans; Hypertension; Leukocytes; Male; Middle Ag | 1984 |
[Calcium antagonists in the treatment of arterial hypertension. Attempt at a differential therapy].
Topics: Adult; Aged; Blood Pressure; Calcium; Calcium Channel Blockers; Diuretics; Drug Therapy, Combination | 1984 |
Calcium entry blockers for the treatment of severe hypertension and hypertensive crisis.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Diltiazem; Drug Therapy, Combination; Heart Ventr | 1984 |
Adrenocortical function in the course of long-term verapamil treatment.
Topics: Adrenal Cortex; Adult; Aldosterone; Female; Humans; Hydrocortisone; Hypertension; Male; Middle Aged; | 1984 |
Response to increases in extracellular calcium in the presence or absence of verapamil in normotensive or hypertensive cardiac muscle.
Topics: Animals; Calcium; Hypertension; In Vitro Techniques; Male; Myocardial Contraction; Papillary Muscles | 1984 |
[The hypertensive crisis].
Topics: Acute Disease; Calcium Channel Blockers; Clonidine; Coronary Disease; Diazoxide; Dihydralazine; Dilt | 1984 |
Verapamil and propranolol in essential hypertension.
Topics: Adult; Aged; Blood Pressure; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; | 1984 |
Effects of verapamil on blood pressure and heart rate in neurogenic hypertensive rats.
Topics: Anesthesia; Animals; Blood Pressure; Heart Rate; Hypertension; Male; Pressoreceptors; Rats; Rats, In | 1984 |
Difference of the inhibitory action of verapamil on the positive inotropic effect of Ca2+ between spontaneously hypertensive and normotensive rat myocardium.
Topics: Animals; Calcium; Dose-Response Relationship, Drug; Heart Atria; Hypertension; Male; Myocardial Cont | 1984 |
Calcium channel blockers. New treatment for cardiovascular disease.
Topics: Adult; Angina Pectoris; Calcium; Calcium Channel Blockers; Cardiomyopathy, Hypertrophic; Cardiovascu | 1983 |
Hemodynamic effects of verapamil in essential hypertension at rest and during exercise.
Topics: Adult; Blood Pressure; Cardiac Output; Heart Rate; Humans; Hypertension; Male; Middle Aged; Oxygen C | 1984 |
The role of a slow channel inhibitor, verapamil, in the management of hypertension.
Topics: Adult; Blood Pressure; Circadian Rhythm; Exercise Test; Female; Heart Rate; Humans; Hypertension; Ma | 1984 |
Calcium influx mediated vasoconstriction: studies in patients with mild and moderate essential hypertension.
Topics: Adult; Blood Pressure; Calcium; Calcium Channel Blockers; Forearm; Humans; Hypertension; Middle Aged | 1983 |
Calcium sensitivity and cardiac performance in genetic and renal models of hypertension.
Topics: Animals; Blood Pressure; Calcium; Cardiac Output; Heart; Hypertension; Hypertension, Renovascular; R | 1983 |
Small increments in plasma calcium concentration reduce the responsiveness of forearm resistance vessels to verapamil in men with primary hypertension.
Topics: Adult; Calcium; Dose-Response Relationship, Drug; Forearm; Humans; Hypertension; Magnesium; Male; Mi | 1984 |
Neurotransmitter release, vascular responsiveness and their calcium-mediated regulation in perfused mesenteric preparation of spontaneously hypertensive rats and DOCA-salt hypertension.
Topics: Animals; Calcium; Desoxycorticosterone; Dose-Response Relationship, Drug; Electric Stimulation; Hype | 1984 |
Drinking water and drug dosage in rat studies.
Topics: Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Bepridil; Blood Pressure; Dose-Response Re | 1983 |
Effect of treatment with chlorthalidone and atenolol on response to dilator agents in the forearm resistance vessels of men with primary hypertension.
Topics: Adult; Aged; Atenolol; Chlorthalidone; Forearm; Humans; Hypertension; Male; Middle Aged; Nitroprussi | 1983 |
[Calcium antagonists: a potent vasodilatory principle and alternative basic antihypertensive therapy].
Topics: Adult; Calcium Channel Blockers; Female; Humans; Hypertension; Male; Middle Aged; Nifedipine; Vasodi | 1983 |
[Effect of vasodilators on the resistance vessels of the forearm in patients with essential hypertension].
Topics: Calcium; Humans; Hypertension; Male; Muscle, Smooth, Vascular; Nitroprusside; Regional Blood Flow; V | 1983 |
Haemodynamic effects of nifedipine in essential hypertension at rest and during exercise.
Topics: Adult; Blood Pressure; Heart Rate; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Nifedipine | 1983 |
Calcium channel blocking agents. Council on scientific affairs.
Topics: Angina Pectoris; Animals; Arrhythmias, Cardiac; Asthma; Calcium Channel Blockers; Cardiomyopathy, Hy | 1983 |
Long-term treatment of arterial hypertension with verapamil.
Topics: Adult; Aged; Humans; Hypertension; Middle Aged; Verapamil | 1984 |
[Calcium antagonists in the management of hypertension].
Topics: Aged; Calcium Channel Blockers; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Nicardipine; | 1984 |
[Effect of isoptin on the microcirculation of hypertension patients].
Topics: Adult; Calcium Channel Blockers; Conjunctiva; Humans; Hypertension; Microcirculation; Middle Aged; V | 1984 |
The long-term management of hypertension with verapamil.
Topics: Aged; Blood Pressure; Calcium Channel Blockers; Cardiac Output; Constipation; Female; Heart Rate; Hu | 1982 |
Calcium channel blockers.
Topics: Angina Pectoris; Angina Pectoris, Variant; Arrhythmias, Cardiac; Calcium Channel Blockers; Diltiazem | 1983 |
The antiarrhythmic effects of verapamil and propranolol in aminophylline toxic dogs.
Topics: Aminophylline; Animals; Arrhythmias, Cardiac; Blood Gas Analysis; Dogs; Electrocardiography; Hemodyn | 1983 |
Therapeutic uses of calcium channel blockers.
Topics: Angina Pectoris; Anti-Arrhythmia Agents; Calcium Channel Blockers; Cardiovascular System; Diltiazem; | 1983 |
Hypotensive action of verapamil in a group of hydralazine-dependent hypertensive patients.
Topics: Adult; Blood Pressure; Electrocardiography; Female; Heart Rate; Humans; Hydralazine; Hypertension; M | 1983 |
Hepatic injury possibly induced by verapamil.
Topics: Alkaline Phosphatase; Chemical and Drug Induced Liver Injury; Female; Humans; Hypertension; Liver; L | 1983 |
Effect of verapamil on blood pressure and lesions in heart and kidney of rats made hypertensive by deoxycorticosterone (DOC).
Topics: Animals; Blood Pressure; Body Weight; Calcium; Coronary Vessels; Desoxycorticosterone; Drinking; Fem | 1983 |
[Calcium antagonists in the treatment of arterial hypertension].
Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Humans; Hypertension; Muscle, Smo | 1983 |
Factors modifying the local arterial hyperresponsiveness of vibration-induced white finger.
Topics: Animals; Arteries; Dogs; Dose-Response Relationship, Drug; Female; Hindlimb; Hypertension; In Vitro | 1983 |
Exaggerated hypotensive responses to calcium antagonists in spontaneously hypertensive rats.
Topics: Action Potentials; Animals; Arginine Vasopressin; Blood Pressure; Calcium Channel Blockers; Diltiaze | 1983 |
Reactivity of isolated digital arteries in hypertension.
Topics: Angiotensin II; Barium; Barium Compounds; Chlorides; Cyproheptadine; Female; Hand; Humans; Hypertens | 1981 |
The role of a slow channel inhibitor, verapamil, in the management of hypertension.
Topics: Adult; Ambulatory Care; Blood Pressure; Calcium Channel Blockers; Circadian Rhythm; Exercise Test; F | 1982 |
Modification of anti-hypertensive action of verapamil by inhibition of endogenous prostaglandin synthesis.
Topics: Aspirin; Drug Interactions; Female; Humans; Hypertension; Male; Middle Aged; Prostaglandins; Verapam | 1982 |
Prostacyclin-induced contraction of isolated aortic strips from normal and spontaneously hypertensive rats (SHR).
Topics: Animals; Aorta, Thoracic; Calcium; Epoprostenol; Female; Hypertension; In Vitro Techniques; Male; Me | 1980 |
Hypertension in a patient with hypercalcemia: captopril and verapamil.
Topics: Adult; Captopril; Drug Therapy, Combination; Female; Humans; Hypercalcemia; Hyperparathyroidism; Hyp | 1982 |
[New hypotensive drugs].
Topics: Antihypertensive Agents; Captopril; Drug Evaluation; Guanfacine; Guanidines; Humans; Hypertension; L | 1981 |
The 24-hour ambulatory blood pressure profile with verapamil.
Topics: Adult; Blood Pressure; Female; Humans; Hypertension; Male; Middle Aged; Physical Exertion; Verapamil | 1982 |
Inhibition by D 600 of norepinephrine- and clonidine-induced responses of the aortae from normotensive (WKY) and spontaneously hypertensive rats (SHR).
Topics: Animals; Aorta; Calcium Channel Blockers; Clonidine; Gallopamil; Hypertension; In Vitro Techniques; | 1982 |
Effects of calcium-entry antagonists in hypertension.
Topics: Calcium; Calcium Channel Blockers; Humans; Hypertension; Nifedipine; Pyridines; Sodium; Verapamil | 1982 |
Inhibition by methoxyverapamil of the responses of smooth muscle from spontaneously hypertensive and normotensive rats.
Topics: Animals; Blood Pressure; Calcium; Calcium Channel Blockers; Drug Interactions; Gallopamil; Hypertens | 1982 |
Response of forearm resistance vessels to verapamil and sodium nitroprusside in normotensive and hypertensive men: evidence for a functional abnormality of vascular smooth muscle in primary hypertension.
Topics: Adult; Arterioles; Dose-Response Relationship, Drug; Ferricyanides; Forearm; Humans; Hypertension; M | 1982 |
[Complications after intravenous administration of anti-arrhythmia agents].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Drug Ad | 1982 |
[Effects of verapamil on arterial blood pressure and heart rate in awake animals with neurogenic and renal hypertension].
Topics: Animals; Blood Pressure; Disease Models, Animal; Heart Rate; Hypertension; Hypertension, Renal; Infu | 1982 |
[Effect of antihypertensive therapy on the oxygen consumption of the myocardium. III. Verapamil and nifedipine].
Topics: Adult; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Myocardium; Nifedipine; Oxygen Consump | 1981 |
[Efficacy of verapamil in severe hypertension and hypertensive emergencies].
Topics: Adult; Blood Pressure; Emergencies; Female; Humans; Hypertension; Male; Middle Aged; Verapamil | 1982 |
[Oral verapamil combined with a diuretic in the treatment of slight and moderate arterial hypertension].
Topics: Adult; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; | 1982 |
Verapamil. A new class of antiarrhythmic agents with a variety of beneficial cardiovascular effects.
Topics: Arrhythmias, Cardiac; Calcium; Cardiomyopathy, Hypertrophic; Drug Therapy, Combination; Heart; Human | 1980 |
Differential effects of D 600 on contractile response of aorta and portal vein from spontaneously hypertensive rats.
Topics: Animals; Aorta; Blood Pressure; Calcium; Gallopamil; Hypertension; Muscle Contraction; Portal Vein; | 1981 |
[Acute effects of nifedipine and verapamil on arterial pressure, at rest and during and after exercise in hypertensive patients].
Topics: Adult; Aged; Blood Pressure; Exercise Test; Female; Humans; Hypertension; Male; Middle Aged; Nifedip | 1980 |
Calcium antagonists.
Topics: Angina Pectoris; Calcium Channel Blockers; Cell Membrane; Diltiazem; Heart; Humans; Hypertension; Mu | 1980 |
[Action of verapamil as a hypotensive agent - analysis of the arterial pressure curve in the cycloergometric test].
Topics: Adult; Aged; Blood Pressure; Electrocardiography; Exercise Test; Female; Humans; Hypertension; Male; | 1981 |
[Behavior of the blood pressure curve during the ergometric stress test, in treated and non-treated hypertensive patients].
Topics: Adult; Blood Pressure; Female; Heart Rate; Humans; Hypertension; Male; Methyldopa; Middle Aged; Phys | 1981 |
[Verapamil as a hypotensive agent. Clinical, laboratory, electro- and echocardiographic study].
Topics: Adult; Aged; Chlorthalidone; Echocardiography; Electrocardiography; Female; Humans; Hypertension; Li | 1981 |
[Evaluation of the antihypertensive effect of verapamil, a long-term study].
Topics: Administration, Oral; Diuretics; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Vera | 1981 |
[Antihypertensive effect of verapamil in patients with and without arteriolar sclerosis at ophthalmologic examination].
Topics: Arteriosclerosis; Blood Pressure; Diuretics; Female; Heart Rate; Humans; Hypertension; Male; Ophthal | 1981 |
[Verapamil in hypertensive emergencies. Analysis of 129 cases].
Topics: Adult; Aged; Emergencies; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Verapamil | 1981 |
[Verapamil in the treatment of hypertensive emergencies].
Topics: Emergencies; Heart Rate; Humans; Hypertension; Infusions, Parenteral; Verapamil | 1981 |
Cardiovascular protection by Ca antagonists.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Cardiovascular System; Coronary Vasospasm; Diltia | 1980 |
Cinepazet relaxation of aortic strips from normal and spontaneously hypertensive rats.
Topics: Animals; Aorta, Thoracic; Female; Hypertension; In Vitro Techniques; Male; Muscle Contraction; Muscl | 1980 |
Acute hypertensive crises.
Topics: Acute Disease; Adult; Aged; Clonidine; Diazoxide; Heart Block; Humans; Hypertension; Injections, Int | 1980 |
Increased function of voltage-dependent Ca++ channels and Ca(++)-activated K+ channels in resting state of femoral arteries from spontaneously hypertensive rats at prehypertensive stage.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 1995 |
Hypothalamic Na+,K(+)-ATPase inhibitor constricts pulmonary arteries of spontaneously hypertensive rats.
Topics: Animals; Dose-Response Relationship, Drug; Hypertension; Hypothalamus; In Vitro Techniques; Male; Ou | 1993 |
Calcium channels in vitamin B6 deficiency-induced hypertension.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 1993 |
Reversal of left ventricular hypertrophy with different classes of drugs causes differing ventricular biochemical changes.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Celiprolol | 1993 |
Pressure control of renal renin release in Lyon hypertensive rats.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 1994 |
Nicardipine, verapamil and response to intubation.
Topics: Antihypertensive Agents; Humans; Hypertension; Intubation, Intratracheal; Nicardipine; Verapamil | 1995 |
Structure and function of the rat basilar artery during chronic nitric oxide synthase inhibition.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Arginine; Basilar Artery | 1995 |
Verapamil-induced parkinsonism.
Topics: Aged; Female; Humans; Hypertension; Parkinson Disease, Secondary; Vasodilator Agents; Verapamil | 1995 |
L-NAME hypertension alters endothelial and smooth muscle function in rat aorta. Prevention by trandolapril and verapamil.
Topics: Acetylcholine; Animals; Antihypertensive Agents; Aorta; Arginine; Blood Pressure; Endothelium, Vascu | 1995 |
[Treatment of hypertension with a fixed calcium antagonist-diuretic combination. Observations from treatment of 5,595 patients].
Topics: Adult; Aged; Blood Pressure; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up | 1995 |
An individualized approach to the hypertensive patient with renal disease: six illustrative case studies.
Topics: Adrenergic alpha-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Arterial Occlusive Dis | 1995 |
A modified isometric test to evaluate blood pressure control with once-daily slow-release verapamil.
Topics: Adult; Blood Pressure; Delayed-Action Preparations; Ergometry; Female; Humans; Hypertension; Isometr | 1993 |
[Calcium antagonists as the initial monotherapy in arterial hypertension].
Topics: Adult; Aged; Humans; Hypertension; Middle Aged; Nifedipine; Verapamil | 1993 |
Endothelial dysfunction in aorta of the spontaneously hypertensive, stroke-prone rat: effects of therapy with verapamil and trandolapril alone and in combination.
Topics: Administration, Oral; Angiotensin-Converting Enzyme Inhibitors; Animals; Body Weight; Cerebrovascula | 1994 |
Experimental vasoprotection by calcium antagonists against calcium-mediated arteriosclerotic alterations.
Topics: Adult; Aged; Aged, 80 and over; Animals; Arteriosclerosis; Calcium; Calcium Channel Blockers; Cells, | 1994 |
Relationship between baseline blood pressure and blood pressure decrease after calcium channel blockers in conscious rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Consciousness; Hypertens | 1994 |
Effect of verapamil and captopril on endothelial injury in the diabetic hypertensive rat.
Topics: Animals; Blood Pressure; Blood Vessels; Body Weight; Captopril; Diabetes Mellitus, Experimental; End | 1994 |
The interaction of the calcium channel blockers verapamil and nifedipine with cyclosporin A in pediatric renal transplant patients.
Topics: Adolescent; Child; Child, Preschool; Cyclosporine; Drug Interactions; Graft Rejection; Half-Life; Hu | 1994 |
[Effects of verapamil on left ventricular mass and diastolic function in hypertensive patients].
Topics: Adult; Blood Pressure; Diastole; Echocardiography; Female; Heart Rate; Humans; Hypertension; Hypertr | 1993 |
The effect of Isoptin SR on blood pressure, heart function and hypertrophy of left ventricle of hypertensive patients.
Topics: Adult; Aged; Blood Pressure; Delayed-Action Preparations; Female; Humans; Hypertension; Hypertrophy, | 1994 |
Thorough assessment reveals drug culprit.
Topics: Adult; Ephedrine; Humans; Hypertension; Male; Nursing Assessment; Verapamil | 1994 |
Verapamil and nifedipine in combination for the treatment of hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Pressure; Drug Therapy, Combination; Edema; Female | 1994 |
Calcium channels in the vascular smooth muscle of spontaneously hypertensive rats.
Topics: Animals; Aorta, Thoracic; Calcium Channels; Hypertension; In Vitro Techniques; Kinetics; Male; Muscl | 1993 |
[Gynecomastia due to verapamil].
Topics: Gynecomastia; Humans; Hypertension; Male; Middle Aged; Time Factors; Verapamil | 1994 |
[Toxic effects of verapamil in chronic renal failure].
Topics: Aged; Female; Humans; Hypertension; Kidney Failure, Chronic; Verapamil | 1994 |
Are all calcium antagonists equally effective for reducing reinfarction rate?
Topics: Adult; Aged; Diltiazem; Humans; Hypertension; Middle Aged; Myocardial Infarction; Proportional Hazar | 1993 |
[Poisoning by delayed-release verapamil in renal insufficiency patients].
Topics: Aged; Aged, 80 and over; Delayed-Action Preparations; Female; Humans; Hypertension; Poisoning; Renal | 1993 |
Differential cerebrovascular responsiveness in spontaneously hypertensive rats following antihypertensive treatment with clonidine and verapamil.
Topics: Animals; Blood Pressure; Body Weight; Cerebrovascular Circulation; Clonidine; Heart Rate; Hypertensi | 1993 |
Effects of verapamil and diltiazem on dopamine release in the central nervous system of spontaneously hypertensive rats.
Topics: Animals; Corpus Striatum; Diltiazem; Dopamine; Electric Stimulation; Hypertension; In Vitro Techniqu | 1993 |
Relationship between blood pressure and smooth muscle tone in aortae of hypertensive rats: roles of [Ca2+].
Topics: Animals; Aorta; Blood Pressure; Calcium; Hypertension; In Vitro Techniques; Muscle Contraction; Musc | 1993 |
[Paroxysmal atrial fibrillation and flutter and "occult" arterial hypertension. The importance of the ambulatory monitoring of the blood pressure. Apropos 2 cases].
Topics: Atenolol; Atrial Fibrillation; Atrial Flutter; Blood Pressure Monitors; Diltiazem; Drug Therapy, Com | 1993 |
[Evaluation of the effect of Isoptin-Retard on central hemodynamics and parameters of diastolic ventricular function in patients with hypertension].
Topics: Adult; Delayed-Action Preparations; Diastole; Drug Evaluation; Female; Gated Blood-Pool Imaging; Hea | 1993 |
[Isoptin-Retard 240 mg in the treatment of mild and moderate arterial hypertension].
Topics: Blood Pressure; Blood Pressure Monitors; Delayed-Action Preparations; Double-Blind Method; Drug Eval | 1993 |
Reversal of cardiogenic shock and severe mitral regurgitation through verapamil in hypertensive hypertrophic cardiomyopathy.
Topics: Aged; Aortic Aneurysm, Abdominal; Aortic Rupture; Cardiomyopathy, Hypertrophic; Humans; Hypertension | 1993 |
In vitro and in vivo electrocardiographic evaluation of the novel calcium antagonist monatepil on cardiac conduction system.
Topics: Anesthesia; Animals; Blood Pressure; Bundle of His; Calcium Channel Blockers; Dibenzothiepins; Dilti | 1993 |
Ethanol induced hypertension in rats: reversibility and role of intracellular cytosolic calcium.
Topics: Alcoholism; Animals; Aorta, Thoracic; Blood Platelets; Blood Pressure; Calcium; Cytosol; Drinking; E | 1993 |
Verapamil prevents the acute hypertensive response to intracerebroventricular cadmium in conscious normotensive rats.
Topics: Acute Disease; Animals; Blood Pressure; Brain; Cadmium; Dose-Response Relationship, Drug; Hypertensi | 1993 |
High-calcium diet in spontaneously hypertensive rats: intervention with calcium antagonist verapamil.
Topics: Animals; Blood Pressure; Calcium, Dietary; Heart Rate; Hypertension; Rats; Rats, Inbred SHR; Verapam | 1993 |
[Long-term treatment with calcium antagonists: advantageous effects and risks].
Topics: Calcium Channel Blockers; Controlled Clinical Trials as Topic; Humans; Hypertension; Myocardial Infa | 1995 |
[Effect of chronic inhibition of nitric oxide synthesis on vascular structure: remodeling or growth?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Arginine; Basilar Artery | 1995 |
Loss of maximum attenuation and receptor reserve for isoprenaline at the beta 2-adrenoceptors of the portal veins of hypertensive rats.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Alprenolol; Animals; Hypertension; Hypertroph | 1995 |
[Changes in cardiohemodynamic indicators during use of verapamil for preventing and treating hypertensive complications of pregnancy].
Topics: Adolescent; Adult; Antihypertensive Agents; Female; Hemodynamics; Humans; Hypertension; Pre-Eclampsi | 1995 |
Individual and combined effects of verapamil or trandolapril on attenuating hypertensive glomerulopathic changes in the stroke-prone rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Calcium | 1996 |
Revisiting calcium channel blockers--from basic facts to clinical practice.
Topics: Aged; Calcium Channel Blockers; Cardiovascular Diseases; Diltiazem; Humans; Hypertension; Nifedipine | 1996 |
Inhibited neutrophil functions in patients treated with nifedipine but not with verapamil or diltiazem.
Topics: Adult; Calcium; Calcium Channel Blockers; Chemotaxis, Leukocyte; Diltiazem; Humans; Hypertension; Ne | 1996 |
Characterization of enhanced 45Ca2+ efflux in cultured vascular smooth muscle cells from spontaneously hypertensive rats.
Topics: Animals; Calcium; Calcium Channel Blockers; Calcium Radioisotopes; Cells, Cultured; Hypertension; Io | 1995 |
Potent vasoconstrictor actions of cyclopiazonic acid and thapsigargin on femoral arteries from spontaneously hypertensive rats.
Topics: Animals; Calcium; Calcium Channel Blockers; Calcium Radioisotopes; Enzyme Inhibitors; Femoral Artery | 1997 |
Lack of vasodilatory response in skeletal muscle blood vessels of aged spontaneously hypertensive rats.
Topics: Age Factors; Animals; Hemodynamics; Hydralazine; Hypertension; Muscle, Skeletal; Rats; Rats, Inbred | 1996 |
Reduction of renal function by angiotensin-converting enzyme inhibitors: effect of verapamil.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Drug Therapy, Combination; | 1997 |
Acute asthma associated with sustained-release verapamil.
Topics: Acute Disease; Aged; Asthma; Blood Pressure; Calcium Channel Blockers; Delayed-Action Preparations; | 1997 |
Effects of aerobic training on exaggerated blood pressure response to exercise in African-Americans with severe systemic hypertension treated with indapamide +/- verapamil +/- enalapril.
Topics: Adult; Aged; Antihypertensive Agents; Black People; Blood Pressure; Combined Modality Therapy; Drug | 1997 |
Effects of enalapril, losartan, and verapamil on blood pressure and glucose metabolism in the Cohen-Rosenthal diabetic hypertensive rat.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Blood Glucose | 1997 |
Verapamil accelerates the transition to heart failure in obese, hypertensive, female SHHF/Mcc-fa(cp) rats.
Topics: Animals; Blood Pressure; Brain; Calcium Channel Blockers; Felodipine; Female; Heart; Heart Failure; | 1997 |
Effect of verapamil on cadmium induced hypertension in rats.
Topics: Animals; Blood Pressure; Cadmium; Calcium Channel Blockers; Heart Rate; Hypertension; Male; Rats; Ra | 1996 |
NOS activity in skeletal muscle from hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Calcium Channel Blockers; Hyperte | 1997 |
Effect of calcium antagonists on plasma norepinephrine levels, heart rate, and blood pressure.
Topics: Adult; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Dihydropyridines; Diltiaz | 1997 |
[Urinary difficulty caused by verapamil].
Topics: Adult; Calcium Channel Blockers; Humans; Hypertension; Male; Urination Disorders; Verapamil | 1997 |
Pheochromocytoma crisis caused by contemporary ergotamine, caffeine, and nimesulide administration.
Topics: Adrenal Gland Neoplasms; Adult; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; A | 1997 |
Covera-HS offers proven protection in hypertension and angina in alignment with circadian rhythm.
Topics: Angina Pectoris; Chronotherapy; Delayed-Action Preparations; Humans; Hypertension; Vasodilator Agent | 1997 |
Obsessive-compulsive disorder: cerebral calcium deficiency as a possible etiologic/pathogenetic factor--a case study.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Brain; Calcium; Calcium Channel Blockers; Enalapril; | 1997 |
[Obesity in the service of Justice. New drug-combination leads to protection of the kidney].
Topics: Antihypertensive Agents; Calcium Channel Blockers; Diabetes Complications; Diabetes Mellitus; Diabet | 1997 |
Renal vascular hyperresponsiveness to elevated ionized calcium in spontaneously hypertensive rat kidneys.
Topics: Animals; Calcium; Calcium Channel Blockers; Enzyme Inhibitors; Hypertension; In Vitro Techniques; om | 1998 |
[Verapamil-associated liver injury].
Topics: Calcium Channel Blockers; Delayed-Action Preparations; Female; Humans; Hypertension; Liver; Liver Fu | 1998 |
The relaxing effect of BDF 9148 on the KCl-contracted aorta isolated from normo- and hyper-tensive rats.
Topics: Aging; Animals; Aorta, Thoracic; Azetidines; Calcium Channel Blockers; Cardiotonic Agents; Electroph | 1998 |
Losartan but not verapamil inhibits angiotensin II-induced tissue endothelin-1 increase: role of blood pressure and endothelial function.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pressure; Calcium Channel B | 1998 |
Antihypertensive action of trandolapril and verapamil in spontaneously hypertensive rats after unilateral nephrectomy.
Topics: Acetylcholine; Animals; Antihypertensive Agents; Aorta; Blood Pressure; Female; Heart; Hypertension; | 1998 |
Verapamil prevents cyclosporine-induced hypertension by modulating endothelin A receptor expression in rat kidney membranes.
Topics: Animals; Blood Pressure; Cell Membrane; Cyclosporine; Endothelin-1; Gene Expression Regulation; Hype | 1998 |
Effects of antihypertensive drugs on autoregulation of RBF and glomerular capillary pressure in SHR.
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Ag | 1998 |
Prevention of arterial structural alterations with verapamil and trandolapril and consequences for mechanical properties in spontaneously hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antigens, CD; Aorta, Thoracic; Arteries; Blood Pr | 1998 |
[Isoptin. Evolution of views from Fleckenstein to the present days].
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers; Coronary Vessels | 1998 |
Involvement of angiotensin II in development of spontaneous nephrosis in Dahl salt-sensitive rats.
Topics: Aging; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; B | 1998 |
Pressure natriuresis in nitric oxide-deficient hypertensive rats: effect of antihypertensive treatments.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl | 1999 |
[Study of the mechanism of regression of left ventricular hypertrophy in hypertension treated with slow-release verapamil].
Topics: Adult; Calcium Channel Blockers; Delayed-Action Preparations; Female; Humans; Hypertension; Hypertro | 1997 |
Antihypertensive effect of trandolapril and verapamil in rats with induced hypertension.
Topics: Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pressure; Body Weight; Drug Synergism; Fema | 1999 |
Efficacy of sublingual verapamil in patients with severe essential hypertension: comparison with sublingual nifedipine.
Topics: Administration, Sublingual; Adult; Aged; Blood Pressure; Calcium Channel Blockers; Female; Headache; | 1999 |
Arterial structural changes with verapamil in spontaneously hypertensive rats.
Topics: Animals; Aorta, Thoracic; Blood Pressure; Calcium Channel Blockers; Carotid Arteries; Collagen; Elas | 1999 |
Stroke-prone spontaneously hypertensive rats lose their ability to auto-regulate cerebral blood flow prior to stroke.
Topics: Animals; Blood Pressure; Cerebrovascular Circulation; Diet; Homeostasis; Hypertension; In Vitro Tech | 1999 |
Impaired potentiation by endothelin-1 and vasopressin of sympathetic contraction in tail artery from hypertensive rats.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Calcium Channel Blockers; | 2000 |
Mesenteric cyclooxygenase products after combined antihypertensive treatment in uninephrectomized SHRs.
Topics: Acetylcholine; Animals; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; D | 2000 |
Effects of KR-30035, a novel multidrug-resistance modulator, on the cardiovascular system of rats in vivo and on the cell cycle of human cancer cells in vitro.
Topics: Animals; Antihypertensive Agents; Antineoplastic Agents; Blood Pressure; Calcium Channel Blockers; C | 2000 |
Effect of verapamil on home self-measurement of blood pressure and heart rate by hypertensive patients. Verapamil-Frequency Research Group.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care Facilities; Blood Pressure; Blood Pressure Monitorin | 2000 |
Effect of antihypertensive drugs on the myocardial microvessels in rats with nitric oxide blockade.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Capillaries; Coronary Circulation; Coronary Vessel | 2000 |
How can hypertensive patients be better treated? The contribution of combination therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Calcium Channe | 2000 |
The effects of anti-hypertensive therapy on the structural, mechanical and metabolic properties of the rat aorta.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Aorta; Hypertension; Ind | 2000 |
[ACE inhibitor and calcium channel blocker in a fixed combination. Lowering blood pressure in diabetic patients].
Topics: Antihypertensive Agents; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypertension; Indoles | 2000 |
Left ventricular midwall function improves with antihypertensive therapy and regression of left ventricular hypertrophy in patients with asymptomatic hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Double-Blind Method; Echocardiogr | 2001 |
Mechanisms of the increased pressor response to vasopressors in the mesenteric bed of nitric oxide-deficient hypertensive rats.
Topics: Acetylcholine; Animals; Antihypertensive Agents; Arteries; Blood Pressure; Disease Models, Animal; D | 2001 |
Effects of COER-verapamil on circadian pattern of forearm vascular resistance and blood pressure.
Topics: Adult; Aged; Blood Pressure; Calcium Channel Blockers; Circadian Rhythm; Delayed-Action Preparations | 2000 |
Calcium buffering of resting, voltage-dependent Ca2+ influx by sarcoplasmic reticulum in femoral arteries from spontaneously hypertensive rats at prehypertensive stage.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 2001 |
Endothelin 1 type a receptor antagonism prevents vascular dysfunction and hypertension induced by 11beta-hydroxysteroid dehydrogenase inhibition: role of nitric oxide.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Acetylcholine; Animals; Blood Pressure; Body Weight; Cells, C | 2001 |
Hypertension and chronotherapy: shifting the treatment paradigm.
Topics: Blood Pressure; Chronotherapy; Humans; Hypertension; Sleep; Vasodilator Agents; Verapamil | 2001 |
Pharmacology of cardiovascular chronotherapeutic agents.
Topics: Antihypertensive Agents; Biomarkers; Blood Pressure; Calcium Channel Blockers; Catecholamines; Chron | 2001 |
The effect of the fast of Ramadan on ambulatory blood pressure in treated hypertensives.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure; Blood P | 2001 |
Effect of essential hypertension on kidney function as measured in rat by dynamic MRI.
Topics: Animals; Calcium Channel Blockers; Contrast Media; Gadolinium DTPA; Glomerular Filtration Rate; Hype | 2002 |
Pharmacokinetics of controlled-release verapamil in healthy volunteers and patients with hypertension or angina.
Topics: Adult; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Female; Humans; Hypertension; Male | 2002 |
Using trade names: a risk factor for accidental drug overdose.
Topics: Adverse Drug Reaction Reporting Systems; Antihypertensive Agents; Drugs, Generic; Electrocardiograph | 2002 |
Clinical pharmacology-physiology conference. A chrono-therapeutic approach to the treatment of hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Bloc | 2001 |
[Treatment of hypertension with a combination of pyridopyridazine derivative with a beta-receptor blocker. Studies on the hemodynamic course (author's transl)].
Topics: Adrenergic beta-Antagonists; Aged; Cardiac Output; Drug Evaluation; Drug Therapy, Combination; Femal | 1978 |
Verapamil in the management of hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Humans; Hypertension; Methyldopa; Middle A | 1979 |
Mitochondrial calcium overload, a cause of essential hypertension.
Topics: Calcium; Humans; Hypercalcemia; Hypertension; Mitochondria, Muscle; Myocardium; Verapamil | 1977 |
[Effect of the long-term administration of verapamil on arterial pressure and water-salt balance in hypertensive patients].
Topics: Adult; Creatinine; Humans; Hypertension; Middle Aged; Sodium; Verapamil; Water; Water-Electrolyte Ba | 1978 |
Verapamil as an antihypertensive agent.
Topics: Animals; Hypertension; Rats; Verapamil | 1979 |
[Action of verapamil on renin activity in essential hypertension].
Topics: Adult; Angiotensin I; Angiotensins; Humans; Hypertension; Middle Aged; Renin; Verapamil | 1978 |
[Action of verapamil in a single oral dose in arterial hypertension. Evaluation by echocardiography and phonomechanocardiography].
Topics: Adult; Aged; Blood Pressure; Echocardiography; Female; Humans; Hypertension; Male; Middle Aged; Myoc | 1979 |
[Verapamil in the treatment of severe rapid onset hypertension. Potentiation of hypotensive drugs and sensitization of pressoreceptors by serial infusion of verapamil].
Topics: Adult; Antihypertensive Agents; Blood Pressure; Diuretics; Drug Synergism; Female; Humans; Hypertens | 1979 |
[Effect of verapamil on the pressure response induced by cycloergometry in hypertensive patients].
Topics: Adult; Blood Pressure; Chlorthalidone; Drug Therapy, Combination; Exercise Test; Female; Humans; Hyp | 1979 |
[Use of verapamil in arterial hypertension].
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Diuretics; Female; Heart Rate; Humans; Hypertensi | 1979 |
Tension development and Ca2+ uptake of isolated aorta from spontaneously hypertensive rats.
Topics: Animals; Aorta; Calcium; Hypertension; In Vitro Techniques; Male; Muscle Contraction; Nifedipine; Ra | 1979 |
[Value of verapamil in long-term treatment of coronary disease, hypertension and functional disorders of the cardiovascular system].
Topics: Adult; Cardiovascular Diseases; Coronary Disease; Female; Humans; Hypertension; Male; Middle Aged; V | 1979 |
[Treatment of severe hypertensive conditions].
Topics: Adolescent; Adult; Diazoxide; Drug Therapy, Combination; Female; Humans; Hypertension; Infusions, Pa | 1979 |
[Calcium antagonists: hemodynamic effects in hypertensive patients].
Topics: Calcium; Hemodynamics; Humans; Hypertension; Nifedipine; Pyridines; Verapamil | 1979 |
[Treatment of hypertensive crises with calcium antagonists].
Topics: Antihypertensive Agents; Calcium; Drug Therapy, Combination; Humans; Hypertension; Hypertension, Ren | 1978 |
[Calcium antagonists: an echocardiographic evaluation of the morphofunctional changes in the left ventricle].
Topics: Calcium; Echocardiography; Female; Heart; Heart Ventricles; Humans; Hypertension; Male; Middle Aged; | 1979 |
[Use of verapamil in the control of hypertensive vascular crisis and effects on the urinary sodium and potassium concentrations and plasma renin activity].
Topics: Blood Pressure; Electrocardiography; Humans; Hypertension; Potassium; Renin; Sodium; Verapamil | 1978 |
[Anti-hypertensive effect of intravenous verapamil in rats with experimental arterial hypertension].
Topics: Animals; Blood Pressure; Heart Rate; Hypertension; Injections, Intravenous; Rats; Verapamil | 1978 |
[Influence of verapamil in arterial hypertensive syndromes. Preliminary considerations].
Topics: Administration, Oral; Humans; Hypertension; Vascular Resistance; Verapamil | 1978 |
[Behavior of plasma renin activity (PRA) after administration of a calcium antagonist].
Topics: Adolescent; Adult; Calcium; Electrolytes; Female; Humans; Hypertension; Male; Middle Aged; Renin; Ve | 1978 |
[Therapy of hypertensive crises].
Topics: Acute Disease; Adrenal Gland Neoplasms; Antihypertensive Agents; Clonidine; Diazoxide; Dihydralazine | 1977 |
[Injectable verapamil as an arterial hypotensive drug--experimental study].
Topics: Animals; Dogs; Hypertension; Isoproterenol; Myocardial Contraction; Verapamil | 1977 |
Verapamil and diazoxide antagonism of agonist-induced contractions of aortic strips from normal and spontaneously hypertensive rats (SHR).
Topics: Animals; Aorta, Thoracic; Diazoxide; Hypertension; In Vitro Techniques; Methoxamine; Muscle Contract | 1975 |
[Verapamil in the treatment of hypertensive attacks].
Topics: Adult; Aged; Drug Evaluation; Female; Humans; Hypertension; Male; Middle Aged; Verapamil | 1975 |
[Influence of anti-arrhythmia agents on electrolyte metabolism].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Coronary Disease; Female; Gallopamil; Humans; Hypertension; Mal | 1976 |
Mitochondrial ATP synthase regulation in heart: defects in hypertension are restored after treatment with captopril.
Topics: Animals; Captopril; Cardiotonic Agents; Cells, Cultured; Electric Stimulation; Hypertension; Isoprot | 1992 |
The antihypertensive effect of verapamil in patients with chronic renal failure.
Topics: Antihypertensive Agents; Diet, Sodium-Restricted; Dietary Proteins; Humans; Hypertension; Kidney Fai | 1992 |
Effects of graded exercise on blood pressure, heart rate, and plasma hormones in cardiac transplant recipients before and during antihypertensive therapy.
Topics: Adult; Atrial Natriuretic Factor; Blood Pressure; Cyclic GMP; Drug Therapy, Combination; Enalapril; | 1992 |
Failure of verapamil and diltiazem to attenuate the pressor response to hypothalamic stimulation: a possible mechanism.
Topics: Animals; Aorta, Thoracic; Blood Pressure; Desoxycorticosterone; Diltiazem; Electric Stimulation; Fem | 1992 |
Calcium entry blockade and agonist-mediated vasoconstriction in hypertensive patients.
Topics: Adrenergic alpha-Agonists; Humans; Hypertension; Nicardipine; Vasoconstrictor Agents; Verapamil | 1990 |
Combined effect of dietary calcium and calcium antagonists on blood pressure reduction in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Calcium, Dietary; Hypertension; Male; Nifedipine; | 1992 |
Concentration/effect relationship and enantioselective analysis of verapamil in hypertensive patients.
Topics: Administration, Oral; Adult; Blood Pressure; Dose-Response Relationship, Drug; Female; Humans; Hyper | 1992 |
[Comparative study of the action of Finoptin, Korinfar and Capoten in patients with stage II hypertensive disease].
Topics: Adult; Aged; Captopril; Female; Humans; Hypertension; Male; Middle Aged; Myocardial Contraction; Nif | 1992 |
Cardiac and vascular effects of chronic angiotensin converting enzyme inhibition at subantihypertensive doses.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Newborn; Bridged Bicyclo Compounds; Brid | 1992 |
Effects of angiotensin converting enzyme inhibitors and calcium antagonists on atrial natriuretic peptide release and action and on albumin excretion rate in hypertensive insulin-dependent diabetic patients.
Topics: Adult; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Calcium Cha | 1992 |
[The efficacy of a 4-year course of drug treatment for patients with juvenile hypertension].
Topics: Adolescent; Adult; Drug Evaluation; Drug Resistance; Hemodynamics; Humans; Hypertension; Nifedipine; | 1992 |
Concentration/effect analysis of antihypertensive drugs: single dose and steady state response to verapamil.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Humans; Hype | 1992 |
Cerebral vascular changes associated with hemorrhagic stroke in hypertension.
Topics: Aging; Animals; Cerebral Arteries; Cerebral Hemorrhage; Cerebrovascular Circulation; Cerebrovascular | 1992 |
[Are all calcium antagonists alike?].
Topics: Calcium Channel Blockers; Coronary Disease; Diltiazem; Humans; Hypertension; Nifedipine; Verapamil | 1992 |
Chronic hydrochlorothiazide and verapamil effects on motor activity in hypertensive baboons.
Topics: Animals; Blood Pressure; Drug Interactions; Hydrochlorothiazide; Hypertension; Male; Motor Activity; | 1992 |
[Isoptin in cardiologic practice].
Topics: Arrhythmias, Cardiac; Arteriosclerosis; Dose-Response Relationship, Drug; Drug Evaluation; Drug Moni | 1992 |
[Verapamil-induced gingivitis hypertrophica: a clinical case].
Topics: Adult; Biopsy; Fibromatosis, Gingival; Gingiva; Gingival Hypertrophy; Humans; Hypertension; Male; Ve | 1992 |
Stevens-Johnson syndrome induced by verapamil.
Topics: Female; Humans; Hypertension; Middle Aged; Stevens-Johnson Syndrome; Verapamil | 1992 |
Evaluation of cardiac performance in hypertension.
Topics: Adult; Coronary Angiography; Echocardiography; Heart; Humans; Hypertension; Injections, Intravenous; | 1992 |
Hypertrichosis and verapamil.
Topics: Humans; Hypertension; Hypertrichosis; Male; Middle Aged; Verapamil | 1991 |
Cardiovascular and renal actions of AHR-16303B, an antagonist of 5-HT2 receptors and calcium channels, in hypertensive and normotensive rats.
Topics: Administration, Oral; Animals; Blood Pressure; Calcium Channel Blockers; Cardiovascular System; Dose | 1991 |
Altered inotropic responses in diabetic cardiomyopathy and hypertensive-diabetic cardiomyopathy.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 1991 |
Protective effects of calcium antagonists on energy and substrate metabolism during ischemia and reperfusion in hypertensive myocardial hypertrophy.
Topics: Adenosine Triphosphate; Animals; Calcium Channel Blockers; Cardiomegaly; Energy Metabolism; Hyperten | 1991 |
Effects of ouabain and verapamil on endothelin-1-induced contraction of mesenteric artery in young spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Body Weight; Endothelins; Heart Rate; Hypertension; In Vitro Techniques; Is | 1991 |
Verapamil and nifedipine in combination for the treatment of hypertrophy heart disease.
Topics: Adrenal Gland Diseases; Blood Pressure; Cardiovascular Diseases; Drug Therapy, Combination; Humans; | 1991 |
[Evaluation of verapamil for hypertension by an isometric exercise test].
Topics: Blood Pressure; Delayed-Action Preparations; Evaluation Studies as Topic; Exercise Test; Humans; Hyp | 1991 |
Verapamil in major depression?
Topics: Aged; Aged, 80 and over; Depressive Disorder; Female; Humans; Hypertension; Life Change Events; Neur | 1991 |
Efficacy of intravenous verapamil in arterial hypertension refractory to three-step antihypertensive therapy.
Topics: Adult; Antihypertensive Agents; Clonidine; Echocardiography; Female; Hemodynamics; Humans; Hydrochlo | 1991 |
Negative inotropic activity of the calcium antagonists isradipine, nifedipine, diltiazem, and verapamil in diseased human myocardium.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Depression, Chemical; Diltiazem; Dose-Response Re | 1991 |
Verapamil and left ventricular hypertrophy.
Topics: Cardiomegaly; Humans; Hypertension; Verapamil | 1991 |
Regression of left ventricular hypertrophy in hypertensive heart transplant recipients treated with enalapril, furosemide, and verapamil.
Topics: Adult; Cardiomegaly; Echocardiography; Electrocardiography; Enalapril; Female; Furosemide; Heart Tra | 1991 |
Acute toxic effects of sustained-release verapamil in chronic renal failure.
Topics: Delayed-Action Preparations; Female; Humans; Hypertension; Kidney Failure, Chronic; Male; Middle Age | 1991 |
[Effect of tetrandrine and verapamil on left ventricular diastolic and systolic function in essential hypertension].
Topics: Adult; Aged; Alkaloids; Benzylisoquinolines; Calcium Channel Blockers; Echocardiography; Female; Hum | 1991 |
Control of hypertension by verapamil enhances renal damage in a rat remnant kidney model.
Topics: Animals; Blood Pressure; Female; Hypertension; Kidney; Nephrectomy; Organ Size; Proteinuria; Rats; R | 1991 |
Lithium and calcium channel blockers: possible neurotoxicity.
Topics: Bipolar Disorder; Drug Therapy, Combination; Female; Humans; Hypertension; Lithium Carbonate; Middle | 1991 |
The influence of age on the pharmacokinetics of verapamil.
Topics: Adult; Aged; Aging; Body Weight; Chromatography, High Pressure Liquid; Female; Half-Life; Humans; Hy | 1991 |
[Beta-adrenoblockaders and calcium antagonists in the treatment of patients with ischemic heart disease combined with hypertension].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aging; Calcium Channel Blockers; Coronary Disease; Drug Ev | 1990 |
Verapamil in major (psychotic) depression.
Topics: Aged; Aged, 80 and over; Depressive Disorder; Female; Humans; Hypertension; Verapamil | 1991 |
Antihypertensive treatment and vessel wall properties of large arteries.
Topics: Adult; Aged; Antihypertensive Agents; Arteries; Arteriosclerosis; Benzopyrans; Carotid Arteries; Eth | 1991 |
Heterogeneous interference of nicardipine, verapamil, and diltiazem with forearm arteriolar responsiveness to adrenergic stimulation in hypertensive patients.
Topics: Arterioles; Diltiazem; Female; Forearm; Humans; Hypertension; Lower Body Negative Pressure; Male; Ni | 1991 |
Calcium entry blockade and agonist-mediated forearm vasoconstriction in hypertensive patients. Difference between nicardipine and verapamil.
Topics: Angiotensin II; Forearm; Humans; Hypertension; Lower Body Negative Pressure; Nicardipine; Phentolami | 1991 |
[Assessment of left ventricular diastolic function of the hypertensive heart using Doppler echocardiography method before and after intravenous administration of verapamil].
Topics: Adult; Aged; Diastole; Echocardiography, Doppler; Female; Heart Ventricles; Humans; Hypertension; In | 1991 |
[The hemodynamic reactions of hypertension patients taking the calcium antagonists finoptin and korinfar].
Topics: Adult; Drug Evaluation; Female; Heart; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Nifedi | 1990 |
[Cardil (diltiazem) in the treatment of patients with ischemic heart disease and hypertension].
Topics: Coronary Disease; Diltiazem; Drug Evaluation; Hemodynamics; Humans; Hypertension; Nifedipine; Verapa | 1990 |
[The effects of slow-release verapamil in relation to plasma concentration in aged hypertensives. A study with continuous monitoring of arterial pressure and electrocardiogram].
Topics: Aged; Blood Pressure; Blood Pressure Monitors; Delayed-Action Preparations; Electrocardiography, Amb | 1990 |
Effect of intravenous infusion of verapamil in patients of severe hypertension.
Topics: Adult; Aged; Blood Pressure; Female; Humans; Hypertension; Infusions, Intravenous; Injections, Intra | 1990 |
[Variants of hemodynamic reactions to the calcium antagonist finoptin in patients with hypertension].
Topics: Adult; Antihypertensive Agents; Blood Pressure; Cardiac Output; Depression, Chemical; Female; Hemody | 1990 |
[Role of external calcium on the growth of aortic smooth muscle cells in SHR].
Topics: Angiotensin II; Animals; Aorta; Calcium; Cells, Cultured; Hypertension; Mitosis; Muscle Development; | 1990 |
Hypertensive-diabetic cardiomyopathy in rats.
Topics: Analysis of Variance; Animals; Biomechanical Phenomena; Cardiomyopathies; Contractile Proteins; Diab | 1990 |
Calcium inhibition of glycolysis contributes to ischaemic injury.
Topics: Animals; Calcium; Coronary Disease; Glycolysis; Hypertension; In Vitro Techniques; Myocardial Reperf | 1990 |
Effects of verapamil and carbon monoxide on blood pressure and heart mass in the spontaneously hypertensive rat.
Topics: Animals; Blood Pressure; Carbon Monoxide; Cardiomegaly; Dose-Response Relationship, Drug; Heart; Hea | 1990 |
Left ventricular hypertrophy in hypertension.
Topics: Aged; Atenolol; Cardiomegaly; Humans; Hypertension; Middle Aged; Placebos; Verapamil | 1990 |
Improvement in left ventricular hypertrophy and left ventricular diastolic function following verapamil therapy in mild to moderate hypertension.
Topics: Adult; Aged; Cardiomegaly; Diastole; Echocardiography, Doppler; Heart Septum; Humans; Hypertension; | 1990 |
[Washout rate in patients with hypertrophic cardiomyopathy and hypertensive cardiac hypertrophy].
Topics: Cardiomegaly; Cardiomyopathy, Hypertrophic; Echocardiography; Exercise Test; Female; Heart; Humans; | 1990 |
Foridone and other calcium antagonists in the treatment of essential hypertension.
Topics: Antihypertensive Agents; Binding, Competitive; Blood Pressure; Calcium Channel Blockers; Calcium Cha | 1990 |
Free radical generation, lipid peroxidation and essential fatty acids in uncontrolled essential hypertension.
Topics: Angiotensin II; Antihypertensive Agents; Endothelium, Vascular; Epoprostenol; Fatty Acids, Essential | 1990 |
The effect of calcium channel blockers on the cyclosporine dose requirement in renal transplant recipients.
Topics: Adult; Calcium Channel Blockers; Cyclosporins; Drug Interactions; Drug Therapy, Combination; Female; | 1990 |
Verapamil in antihypertensive treatment of patients on renal replacement therapy--clinical implications and pharmacokinetics.
Topics: Adult; Blood Pressure; Delayed-Action Preparations; Female; Heart Rate; Hemofiltration; Humans; Hype | 1990 |
Direct vascular and myocardial effects of nisoldipine.
Topics: Adult; Aged; Blood Pressure; Brachial Artery; Cardiac Output; Coronary Vessels; Female; Heart; Human | 1990 |
In vitro caffeine induced aortic smooth muscle reactivity in rat.
Topics: Animals; Aorta; Caffeine; Hypertension; In Vitro Techniques; Magnesium; Male; Muscle, Smooth, Vascul | 1990 |
Antihypertensive properties of the novel calcium antagonist (1S,2S)-2-[2-[[3-(2-benzimidazolyl)propyl]methylamino] ethyl]-6- fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphthyl methoxyacetate dihydrochloride in rat models of hypertension. Comparison with ver
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Blood Pressure; Calcium Channel Blockers; Desoxyco | 1990 |
Effect of calcium antagonists on aortae isolated from normotensive and hypertensive rats: relaxation and calcium influx blockade.
Topics: Animals; Aorta; Calcium; Diltiazem; Female; Hypertension; In Vitro Techniques; Male; Nitrendipine; R | 1990 |
Time course of cardiac performance in hypertensive patients after verapamil assessed by nuclear ventriculography.
Topics: Administration, Oral; Adult; Blood Pressure; Electrocardiography; Female; Heart Ventricles; Humans; | 1990 |
[Adhesion, migration and phagocytic behavior of blood granulocytic neutrophils from the rat and humans in essential hypertension].
Topics: Adult; Animals; Cell Adhesion; Cells, Cultured; Chemotaxis, Leukocyte; Humans; Hypertension; Leukocy | 1990 |
Calcium channel blocking drugs. Part II: Clinical applications.
Topics: Angina Pectoris; Angina Pectoris, Variant; Angina, Unstable; Arrhythmias, Cardiac; Calcium Channel B | 1985 |
Verapamil pharmacodynamics and disposition in obese hypertensive patients.
Topics: Adult; Blood Pressure; Electrocardiography; Female; Humans; Hypertension; Infusions, Intravenous; Ma | 1988 |
Hypertension with orthostatic hypotension: interest of verapamil.
Topics: Adult; Aged; Blood Pressure; Domperidone; Female; Follow-Up Studies; Heart Rate; Humans; Hypertensio | 1987 |
Disparate effects of angiotensin converting enzyme inhibitor and calcium blocker treatment on the preservation of renal structure and function following subtotal nephrectomy or streptozotocin-induced diabetes in the rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium Channel Blockers; Diabetes Mellitus, Expe | 1987 |
Calcium channel blockade with verapamil. Effects on blood pressure, renal, and myocardial adrenergic, cholinergic, and calcium channel receptors in inbred Dahl hypertension-sensitive (S/JR) and hypertension-resistant (R/JR) rats.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Disease Susceptibility; Heart Rate; Hypertension; | 1988 |
Is the increased responsiveness to verapamil in the forearm resistance vessels of patients with hypertension a consequence of structural change?
Topics: Dose-Response Relationship, Drug; Forearm; Humans; Hypertension; Models, Biological; Nitroprusside; | 1988 |
Calcium antagonists into the nineties: appraisal and future trends. Verapamil satellite symposium to the 25th anniversary International Symposium on Calcium Antagonists. Basel, Switzerland, February 12, 1988.
Topics: Animals; Calcium Channel Blockers; Humans; Hypertension; Verapamil | 1989 |
Noninvasive blood pressure monitoring evaluation of verapamil slow-release 240-mg antihypertensive effectiveness.
Topics: Blood Pressure; Blood Pressure Determination; Circadian Rhythm; Delayed-Action Preparations; Evaluat | 1989 |
Treatment of mild to moderate hypertension with verapamil slow-release in outpatients. Collaborative Group of the Spanish League for the Fight Against Hypertension.
Topics: Aged; Aging; Blood Pressure; Delayed-Action Preparations; Female; Heart Rate; Humans; Hypertension; | 1989 |
Serum gonadotropins in postmenopausal women after long-term verapamil treatment.
Topics: Aged; Blood Pressure; Female; Follicle Stimulating Hormone; Gonadotropins; Humans; Hypertension; Lut | 1989 |
Treatment of resistant hypertension: 3 years of follow-up with the combination of verapamil and methyldopa.
Topics: Adult; Blood Pressure; Drug Resistance; Drug Therapy, Combination; Electrocardiography; Female; Hear | 1989 |
Verapamil versus nicardipine in rest and exercise hypertension.
Topics: Blood Pressure; Exercise; Heart Rate; Humans; Hypertension; Nicardipine; Verapamil | 1989 |
Development of hypertension and life span in stroke-prone spontaneously hypertensive rats during oral long-term treatment with various antihypertensive drugs.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cerebrovascular Disorders; Dihydralazine; Heart; H | 1989 |
[Regression of hypertension-induced left heart enlargement in an endurance athlete treated with verapamil RR].
Topics: Blood Pressure; Cardiac Volume; Cardiomegaly; Echocardiography; Exercise Test; Follow-Up Studies; Hu | 1989 |
Calcium entry blockade and alpha-adrenergic vascular reactivity in human beings: differences between nicardipine and verapamil.
Topics: Adult; Female; Forearm; Histamine; Humans; Hypertension; Male; Middle Aged; Nicardipine; Norepinephr | 1989 |
[Calcium antagonists vs ACE inhibitors in the treatment of essential arterial hypertension in the aged].
Topics: Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Diltiazem; Dr | 1989 |
Erythrocyte cation transport in obesity, hypertension, and during antihypertensive drug therapy.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Cations; Erythrocytes | 1989 |
[Therapy of acute myocardial infarct].
Topics: Acidosis; Analgesics; Atropine; Bicarbonates; Bradycardia; Cardiac Complexes, Premature; Critical Ca | 1985 |
[New approach to the development of Ca antagonists].
Topics: Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Coronary Disease; Humans; Hypertension; Nic | 1989 |
[Calcium antagonists in the treatment of hypertension].
Topics: Calcium Channel Blockers; Diltiazem; Humans; Hypertension; Nicardipine; Nifedipine; Verapamil | 1989 |
[Calcium antagonists (finoptin and senzit) in the treatment of cerebrovascular disorders].
Topics: Adult; Age Factors; Arteriosclerosis; Cerebrovascular Disorders; Drug Evaluation; Fendiline; Humans; | 1989 |
[Combination therapy with isosorbide dinitrate and verapamil in patients with coronary heart disease and hypertension: effect on blood pressure, ischemia and left ventricular function].
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Cardiac Output; Coronary Circulation; Coronary Disease | 1989 |
[The use of calcium antagonists for treating hypertension].
Topics: Calcium Channel Blockers; Diltiazem; Humans; Hypertension; Nifedipine; Verapamil | 1989 |
[Nifedipine and verapamil in the treatment of ischemic heart disease and hypertension].
Topics: Angina Pectoris; Coronary Disease; Dose-Response Relationship, Drug; Humans; Hypertension; Nifedipin | 1989 |
The effects of calcium channel blockade on blood pressure and calcium metabolism.
Topics: Blood Pressure; Calcium; Calcium Channel Blockers; Diet, Sodium-Restricted; Humans; Hypertension; Ve | 1989 |
[The efficacy of calcium antagonists in circulatory failure in elderly patients with hypertension].
Topics: Aged; Calcium Channel Blockers; Digoxin; Dose-Response Relationship, Drug; Drug Evaluation; Drug The | 1989 |
Hydrochlorothiazide is not additive to verapamil in treating essential hypertension.
Topics: Blood Pressure; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; | 1989 |
Calcium antagonists as first-choice therapy for low-renin essential hypertension.
Topics: Antihypertensive Agents; Biomarkers; Calcium Channel Blockers; Cardiovascular System; Humans; Hypert | 1989 |
[The use of digoxin, lasix and finoptin in treating circulatory failure in hypertension].
Topics: Aged; Aldosterone; Digoxin; Drug Therapy, Combination; Female; Furosemide; Heart Failure; Humans; Hy | 1989 |
Left ventricular diastolic filling improvement obtained by intravenous verapamil in mild to moderate essential hypertension: a complex effect.
Topics: Adult; Aged; Diastole; Female; Heart Ventricles; Hemodynamics; Humans; Hypertension; Infusions, Intr | 1989 |
Effects of ketanserin, verapamil and diltiazem on vascular sympathetic nerve activity in hypertension.
Topics: Animals; Blood Pressure; Diltiazem; Dose-Response Relationship, Drug; Electric Stimulation; Hyperten | 1989 |
[Effect of digoxin, furosemide and finoptin on the central hemodynamics in hypertension].
Topics: Aged; Chronic Disease; Digoxin; Drug Evaluation; Drug Therapy, Combination; Female; Furosemide; Hear | 1989 |
Comparative effects of verapamil and nitroprusside on left ventricular function in patients with hypertension.
Topics: Adult; Cardiac Catheterization; Echocardiography; Female; Ferricyanides; Heart; Humans; Hypertension | 1989 |
[Acute hypotensive effect after sublingual verapamil].
Topics: Administration, Sublingual; Adult; Aged; Blood Pressure; Female; Humans; Hypertension; Male; Middle | 1989 |
[Therapeutic effect of verapamil in hypertension: an analysis of 52 cases].
Topics: Adult; Female; Humans; Hypertension; Male; Middle Aged; Nifedipine; Verapamil | 1989 |
Studies of a new fatty acid analog (DMIVN) in hypertensive rats and the effect of verapamil using ARG microimaging.
Topics: Animals; Autoradiography; Fatty Acids, Unsaturated; Hypertension; Iodine Radioisotopes; Myocardium; | 1989 |
Effects of calcium antagonists on membrane fluidity in hypertension--an electron spin resonance study.
Topics: Adult; Animals; Diltiazem; Electron Spin Resonance Spectroscopy; Erythrocyte Membrane; Female; Human | 1988 |
[Effect of enalapril, furosemide and verapamil on cyclosporin concentration in whole blood].
Topics: Adult; Cyclosporins; Enalapril; Female; Furosemide; Heart Transplantation; Humans; Hypertension; Lun | 1988 |
Calcium antagonists and hypertension.
Topics: Aging; Aniline Compounds; Animals; Blood Pressure; Calcium Channel Blockers; Catecholamines; Dihydro | 1988 |
Clinical pharmacology of vasodilator drugs.
Topics: Adrenergic alpha-Antagonists; Calcium Channel Blockers; Coronary Disease; Humans; Hydralazine; Hyper | 1985 |
Prevention of atheromatous heart disease.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aloe; Angina Pectoris; Blood Glucose; Cholesterol; Cholest | 1985 |
Treatment of hypertension with calcium antagonists.
Topics: Adrenergic beta-Antagonists; Aged; Calcium Channel Blockers; Costs and Cost Analysis; Diuretics; Fem | 1985 |
Comparison of calcium antagonists with other antihypertensive agents.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Calcium Channel Blockers; Humans; Hypertension | 1986 |
Paradoxical effect of sodium restriction on blood pressure in people on slow-channel calcium blocking drugs.
Topics: Blood Pressure; Diet, Sodium-Restricted; Humans; Hypertension; Nifedipine; Time Factors; Verapamil | 1986 |
Verapamil, low-sodium regimens, and blood pressure.
Topics: Adult; Blood Pressure; Diet, Sodium-Restricted; Female; Humans; Hypertension; Male; Middle Aged; Ver | 1986 |
Verapamil antagonizes forearm vasoconstriction mediated by selective alpha 1- and alpha 2-agonists in hypertensive patients.
Topics: Adrenergic alpha-Agonists; Adult; Azepines; Female; Forearm; Humans; Hypertension; Male; Methoxamine | 1986 |
[Follow-up study of 48 athletes with stage I hypertension with and without pharmacotherapy].
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Blood Pressure; Cardiac Volume; Echocar | 1988 |
Effect of calcium entry blockers on blood pressure and vasoconstrictor responses to alpha-1 adrenoceptor stimulation in conscious spontaneously hypertensive rats.
Topics: Administration, Oral; Adrenergic alpha-Agonists; Animals; Aorta, Thoracic; Binding, Competitive; Blo | 1987 |
Chronic hypotensive effects of verapamil in angiotensin hypertension are steroid independent.
Topics: Aldosterone; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Chronic Disease; Dogs | 1989 |
[Arterial hypertension with orthostatic hypotension caused by dysregulation of the baroreflex. Correction with domperidone and verapamil].
Topics: Domperidone; Drug Therapy, Combination; Humans; Hypertension; Hypotension, Orthostatic; Male; Middle | 1986 |
[Treatment of hypertension with a delayed-action form of verapamil and its effect on hypertrophy and function of the left ventricle].
Topics: Aged; Cardiomegaly; Delayed-Action Preparations; Female; Heart; Hemodynamics; Humans; Hypertension; | 1987 |
[Hemodynamic effect of a combination of prazosin with cardiac depressants in the treatment of hypertension].
Topics: Anti-Arrhythmia Agents; Celiprolol; Clonidine; Drug Evaluation; Drug Synergism; Drug Therapy, Combin | 1988 |
Effects of long-term verapamil treatment on blood pressure, cardiac hypertrophy and collagen metabolism in spontaneously hypertensive rats.
Topics: Animals; Aorta; Blood Pressure; Cardiomegaly; Collagen; Female; Heart; Hydroxyproline; Hypertension; | 1985 |
The effect of long-term verapamil treatment on the secretion of cortisol and aldosterone in subjects with normal and high blood pressure.
Topics: Adrenal Cortex; Adrenocorticotropic Hormone; Adult; Aldosterone; Female; Humans; Hydrocortisone; Hyp | 1985 |
Adrenergic activity and left ventricular function during treatment of essential hypertension with calcium antagonists.
Topics: Adult; Blood Pressure; Epinephrine; Female; Heart; Heart Rate; Humans; Hypertension; Isoproterenol; | 1986 |
[Calcium channel blockers and angiotensin converting enzyme inhibitors in the treatment of high blood pressure].
Topics: Calcium Channel Blockers; Captopril; Drug Interactions; Enalapril; Humans; Hypertension; Nifedipine; | 1986 |
[Effect of the treatment with captopril and verapamil on left-ventricular function in patients with primary arterial hypertension].
Topics: Adult; Captopril; Female; Heart Ventricles; Humans; Hypertension; Male; Middle Aged; Myocardial Cont | 1988 |
Increased cyclosporine blood concentrations due to verapamil administration.
Topics: Creatinine; Cyclosporins; Delayed-Action Preparations; Drug Interactions; Humans; Hypertension; Kidn | 1988 |
The effect of alkaline pH and transmural pressure on arterial constriction and membrane potential of hypertensive cerebral arteries.
Topics: Animals; Carbon Dioxide; Cerebral Arteries; Hydrogen-Ion Concentration; Hypertension; Membrane Poten | 1987 |
Once-daily verapamil in hypertension: intra-arterial recording of blood pressure.
Topics: Adult; Blood Pressure; Delayed-Action Preparations; Female; Humans; Hypertension; Male; Middle Aged; | 1988 |
Diuretics and calcium antagonists in hypertension.
Topics: Bendroflumethiazide; Diuretics; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension | 1988 |
A combination of verapamil, captopril, and diuretic in the treatment of severe hypertension.
Topics: Adult; Captopril; Diuretics; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle A | 1988 |
[Treatment of human arterial hypertension. Role of calcium channel inhibitors].
Topics: Antihypertensive Agents; Calcium Channel Blockers; Drug Therapy, Combination; Emergencies; Humans; H | 1985 |
Nifedipine in severely hypertensive patients with congestive heart failure and preserved ventricular systolic function.
Topics: Aged; Cardiomegaly; Electrocardiography; Female; Heart Failure; Heart Ventricles; Humans; Hypertensi | 1985 |
Verapamil withdrawal as a possible cause of myocardial infarction in a hypertensive woman with a normal coronary angiogram.
Topics: Adult; Coronary Angiography; Female; Humans; Hypertension; Myocardial Infarction; Substance Withdraw | 1988 |
Liver injury due to verapamil.
Topics: Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Female; Humans; Hypertension; Mid | 1988 |
No metabolic side effects of long-term treatment with verapamil in hypertension.
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Humans; Hypertension; Lipids; Middle Aged; Prospective S | 1988 |
Relationships between verapamil plasma concentrations and its antihypertensive action.
Topics: Adult; Blood Pressure; Drug Evaluation; Drug Therapy, Combination; Electrocardiography; Female; Hear | 1988 |
[Calcium inhibitors and treatment of arterial hypertension].
Topics: Calcium Channel Blockers; Dihydropyridines; Diltiazem; Hypertension; Verapamil | 1988 |
Comparison of the cardiovascular effects of trans-diclofurime with different types of calcium antagonists in conscious spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Diltiazem; Heart Rate; Hemodynamics; Hypertension | 1988 |
Antihypertensive effects of intravenous administration of benidipine hydrochloride and some other calcium antagonists in conscious, spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diltiazem; Dose-Response | 1988 |
Hypertensive effects of calcium infusion in subjects with normotension and hypertension.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Blood Pressure; Calcium; Female; Humans; Hypercalcemia; | 1988 |
Effects of verapamil and nifedipine on systemic hemodynamics in spontaneously hypertensive rats.
Topics: Animals; Consciousness; Dose-Response Relationship, Drug; Hemodynamics; Hypertension; Male; Nifedipi | 1988 |
Effect of verapamil and sodium nitroprusside on hindlimb vascular resistance in New Zealand genetically hypertensive and Japanese spontaneously hypertensive rats.
Topics: Animals; Ferricyanides; Hindlimb; Hypertension; Nitroprusside; Rats; Rats, Inbred SHR; Rats, Inbred | 1988 |
[Changes in the functional level of baroreceptors under the action of verapamil in arterial hypertension].
Topics: Adult; Blood Pressure; Female; Humans; Hypertension; Male; Middle Aged; Phenylephrine; Pressorecepto | 1988 |
Effect of calcium blocking agent verapamil on blood pressure, ventricular contractility, parathyroid hormone, calcium and phosphorus in plasma, catecholamines, corticosterone and plasma renin activity in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Calcium; Catecholamines; Corticosterone; Hypertension; Male; Myocardial Con | 1988 |
The combination of verapamil and captopril in the treatment of essential hypertension.
Topics: Captopril; Drug Therapy, Combination; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; P | 1987 |
Verapamil caused depression, confusion, and impotence.
Topics: Cognition Disorders; Confusion; Depressive Disorder; Erectile Dysfunction; Female; Humans; Hypertens | 1988 |
[Hypotensive effect of furosemide and verapamil in the elderly].
Topics: Aged; Blood Pressure; Furosemide; Humans; Hypertension; Middle Aged; Verapamil | 1988 |
[Calcium metabolism in arterial hypertension. II. Changes in thrombocyte sensitivity to verapamil].
Topics: Adult; Aged; Blood Platelets; Calcium; Drug Interactions; Epinephrine; Humans; Hypertension; In Vitr | 1988 |
The effect of verapamil on cerebral cortical and spinal cord blood flow during proximal descending thoracic aortic occlusion.
Topics: Animals; Aorta, Thoracic; Cerebral Cortex; Constriction; Dogs; Hypertension; Hypotension; Ischemia; | 1988 |
Verapamil in the treatment of severe postpartum hypertension.
Topics: Adult; Blood Pressure; Female; Heart Rate; Humans; Hypertension; Pregnancy; Prospective Studies; Pro | 1988 |
Vasoconstrictor effects of endogenous digitalis-like factors extracted from urine of hypertensive patients.
Topics: Animals; Arteries; Blood Proteins; Cardenolides; Digoxin; Dogs; Ear, External; Epinephrine; Humans; | 1987 |
Calcium channel antagonists--cardiovascular therapy for the eighties?
Topics: Angina Pectoris; Arrhythmias, Cardiac; Calcium Channel Blockers; Cardiovascular Diseases; Diltiazem; | 1986 |
Effects of calcium entry blockers on blood pressure and heart rate in neurogenic hypertensive dogs.
Topics: Animals; Bepridil; Blood Pressure; Calcium Channel Blockers; Denervation; Diltiazem; Dogs; Female; H | 1987 |
Similarities and differences in the antihypertensive effect of two calcium antagonist drugs, verapamil and nifedipine.
Topics: Adult; Blood Pressure; Echocardiography; Epinephrine; Female; Heart Rate; Humans; Hypertension; Male | 1986 |
Once a day verapamil in essential hypertension.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Delayed-Action Preparations; Female; Humans; Hyperte | 1986 |
Antihypertensive drugs inhibit hypertension-associated aortic DNA synthesis in the rat.
Topics: Animals; Antihypertensive Agents; Captopril; DNA; Female; Hydralazine; Hypertension; Hypertension, R | 1986 |
Calcium metabolism in essential hypertensive patients treated by verapamil.
Topics: Adult; Aged; Calcium; Female; Humans; Hypertension; Male; Middle Aged; Parathyroid Hormone; Phosphat | 1986 |
Verapamil for hypertension.
Topics: Costs and Cost Analysis; Delayed-Action Preparations; Drug Interactions; Humans; Hypertension; Verap | 1987 |
Cardiovascular effects of verapamil in patients with essential hypertension.
Topics: Administration, Oral; Delayed-Action Preparations; Female; Hemodynamics; Humans; Hypertension; Injec | 1987 |
Can blood pressure reduction induced by slow calcium channel blockade (verapamil) be reversed by calcium infusion?
Topics: Adult; Blood Pressure; Calcium Gluconate; Gluconates; Heart Rate; Humans; Hypertension; Male; Middle | 1987 |
[Geometry and diastolic function of the left ventricle in light-to-moderate essential hypertension: effect of acute administration of verapamil].
Topics: Adult; Aged; Diastole; Echocardiography; Heart Ventricles; Hemodynamics; Humans; Hypertension; Middl | 1987 |
Ca2+ influx in spontaneously hypertensive rats is sensitive to calcium antagonists.
Topics: Animals; Aorta, Thoracic; Calcium; Calcium Channel Blockers; Hypertension; In Vitro Techniques; Male | 1987 |
Comparison of sustained release verapamil and hydrochlorothiazide in hypertension--effect on blood pressure and metabolic variables.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Cholesterol; Delayed-Action Preparations; Female; Humans | 1987 |
Assessment of 'once daily' verapamil for the treatment of hypertension using ambulatory, intra-arterial blood pressure recording.
Topics: Adult; Aged; Blood Pressure; Blood Pressure Determination; Delayed-Action Preparations; Drug Adminis | 1987 |
Efficacy of verapamil--hydrochlorothiazide-spironolactone therapy in hypertensive black patients.
Topics: Adult; Aged; Black People; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hydrochlorothi | 1987 |
Two factors associated with increased uptake of calcium in platelets from essential hypertensive patients.
Topics: Adult; Aged; Aged, 80 and over; Animals; Biological Transport, Active; Blood Platelets; Calcium; Fem | 1987 |
Plasma lipid profile in verapamil-treated hypertensive patients.
Topics: Cholesterol; Diabetes Mellitus, Type 2; Humans; Hypertension; Lipids; Lipoproteins, HDL; Lipoprotein | 1987 |
Serum ionized calcium--a predictor of therapeutic response to slow calcium channel blockade in essential hypertension.
Topics: Adult; Aged; Blood Pressure; Calcium; Delayed-Action Preparations; Heart Rate; Humans; Hypertension; | 1987 |
Hypertension therapy--an update.
Topics: Adult; Aged; Female; Humans; Hypertension; Male; Middle Aged; Verapamil | 1987 |
Neurotransmitter release, vascular responsiveness and their suppression by Ca-antagonist in perfused mesenteric vasculature of DOCA-salt hypertensive rats.
Topics: Animals; Desoxycorticosterone; Electric Stimulation; Hypertension; In Vitro Techniques; Male; Mesent | 1986 |
Verapamil pharmacodynamics and disposition in young and elderly hypertensive patients. Altered electrocardiographic and hypotensive responses.
Topics: Administration, Oral; Adult; Aged; Aging; Blood Pressure; Electrocardiography; Heart Rate; Humans; H | 1986 |
[Use of verapamil in essential hypertension].
Topics: Adult; Female; Humans; Hypertension; Male; Middle Aged; Verapamil | 1986 |
Nifedipine or verapamil counteracts hypertension in gravid ewes.
Topics: Animals; Blood Gas Analysis; Female; Hypertension; Nifedipine; Norepinephrine; Pre-Eclampsia; Pregna | 1986 |
Pharmacokinetics of conventional and slow-release verapamil.
Topics: Adult; Aged; Aged, 80 and over; Delayed-Action Preparations; Humans; Hypertension; Kinetics; Middle | 1986 |
[Characteristics of the effect of verapamil on blood circulation].
Topics: Adult; Aged; Blood Circulation; Drug Evaluation; Electrocardiography; Female; Hemodynamics; Humans; | 1986 |
The hemodynamics of calcium-channel antagonists in hypertension: vascular and myocardial responses.
Topics: Adult; Aged; Calcium Channel Blockers; Cardiovascular System; Female; Hemodynamics; Humans; Hyperten | 1987 |
Hypertension with marked left ventricular hypertrophy.
Topics: Aged; Cardiomyopathy, Hypertrophic; Female; Humans; Hypertension; Radionuclide Imaging; Verapamil | 1986 |
Dose initiation of calcium antagonists in the treatment of hypertension.
Topics: Adult; Aged; Aged, 80 and over; Calcium Channel Blockers; Delayed-Action Preparations; Female; Human | 1986 |
The effects of verapamil on renal blood flow, renal function, and neurohormonal profiles in patients with moderate to severe hypertension.
Topics: Adult; Aged; Female; Glomerular Filtration Rate; Humans; Hypertension; Kidney; Male; Middle Aged; Re | 1986 |
The effect of short-term oral verapamil on exercise hemodynamics and oxygen delivery in patients with hypertension.
Topics: Administration, Oral; Adult; Aged; Drug Administration Schedule; Female; Hemodynamics; Humans; Hyper | 1986 |
Enhanced calcium-sensitivity of erythrocytes in hypertension--calcium-induced changes of erythrocyte osmotic fragility in essential hypertension.
Topics: Adult; Calcium; Calmodulin; Diltiazem; Erythrocytes; Female; Humans; Hypertension; Male; Osmotic Fra | 1986 |
Effects of intravenous verapamil administration on left ventricular diastolic function in systemic hypertension.
Topics: Adolescent; Adult; Blood Pressure; Diastole; Female; Heart Rate; Heart Ventricles; Humans; Hypertens | 1987 |
Comparative effects on blood pressure of different calcium-blocking agents.
Topics: Aged; Blood Pressure; Calcium Channel Blockers; Diltiazem; Diuretics; Female; Humans; Hypertension; | 1986 |
[Experimental models of the use of calcium antagonists in arterial hypertension].
Topics: Animals; Blood Pressure; Heart Rate; Hypertension; Hypertension, Renovascular; Male; Nifedipine; Rat | 1986 |
Verapamil and norverapamil in plasma and breast milk during breast feeding.
Topics: Adult; Breast Feeding; Female; Humans; Hypertension; Infant; Infant Nutritional Physiological Phenom | 1987 |
Effect of a calcium antagonist: verapamil on resting blood pressure and pressor response to dynamic exercise.
Topics: Adult; Aldosterone; Blood Pressure; Catecholamines; Female; Heart Rate; Humans; Hypertension; Male; | 1985 |
Vasodilatory effect of nicardipine and verapamil in the forearm of hypertensive as compared with normotensive man.
Topics: Adult; Aged; Blood Pressure; Calcium Channel Blockers; Forearm; Humans; Hypertension; Middle Aged; N | 1985 |
The efficacy of a slow-release formulation of verapamil.
Topics: Delayed-Action Preparations; Humans; Hypertension; Verapamil | 1985 |
Calcium-channel blockers in acute hypertension.
Topics: Acute Disease; Blood Pressure; Calcium Channel Blockers; Costs and Cost Analysis; Emergencies; Heart | 1985 |
[Effect of calcium inhibitors on sympathetic activity].
Topics: Administration, Oral; Calcium; Epinephrine; Humans; Hypertension; Norepinephrine; Sympathetic Nervou | 1985 |
Exercise hemodynamics and oxygen delivery in human hypertension. Response to verapamil.
Topics: Adult; Aged; Blood Gas Analysis; Dose-Response Relationship, Drug; Female; Heart; Hemodynamics; Huma | 1986 |
On the mechanism of the anti-hypertensive effect of Ca++-blockers.
Topics: Anesthesia; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dogs; Heart | 1986 |
A symposium: Calcium antagonists in hypertension--focus on verapamil. November 15-17, 1985, Mexico City, Mexico. November 27, 1984, Bangkok, Thailand.
Topics: Animals; Calcium Channel Blockers; Humans; Hypertension; Verapamil | 1986 |
Left ventricular function after a single large dose of verapamil.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Cardiac Output; Drug Evaluation; Female; Heart; H | 1986 |
Efficacy of verapamil in patients resistant to other antihypertensive therapy.
Topics: Adult; Angiotensin II; Blood Pressure; Electrocardiography; Female; Humans; Hypertension; Infusions, | 1986 |
Short- and long-term treatment of mild to moderate hypertension with verapamil.
Topics: Blood Pressure; Drug Administration Schedule; Drug Therapy, Combination; Female; Heart Rate; Humans; | 1986 |
Calcium antagonists in systemic hypertension: focus on verapamil. Concluding remarks. Part I.
Topics: Animals; Calcium; Calcium Channel Blockers; Humans; Hypertension; Renin-Angiotensin System; Research | 1986 |
Twice-daily administration of oral verapamil in the treatment of essential hypertension.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Drug Administration Schedule; Drug Evaluation; Fe | 1986 |
Functional differences in blood vessels determined from studies with calcium-channel blockers. Functional changes in forearm resistance vessels of men with primary hypertension.
Topics: Calcium Channel Blockers; Elbow; Forearm; Hand; Humans; Hypertension; Male; Muscle Contraction; Musc | 1985 |
[Treatment of arterial hypertension with calcium antagonists].
Topics: Blood Volume; Cardiac Output; Heart Rate; Humans; Hypertension; Nifedipine; Vascular Resistance; Ver | 1985 |
Verapamil effect on renal function of normotensive and hypertensive rats.
Topics: Absorption; Animals; Blood Pressure; Calcium; Glomerular Filtration Rate; Hemodynamics; Hypertension | 1985 |
Glomerular response to verapamil by isolated spontaneously hypertensive rat kidney.
Topics: Animals; Glomerular Filtration Rate; Hypertension; Kidney Glomerulus; Male; Norepinephrine; Rats; Ra | 1985 |
Clearance-based oral drug interaction between verapamil and metoprolol and comparison with atenolol.
Topics: Administration, Oral; Angina Pectoris; Atenolol; Drug Interactions; Drug Therapy, Combination; Femal | 1985 |
[Verapamil 240 mg--effective blood pressure reduction by a single dose?].
Topics: Blood Pressure; Delayed-Action Preparations; Drug Administration Schedule; Female; Humans; Hypertens | 1985 |
Enhanced myogenic depolarization in hypertensive cerebral arterial muscle.
Topics: Action Potentials; Animals; Cerebral Arteries; Electrophysiology; Hypertension; Male; Membrane Poten | 1985 |
[Antihypertensive effect of long-term oral therapy with verapamil in elderly patients].
Topics: Aged; Female; Humans; Hypertension; Male; Verapamil | 1985 |
[Treatment of essential hypertension (hypertensive disease) with verapamil and hydrochlorothiazide].
Topics: Adult; Blood Pressure; Chronic Disease; Drug Evaluation; Drug Therapy, Combination; Female; Humans; | 1985 |
Hemodynamic effects of calcium channel blockers at rest and during exercise in essential hypertension.
Topics: Adult; Calcium Channel Blockers; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Nifedipine; | 1985 |
[Arrhythmias in the elderly patients: atrial fibrillation].
Topics: Aged; Aging; Atrial Fibrillation; Coronary Disease; Diltiazem; Humans; Hypertension; Mitral Valve In | 1985 |
[Verapamil for regulation of cardiac rhythm disorders. Experience with our own patients].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Circulation; Cardiac Complexes, Pre | 1970 |
[Treatment of tachycardiac arrhythmias and arterial hypertension with verapamil].
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Circulation; Blood Pressure; | 1970 |
[Hypertensive emergencies].
Topics: Brain Edema; Clonidine; Diazoxide; Digitalis Glycosides; Diuretics; Drug Combinations; Emergencies; | 1974 |
Verapamil in cardiology.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Anura; Arrhythmi | 1974 |
[The treatment of heart arrhythmia with the heart sympatholytic iproveratril].
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardiac Com | 1967 |
Treatment for hypertension.
Topics: Antihypertensive Agents; Drug Synergism; Ergoloid Mesylates; Humans; Hypertension; Verapamil | 1973 |
Treatment for hypertension.
Topics: Ergoloid Mesylates; Humans; Hypertension; Verapamil | 1973 |
[The effect of isoptin on changes in the concentration of potassium in the bodies of patients with hypertension and coronary insufficiency].
Topics: Adult; Coronary Disease; Female; Humans; Hypertension; Male; Middle Aged; Potassium; Verapamil | 1972 |
Letter: Treatment for hypertension.
Topics: Drug Synergism; Humans; Hypertension; Reserpine; Verapamil | 1973 |
[Verapamil (Isoptin)].
Topics: Angina Pectoris; Arrhythmias, Cardiac; Heart Rate; Humans; Hypertension; Myocardium; Vasodilator Age | 1974 |
Letter: Drug combinations in the treatment of hypertension.
Topics: Drug Synergism; Humans; Hypertension; Reserpine; Verapamil | 1974 |
[Clinical pathophysiological studies on coronary circulation. 3. The effects of so-called coronary vasodilator agents on coronary circulation in various diseases].
Topics: Adolescent; Adult; Aged; Benzoates; Benzofurans; Blood Flow Velocity; Blood Pressure; Coronary Disea | 1971 |
Immediate effects of intravenous verapamil on atrial fibrillation.
Topics: Adult; Aged; Analysis of Variance; Arteriosclerosis; Atrial Fibrillation; Depression, Chemical; Elec | 1971 |
[Clinical trials of the effect of verapamil in subjects with angina pectoris].
Topics: Adult; Aged; Angina Pectoris; Anti-Arrhythmia Agents; Arteriosclerosis; Coronary Disease; Female; He | 1970 |
[Therapy of hypertension].
Topics: Adrenal Gland Neoplasms; Aniline Compounds; Antihypertensive Agents; Diuretics; Female; Guanethidine | 1971 |